Effects/O of/O a/O leukemia/O -/O associated/O gain/O -/O of/O -/O function/O mutation/O of/O SHP-2/O phosphatase/O on/O interleukin-3/O signaling/O ./O
Mutations/B-Var in/O SHP-2/B-Gene phosphatase/B-Enzyme that/O cause/O hyperactivation/B-PosReg of/O its/O catalytic/B-MPA activity/I-MPA have/O been/O identified/O in/O human/O leukemias/B-Disease ,/O particularly/O juvenile/B-Disease myelomonocytic/I-Disease leukemia/I-Disease ,/O which/O is/O characterized/O by/O hypersensitivity/O of/O myeloid/O progenitor/O cells/O to/O granulocyte/O macrophage/O colony/O -/O stimulating/O factor/O and/O interleukin/O (/O IL)-3/O ./O
However/O ,/O the/O molecular/O mechanisms/O by/O which/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutations/O of/O SHP-2/O induce/O hematopoietic/O malignancies/O are/O not/O fully/O understood/O ./O
Our/O previous/O studies/O have/O shown/O that/O SHP-2/O plays/O an/O essential/O role/O in/O IL-3/O signal/O transduction/O in/O both/O catalytic/O -/O dependent/O and/O -independent/O manners/O and/O that/O overexpression/O (/O 5/O -/O 6-fold/O )/O of/O wild/O type/O (/O WT/O )/O SHP-2/O attenuates/O IL-3-mediated/O hematopoietic/O cell/O function/O through/O accelerated/O dephosphorylation/O of/O STAT5/O ./O
These/O results/O raised/O the/O possibility/O that/O SHP-2-associated/O leukemias/O are/O not/O solely/O attributed/O to/O the/O increased/O catalytic/O activity/O of/O GOF/O mutant/O SHP-2/O ./O
GOF/O mutant/O SHP-2/O must/O have/O gained/O additional/O capacities/O ./O
To/O test/O this/O possibility/O ,/O we/O investigated/O effects/O of/O a/O GOF/O mutation/O of/O SHP-2/O (/O SHP-2/O E76/O K/O )/O on/O hematopoietic/O cell/O function/O and/O IL-3/O signal/O transduction/O by/O comparing/O with/O those/O of/O overexpressed/O WT/O SHP-2/O ./O
Our/O results/O showed/O that/O SHP-2/B-Gene E76/B-Var K/I-Var mutation/I-Var caused/O myeloproliferative/B-Disease disease/I-Disease in/O mice/O ,/O while/O overexpression/O of/O WT/O SHP-2/O decreased/O hematopoietic/O potential/O of/O the/O transduced/O cells/O in/O recipient/O animals/O ./O
The/O E76/B-Var K/I-Var mutation/O in/O the/O N/O -/O terminal/O Src/O homology/O 2/O domain/O increased/B-PosReg interactions/B-Interaction of/O mutant/B-Var SHP-2/B-Gene with/O Grb2/B-Protein ,/O Gab2/O ,/O and/O p85/O ,/O leading/O to/O hyperactivation/B-PosReg of/O IL-3-induced/B-Pathway Erk/I-Pathway and/I-Pathway phosphatidylinositol/I-Pathway 3-kinase/I-Pathway (/I-Pathway PI3/I-Pathway K/I-Pathway )/I-Pathway pathways/I-Pathway ./O
In/O addition/O ,/O despite/O the/O substantial/O increase/B-PosReg in/O the/O catalytic/B-MPA activity/I-MPA ,/O dephosphorylation/B-MPA of/I-MPA STAT5/I-MPA by/O SHP-2/B-Gene E76/B-Var K/I-Var was/O dampened/B-NegReg ./O
Furthermore/O ,/O catalytically/O inactive/O SHP-2/B-Gene E76/B-Var K/I-Var with/O an/O additional/O C459S/B-Var mutation/O retained/O the/O capability/O to/O increase/B-PosReg the/O interaction/B-Interaction with/O Gab2/B-Protein and/O to/O enhance/B-PosReg the/O activation/O of/O the/O PI3/B-Pathway K/I-Pathway pathway/I-Pathway ./O
Taken/O together/O ,/O these/O studies/O suggest/O that/O in/O addition/O to/O the/O elevated/O catalytic/O activity/O ,/O fundamental/O changes/O in/O physical/O and/O functional/O interactions/O between/O GOF/O mutant/O SHP-2/O and/O signaling/O partners/O also/O play/O an/O important/O role/O in/O SHP-2-related/O leukemigenesis/O ./O
Genetic/O modifiers/O of/O the/O Drosophila/O blue/O cheese/O gene/O link/O defects/O in/O lysosomal/O transport/O with/O decreased/O life/O span/O and/O altered/O ubiquitinated/O -/O protein/O profiles/O ./O
Defects/O in/O lysosomal/O trafficking/O pathways/O lead/O to/O decreased/O cell/O viability/O and/O are/O associated/O with/O progressive/O disorders/O in/O humans/O ./O
Previously/O we/O have/O found/O that/O loss/O -/O of/O -/O function/O (/O LOF/O )/O mutations/B-Var in/O the/O Drosophila/O gene/O blue/O cheese/O (/B-Gene bchs/I-Gene )/I-Gene lead/O to/O reduced/B-NegReg adult/B-CPA life/I-CPA span/I-CPA ,/O increased/B-PosReg neuronal/B-CPA death/I-CPA ,/O and/O widespread/B-CPA CNS/I-CPA degeneration/B-NegReg that/O is/O associated/O with/O the/O formation/O of/O ubiquitinated/O -/O protein/O aggregates/O ./O
To/O identify/O potential/O genes/O that/O participate/O in/O the/O bchs/O functional/O pathway/O ,/O we/O conducted/O a/O genetic/O modifier/O screen/O based/O on/O alterations/O of/O an/O eye/O phenotype/O that/O arises/O from/O high/O -/O level/O overexpression/O of/O Bchs/O ./O
We/O found/O that/O mutations/O in/O select/O autophagic/O and/O endocytic/O trafficking/O genes/O ,/O defects/O in/O cytoskeletal/O and/O motor/O proteins/O ,/O as/O well/O as/O mutations/O in/O the/O SUMO/O and/O ubiquitin/O signaling/O pathways/O behave/O as/O modifiers/O of/O the/O Bchs/O gain/O -/O of/O -/O function/O (/O GOF/O )/O eye/O phenotype/O ./O
Individual/O mutant/O alleles/O that/O produced/O viable/O adults/O were/O further/O examined/O for/O bchs/O -/O like/O phenotypes/O ./O
Mutations/B-Var in/O several/O lysosomal/B-Gene trafficking/I-Gene genes/I-Gene resulted/O in/O significantly/O decreased/B-NegReg adult/B-CPA life/I-CPA spans/I-CPA and/O several/O mutants/O showed/O changes/B-Reg in/O ubiquitinated/B-MPA protein/I-MPA profiles/I-MPA as/O young/O adults/O ./O
This/O work/O represents/O a/O novel/O approach/O to/O examine/O the/O role/O that/O lysosomal/O transport/O and/O function/O have/O on/O adult/O viability/O ./O
The/O genes/O characterized/O in/O this/O study/O have/O direct/O human/O homologs/O ,/O suggesting/O that/O similar/O defects/O in/O lysosomal/O transport/O may/O play/O a/O role/O in/O human/O health/O and/O age/O -/O related/O processes/O ./O
Isolation/O and/O characterization/O of/O a/O novel/O human/O RGS/O mutant/O displaying/O gain/O -/O of/O -/O function/O activity/O ./O
Regulator/O of/O G/O protein/O signaling/O (/O RGS/O )/O proteins/O play/O a/O crucial/O role/O in/O the/O adaptation/O of/O cells/O to/O stimulation/B-PosReg by/O G/B-Protein protein/I-Protein -/I-Protein coupled/I-Protein receptors/I-Protein via/O heterotrimeric/B-Protein G/I-Protein proteins/I-Protein ./O
Alterations/B-Var in/O RGS/B-Protein function/O have/O been/O implicated/B-Reg in/O a/O wide/O range/O of/O disease/B-Disease states/O ,/O leading/O to/O many/O researchers/O focusing/O on/O controlling/O the/O action/O of/O these/O regulatory/O proteins/O ./O
Previous/O studies/O have/O centered/O on/O reducing/O or/O inhibiting/O the/O action/O of/O RGS/O proteins/O ,/O utilizing/O inactive/O mutants/O or/O small/O molecular/O RGS/O inhibitors/O ./O
Here/O we/O describe/O the/O isolation/O and/O characterization/O of/O a/O novel/O human/O RGS4/B-Var mutant/I-Var which/O displays/O enhanced/B-PosReg or/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O activity/O ./O
RGS4(S30C/O )/O demonstrates/O GOF/O activity/O both/O in/O an/O in/O vivo/O yeast/B-Pathway -/I-Pathway based/I-Pathway signalling/I-Pathway pathway/I-Pathway and/O in/O vitro/O against/O the/O Galpha(o1/B-Protein )/I-Protein subunit/I-Protein contained/I-Protein in/I-Protein an/I-Protein alpha(2A)-adrenoreceptor/I-Protein -/I-Protein Galpha(o1)(C351I/I-Protein )/I-Protein fusion/I-Protein protein/I-Protein ./O
Mutational/O analysis/O of/O serine/O 30/O identified/O a/O number/O of/O alternative/O substitutions/O that/O result/O in/O GOF/O activity/O ./O
GOF/O activity/O was/O retained/O upon/O transposition/O of/O the/O serine/O 30-cysteine/O mutation/O to/O the/O equivalent/O serine/O residue/O in/O human/O RGS16/O ./O
As/O with/O previously/O identified/O GOF/O mutants/O ,/O RGS4(S30C/B-Var //I-Var S30F/I-Var //I-Var S30/I-Var K/I-Var )/I-Var demonstrate/O increased/B-PosReg steady/O state/O protein/B-MPA levels/I-MPA ,/O however/O these/O mutants/O also/O demonstrate/O enhanced/B-PosReg GAP/B-MPA activity/I-MPA through/O an/O additional/O mechanism/O distinct/O from/O the/O increased/O protein/O content/O ./O
The/O identification/O of/O human/O RGS/O mutants/O with/O GOF/O activity/O may/O provide/O novel/O therapeutic/O agents/O for/O the/O treatment/O of/O signaling/O -/O based/O diseases/O and/O the/O ability/O to/O transpose/O these/O mutations/O to/O other/O human/O RGS/O proteins/O extends/O their/O application/O to/O multiple/O pathways/O ./O
Conditional/O RNA/O interference/O in/O vivo/O to/O study/O mutant/O p53/O oncogenic/O gain/O of/O function/O on/O tumor/O malignancy/O ./O
Mutant/B-Var p53/B-Gene proteins/B-Protein are/O thought/O to/O have/O acquired/O a/O "/B-PosReg gain/I-PosReg of/I-PosReg function/I-PosReg "/I-PosReg (/O GOF/O )/O activity/O that/O mainly/O contributes/O to/O tumor/B-CPA aggressiveness/I-CPA ./O
Previously/O we/O reported/O that/O constitutive/O downregulation/B-NegReg of/O mutant/B-Var p53/B-Gene by/O RNA/B-MPA interference/I-MPA reduces/B-NegReg the/O tumorigenicity/B-CPA of/I-CPA cancer/I-CPA cells/I-CPA in/I-CPA an/I-CPA animal/I-CPA model/I-CPA ;/I-CPA however/O ,/O effects/O of/O adaptation/O to/O long/O -/O term/O mutant/O p53/O inhibition/O could/O not/O be/O excluded/O ./O
To/O address/O this/O point/O ,/O mimicking/O more/O physiological/O conditions/O ,/O we/O now/O describe/O the/O establishment/O of/O a/O lentiviral/O -/O based/O system/O for/O conditional/O interference/O with/O mutant/O p53/O expression/O ./O
In/O vivo/O studies/O assessed/O the/O efficacy/O of/O conditional/B-MPA RNA/I-MPA interference/I-MPA in/O inhibiting/B-NegReg gain/O of/O function/O activity/B-MPA of/O mutant/B-Var p53/B-Gene proteins/B-Protein by/O reducing/O tumor/O growth/O ability/O ./O
Moreover/O by/O using/O this/O system/O ,/O microarray/O data/O were/O validated/O in/O vitro/O and/O in/O vivo/O and/O putative/O mutant/O p53/O target/O genes/O that/O may/O contribute/O to/O its/O gain/O of/O function/O effects/O in/O cancer/O were/O identified/O ./O
Results/O are/O confirmatory/O that/O depletion/B-MPA of/O mutant/B-Var p53/B-Gene protein/B-Protein impacts/B-Reg on/O tumor/B-CPA malignancy/I-CPA and/O validated/O the/O inducible/O lentiviral/O -/O based/O system/O as/O an/O efficient/O tool/O to/O study/O the/O gain/O of/O function/O activity/O of/O human/O tumor/O derived/O p53/O mutants/O ./O
Identification/O and/O functional/O analysis/O of/O novel/O variants/O of/O the/O human/O melanocortin/O 1/O receptor/O found/O in/O melanoma/O patients/O ./O
The/O melanocortin/O 1/O receptor/O ,/O a/O Gs/O protein/O -/O coupled/O receptor/O expressed/O in/O epidermal/O melanocytes/O ,/O is/O a/O major/O determinant/O of/O skin/O pigmentation/O and/O phototype/O and/O an/O important/O contributor/O to/O melanoma/O risk/O ./O
MC1R/O activation/O stimulates/O synthesis/O of/O black/O ,/O strongly/O photoprotective/O eumelanin/O pigments/O ./O
Several/O MC1R/O alleles/O are/O associated/O with/O red/O hair/O ,/O fair/O skin/O ,/O increased/O sensitivity/O to/O ultraviolet/O radiation/O ,/O and/O increased/O skin/O cancer/O risk/O ./O
The/O MC1R/O gene/O is/O highly/O polymorphic/O ,/O but/O only/O a/O few/O naturally/O occurring/O alleles/O have/O been/O functionally/O characterized/O ,/O which/O complicates/O the/O establishment/O of/O accurate/O correlations/O between/O the/O signaling/O properties/O of/O mutant/O alleles/O and/O defined/O cutaneous/O phenotypes/O ./O
We/O report/O the/O functional/O characterization/O of/O six/O MC1R/B-Gene alleles/O found/O in/O Spanish/O melanoma/B-Disease patients/O ./O
Two/O variants/O (/O c.152T/O >/O C/O ,/O p/O ./O Val51Ala/O and/O c.865T/O >/O C/O ,/O p/O ./O Cys289Arg/O )/O have/O never/O been/O described/O ,/O and/O the/O others/O (/O c.112G/O >/O A/O ,/O p/O ./O Val38Met/O ;/O c.122C/O >/O T/O ,/O p/O ./O Ser41Phe/O ;/O c.383T/O >/O C/O ,/O p/O ./O Met128Thr/O ;/O and/O c.842A/O >/O G/O ,/O p/O ./O Asn281Ser/O )/O have/O not/O been/O analyzed/O for/O function/O ./O
p/B-Var ./I-Var Asn281Ser/I-Var corresponds/O to/O a/O functionally/O silent/B-NegReg polymorphism/B-MPA ./O
The/O other/O mutations/O are/O associated/O with/O varying/O degrees/O of/O loss/O of/O function/O (/O LOF/O )/O ,/O from/O moderate/O decreases/B-NegReg in/O coupling/B-MPA to/O the/O cAMP/B-Pathway pathway/I-Pathway (/B-Var p/I-Var ./I-Var Val38Met/I-Var and/O p/B-Var ./I-Var Val51Ala/I-Var )/I-Var to/O nearly/O complete/O absence/B-NegReg of/O functional/B-MPA coupling/I-MPA (/B-Var p/I-Var ./I-Var Ser41Phe/I-Var ,/O p/B-Var ./I-Var Met128Thr/I-Var ,/O and/O p/B-Var ./I-Var Cys289Arg/I-Var )/I-Var ./O
The/O LOF/O p/B-Var ./I-Var Met128Thr/I-Var and/O p/B-Var ./I-Var Cys289Arg/I-Var mutants/O are/O trafficked/O to/O the/O cell/O surface/O ,/O but/O are/O unable/B-NegReg to/O bind/B-Interaction agonists/O efficiently/O ./O
Conversely/O ,/O LOF/O of/O p/B-Var ./I-Var Val38Met/I-Var ,/O p/B-Var ./I-Var Ser41Phe/I-Var ,/O and/O p/B-Var ./I-Var Val51Ala/I-Var is/O due/O to/O reduced/B-NegReg cell/B-CPA surface/I-CPA expression/I-CPA as/O a/O consequence/O of/O retention/O in/O the/O endoplasmic/O reticulum/O (/O ER/O )/O ./O
Therefore/O ,/O LOF/O of/O MC1R/O alleles/O is/O frequently/O associated/O with/O aberrant/O forward/O trafficking/O and/O accumulation/O within/O the/O ER/O or/O with/O inability/O to/O bind/O properly/O the/O activatory/O ligand/O ./O
Elevated/O expression/O of/O p53/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O R175H/B-Var in/O endometrial/O cancer/O cells/O can/O increase/O the/O invasive/O phenotypes/O by/O activation/O of/O the/O EGFR/B-Pathway //I-Pathway PI3K/I-Pathway //I-Pathway AKT/I-Pathway pathway/I-Pathway ./O
BACKGROUND/O :/O p53/O is/O the/O most/O commonly/O mutated/O tumor/O suppressor/O gene/O in/O human/O cancers/O ./O
In/O addition/O to/O the/O loss/O of/O tumor/O suppression/O function/O and/O exertion/O of/O dominant/O -/O negative/O effects/O over/O the/O remaining/O wild/O -/O type/O protein/O ,/O several/O p53/O mutants/O can/O gain/O novel/O oncogenic/O functions/O (/O gain/O -/O of/O -/O function/O ,/O GOF/O )/O that/O actively/O regulate/O cancer/O development/O and/O progression/O ./O
In/O human/O endometrial/O cancer/O ,/O p53/B-Gene mutation/B-Var is/O more/O often/O associated/B-Reg with/O aggressive/B-Disease nonendometrioid/I-Disease cancer/I-Disease ./O
However/O ,/O it/O was/O unknown/O if/O p53/O mutants/O contributed/O to/O endometrial/O cancer/O progression/O through/O the/O GOF/O properties/O ./O
METHODS/O :/O To/O clarify/O the/O relationship/O between/O expression/O of/O p53/O GOF/O mutation/O (/O p53-R175H/O )/O and/O invasive/O potential/O of/O human/O endometrial/O cancer/O KLE/O cells/O ,/O we/O tested/B-Reg the/O consequences/O of/O up/B-PosReg -/I-PosReg regulation/I-PosReg and/O down/B-NegReg -/I-NegReg regulation/I-NegReg of/O p53-R175H/O in/O KLE/O cells/O by/O inducing/B-Reg p53-R175H/B-Protein expression/I-Protein vector/I-Protein or/O suppressing/B-NegReg the/O p53/B-Gene gene/I-Gene with/O short/O hairpin/O RNA/O ./O
RESULTS/O :/O We/O found/O that/O forced/O over/B-PosReg -/I-PosReg expression/I-PosReg of/O p53-R175H/B-Var significantly/O promoted/B-PosReg cell/B-CPA migration/I-CPA and/O invasion/B-CPA ,/O and/O induced/O activation/B-PosReg of/O the/O epidermal/B-Pathway growth/I-Pathway factor/I-Pathway receptor/I-Pathway (/I-Pathway EGFR)/phosphatidylinositol/I-Pathway 3-kinase/I-Pathway (/I-Pathway PI3K)/AKT/I-Pathway pathway/I-Pathway ./O
Conversely/O ,/O suppression/B-NegReg of/O p53-R175H/B-Protein with/O short/B-Gene hairpin/I-Gene RNA/I-Gene significantly/O inhibited/B-NegReg cell/B-CPA migration/I-CPA and/I-CPA invasion/I-CPA ,/O and/O resulted/O in/O attenuation/B-NegReg of/O EGFR/B-Pathway //I-Pathway PI3K/I-Pathway //I-Pathway AKT/I-Pathway pathway/I-Pathway ./O
CONCLUSION/O :/O These/O findings/O show/O for/O the/O first/O time/O that/O elevated/B-PosReg expression/B-MPA of/O p53-R175H/B-Var mutant/O may/O exert/O gain/B-MPA -/I-MPA of/I-MPA -/I-MPA function/I-MPA activity/I-MPA to/O activate/B-PosReg the/O EGFR/B-Pathway //I-Pathway PI3K/I-Pathway //I-Pathway AKT/I-Pathway pathway/I-Pathway and/O thus/O may/O contribute/B-Reg to/O the/O invasive/O phenotype/O in/O endometrial/B-Disease cancer/I-Disease ./O
The/O tyrosine/O phosphatase/O Shp2/O in/O development/O and/O cancer/O ./O
Deregulation/O of/O signaling/O pathways/O ,/O through/O mutation/O or/O other/O molecular/O changes/O ,/O can/O ultimately/O result/O in/O disease/O ./O
The/O tyrosine/O phosphatase/O Shp2/O has/O emerged/O as/O a/O major/O regulator/O of/O receptor/O tyrosine/O kinase/O (/O RTK/O )/O and/O cytokine/O receptor/O signaling/O ./O
In/O the/O last/O decade/O ,/O germline/O mutations/O in/O the/O human/O PTPN11/O gene/O ,/O encoding/O Shp2/O ,/O were/O linked/O to/O Noonan/O (/O NS/O )/O and/O LEOPARD/O syndromes/O ,/O two/O multisymptomatic/O developmental/O disorders/O that/O are/O characterized/O by/O short/O stature/O ,/O craniofacial/O defects/O ,/O cardiac/O defects/O ,/O and/O mental/O retardation/O ./O
Somatic/O Shp2/B-Gene mutations/B-Var are/O also/O associated/B-Reg with/O several/O types/O of/O human/O malignancies/O ,/O such/O as/O the/O most/O common/O juvenile/O leukemia/O ,/O juvenile/B-Disease myelomonocytic/I-Disease leukemia/I-Disease (/O JMML/O )/O ./O
Whereas/O NS/B-Disease and/O JMML/B-Disease are/O caused/O by/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var of/O Shp2/B-Gene ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O mutations/B-Var are/O thought/O to/O be/O associated/O with/O LEOPARD/B-Disease syndrome/I-Disease ./O
Animal/O models/O that/O carry/O conditional/O LOF/O and/O GOF/O mutations/O have/O allowed/O a/O better/O understanding/O of/O the/O mechanism/O of/O Shp2/O function/O in/O disease/O ,/O and/O shed/O light/O on/O the/O role/O of/O Shp2/O in/O signaling/O pathways/O that/O control/O decisive/O events/O during/O embryonic/O development/O or/O during/O cellular/O transformation/O //O tumorigenesis/O ./O
Mutant/B-Var p53/B-Gene facilitates/B-PosReg somatic/B-CPA cell/I-CPA reprogramming/I-CPA and/O augments/B-NegReg the/O malignant/B-CPA potential/I-CPA of/I-CPA reprogrammed/I-CPA cells/I-CPA ./O
p53/B-Gene deficiency/B-Var enhances/B-PosReg the/O efficiency/O of/O somatic/B-CPA cell/I-CPA reprogramming/I-CPA to/O a/O pluripotent/O state/O ./O
As/O p53/O is/O usually/O mutated/O in/O human/O tumors/O and/O many/O mutated/B-Var forms/O of/O p53/B-Gene gain/B-PosReg novel/O activities/B-MPA ,/O we/O studied/O the/O influence/O of/O mutant/O p53/O (/O mut/O -/O p53/O )/O on/O somatic/O cell/O reprogramming/O ./O
Our/O data/O indicate/O a/O novel/O gain/B-PosReg of/O function/B-MPA (/O GOF/O )/O property/O for/O mut/B-Var -/I-Var p53/I-Var ,/O which/O markedly/O enhanced/B-PosReg the/O efficiency/O of/O the/O reprogramming/B-CPA process/I-CPA compared/O with/O p53/O deficiency/O ./O
Importantly/O ,/O this/O novel/O activity/B-MPA of/O mut/B-Gene -/I-Gene p53/I-Gene induced/O alterations/B-Reg in/O the/O characteristics/B-CPA of/I-CPA the/I-CPA reprogrammed/I-CPA cells/I-CPA ./O
Although/O p53/O knockout/O (/O KO/O )/O cells/O reprogrammed/O with/O only/O Oct4/O and/O Sox2/O maintained/O their/O pluripotent/B-MPA capacity/I-MPA in/O vivo/O ,/O reprogrammed/O cells/O expressing/O mutant/B-Var p53/B-Gene lost/B-NegReg this/O capability/O and/O gave/B-Reg rise/I-Reg to/O malignant/B-CPA tumors/I-CPA ./O
This/O novel/O GOF/O of/O mut/O -/O p53/O is/O not/O attributed/O to/O its/O effect/O on/O proliferation/O ,/O as/O both/O p53/O KO/O and/O mut/O -/O p53/O cells/O displayed/O similar/O proliferation/O rates/O ./O
In/O addition/O ,/O we/O demonstrate/O an/O oncogenic/B-MPA activity/I-MPA of/O Klf4/O ,/O as/O its/O overexpression/B-PosReg in/O either/O p53/O KO/O or/O mut/B-Gene -/I-Gene p53/I-Gene cells/O induced/B-PosReg aggressive/B-CPA tumors/I-CPA ./O
Overall/O ,/O our/O data/O show/O that/O reprogrammed/O cells/O with/O the/O capacity/O to/O differentiate/O into/O the/O three/O germ/O layers/O in/O vitro/O can/O form/O malignant/O tumors/O ,/O suggesting/O that/O in/O genetically/O unstable/O cells/O ,/O such/O as/O those/O in/O which/O p53/B-Gene is/O mutated/B-Var ,/O reprogramming/B-CPA may/O result/B-Reg in/I-Reg the/O generation/O of/O cells/B-CPA with/I-CPA malignant/I-CPA tumor/I-CPA -/I-CPA forming/I-CPA potential/I-CPA ./O
The/O combined/O impact/O of/O CYP2C19/O and/O CYP2B6/O pharmacogenetics/O on/O cyclophosphamide/O bioactivation/O ./O
AIMS/O :/O The/O role/O of/O CYP/O pharmacogenetics/O in/O the/O bioactivation/O of/O cyclophosphamide/O is/O still/O controversial/O ./O
Recent/O clinical/O studies/O have/O suggested/O a/O role/O for/O either/O CYP2C19/O or/O CYP2B6/O ./O
The/O aim/O of/O this/O study/O was/O to/O clarify/O the/O role/O of/O these/O pharmacogenes/O ./O
METHODS/O :/O We/O used/O a/O combined/O in/O vitro/O -/O in/O vivo/O approach/O to/O determine/O the/O role/O of/O these/O pharmacogenes/O in/O the/O bioactivation/O of/O the/O prodrug/O to/O 4-hydroxy/O cyclophosphamide/O (/O 4-OHCP/O )/O ./O
Cyclophosphamide/O metabolism/O was/O determined/O in/O a/O human/O liver/O biobank/O (/O n=/O 14/O )/O and/O in/O patients/O receiving/O the/O drug/O for/O treatment/O of/O lupus/O nephritis/O (/O n=/O 16/O )/O RESULTS/O :/O In/O livers/O of/O known/O CYP2C19/O and/O CYP2B6/O genotype/O and/O protein/O expression/O we/O observed/O that/O there/O was/O a/O combined/B-Interaction role/O for/O both/O CYP2C19/B-Var and/O CYP2B6/B-Var in/O the/O bioactivation/B-MPA of/I-MPA cyclophosphamide/I-MPA in/O vitro/O ./O
The/O presence/O of/O at/O least/O one/O loss/O of/O function/O (/O LoF/O )/O allele/O at/O either/O CYP2C19/B-Var or/O CYP2B6/B-Var resulted/O in/O a/O significant/O decrease/B-NegReg in/O both/O V(max/B-MPA )/I-MPA (/I-MPA P=/I-MPA 0.028/I-MPA )/I-MPA and/I-MPA CL(int/I-MPA )/I-MPA (/I-MPA P=/I-MPA 0.0017/I-MPA )/I-MPA compared/O with/O livers/O with/O no/O LoF/O alleles/O ./O
This/O dual/O genotype/O relationship/O was/O also/O observed/O in/O a/O preliminary/O clinical/O study/O ,/O with/O patients/O who/O had/O ≥1/O LoF/O allele/O at/O either/O CYP2C19/B-Var or/O CYP2B6/B-Var also/O displaying/O significantly/O (/O P=/O 0.0316/O )/O lower/B-NegReg bioactivation/B-MPA of/I-MPA cyclophosphamide/I-MPA ./O
The/O mean/O 4-OHCP/O :/O CP/O bioactivation/O ratio/O was/O 0.0014/O (/O 95/O %/O CI/O 0.0007/O ,/O 0.002/O )/O compared/O with/O 0.0071/O (/O 95/O %/O CI/O 0.0001/O ,/O 0.014/O )/O in/O patients/O with/O no/O LoF/O alleles/O at/O either/O of/O these/O genes/O ./O
CONCLUSIONS/O :/O The/O presence/O of/O ≥1/O LoF/O allele(s/O )/O at/O either/O CYP2B6/B-Var or/O CYP2C19/B-Var appeared/O to/O result/O in/O decreased/B-NegReg bioactivation/B-MPA of/I-MPA cyclophosphamide/I-MPA both/O in/O vitro/O and/O in/O patients/O ./O
Further/O clinical/O studies/O to/O confirm/O this/O relationship/O are/O warranted/O ./O
Mutant/O p53/O R248Q/O but/O not/O R248W/O enhances/O in/O vitro/O invasiveness/O of/O human/O lung/O cancer/O NCI/O -/O H1299/O cells/O ./O
More/O than/O half/O of/O all/O human/B-Disease cancers/I-Disease are/O associated/B-Reg with/O mutations/B-Var of/O the/O TP53/B-Gene gene/O ./O
In/O regard/O to/O the/O functional/O interaction/O with/O the/O remaining/O wild/O -/O type/O (/O WT/O )/O p53/O allele/O ,/O p53/O mutations/O are/O classified/O into/O two/O types/O ,/O recessive/O and/O dominant/B-Var -/I-Var negative/I-Var (/I-Var DN/I-Var )/I-Var mutations/I-Var ./O
The/O latter/O mutant/O protein/O has/O a/O DN/B-MPA activity/I-MPA over/B-PosReg the/I-PosReg remaining/I-PosReg WT/I-PosReg allele/I-PosReg ./O
We/O previously/O showed/O that/O the/O DN/O p53/O mutant/O was/O useful/O as/O a/O predictor/O of/O poor/O outcome/O or/O a/O risk/O factor/O for/O metastatic/O recurrence/O in/O patients/O with/O some/O types/O of/O cancers/O ,/O regardless/O of/O the/O presence/O or/O absence/O of/O loss/O of/O heterozygosity/O (/O LOH/O )/O of/O WT/O p53/O ,/O suggesting/O that/O the/O DN/B-Var p53/B-Gene had/O '/B-PosReg gain/I-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/I-PosReg GOF/I-PosReg )/I-PosReg '/I-PosReg activity/I-PosReg besides/O the/O transdominance/O function/O ./O
In/O this/O study/O ,/O we/O investigated/O GOF/O activity/O of/O two/O DN/O p53/O mutants/O which/O had/O a/O point/O mutation/O at/O codon/O 248/O (/O R248Q/O and/O R248W/O )/O ,/O one/O of/O the/O hot/O spots/O ,/O by/O transfecting/O them/O respectively/O into/O H1299/O cells/O which/O originally/O expressed/O no/O p53/O protein/O ./O
Growth/O activity/O of/O the/O transfectants/O with/O the/O two/O mutants/O was/O not/O different/O from/O that/O of/O parent/O or/O Mock/O transfectants/O ./O
Meanwhile/O ,/O in/O vitro/B-CPA invasions/I-CPA of/I-CPA Matrigel/I-CPA and/I-CPA type/I-CPA I/I-CPA collagen/I-CPA gel/I-CPA by/O R248Q/B-Var -/I-Var transfectants/I-Var were/O significantly/O higher/B-PosReg than/O those/O by/O R248W/O -/O transfectants/O or/O the/O control/O cells/O ./O
However/O ,/O there/O were/O no/O differences/O in/O cell/O motile/O activities/O ,/O expressions/O of/O extracellular/O matrix/O -/O degradative/O enzymes/O such/O as/O matrix/O metalloproteinases/O ,/O urokinase/O -/O type/O plasminogen/O activator/O and/O heparanase/O ,/O and/O their/O inhibitors/O ,/O between/O R248Q-/O and/O R248W/O -/O transfectants/O ./O
These/O findings/O indicate/O that/O the/O p53/O mutants/O have/O a/O different/O quality/O in/O GOF/O activities/O even/O if/O the/O mutations/O occurred/O at/O the/O same/O codon/O ./O
And/O detailed/O information/O of/O the/O status/O of/O p53/O ,/O including/O transdominancy/O and/O GOF/O activity/O ,/O is/O expected/O to/O be/O useful/O for/O diagnosis/O and/O therapeutic/O strategy/O fitting/O the/O individual/O patients/O ./O
Gain/O -/O of/O -/O function/O mutant/B-Var p53/B-Gene upregulates/B-PosReg CXC/B-MPA chemokines/I-MPA and/O enhances/B-PosReg cell/B-CPA migration/I-CPA ./O
The/O role/O of/O dominant/O transforming/O p53/O in/O carcinogenesis/O is/O poorly/O understood/O ./O
Our/O previous/O data/O suggested/O that/O aberrant/B-Var p53/B-Protein proteins/I-Protein can/O enhance/B-PosReg tumorigenesis/B-CPA and/I-CPA metastasis/I-CPA ./O
Here/O ,/O we/O examined/O potential/O mechanisms/O through/O which/O gain/O -/O of/O -/O function/O (/O GOF/O )/O p53/O proteins/O can/O induce/O motility/O ./O
Cells/O expressing/O GOF/O p53/B-Var -R175H/I-Var ,/O -R273H/I-Var and/I-Var -D281/I-Var G/I-Var showed/O enhanced/B-PosReg migration/B-CPA ,/O which/O was/O reversed/O by/O RNA/O interference/O (/O RNAi/O )/O or/O transactivation/O -/O deficient/O mutants/O ./O
In/O cells/O with/O engineered/O or/O endogenous/O p53/O mutants/O ,/O enhanced/O migration/O was/O reduced/O by/O downregulation/O of/O nuclear/O factor/O -/O kappaB2/O ,/O a/O GOF/O p53/O target/O ./O
We/O found/O that/O GOF/B-Var p53/I-Var proteins/O upregulate/B-PosReg CXC/B-MPA -/I-MPA chemokine/I-MPA expression/I-MPA ,/O the/O inflammatory/O mediators/O that/O contribute/O to/O multiple/O aspects/O of/O tumorigenesis/O ./O
Elevated/B-PosReg expression/B-MPA of/O CXCL5/O ,/O CXCL8/O and/O CXCL12/O was/O found/O in/O cells/O expressing/O oncogenic/B-Var p53/I-Var ./O
Transcription/B-MPA was/O elevated/B-PosReg as/O CXCL5/B-MPA and/I-MPA CXCL8/I-MPA promoter/I-MPA activity/I-MPA was/O higher/B-PosReg in/O cells/O expressing/O GOF/B-Var p53/I-Var ,/O whereas/O wild/O -/O type/O p53/O repressed/O promoter/O activity/O ./O
Chromatin/O immunoprecipitation/O assays/O revealed/O enhanced/O presence/O of/O acetylated/O histone/O H3/O on/O the/O CXCL5/O promoter/O in/O H1299/O //O R273H/O cells/O ,/O in/O agreement/O with/O increased/O transcriptional/O activity/O of/O the/O promoter/O ,/O whereas/O RNAi/O -/O mediated/O repression/O of/O CXCL5/O inhibited/O cell/O migration/O ./O
Consistent/O with/O this/O ,/O knockdown/O of/O the/O endogenous/B-Var mutant/I-Var p53/B-Gene in/O lung/O cancer/O or/O melanoma/O cells/O reduced/B-NegReg CXCL5/B-MPA expression/I-MPA and/O cell/B-CPA migration/I-CPA ./O
Furthermore/O ,/O short/O hairpin/O RNA/O knockdown/O of/O mutant/B-Var p53/B-Gene in/O MDA/O -/O MB-231/O cells/O reduced/B-NegReg expression/B-MPA of/I-MPA a/I-MPA number/I-MPA of/I-MPA key/I-MPA targets/I-MPA ,/O including/O several/O chemokines/O and/O other/O inflammatory/O mediators/O ./O
Finally/O ,/O CXCL5/B-MPA expression/I-MPA was/O also/O elevated/B-PosReg in/O lung/B-Disease tumor/I-Disease samples/O containing/O GOF/B-Var p53/I-Var ,/O indicating/O relevance/O to/O human/O cancer/O ./O
The/O data/O suggest/O a/O mechanistic/O link/O between/O GOF/O p53/O proteins/O and/O chemokines/O in/O enhanced/O cell/O motility/O ./O
Allele/O specific/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg activity/B-MPA of/O p53/B-Gene mutants/B-Var in/O lung/B-Disease cancer/I-Disease cells/O ./O
p53/B-Gene mutations/B-Var are/O mostly/O single/O amino/O acid/O changes/O resulting/B-Reg in/I-Reg expression/B-MPA of/O a/O stable/O mutant/O protein/O with/O "/B-PosReg gain/I-PosReg of/I-PosReg function/I-PosReg "/I-PosReg (/O GOF/O )/O activity/B-MPA having/O a/O dominant/O oncogenic/O role/O rather/O than/O simple/O loss/O of/O function/O of/O wild/O -/O type/O p53/O ./O
Knock/O -/O down/O of/O mutant/O p53/O in/O human/O lung/O cancer/O cell/O lines/O with/O different/O endogenous/O p53/B-Gene mutants/B-Var results/O in/O loss/B-NegReg of/O GOF/O activity/B-MPA as/O shown/O by/O lowering/B-NegReg of/O cell/B-CPA growth/I-CPA rate/I-CPA ./O
Two/O lung/O cancer/O cell/O lines/O ,/O ABC1/O and/O H1437/O ,/O carrying/O endogenous/O mutants/B-Var p53-P278S/I-Var and/I-Var -R267P/I-Var ,/O show/O reduction/B-NegReg in/O growth/B-MPA rate/I-MPA on/O knock/O -/O down/O on/O p53/O levels/O ./O
However/O ,/O whereas/O reduction/B-NegReg of/O the/O p53/B-Var level/O induces/O loss/B-NegReg of/O tumorigenicity/B-MPA in/O nude/O mice/O for/O ABC1/O cells/O ,/O it/O escalates/B-PosReg tumorigenicity/B-MPA for/O H1437/O cells/O ./O
We/O have/O tested/O their/O transactivation/O potential/O on/O p53/O target/O gene/O promoters/O by/O performing/O transient/O transcriptional/O assays/O in/O the/O p53-null/O H1299/O lung/O cancer/O cell/O line/O ./O
Interestingly/O ,/O while/O the/O mutant/O p53/O target/O promoter/O Axl/O was/O activated/O by/O both/O the/O mutants/O ,/O the/O p21/O promoter/O was/O activated/O by/O p53-R267P/O and/O wild/O -/O type/O p53/O but/O not/O by/O p53-P278S/O ;/O showing/O a/O clear/O difference/O in/O transcriptional/O activity/O between/O the/O two/O mutants/O ./O
Our/O results/O demonstrate/O allele/O specificity/O between/O GOF/O p53/O mutants/O and/O attempt/O to/O show/O that/O the/O specificity/O is/O dependent/O on/O the/O transactivation/O property/O of/O GOF/O p53/O ;/O it/O also/O suggests/O importance/O of/O p21/O activation/O in/O tumor/O suppression/O by/O p53/O ./O
Gain/O -/O of/O -/O Function/O Activity/O of/O Mutant/O p53/O in/O Lung/O Cancer/O through/O Up/O -/O Regulation/O of/O Receptor/O Protein/O Tyrosine/O Kinase/O Axl/O ./O
p53/O mutations/O are/O present/O in/O up/O to/O 70/O %/O of/O lung/O cancer/O ./O
Cancer/O cells/O with/O p53/B-Gene mutations/B-Var ,/O in/O general/O ,/O grow/B-CPA more/O aggressively/B-PosReg than/O those/O with/O wild/O -/O type/O p53/O or/O no/O p53/O ./O
Expression/O of/O tumor/O -/O derived/O mutant/B-Var p53/B-Gene in/O cells/O leads/O to/O up/B-PosReg -/I-PosReg regulated/I-PosReg expression/B-MPA of/I-MPA genes/I-MPA that/O may/O affect/B-Reg cell/B-CPA growth/I-CPA and/O oncogenesis/B-CPA ./O
In/O our/O study/O of/O this/O aggressive/O phenotype/O ,/O we/O have/O investigated/O the/O receptor/O protein/O tyrosine/B-Enzyme kinase/I-Enzyme Axl/I-Enzyme ,/O which/O is/O up/B-PosReg -/I-PosReg regulated/I-PosReg by/O p53/B-Gene mutants/B-Var at/O both/O RNA/O and/O protein/O levels/O in/O H1299/O lung/O cancer/O cells/O expressing/O mutants/O p53-R175H/O ,/O -R273H/O ,/O and/O -D281G./O Knockdown/O of/O endogenous/O mutant/O p53/O levels/O in/O human/O lung/O cancer/O cells/O H1048/O (/O p53-R273C/O )/O and/O H1437/O (/O p53-R267P/O )/O led/O to/O a/O reduction/O in/O the/O level/O of/O Axl/O as/O well/O ./O
This/O effect/O on/O Axl/O expression/O is/O refractory/O to/O the/O mutations/O at/O positions/O 22/O and/O 23/O of/O p53/O ,/O suggesting/O that/O p53/O 's/O transactivation/O domain/O may/O not/O play/O a/O critical/O role/O in/O the/O up/O -/O regulation/O of/O Axl/O gene/O expression/O ./O
Chromatin/O immunoprecipitation/O (/O ChIP/O )/O assays/O carried/O out/O with/O acetylated/O histone/O antibodies/O demonstrated/O induced/O histone/B-Reg acetylation/B-MPA on/I-MPA the/I-MPA Axl/I-MPA promoter/I-MPA region/I-MPA by/O mutant/B-Var p53/B-Gene ./O
Direct/O mutant/O p53/O nucleation/O on/O the/O Axl/O promoter/O was/O demonstrated/O by/O ChIP/O assays/O using/O antibodies/O against/O p53/O ./O
The/O Axl/O promoter/O has/O a/O p53/O //O p63/O binding/O site/O ,/O which/O however/O is/O not/O required/O for/O mutant/O p53-mediated/O transactivation/O ./O
Knockdown/O of/O Axl/O by/O Axl/O -/O specific/O RNAi/O caused/O a/O reduction/O of/O gain/O -/O of/O -/O function/O (/O GOF/O )/O activities/O ,/O reducing/O the/O cell/O growth/O rate/O and/O motility/O rate/O in/O lung/O cancer/O cells/O expressing/O mutant/O p53/O ./O
This/O indicates/O that/O for/O lung/O cancer/O cell/O lines/O with/O mutant/B-Var p53/B-Gene ,/O GOF/O activities/B-MPA are/O mediated/B-Reg in/O part/O through/O Axl/B-Protein ./O
Gain/O -/O of/O -/O function/O mutations/O in/O PDR1/O ,/O a/O regulator/O of/O antifungal/O drug/O resistance/O in/O Candida/O glabrata/O ,/O control/O adherence/O to/O host/O cells/O ./O
Candida/O glabrata/O is/O an/O emerging/O opportunistic/O pathogen/O that/O is/O known/O to/O develop/O resistance/O to/O azole/O drugs/O due/O to/O increased/O drug/O efflux/O ./O
The/O mechanism/O consists/O of/O CgPDR1-mediated/O upregulation/O of/O ATP/O -/O binding/O cassette/O transporters/O ./O
A/O range/O of/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var in/O CgPDR1/B-Gene have/O been/O found/O to/O lead/B-PosReg not/O only/O to/O azole/B-MPA resistance/I-MPA but/O also/O to/O enhanced/B-PosReg virulence/B-MPA ./O
This/O implicates/B-Reg CgPDR1/B-Gene in/O the/O regulation/B-MPA of/O the/O interaction/B-Interaction of/O C./O glabrata/O with/O the/O host/O ./O
To/O identify/O specific/O CgPDR1-regulated/O steps/O of/O the/O host/O -/O pathogen/O interaction/O ,/O we/O investigated/O in/O this/O work/O the/O interaction/O of/O selected/O CgPDR1/O GOF/O mutants/O with/O murine/O bone/O marrow/O -/O derived/O macrophages/O and/O human/O acute/O monocytic/O leukemia/O cell/O line/O (/O THP-1)-derived/O macrophages/O ,/O as/O well/O as/O different/O epithelial/O cell/O lines/O ./O
GOF/O mutations/B-Var in/O CgPDR1/B-Gene did/O not/O influence/O survival/O and/O replication/O within/O macrophages/O following/O phagocytosis/O but/O led/O to/O decreased/B-NegReg adherence/B-CPA to/I-CPA and/I-CPA uptake/I-CPA by/I-CPA macrophages/I-CPA ./O
This/O may/O allow/O evasion/O from/O the/O host/O 's/O innate/O cellular/O immune/O response/O ./O
The/O interaction/O with/O epithelial/O cells/O revealed/O an/O opposite/O trend/O ,/O suggesting/O that/O GOF/O mutations/B-Var in/O CgPDR1/B-Gene may/O favor/B-PosReg epithelial/B-CPA colonization/I-CPA of/O the/O host/O by/O C./O glabrata/O through/O increased/B-PosReg adherence/B-CPA to/O epithelial/O cell/O layers/O ./O
These/O data/O reveal/O that/O GOF/O mutations/B-Var in/O CgPDR1/B-Gene modulate/B-Reg the/O interaction/B-Interaction with/O host/O cells/O in/O ways/O that/O may/O contribute/O to/O increased/B-PosReg virulence/B-MPA ./O
Mutant/O p53/O prolongs/O NF/O -/O κB/O activation/O and/O promotes/O chronic/O inflammation/O and/O inflammation/O -/O associated/O colorectal/O cancer/O ./O
The/O tumor/O suppressor/O p53/O is/O frequently/O mutated/O in/O human/O cancer/O ./O
Common/O mutant/O p53/O (/O mutp53/O )/O isoforms/O can/O actively/O promote/O cancer/O through/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mechanisms/O ./O
We/O report/O that/O mutp53/O prolongs/O TNF/O -/O α/O -/O induced/O NF/O -/O κB/O activation/O in/O cultured/O cells/O and/O intestinal/O organoid/O cultures/O ./O
Remarkably/O ,/O when/O exposed/O to/O dextran/O sulfate/O sodium/O ,/O mice/O harboring/O a/O germline/O p53/O mutation/O develop/O severe/O chronic/O inflammation/O and/O persistent/O tissue/O damage/O ,/O and/O are/O highly/O prone/O to/O inflammation/O -/O associated/O colon/O cancer/O ./O
This/O mutp53/O GOF/O is/O manifested/O by/O rapid/O onset/O of/O flat/O dysplastic/O lesions/O that/O progress/B-PosReg to/O invasive/B-Disease carcinoma/I-Disease with/O mutp53/B-Var accumulation/B-PosReg and/O augmented/O NF/B-Protein -/I-Protein κB/I-Protein activation/B-PosReg ,/O faithfully/O recapitulating/O features/O frequently/O observed/O in/O human/O colitis/B-Disease -/I-Disease associated/I-Disease colorectal/I-Disease cancer/I-Disease (/O CAC/O )/O ./O
These/O findings/O might/O explain/O the/O early/O appearance/O of/O p53/O mutations/O in/O human/O CAC/O ./O
Clinical/O relevance/O of/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var of/O p53/B-Gene in/O high/B-Disease -/I-Disease grade/I-Disease serous/I-Disease ovarian/I-Disease carcinoma/I-Disease ./O
PURPOSE/O :/O Inactivation/O of/O TP53/O ,/O which/O occurs/O predominantly/O by/O missense/O mutations/O in/O exons/O 4/O -/O 9/O ,/O is/O a/O major/O genetic/O alteration/O in/O a/O subset/O of/O human/O cancer/O ./O
In/O spite/O of/O growing/O evidence/O that/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var of/O p53/B-Gene also/O have/O oncogenic/B-CPA activity/I-CPA ,/O little/O is/O known/O about/O the/O clinical/O relevance/O of/O these/O mutations/O ./O
METHODS/O :/O The/O clinicopathological/O features/O of/O high/O -/O grade/O serous/O ovarian/O carcinoma/O (/O HGS/O -/O OvCa/O )/O patients/O with/O GOF/O p53/O mutations/O were/O evaluated/O according/O to/O a/O comprehensive/O somatic/O mutation/O profile/O comprised/O of/O whole/O exome/O sequencing/O ,/O mRNA/O expression/O ,/O and/O protein/O expression/O profiles/O obtained/O from/O the/O Cancer/O Genome/O Atlas/O (/O TCGA/O )/O ./O
RESULTS/O :/O Patients/O with/O a/O mutant/O p53/B-Protein protein/I-Protein (/O mutp53/O )/O with/O a/O GOF/O mutation/B-Var showed/O higher/B-PosReg p53/B-MPA mRNA/I-MPA and/I-MPA protein/I-MPA expression/I-MPA levels/I-MPA than/O patients/O with/O p53/O mutation/O with/O no/O evidence/O of/O GOF/O (/O NE/O -/O GOF/O )/O ./O
GOF/O mutations/O were/O more/O likely/O to/O occur/O within/O mutational/O hotspots/O ,/O and/O at/O CpG/O sites/O ,/O and/O resulted/O in/O mutp53/O with/O higher/O functional/O severity/O (/O FS/O )/O scores/O ./O
Clinically/O ,/O patients/O with/O GOF/O mutations/B-Var showed/O a/O higher/B-PosReg frequency/O of/O platinum/B-CPA resistance/I-CPA (/O 22/58/O ,/O 37.9/O %/O )/O than/O patients/O with/O NE/O -/O GOF/O mutations/O (/O 12/56/O ,/O 21.4/O %/O )/O (/O p=0.054/O )/O ./O
Furthermore/O ,/O patients/O with/O GOF/O mutations/B-Var were/O more/O likely/O to/O develop/B-PosReg distant/B-CPA metastasis/I-CPA (/O 36/55/O ,/O 65.5/O %/O )/O than/O local/O recurrence/O (/O 19/55/O ,/O 34.5/O %/O )/O ,/O whereas/O patients/O with/O NE/O -/O GOF/O mutations/O showed/O a/O higher/O frequency/O of/O locoregional/O recurrence/O (/O 26/47/O ,/O 55.3/O %/O )/O than/O distant/O metastasis/O (/O 21/47/O ,/O 44.7/O %/O )/O (/O p=0.035/O )/O ./O
There/O were/O no/O differences/O in/O overall/O or/O progression/O -/O free/O survival/O between/O patients/O with/O GOF/O or/O NE/O -/O GOF/O mutp53/O ./O
CONCLUSION/O :/O This/O study/O demonstrates/O that/O patient/O with/O GOF/B-PosReg mutp53/B-Var is/O characterized/O by/O a/O greater/B-PosReg likelihood/O of/O platinum/B-CPA treatment/I-CPA resistance/I-CPA and/O distant/B-CPA metastatic/I-CPA properties/I-CPA in/O HGS/B-Disease -/I-Disease OvCa/I-Disease ./O
Spliced/O MDM2/O isoforms/O promote/O mutant/O p53/O accumulation/O and/O gain/O -/O of/O -/O function/O in/O tumorigenesis/O ./O
The/O tumour/O suppressor/O p53/O is/O frequently/O mutated/O in/O tumours/O ./O
Mutant/B-Var p53/B-Protein (/O Mutp53/O )/O proteins/O often/O gain/B-PosReg new/I-PosReg activities/I-PosReg in/O promoting/B-CPA tumorigenesis/I-CPA ,/O defined/O as/O gain/O -/O of/O -/O function/O (/O GOF/O )/O ./O
Mutp53/O can/O accumulate/O to/O high/O levels/O in/O tumours/O ,/O which/O promotes/O mutp53/B-Var GOF/B-PosReg in/O tumorigenesis/B-CPA ./O
The/O mechanism/O of/O mutp53/O accumulation/O is/O poorly/O understood/O ./O
Here/O we/O find/O that/O MDM2/O isoforms/O promote/O mutp53/O accumulation/O in/O tumours/O ./O
MDM2/O isoform/O B/O (/O MDM2-B/O )/O ,/O the/O MDM2/O isoform/O most/O frequently/O over/O -/O expressed/O in/O human/O tumours/O ,/O interacts/O with/O full/O -/O length/O MDM2/O to/O inhibit/O MDM2-mediated/O mutp53/O degradation/O ,/O promoting/O mutp53/O accumulation/O and/O GOF/O in/O tumorigenesis/O ./O
Furthermore/O ,/O MDM2-B/O overexpression/O correlates/O with/O mutp53/O accumulation/O in/O human/O tumours/O ./O
In/O mutp53/O knock/O -/O in/O mice/O ,/O a/O MDM2/O isoform/O similar/O to/O human/O MDM2-B/O is/O overexpressed/O in/O the/O majority/O of/O tumours/O ,/O which/O promotes/O mutp53/O accumulation/O and/O tumorigenesis/O ./O
Thus/O ,/O overexpression/O of/O MDM2/O isoforms/O promotes/O mutp53/O accumulation/O in/O tumours/O ,/O contributing/O to/O mutp53/B-Var GOF/B-PosReg in/O tumorigenesis/B-CPA ./O
This/O may/O be/O an/O important/O mechanism/O by/O which/O MDM2/O isoforms/O promote/O tumorigenesis/O ./O
Mutant/B-Var p53/B-Gene gain/B-PosReg of/I-PosReg function/I-PosReg can/O be/O at/O the/O root/O of/O dedifferentiation/O of/O human/B-Disease osteosarcoma/I-Disease MG63/O cells/O into/O 3AB/O -/O OS/O cancer/O stem/O cells/O ./O
Osteosarcoma/O is/O a/O highly/O metastatic/O tumor/O affecting/O adolescents/O ,/O for/O which/O there/O is/O no/O second/O -/O line/O chemotherapy/O ./O
As/O suggested/O for/O most/O tumors/O ,/O its/O capability/O to/O overgrow/O is/O probably/O driven/O by/O cancer/O stem/O cells/O (/O CSCs/O )/O ,/O and/O finding/O new/O targets/O to/O kill/O CSCs/O may/O be/O critical/O for/O improving/O patient/O survival/O ./O
TP53/O is/O the/O most/O frequently/O mutated/O tumor/O suppressor/O gene/O in/O cancers/O and/O mutant/O p53/O protein/O (/O mutp53/O )/O can/O acquire/O gain/O of/O function/O (/O GOF/O )/O strongly/O contributing/O to/O malignancy/O ./O
Studies/O thus/O far/O have/O not/O shown/O p53-GOF/O in/O osteosarcoma/O ./O
Here/O ,/O we/O investigated/O TP53/O gene/O status/O //O role/O in/O 3AB/O -/O OS/O cells/O -/O a/O highly/O aggressive/O CSC/O line/O previously/O selected/O from/O human/O osteosarcoma/O MG63/O cells/O -/O to/O evaluate/O its/O involvement/O in/O promoting/O proliferation/O ,/O invasiveness/O ,/O resistance/O to/O apoptosis/O and/O stemness/O ./O
By/O RT/O -/O PCR/O ,/O methylation/O -/O specific/O PCR/O ,/O fluorescent/O in/O situ/O hybridization/O ,/O DNA/O sequence/O ,/O western/O blot/O and/O immunofluorescence/O analyses/O ,/O we/O have/O shown/O that/O -/O in/O comparison/O with/O parental/O MG63/O cells/O where/O TP53/O gene/O is/O hypermethylated/O ,/O rearranged/O and/O in/O single/O copy/O -/O in/O 3AB/O -/O OS/O cells/O ,/O TP53/O is/O unmethylated/O ,/O rearranged/O and/O in/O multiple/O copies/O ,/O and/O mutp53/O (/O p53-R248W/O //O P72R/O )/O is/O post/O -/O translationally/O modified/O and/O with/O nuclear/O localization/O ./O
p53-R248W/O //O P72R/O -/O knockdown/O by/O short/O -/O interfering/O RNA/O reduced/O the/O growth/O and/O replication/O rate/O of/O 3AB/O -/O OS/O cells/O ,/O markedly/O increasing/O cell/O cycle/O inhibitor/O levels/O and/O sensitized/O 3AB/O -/O OS/O cells/O to/O TRAIL/O -/O induced/O apoptosis/O by/O DR5/O up/O -/O regulation/O ;/O moreover/O ,/O it/O strongly/O decreased/O the/O levels/O of/O stemness/O and/O invasiveness/O genes/O ./O
We/O have/O also/O found/O that/O the/O ectopic/O expression/O of/O p53-R248W/B-Var //I-Var P72R/I-Var in/O MG63/O cells/O promoted/B-PosReg cancer/B-CPA stem/I-CPA -/I-CPA like/I-CPA features/I-CPA ,/O as/O high/B-CPA proliferation/I-CPA rate/I-CPA ,/O sphere/B-CPA formation/I-CPA ,/O clonogenic/B-CPA growth/I-CPA ,/O high/B-CPA migration/I-CPA and/O invasive/B-CPA ability/I-CPA ;/I-CPA furthermore/O ,/O it/O strongly/O increased/B-PosReg the/O levels/B-MPA of/I-MPA stemness/I-MPA proteins/I-MPA ./O
Overall/O ,/O the/O findings/O suggest/O the/O involvement/B-Reg of/O p53-R248W/B-Var //I-Var P72R/I-Var at/O the/O origin/B-CPA of/I-CPA the/I-CPA aberrant/I-CPA characters/I-CPA of/I-CPA the/I-CPA 3AB/I-CPA -/I-CPA OS/I-CPA cells/I-CPA with/O the/O hypothesis/O that/O its/O GOF/O can/O be/O at/O the/O root/O of/O the/O dedifferentiation/O of/O MG63/O cells/O into/O CSCs/O ./O
Unequal/O prognostic/O potentials/O of/O p53/O gain/O -/O of/O -/O function/O mutations/O in/O human/O cancers/O associate/O with/O drug/O -/O metabolizing/O activity/O ./O
Mutation/O of/O p53/O is/O the/O most/O common/O genetic/O change/O in/O human/O cancer/O ,/O causing/O complex/O effects/O including/O not/O only/O loss/O of/O wild/O -/O type/O function/O but/O also/O gain/O of/O novel/O oncogenic/O functions/O (/O GOF/O )/O ./O
It/O is/O increasingly/O likely/O that/O p53-hotspot/O mutations/O may/O confer/O different/O types/O and/O magnitudes/O of/O GOF/O ,/O but/O the/O evidences/O are/O mainly/O supported/O by/O cellular/O and/O transgenic/O animal/O models/O ./O
Here/O we/O combine/O large/O -/O scale/O cancer/O genomic/O data/O to/O characterize/O the/O prognostic/O significance/O of/O different/O p53/O mutations/O in/O human/O cancers/O ./O
Unexpectedly/O ,/O only/O mutations/O on/O the/O Arg248/O and/O Arg282/O positions/O displayed/O significant/O association/O with/O shorter/O patient/O survival/O ,/O but/O such/O association/O was/O not/O evident/O for/O other/O hotspot/O GOF/O mutations/O ./O
Gene/O set/O enrichment/O analysis/O on/O these/O mutations/B-Var revealed/O higher/B-PosReg activity/B-MPA of/O drug/B-Enzyme -/I-Enzyme metabolizing/I-Enzyme enzymes/I-Enzyme ,/O including/O the/O CYP3A4/B-Enzyme cytochrome/I-Enzyme P450/I-Enzyme ./O
Ectopic/B-MPA expression/I-MPA of/O p53/B-Gene mutant/B-Var R282W/I-Var in/O H1299/O and/O SaOS2/O cells/O significantly/O upregulated/B-PosReg CYP3A4/B-MPA mRNA/I-MPA and/I-MPA protein/I-MPA levels/I-MPA ,/O and/O cancer/O cell/O lines/O bearing/O mortality/O -/O associated/O p53/B-Gene mutations/B-Var display/O higher/B-PosReg CYP3A4/B-Enzyme expression/B-MPA and/O resistance/B-CPA to/O several/O CYP3A4-metabolized/O chemotherapeutic/O drugs/O ./O
Our/O results/O suggest/O that/O p53/O mutations/O have/O unequal/O GOF/O activities/O in/O human/O cancers/O ,/O and/O future/O evaluation/O of/O p53/O as/O a/O cancer/O biomarker/O should/O consider/O which/O mutation/O is/O present/O in/O the/O tumor/O ,/O rather/O than/O having/O comparison/O between/O wild/O -/O type/O and/O mutant/O genotypes/O ./O
Disruption/O of/O the/O temporally/O regulated/O cloaca/O endodermal/O β/O -/O catenin/O signaling/O causes/O anorectal/O malformations/O ./O
The/O cloaca/O is/O temporally/O formed/O and/O eventually/O divided/O by/O the/O urorectal/O septum/O (/O URS/O )/O during/O urogenital/O and/O anorectal/O organ/O development/O ./O
Although/O congenital/O malformations/O ,/O such/O as/O anorectal/B-Disease malformations/I-Disease (/O ARMs/O )/O ,/O are/O frequently/O observed/O during/O this/O process/O ,/O the/O underlying/O pathogenic/O mechanisms/O remain/O unclear/O ./O
β/O -/O Catenin/O is/O a/O critical/O component/O of/O canonical/O Wnt/O signaling/O and/O is/O essential/O for/O the/O regulation/O of/O cell/O differentiation/O and/O morphogenesis/O during/O embryogenesis/O ./O
The/O expression/O of/O β/O -/O catenin/O is/O observed/O in/O endodermal/O epithelia/O ,/O including/O URS/O epithelia/O ./O
We/O modulated/O the/O β/O -/O catenin/O gene/O conditionally/O in/O endodermal/O epithelia/O by/O utilizing/O tamoxifen/O -/O inducible/O Cre/O driver/O line/O (/O Shh(CreERT2/O )/O )/O ./O
Both/O β/B-Protein -/I-Protein catenin/I-Protein loss-/B-NegReg and/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O LOF/O and/O GOF/O )/O mutants/B-Var displayed/O abnormal/O clefts/B-CPA in/I-CPA the/I-CPA perineal/I-CPA region/I-CPA and/O hypoplastic/B-CPA elongation/I-CPA of/I-CPA the/I-CPA URS/I-CPA ./O
The/O mutants/B-Var also/O displayed/O reduced/B-NegReg cell/B-CPA proliferation/I-CPA in/I-CPA the/I-CPA URS/I-CPA mesenchyme/I-CPA ./O
In/O addition/O ,/O the/O β/B-Protein -/I-Protein catenin/I-Protein GOF/O mutants/B-Var displayed/O reduced/O apoptosis/O and/O subsequently/O increased/O apoptosis/O in/O the/O URS/O epithelium/O ./O
This/O instability/O possibly/O resulted/O in/O reduced/B-NegReg expression/B-MPA levels/I-MPA of/O differentiation/O markers/O ,/O such/O as/O keratin/B-Protein 1/I-Protein and/O filaggrin/B-Protein ,/O in/O the/O perineal/O epithelia/O ./O
The/O expression/B-MPA of/O bone/B-Gene morphogenetic/I-Gene protein/I-Gene (/I-Gene Bmp/I-Gene )/I-Gene genes/I-Gene ,/O such/O as/O Bmp4/B-Gene and/O Bmp7/B-Gene ,/O was/O also/O ectopically/O induced/B-PosReg in/O the/O epithelia/O of/O the/O URS/O in/O the/O β/B-Protein -/I-Protein catenin/I-Protein GOF/O mutants/B-Var ./O
The/O expression/B-MPA of/O the/O Msx2/B-Gene gene/I-Gene and/O phosphorylated/O -/O Smad1/5/8/O ,/O possible/O readouts/B-MPA of/I-MPA Bmp/I-MPA signaling/I-MPA ,/O was/O also/O increased/B-PosReg in/O the/O mutants/B-Var ./O
Moreover/O ,/O we/O introduced/O an/O additional/O mutation/O for/O a/O Bmp/O receptor/O gene/O :/O BmprIA/O ./O
The/O Shh(CreERT2/+/O )/O ;/O β/O -/O catenin(flox(ex3)/+/O )/O ;/O BmprIA(flox/-/O )/O mutants/O displayed/O partial/O restoration/O of/O URS/O elongation/O compared/O with/O the/O β/O -/O catenin/O GOF/O mutants/O ./O
These/O results/O indicate/O that/O some/O ARM/B-Disease phenotypes/O in/O the/O β/B-Protein -/I-Protein catenin/I-Protein GOF/B-PosReg mutants/B-Var were/O caused/B-Reg by/I-Reg abnormal/O Bmp/B-MPA signaling/I-MPA ./O
The/O current/O analysis/O revealed/O the/O close/O relation/O of/O endodermal/O β/O -/O catenin/O signaling/O to/O the/O ARM/O phenotypes/O ./O
These/O results/O are/O considered/O to/O shed/O light/O on/O the/O pathogenic/O mechanisms/O of/O human/O ARMs/O ./O
Dysregulation/O of/O Wnt/O inhibitory/O factor/O 1/O (/O Wif1/O )/O expression/O resulted/O in/O aberrant/O Wnt/O -/O β/O -/O catenin/O signaling/O and/O cell/O death/O of/O the/O cloaca/O endoderm/O ,/O and/O anorectal/O malformations/O ./O
In/O mammalian/O urorectal/O development/O ,/O the/O urorectal/O septum/O (/O urs/O )/O descends/O from/O the/O ventral/O body/O wall/O to/O the/O cloaca/O membrane/O (/O cm/O )/O to/O partition/O the/O cloaca/O into/O urogenital/O sinus/O and/O rectum/O ./O
Defective/O urs/O growth/O results/O in/O human/O congenital/O anorectal/O malformations/O (/O ARMs/O )/O ,/O and/O their/O pathogenic/O mechanisms/O are/O unclear/O ./O
Recent/O studies/O only/O focused/O on/O the/O importance/O of/O urs/O mesenchyme/O proliferation/O ,/O which/O is/O induced/O by/O endoderm/O -/O derived/O Sonic/O Hedgehog/O (/O Shh/O )/O ./O
Here/O ,/O we/O showed/O that/O the/O programmed/O cell/O death/O of/O the/O apical/O urs/O and/O proximal/O cm/O endoderm/O is/O particularly/O crucial/O for/O the/O growth/O of/O urs/O during/O septation/O ./O
The/O apoptotic/O endoderm/O was/O closely/O associated/O with/O the/O tempo/O -/O spatial/O expression/O of/O Wnt/O inhibitory/O factor/O 1/O (/O Wif1/O )/O ,/O which/O is/O an/O inhibitor/O of/O Wnt/O -/O β/O -/O catenin/O signaling/O ./O
In/O Wif1(lacZ/O //O lacZ/O )/O mutant/O mice/O and/O cultured/O urorectum/O with/O exogenous/O Wif1/O ,/O cloaca/O septation/O was/O defective/O with/O undescended/O urs/O and/O hypospadias/O -/O like/O phenotypes/O ,/O and/O such/O septation/O defects/O were/O also/O observed/O in/O Shh(-/-/O )/O mutants/O and/O in/O endodermal/O β/O -/O catenin/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutants/O ./O
In/O addition/O ,/O Wif1/O and/O Shh/O were/O expressed/O in/O a/O complementary/O manner/O in/O the/O cloaca/O endoderm/O ,/O and/O Wif1/O was/O ectopically/O expressed/O in/O the/O urs/O and/O cm/O associated/O with/O excessive/O endodermal/O apoptosis/O and/O septation/O defects/O in/O Shh(-/-/O )/O mutants/O ./O
Furthermore/O ,/O apoptotic/B-CPA cells/I-CPA were/O markedly/O reduced/B-NegReg in/O the/O endodermal/B-Protein β/I-Protein -/I-Protein catenin/I-Protein GOF/B-PosReg mutant/B-Var embryos/O ,/O which/O counteracted/O the/O inhibitory/O effects/O of/O Wif1/O ./O
Taken/O altogether/O ,/O these/O data/O suggest/O that/O regulated/O expression/O of/O Wif1/O is/O critical/O for/O the/O growth/O of/O the/O urs/O during/O cloaca/O septation/O ./O
Hence/O ,/O Wif1/O governs/O cell/O apoptosis/O of/O urs/O endoderm/O by/O repressing/O β/O -/O catenin/O signal/O ,/O which/O may/O facilitate/O the/O protrusion/O of/O the/O underlying/O proliferating/O mesenchymal/O cells/O towards/O the/O cm/O for/O cloaca/O septation/O ./O
Dysregulation/O of/O this/O endodermal/O Shh/O -/O Wif1-β/O -/O catenin/O signaling/O axis/O contributes/O to/O ARM/O pathogenesis/O ./O
Significance/O of/O the/O melanocortin/O 1/O receptor/O in/O the/O DNA/O damage/O response/O of/O human/O melanocytes/O to/O ultraviolet/O radiation/O ./O
Activation/O of/O the/O melanocortin/O 1/O receptor/O (/O MC1R/O )/O by/O α/O -/O melanocortin/O (/O α/O -/O MSH/O )/O stimulates/O eumelanin/O synthesis/O and/O enhances/O repair/O of/O ultraviolet/O radiation/O (/O UV)-induced/O DNA/O damage/O ./O
We/O report/O on/O the/O DNA/O damage/O response/O (/O DDR/O )/O of/O human/O melanocytes/O to/O UV/O and/O its/O enhancement/O by/O α/O -/O MSH/O ./O
α/O -/O MSH/O up/O -/O regulated/O the/O levels/O of/O XPC/O ,/O the/O enzyme/O that/O recognizes/O DNA/O damage/O sites/O ,/O enhanced/O the/O UV/O -/O induced/O phosphorylation/O of/O the/O DNA/O damage/O sensors/O ataxia/O telangiectasia/O and/O Rad3-related/O (/O ATR/O )/O and/O ataxia/O telangiectasia/O mutated/O (/O ATM/O )/O and/O their/O respect/O -/O ive/O substrates/O checkpoint/O kinases/O 1/O and/O 2/O ,/O and/O increased/O phosphorylated/O H2AX/O (/O γH2AX/O )/O formation/O ./O
These/O effects/O required/O functional/O MC1R/O and/O were/O absent/O in/O melanocytes/O expressing/O loss/O of/O function/O (/O LOF/O )/O MC1R./O The/O levels/O of/O wild/O -/O type/O p53-induced/O phosphatase/O 1/O (/O Wip1/O )/O ,/O which/O dephosphorylates/O γH2AX/O ,/O correlated/O inversely/O with/O γH2AX/O ./O
We/O propose/O that/O α/O -/O MSH/O increases/O UV/O -/O induced/O γH2AX/O to/O facilitate/O formation/O of/O DNA/O repair/O complexes/O and/O repair/O of/O DNA/O photoproducts/O ,/O and/O LOF/B-Var of/O MC1R/B-Protein compromises/B-NegReg the/O DDR/B-MPA and/O genomic/B-CPA stability/I-CPA of/I-CPA melanocytes/I-CPA ./O
Assessing/O the/O functional/O consequence/O of/O loss/O of/O function/O variants/O using/O electronic/O medical/O record/O and/O large/O -/O scale/O genomics/O consortium/O efforts/O ./O
Estimates/O from/O large/O scale/O genome/O sequencing/O studies/O indicate/O that/O each/O human/O carries/O up/O to/O 20/O genetic/O variants/O that/O are/O predicted/O to/O results/O in/O loss/O of/O function/O (/O LOF/O )/O of/O protein/O -/O coding/O genes/O ./O
While/O some/O are/O known/O disease/O -/O causing/O variants/O or/O common/O ,/O tolerated/O ,/O LOFs/O in/O non/O -/O essential/O genes/O ,/O the/O majority/O remain/O of/O unknown/O consequence/O ./O
We/O explore/O the/O possibility/O of/O using/O imputed/O GWAS/O data/O from/O large/O biorepositories/O such/O as/O the/O electronic/O medical/O record/O and/O genomics/O (/O eMERGE/O )/O consortium/O to/O determine/O the/O effects/O of/O rare/O LOFs/O ./O
Here/O ,/O we/O show/O that/O two/O hypocholesterolemia/B-Disease -/I-Disease associated/I-Disease LOF/B-NegReg mutations/B-Var in/O the/O PCSK9/B-Gene gene/O can/O be/O accurately/O imputed/O into/O large/O -/O scale/O GWAS/O datasets/O which/O raises/O the/O possibility/O of/O assessing/O LOFs/O through/O genomics/O -/O linked/O medical/O records/O ./O
PDGF/O ,/O pericytes/O and/O the/O pathogenesis/O of/O idiopathic/O basal/O ganglia/O calcification/O (/O IBGC/O )/O ./O
Platelet/O -/O derived/O growth/O factors/O (/O PDGFs/O )/O are/O important/O mitogens/O for/O various/O types/O of/O mesenchymal/O cells/O ,/O and/O as/O such/O ,/O they/O exert/O critical/O functions/O during/O organogenesis/O in/O mammalian/O embryonic/O and/O early/O postnatal/O development/O ./O
Increased/O or/O ectopic/B-Var PDGF/B-Protein activity/B-MPA may/O also/O cause/B-Reg or/O contribute/B-Reg to/O diseases/O such/O as/O cancer/B-Disease and/O tissue/B-Disease fibrosis/I-Disease ./O
Until/O recently/O ,/O no/O loss/O -/O of/O -/O function/O (/O LOF/O )/O mutations/O in/O PDGF/O or/O PDGF/O receptor/O genes/O were/O reported/O as/O causally/O linked/O to/O a/O human/O disease/O ./O
This/O changed/O in/O 2013/O when/O reports/O appeared/O on/O presumed/O LOF/B-NegReg mutations/B-Var in/O the/O genes/O encoding/O PDGF/B-Gene -/I-Gene B/I-Gene and/O its/O receptor/O PDGF/O receptor/O -/O beta/O (/B-Gene PDGF/I-Gene -/I-Gene Rβ/I-Gene )/I-Gene in/O familial/B-Disease idiopathic/I-Disease basal/I-Disease ganglia/I-Disease calcification/I-Disease (/O IBGC/O )/O ,/O a/O brain/O disease/O characterized/O by/O anatomically/O localized/O calcifications/O in/O or/O near/O the/O blood/O microvessels/O ./O
Here/O ,/O we/O review/O PDGF/O -/O B/O and/O PDGF/O -/O Rβ/O biology/O with/O special/O reference/O to/O their/O functions/O in/O brain/O -/O blood/O vessel/O development/O ,/O pericyte/O recruitment/O and/O the/O regulation/O of/O the/O blood/O -/O brain/O barrier/O ./O
We/O also/O discuss/O various/O scenarios/O for/O IBGC/O pathogenesis/O suggested/O by/O observations/O in/O patients/O and/O genetically/O engineered/O animal/O models/O of/O the/O disease/O ./O
Mutant/B-Var p53/B-Gene gains/O new/O function/O in/O promoting/B-PosReg inflammatory/B-MPA signals/I-MPA by/O repression/B-NegReg of/O the/O secreted/O interleukin-1/O receptor/O antagonist/O ./O
The/O TP53/B-Gene tumor/I-Gene -/I-Gene suppressor/I-Gene gene/I-Gene is/O frequently/O mutated/O in/O human/O cancer/O ./O
Missense/B-Var mutations/I-Var can/O add/O novel/O functions/O (/O gain/O -/O of/O -/O function/O ,/O GOF/O )/O that/O promote/B-PosReg tumor/B-CPA malignancy/I-CPA ./O
Here/O we/O report/O that/O mutant/B-Var (/O mut/O )/O p53/B-Gene promotes/B-PosReg tumor/B-CPA malignancy/I-CPA by/O suppressing/B-NegReg the/O expression/B-MPA of/O a/O natural/O occurring/O anti/O -/O inflammatory/O cytokine/O ,/O the/O secreted/O interleukin-1/O receptor/O antagonist/O (/O sIL-1Ra/O ,/O IL1RN/O )/O ./O
We/O show/O that/O mutp53/B-Var but/O not/O wild/O -/O type/O (/O wt/O )/O p53/O suppresses/B-NegReg the/O sIL-1Ra/B-MPA production/I-MPA in/O conditioned/O media/O of/O cancer/O cells/O ./O
Moreover/O ,/O mutp53/O ,/O but/O not/O wtp53/O ,/O binds/O physically/O the/O sIL-1Ra/O promoter/O and/O the/O protein/O -/O protein/O interaction/O with/O the/O transcriptional/O co/O -/O repressor/O MAFF/O (/O v/O -/O MAF/O musculoaponeurotic/O fibrosarcoma/O oncogene/O family/O ,/O protein/O F/O )/O is/O required/O for/O mutp53-induced/O sIL-1Ra/O suppression/O ./O
Remarkably/O ,/O when/O exposed/O to/O IL-1/O beta/O (/O IL-1β/O )/O inflammatory/O stimuli/O ,/O mutp53/O sustains/O a/O ready/O -/O to/O -/O be/O -/O activated/O in/O vitro/O and/O in/O vivo/O cancer/O cells/O '/O response/O through/O the/O sIL-1Ra/O repression/O ./O
Taken/O together/O ,/O these/O results/O identify/O sIL-1Ra/O as/O a/O novel/O mutp53/O target/O gene/O ,/O whose/O suppression/O might/O be/O required/O to/O generate/O a/O chronic/O pro/O -/O inflammatory/O tumor/O microenvironment/O through/O which/O mutp53/O promotes/O tumor/O malignancy/O ./O
Rare/O variants/O in/O PPARG/O with/O decreased/O activity/O in/O adipocyte/O differentiation/O are/O associated/O with/O increased/O risk/O of/O type/O 2/O diabetes/O ./O
Peroxisome/O proliferator/O -/O activated/O receptor/O gamma/O (/O PPARG/O )/O is/O a/O master/O transcriptional/O regulator/O of/O adipocyte/O differentiation/O and/O a/O canonical/O target/O of/O antidiabetic/O thiazolidinedione/O medications/O ./O
In/O rare/O families/O ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O mutations/B-Var in/O PPARG/B-Gene are/O known/O to/O cosegregate/O with/O lipodystrophy/B-Disease and/O insulin/B-Disease resistance/I-Disease ;/I-Disease in/O the/O general/O population/O ,/O the/O common/O P12A/B-Var variant/O is/O associated/O with/O a/O decreased/B-NegReg risk/O of/O type/B-Disease 2/I-Disease diabetes/I-Disease (/O T2D/O )/O ./O
Whether/O and/O how/O rare/O variants/O in/O PPARG/O and/O defects/O in/O adipocyte/O differentiation/O influence/O risk/O of/O T2D/O in/O the/O general/O population/O remains/O undetermined/O ./O
By/O sequencing/O PPARG/O in/O 19,752/O T2D/O cases/O and/O controls/O drawn/O from/O multiple/O studies/O and/O ethnic/O groups/O ,/O we/O identified/O 49/O previously/O unidentified/O ,/O nonsynonymous/O PPARG/O variants/O (/O MAF/O </O 0.5/O %/O )/O ./O
Considered/O in/O aggregate/O (/O with/O or/O without/O computational/O prediction/O of/O functional/O consequence/O )/O ,/O these/O rare/O variants/O showed/O no/O association/O with/O T2D/O (/O OR/O =/O 1.35/O ;/O P/O =/O 0.17/O )/O ./O
The/O function/O of/O the/O 49/O variants/O was/O experimentally/O tested/O in/O a/O novel/O high/O -/O throughput/O human/O adipocyte/O differentiation/O assay/O ,/O and/O nine/O were/O found/O to/O have/O reduced/O activity/O in/O the/O assay/O ./O
Carrying/O any/O of/O these/O nine/O LOF/O variants/O was/O associated/O with/O a/O substantial/O increase/O in/O risk/O of/O T2D/O (/O OR/O =/O 7.22/O ;/O P/O =/O 0.005/O )/O ./O
The/O combination/O of/O large/O -/O scale/O DNA/O sequencing/O and/O functional/O testing/O in/O the/O laboratory/O reveals/O that/O approximately/O 1/O in/O 1,000/O individuals/O carries/O a/O variant/B-Var in/O PPARG/B-Gene that/O reduces/B-NegReg function/B-CPA in/I-CPA a/I-CPA human/I-CPA adipocyte/I-CPA differentiation/I-CPA assay/I-CPA and/O is/O associated/B-Reg with/O a/O substantial/O risk/O of/O T2D./B-Disease Loss/O -/O of/O -/O function/O de/O novo/O mutations/O play/O an/O important/O role/O in/O severe/O human/O neural/O tube/O defects/O ./O
BACKGROUND/O :/O Neural/B-Disease tube/I-Disease defects/I-Disease (/O NTDs/O )/O are/O very/O common/O and/O severe/O birth/O defects/O that/O are/O caused/O by/O failure/O of/O neural/O tube/O closure/O and/O that/O have/O a/O complex/O aetiology/O ./O
Anencephaly/O and/O spina/O bifida/O are/O severe/O NTDs/O that/O affect/O reproductive/O fitness/O and/O suggest/O a/O role/O for/O de/O novo/O mutations/O (/O DNMs/O )/O in/O their/O aetiology/O ./O
METHODS/O :/O We/O used/O whole/O -/O exome/O sequencing/O in/O 43/O sporadic/O cases/O affected/O with/O myelomeningocele/O or/O anencephaly/O and/O their/O unaffected/O parents/O to/O identify/O DNMs/O in/O their/O exomes/O ./O
RESULTS/O :/O We/O identified/O 42/O coding/O DNMs/O in/O 25/O cases/O ,/O of/O which/O 6/O were/O loss/O of/O function/O (/O LoF/O )/O showing/O a/O higher/O rate/O of/O LoF/O DNM/O in/O our/O cohort/O compared/O with/O control/O cohorts/O ./O
Notably/O ,/O we/O identified/O two/O protein/B-NegReg -/I-NegReg truncating/I-NegReg DNMs/B-Var in/O two/O independent/O cases/O in/O SHROOM3/B-Gene ,/O previously/O associated/O with/O NTDs/O only/O in/O animal/O models/O ./O
We/O have/O demonstrated/O a/O significant/O enrichment/O of/O LoF/B-NegReg DNMs/B-Var in/O this/O gene/O in/O NTDs/B-Disease compared/O with/O the/O gene/O specific/O DNM/O rate/O and/O to/O the/O DNM/O rate/O estimated/O from/O control/O cohorts/O ./O
We/O also/O identified/O one/O nonsense/O DNM/O in/O PAX3/O and/O two/O potentially/O causative/O missense/O DNMs/O in/O GRHL3/O and/O PTPRS/O ./O
CONCLUSIONS/O :/O Our/O study/O demonstrates/O an/O important/O role/O of/O LoF/B-NegReg DNMs/B-Var in/O the/O development/O of/O NTDs/B-Disease and/O strongly/O implicates/O SHROOM3/B-Gene in/O its/O aetiology/O ./O
Analysis/O of/O loss/O -/O of/O -/O function/O variants/O and/O 20/O risk/O factor/O phenotypes/O in/O 8,554/O individuals/O identifies/O loci/O influencing/O chronic/O disease/O ./O
A/O typical/O human/O exome/O harbors/O dozens/O of/O loss/O -/O of/O -/O function/O (/O LOF/O )/O variants/O ,/O which/O can/O lower/O disease/O risk/O factor/O levels/O and/O affect/O drug/O efficacy/O ./O
We/O hypothesized/O that/O LOF/O variants/O are/O enriched/O in/O genes/O influencing/O risk/O factor/O levels/O and/O the/O onset/O of/O common/O chronic/O diseases/O ,/O such/O as/O cardiovascular/O disease/O and/O diabetes/O ./O
To/O test/O this/O hypothesis/O ,/O we/O sequenced/O the/O exomes/O of/O 8,554/O individuals/O and/O analyzed/O the/O effects/O of/O predicted/O LOF/O variants/O on/O 20/O chronic/O disease/O risk/O factor/O phenotypes/O ./O
Analysis/O of/O this/O sample/O as/O discovery/O and/O replication/O strata/O of/O equal/O size/O verified/O two/O relationships/O in/O well/O -/O studied/O genes/O (/O PCSK9/O and/O APOC3/O )/O and/O identified/O eight/O new/O loci/O ./O
Previously/O unknown/O relationships/O included/O elevated/B-PosReg fasting/O glucose/B-MPA in/O carriers/O of/O heterozygous/O LOF/B-NegReg variation/B-Var in/O TXNDC5/B-Gene ,/O which/O encodes/O a/O biomarker/O for/O type/O 1/O diabetes/O progression/O ,/O and/O apparent/O recessive/B-NegReg effects/I-NegReg of/O C1QTNF8/B-Gene on/O serum/B-MPA magnesium/I-MPA levels/I-MPA ./O
These/O data/O demonstrate/O the/O utility/O of/O functional/O -/O variant/O annotation/O within/O a/O large/O sample/O of/O deeply/O phenotyped/O individuals/O for/O gene/O discovery/O ./O
Mutant/O p53/O -/O Heat/O Shock/O Response/O Oncogenic/O Cooperation/O :/O A/O New/O Mechanism/O of/O Cancer/O Cell/O Survival/O ./O
The/O main/O tumor/O suppressor/O function/O of/O p53/O as/O a/O "/O guardian/O of/O the/O genome/O "/O is/O to/O respond/O to/O cellular/O stress/O by/O transcriptional/O activation/O of/O apoptosis/O ,/O growth/O arrest/O ,/O or/O senescence/O in/O damaged/O cells/O ./O
Not/O surprisingly/O ,/O mutations/O in/O the/O p53/O gene/O are/O the/O most/O frequent/O genetic/O alteration/O in/O human/O cancers/O ./O
Importantly/O ,/O mutant/B-Var p53/B-Gene (/O mutp53/O )/O proteins/B-Protein not/O only/O lose/B-NegReg their/O wild/O -/O type/O tumor/B-CPA suppressor/I-CPA activity/I-CPA but/O also/O can/O actively/O promote/B-PosReg tumor/B-CPA development/I-CPA ./O
Two/O main/O mechanisms/O accounting/O for/O mutp53/B-Var proto/O -/O oncogenic/O activity/O are/O inhibition/O of/O the/O wild/O -/O type/O p53/O in/O a/O dominant/O -/O negative/O fashion/O and/O gain/B-PosReg of/O additional/O oncogenic/B-CPA activities/I-CPA known/O as/O gain/O -/O of/O -/O function/O (/O GOF/O )/O ./O
Here/O ,/O we/O discuss/O a/O novel/O mechanism/O of/O mutp53/B-Var GOF/O ,/O which/O relies/O on/O its/O oncogenic/O cooperation/O with/O the/O heat/O shock/O machinery/O ./O
This/O coordinated/O adaptive/O mechanism/O renders/O cancer/O cells/O more/B-PosReg resistant/B-CPA to/O proteotoxic/O stress/O and/O provides/O both/O ,/O a/O strong/O survival/B-CPA advantage/I-CPA to/O cancer/O cells/O and/O a/O promising/O means/O for/O therapeutic/O intervention/O ./O
Identification/O and/O functional/O characterization/O of/O natural/O human/O melanocortin/O 1/O receptor/O mutant/O alleles/O in/O Pakistani/O population/O ./O
Melanocortin/O 1/O receptor/O (/O MC1R/O )/O ,/O a/O Gs/O protein/O -/O coupled/O receptor/O of/O the/O melanocyte/O 's/O plasma/O membrane/O ,/O is/O a/O major/O determinant/O of/O skin/O pigmentation/O and/O phototype/O ./O
Upon/O activation/O by/O α/O -/O melanocyte/O stimulating/O hormone/O ,/O MC1R/O triggers/O the/O cAMP/O cascade/O to/O stimulate/O eumelanogenesis/O ./O
We/O used/O whole/O -/O exome/O sequencing/O to/O identify/O causative/O alleles/O in/O Pakistani/O families/O with/O skin/O and/O hair/O hypopigmentation/O ./O
Six/O MC1R/O mutations/O segregated/O with/O the/O phenotype/O in/O seven/O families/O ,/O including/O a/O p/O ./O Val174del/O in/O -/O frame/O deletion/O and/O a/O p/O ./O Tyr298/O */O nonsense/O mutation/O ,/O that/O were/O analyzed/O for/O function/O in/O heterologous/O HEK293/O cells/O ./O
p/B-Var ./I-Var Tyr298/I-Var */I-Var MC1R/B-Gene showed/O no/B-NegReg agonist/B-MPA -/I-MPA induced/I-MPA signaling/I-MPA to/O the/O cAMP/B-Pathway or/O ERK/B-Pathway pathways/I-Pathway ,/O nor/B-NegReg detectable/O agonist/B-Interaction binding/I-Interaction ./O
Conversely/O ,/O signaling/O was/O comparable/O for/O p/B-Var ./I-Var Val174del/I-Var and/O wild/O -/O type/O in/O HEK/O cells/O overexpressing/O the/O proteins/O ,/O but/O binding/O analysis/O suggested/O impaired/B-NegReg cell/B-MPA surface/I-MPA expression/I-MPA ./O
Flow/O cytometry/O and/O confocal/O imaging/O studies/O revealed/O reduced/B-NegReg plasma/B-MPA membrane/I-MPA expression/I-MPA of/O p/B-Var ./I-Var Val174del/I-Var and/O p/B-Var ./I-Var Tyr298/I-Var */I-Var ./O
Therefore/O ,/O p/B-Var ./I-Var Tyr298/I-Var */I-Var was/O a/O total/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O allele/O ,/O while/O p/B-Var ./I-Var Val174del/I-Var displayed/O a/O partial/B-NegReg LOF/I-NegReg attribute/O ./O
Gain/O -/O of/O -/O function/O p53/O mutants/O co/O -/O opt/O chromatin/O pathways/O to/O drive/O cancer/O growth/O ./O
TP53/O (/O which/O encodes/O p53/O protein/O )/O is/O the/O most/O frequently/O mutated/O gene/O among/O all/O human/O cancers/O ./O
Prevalent/O p53/B-Gene missense/B-Var mutations/I-Var abrogate/B-NegReg its/O tumour/B-CPA suppressive/I-CPA function/I-CPA and/O lead/O to/O a/O '/B-PosReg gain/I-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg '/I-PosReg (/O GOF/O )/O that/O promotes/B-PosReg cancer/B-Disease ./O
Here/O we/O show/O that/O p53/B-Gene GOF/B-PosReg mutants/B-Var bind/O to/O and/O upregulate/B-PosReg chromatin/B-Gene regulatory/I-Gene genes/I-Gene ,/O including/O the/O methyltransferases/B-Enzyme MLL1/I-Enzyme (/O also/O known/O as/O KMT2A/O )/O ,/O MLL2/B-Enzyme (/O also/O known/O as/O KMT2D/O )/O ,/O and/O acetyltransferase/B-Enzyme MOZ/I-Enzyme (/O also/O known/O as/O KAT6A/O or/O MYST3/O )/O ,/O resulting/O in/O genome/O -/O wide/O increases/B-PosReg of/O histone/B-MPA methylation/I-MPA and/O acetylation/B-MPA ./O
Analysis/O of/O The/O Cancer/O Genome/O Atlas/O shows/O specific/O upregulation/B-PosReg of/O MLL1/B-Enzyme ,/O MLL2/B-Enzyme ,/O and/O MOZ/B-Enzyme in/O p53/B-Gene GOF/B-Var patient/O -/O derived/O tumours/O ,/O but/O not/O in/O wild/O -/O type/O p53/O or/O p53/O null/O tumours/O ./O
Cancer/O cell/O proliferation/O is/O markedly/O lowered/O by/O genetic/O knockdown/O of/O MLL1/O or/O by/O pharmacological/O inhibition/O of/O the/O MLL1/O methyltransferase/O complex/O ./O
Our/O study/O reveals/O a/O novel/O chromatin/O mechanism/O underlying/O the/O progression/O of/O tumours/O with/O GOF/O p53/O ,/O and/O suggests/O new/O possibilities/O for/O designing/O combinatorial/O chromatin/O -/O based/O therapies/O for/O treating/O individual/O cancers/O driven/O by/O prevalent/O GOF/O p53/O mutations/O ./O
DNA/O damage/O -/O induced/O ephrin/O -/O B2/O reverse/O signaling/O promotes/O chemoresistance/O and/O drives/O EMT/O in/O colorectal/O carcinoma/O harboring/O mutant/O p53/O ./O
Mutation/O in/O the/O TP53/O gene/O positively/O correlates/O with/O increased/O incidence/O of/O chemoresistance/O in/O different/O cancers/O ./O
In/O this/O study/O ,/O we/O investigated/O the/O mechanism/O of/O chemoresistance/O and/O epithelial/O -/O to/O -/O mesenchymal/O transition/O (/O EMT/O )/O in/O colorectal/O cancer/O involving/O the/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutant/O p53/O //O ephrin/O -/O B2/O signaling/O axis/O ./O
Bioinformatic/O analysis/O of/O the/O NCI-60/O data/O set/O and/O subsequent/O hub/O prediction/O identified/O EFNB2/O as/O a/O possible/O GOF/O mutant/O p53/O target/O gene/O ,/O responsible/O for/O chemoresistance/O ./O
We/O show/O that/O the/O mutant/B-Var p53-NF/B-Gene -/I-Gene Y/I-Gene complex/O transcriptionally/O upregulates/B-PosReg EFNB2/B-Gene expression/B-MPA in/O response/B-MPA to/I-MPA DNA/I-MPA damage/I-MPA ./O
Moreover/O ,/O the/O acetylated/O form/O of/O mutant/B-Var p53/B-Gene protein/B-Protein is/O recruited/B-PosReg on/O the/O EFNB2/O promoter/O and/O positively/O regulates/B-Reg its/O expression/B-MPA in/O conjunction/O with/O coactivator/O p300/O ./O
In/O vitro/O cell/O line/O and/O in/O vivo/O nude/O mice/O data/O show/O that/O EFNB2/O silencing/O restores/O chemosensitivity/O in/O mutant/O p53-harboring/O tumors/O ./O
In/O addition/O ,/O we/O observed/O high/O expression/O of/O EFNB2/O in/O patients/O having/O neoadjuvant/O non/O -/O responder/O colorectal/O carcinoma/O compared/O with/O those/O having/O responder/O version/O of/O the/O disease/O ./O
In/O the/O course/O of/O deciphering/O the/O drug/O resistance/O mechanism/O ,/O we/O also/O show/O that/O ephrin/O -/O B2/O reverse/O signaling/O induces/B-PosReg ABCG2/B-Gene expression/B-MPA after/O drug/O treatment/O that/O involves/O JNK/B-MPA -/I-MPA c/I-MPA -/I-MPA Jun/I-MPA signaling/I-MPA in/O mutant/B-Var p53/B-Gene cells/O ./O
Moreover/O ,/O 5-fluorouracil/O -/O induced/O ephrin/O -/O B2/O reverse/O signaling/O promotes/O tumorigenesis/O through/O the/O Src/O -/O ERK/O pathway/O ,/O and/O drives/O EMT/O via/O the/O Src/O -/O FAK/O pathway/O ./O
We/O thus/O conclude/O that/O targeting/O ephrin/O -/O B2/O might/O enhance/O the/O therapeutic/O potential/O of/O DNA/O -/O damaging/O chemotherapeutic/O agents/O in/O mutant/O p53-bearing/O human/O tumors/O ./O
Cell/O Death/O and/O Differentiation/O advance/O online/O publication/O ,/O 23/O October/O 2015/O ;/O doi:10.1038/O //O cdd.2015.133/O ./O
Urine/O -/O sample/O -/O derived/O human/O induced/O pluripotent/O stem/O cells/O as/O a/O model/O to/O study/O PCSK9-mediated/O autosomal/O dominant/O hypercholesterolemia/O ./O
Proprotein/O convertase/O subtilisin/O kexin/O type/O 9/O (/O PCSK9/O )/O is/O a/O critical/O modulator/O of/O cholesterol/O homeostasis/O ./O
Whereas/O PCSK9/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var are/O associated/O with/O autosomal/B-Disease dominant/I-Disease hypercholesterolemia/I-Disease (/O ADH/O )/O and/O premature/B-Disease atherosclerosis/I-Disease ,/O PCSK9/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O mutations/B-Var have/B-PosReg a/O cardio/B-CPA -/I-CPA protective/I-CPA effect/I-CPA and/O in/O some/O cases/O can/O lead/O to/O familial/B-Disease hypobetalipoproteinemia/I-Disease (/O FHBL/O )/O ./O
However/O ,/O limitations/O of/O the/O currently/O available/O cellular/O models/O preclude/O deciphering/O the/O consequences/O of/O PCSK9/O mutation/O further/O ./O
We/O aimed/O to/O validate/O urine/O -/O sample/O -/O derived/O human/O induced/O pluripotent/O stem/O cells/O (/O UhiPSCs/O )/O as/O an/O appropriate/O tool/O to/O model/O PCSK9-mediated/O ADH/O and/O FHBL/O ./O
To/O achieve/O our/O goal/O ,/O urine/O -/O sample/O -/O derived/O somatic/O cells/O were/O reprogrammed/O into/O hiPSCs/O by/O using/O episomal/O vectors/O ./O
UhiPSC/O were/O efficiently/O differentiated/O into/O hepatocyte/O -/O like/O cells/O (/O HLCs/O )/O ./O
Compared/O to/O control/O cells/O ,/O cells/O originally/O derived/O from/O an/O individual/O with/O ADH/O (/O HLC/O -/O S127R/O )/O secreted/O less/O PCSK9/O in/O the/O media/O (/O -38.5/O %/O ;/O P=0.038/O )/O and/O had/O a/O 71/O %/O decrease/O (/O P<0.001/O )/O of/O low/O -/O density/O lipoprotein/O (/O LDL/O )/O uptake/O ,/O whereas/O cells/O originally/O derived/O from/O an/O individual/O with/O FHBL/O (/O HLC/O -/O R104C/O //O V114A/O )/O displayed/O a/O strong/O decrease/O in/O PCSK9/O secretion/O (/O -89.7/O %/O ;/O P<0.001/O )/O and/O had/O a/O 106/O %/O increase/O (/O P=0.0104/O )/O of/O LDL/O uptake/O ./O
Pravastatin/O treatment/O significantly/O enhanced/O LDL/O receptor/O (/O LDLR/O )/O and/O PCSK9/O mRNA/O gene/O expression/O ,/O as/O well/O as/O PCSK9/O secretion/O and/O LDL/O uptake/O in/O both/O control/O and/O S127R/O HLCs/O ./O
Pravastatin/O treatment/O of/O multiple/O clones/O led/O to/O an/O average/O increase/O of/O LDL/O uptake/O of/O 2.19±0.77-fold/O in/O HLC/O -/O S127R/O compared/O to/O 1.38±0.49/O fold/O in/O control/O HLCs/O (/O P<0.01/O )/O ,/O in/O line/O with/O the/O good/O response/O to/O statin/O treatment/O of/O individuals/O carrying/O the/O S127R/O mutation/O (/O mean/O LDL/O cholesterol/O reduction=60.4/O %/O ,/O n=5/O )/O ./O
In/O conclusion/O ,/O urine/O samples/O provide/O an/O attractive/O and/O convenient/O source/O of/O somatic/O cells/O for/O reprogramming/O and/O hepatocyte/O differentiation/O ,/O but/O also/O a/O powerful/O tool/O to/O further/O decipher/O PCSK9/O mutations/O and/O function/O ./O
Recurrent/O MLK4/B-Gene Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg Mutations/B-Var Suppress/B-NegReg JNK/B-Pathway Signaling/I-Pathway to/O Promote/B-PosReg Colon/B-Disease Tumorigenesis/I-Disease ./O
MLK4/O is/O a/O member/O of/O the/O mixed/O -/O lineage/O family/O of/O kinases/O that/O regulate/O the/O JNK/O ,/O p38/O ,/O and/O ERK/O kinase/O signaling/O pathways/O ./O
MLK4/O mutations/O have/O been/O identified/O in/O various/O human/O cancers/O ,/O including/O frequently/O in/O colorectal/O cancer/O ,/O where/O their/O function/O and/O pathobiological/O importance/O have/O been/O uncertain/O ./O
In/O this/O study/O ,/O we/O assessed/O the/O functional/O consequences/O of/O MLK4/O mutations/O in/O colon/O tumorigenesis/O ./O
Biochemical/O data/O indicated/O that/O a/O majority/O of/O MLK4/B-Gene mutations/B-Var are/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O mutations/O that/O can/O exert/O dominant/O -/O negative/O effects/O ./O
In/O seeking/O to/O understand/O the/O abrogated/O activity/O of/O these/O mutants/O ,/O we/O elucidated/O a/O new/O MLK4/O catalytic/O domain/O structure/O ./O
To/O determine/O whether/O MLK4/O is/O required/O to/O maintain/O tumorigenic/O phenotypes/O ,/O we/O reconstituted/O its/O signaling/O axis/O in/O colon/O cancer/O cells/O harboring/O MLK4-inactivating/O mutations/O ./O
We/O found/O that/O restoring/O MLK4/O activity/O reduced/O cell/O viability/O ,/O proliferation/O ,/O and/O colony/O formation/O in/O vitro/O and/O delayed/O tumor/O growth/O in/O vivo/O ./O
Mechanistic/O investigations/O established/O that/O restoring/O the/O function/O of/O MLK4/O selectively/O induced/O the/O JNK/O pathway/O and/O its/O downstream/O targets/O ,/O cJUN/O ,/O ATF3/O ,/O and/O the/O cyclin/O -/O dependent/O kinase/O inhibitors/O CDKN1A/O and/O CDKN2B./O Our/O work/O indicates/O that/O MLK4/B-Gene is/O a/O novel/O tumor/O -/O suppressing/O kinase/O harboring/O frequent/O LOF/B-NegReg mutations/B-Var that/O lead/O to/O diminished/B-NegReg signaling/B-MPA in/O the/O JNK/B-Pathway pathway/I-Pathway and/O enhanced/B-PosReg proliferation/B-CPA in/O colon/O cancer/O ./O
Cancer/O Res/O ;/O 76(3/O )/O ;/O 1/O -/O 12/O ./O
©/O 2015/O AACR/O ./O
Transcriptome/O profiling/O identifies/O genes/O and/O pathways/O deregulated/O upon/O floxuridine/O treatment/O in/O colorectal/O cancer/O cells/O harboring/O GOF/O mutant/O p53/O ./O
Mutation/O in/O TP53/O is/O a/O common/O genetic/O alteration/O in/O human/O cancers/O ./O
Certain/O tumor/O associated/O p53/B-Gene missense/B-Var mutants/I-Var acquire/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O properties/O and/O confer/O oncogenic/O phenotypes/O including/O enhanced/B-PosReg chemoresistance/B-CPA ./O
The/O colorectal/O cancers/O (/O CRC/O )/O harboring/O mutant/O p53/O are/O generally/O aggressive/O in/O nature/O and/O difficult/O to/O treat/O ./O
To/O identify/O a/O potential/O gene/O expression/O signature/O of/O GOF/O mutant/O p53-driven/O acquired/O chemoresistance/O in/O CRC/O ,/O we/O performed/O transcriptome/O profiling/O of/O floxuridine/O (/O FUdR/O )/O treated/O SW480/O cells/O expressing/O mutant/O p53(R273H/O )/O (/O GEO/O #/O :/O GSE77533/O )/O ./O
We/O obtained/O several/O genes/O differentially/O regulated/O between/O FUdR/O treated/O and/O untreated/O cells/O ./O
Further/O ,/O functional/O characterization/O and/O pathway/O analysis/O revealed/O significant/O enrichment/O of/O crucial/O biological/O processes/O and/O pathways/O upon/O FUdR/O treatment/O in/O SW480/O cells/O ./O
Our/O data/O suggest/O that/O in/O response/O to/O chemotherapeutics/O treatment/O ,/O cancer/O cells/O with/O GOF/B-PosReg mutant/B-Var p53/B-Gene can/O modulate/B-Reg key/B-Pathway cellular/I-Pathway pathways/I-Pathway to/O withstand/B-CPA the/I-CPA cytotoxic/I-CPA effect/I-CPA of/I-CPA the/I-CPA drugs/I-CPA ./O
The/O genes/O and/O pathways/O identified/O in/O the/O present/O study/O can/O be/O further/O validated/O and/O targeted/O for/O better/O chemotherapy/O response/O in/O colorectal/O cancer/O patients/O harboring/O mutant/O p53/O ./O
TBR1/O regulates/O autism/O risk/O genes/O in/O the/O developing/O neocortex/O ./O
Exome/O sequencing/O studies/O have/O identified/O multiple/O genes/O harboring/O de/O novo/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O variants/B-Var in/O individuals/O with/O autism/B-Disease spectrum/I-Disease disorders/I-Disease (/O ASD/O )/O ,/O including/O TBR1/B-Gene ,/O a/O master/O regulator/O of/O cortical/O development/O ./O
We/O performed/O ChIP/O -/O seq/O for/O TBR1/O during/O mouse/O cortical/O neurogenesis/O and/O show/O that/O TBR1-bound/O regions/O are/O enriched/O adjacent/O to/O ASD/O genes/O ./O
ASD/O genes/O were/O also/O enriched/O among/O genes/O that/O are/O differentially/O expressed/O in/O Tbr1/O knockouts/O ,/O which/O together/O with/O the/O ChIP/O -/O seq/O data/O ,/O suggests/O direct/O transcriptional/O regulation/O ./O
Of/O the/O nine/O ASD/O genes/O examined/O ,/O seven/O were/O misexpressed/O in/O the/O cortices/O of/O Tbr1/O knockout/O mice/O ,/O including/O six/O with/O increased/O expression/O in/O the/O deep/O cortical/O layers/O ./O
ASD/O genes/O with/O adjacent/O cortical/O TBR1/O ChIP/O -/O seq/O peaks/O also/O showed/O unusually/O low/O levels/O of/O LoF/O mutations/O in/O a/O reference/O human/O population/O and/O among/O Icelanders/O ./O
We/O then/O leveraged/O TBR1/O binding/O to/O identify/O an/O appealing/O subset/O of/O candidate/O ASD/O genes/O ./O
Our/O findings/O highlight/O a/O TBR1-regulated/O network/O of/O ASD/O genes/O in/O the/O developing/O neocortex/O that/O are/O relatively/O intolerant/O to/O LoF/O mutations/O ,/O indicating/O that/O these/O genes/O may/O play/O critical/O roles/O in/O normal/O cortical/O development/O ./O
A/O rare/O DNA/O contact/O mutation/B-Var in/O cancer/O confers/B-PosReg p53/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg and/O tumor/B-CPA cell/I-CPA survival/I-CPA via/O TNFAIP8/B-Gene induction/O ./O
The/O p53/O tumor/O suppressor/O gene/O encodes/O a/O sequence/O -/O specific/O transcription/O factor/O ./O
Mutations/B-Var in/O the/O coding/O sequence/O of/O p53/B-Gene occur/O frequently/O in/O human/O cancer/O and/O often/O result/B-Reg in/I-Reg single/O amino/O acid/O substitutions/B-Var (/O missense/O mutations/O )/O in/O the/O DNA/O binding/B-Interaction domain/O (/O DBD/O )/O ,/O blocking/B-NegReg normal/O tumor/B-CPA suppressive/I-CPA functions/I-CPA ./O
In/O addition/O to/O the/O loss/O of/O canonical/O functions/O ,/O some/O missense/B-Var mutations/I-Var in/O p53/B-Gene confer/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O activities/B-CPA to/I-CPA tumor/I-CPA cells/I-CPA ./O
While/O many/O missense/O mutations/O in/O p53/O cluster/O at/O six/O "/O hotspot/O "/O amino/O acids/O ,/O the/O majority/O of/O mutations/O in/O human/O cancer/O occur/O elsewhere/O in/O the/O DBD/O and/O at/O a/O much/O lower/O frequency/O ./O
We/O report/O here/O that/O mutations/B-Var at/I-Var K120/I-Var ,/O a/O non/O -/O hotspot/O DNA/O contact/O residue/O ,/O confer/B-PosReg p53/B-Gene with/O the/O previously/O unrecognized/O ability/B-MPA to/O bind/B-Interaction and/O activate/B-PosReg the/O transcription/B-MPA of/O the/O pro/O -/O survival/O TNFAIP8/B-Gene gene/O ./O
Mutant/O K120/O p53/O binds/O the/O TNFAIP8/O locus/O at/O a/O cryptic/O p53/O response/O element/O that/O is/O not/O occupied/O by/O wild/O -/O type/O p53/O ./O
Furthermore/O ,/O induction/O of/O TNFAIP8/O is/O critical/O for/O the/O evasion/O of/O apoptosis/O by/O tumor/O cells/O expressing/O the/O K120R/O variant/O of/O p53/O ./O
These/O findings/O identify/O induction/O of/O pro/O -/O survival/O targets/O as/O a/O mechanism/O of/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg activity/B-MPA for/O mutant/B-Var p53/B-Gene and/O will/O likely/O broaden/O our/O understanding/O of/O this/O phenomenon/O beyond/O the/O limited/O number/O of/O GOF/O activities/O currently/O reported/O for/O hotspot/O mutants/O ./O
De/O Novo/O Mutations/B-Var in/O SON/B-Gene Disrupt/O RNA/O Splicing/O of/O Genes/O Essential/O for/O Brain/O Development/O and/O Metabolism/O ,/O Causing/B-Reg an/O Intellectual/B-Disease -/I-Disease Disability/I-Disease Syndrome/I-Disease ./O
The/O overall/O understanding/O of/O the/O molecular/O etiologies/O of/O intellectual/O disability/O (/O ID/O )/O and/O developmental/O delay/O (/O DD/O )/O is/O increasing/O as/O next/O -/O generation/O sequencing/O technologies/O identify/O genetic/O variants/O in/O individuals/O with/O such/O disorders/O ./O
However/O ,/O detailed/O analyses/O conclusively/O confirming/O these/O variants/O ,/O as/O well/O as/O the/O underlying/O molecular/O mechanisms/O explaining/O the/O diseases/O ,/O are/O often/O lacking/O ./O
Here/O ,/O we/O report/O on/O an/O ID/B-Disease syndrome/I-Disease caused/O by/O de/O novo/O heterozygous/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O mutations/B-Var in/O SON/B-Gene ./O
The/O syndrome/O is/O characterized/O by/O ID/O and/or/O DD/O ,/O malformations/O of/O the/O cerebral/O cortex/O ,/O epilepsy/O ,/O vision/O problems/O ,/O musculoskeletal/O abnormalities/O ,/O and/O congenital/O malformations/O ./O
Knockdown/O of/O son/O in/O zebrafish/O resulted/O in/O severe/O malformation/O of/O the/O spine/O ,/O brain/O ,/O and/O eyes/O ./O
Importantly/O ,/O analyses/O of/O RNA/O from/O affected/O individuals/O revealed/O that/O genes/O critical/O for/O neuronal/B-CPA migration/I-CPA and/O cortex/B-CPA organization/I-CPA (/O TUBG1/O ,/O FLNA/O ,/O PNKP/O ,/O WDR62/O ,/O PSMD3/O ,/O and/O HDAC6/O )/O and/O metabolism/B-CPA (/O PCK2/O ,/O PFKL/O ,/O IDH2/O ,/O ACY1/O ,/O and/O ADA/O )/O are/O significantly/O downregulated/B-NegReg because/O of/O the/O accumulation/B-PosReg of/O mis/O -/O spliced/O transcripts/O resulting/O from/O erroneous/B-Var SON/I-Var -/I-Var mediated/I-Var RNA/I-Var splicing/I-Var ./O
Our/O data/O highlight/O SON/O as/O a/O master/O regulator/O governing/O neurodevelopment/O and/O demonstrate/O the/O importance/O of/O SON/O -/O mediated/O RNA/O splicing/O in/O human/O development/O ./O
The/O anti/B-MPA -/I-MPA adipogenic/I-MPA effect/I-MPA of/O peripheral/O blood/O mononuclear/O cells/O is/O absent/B-NegReg with/O PCSK9/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/B-Var ./O
OBJECTIVE/O :/O To/O determine/O the/O effect/O of/O (/O 1/O )/O an/O oral/O fat/O load/O and/O (/O 2/O )/O pro/O -/O protein/O convertase/O subtilisin/O //O kexin/O type/O (/O PCSK/O )/O 9/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O variant/B-Var status/O on/O the/O ability/O of/O peripheral/O blood/O mononuclear/O cells/O (/O PBMC/O )/O to/O inhibit/B-NegReg human/B-MPA adipogenesis/I-MPA ./O
METHODS/O :/O PBMC/O from/O subjects/O with/O one/O or/O more/O PCSK9/O LOF/O variants/O versus/O non/O -/O variant/O controls/O were/O compared/O in/O the/O fasting/O state/O and/O after/O an/O oral/O fat/O load/O ./O
RESULTS/O :/O Fasting/O triglyceride/O (/O TG/O )/O levels/O were/O lower/O in/O the/O LOF/O variant/O versus/O non/O -/O variant/O group/O but/O rose/O to/O the/O same/O level/O after/O the/O oral/O fat/O load/O ./O
Conditioned/O medium/O from/O PBMC/O was/O obtained/O in/O fasting/O (/O PBMC/O -/O CM/O -/O F/O )/O and/O 4-h/O postprandial/O (/O PBMC/O -/O CM/O -/O PP/O )/O states/O ./O
PBMC/O -/O CM/O -/O PP/O from/O non/O -/O variant/O controls/O inhibited/O adipogenesis/O of/O human/O preadipocytes/O more/O than/O did/O PBMC/O -/O CM/O -/O F./O In/O contrast/O ,/O PBMC/O -/O CM/O -/O F/O or/O -PP/O from/O PCSK9/B-Gene LOF/B-NegReg variant/B-Var subjects/O had/O no/O effect/O on/O adipogenesis/B-MPA ./O
After/O the/O oral/O fat/O load/O ,/O PBMC/O from/O PCSK9/B-Gene LOF/B-NegReg variant/B-Var subjects/O showed/O significant/O increases/B-PosReg in/O mRNA/B-MPA levels/I-MPA of/I-MPA interleukin-1β/I-MPA ,/O tumor/B-MPA necrosis/I-MPA factor/I-MPA -/I-MPA α/I-MPA ,/O sterol/B-MPA regulatory/I-MPA element/I-MPA binding/I-MPA protein-1c/I-MPA ,/O CD36/B-MPA ,/O and/O monocyte/O chemoattractant/O protein-1/O (/O MCP-1/O )/O ,/O only/O MCP-1/O mRNA/O levels/O increased/O in/O PBMC/O from/O non/O -/O variant/O controls/O ./O
CONCLUSIONS/O :/O The/O absence/B-NegReg of/O anti/B-MPA -/I-MPA adipogenic/I-MPA action/I-MPA of/O PBMC/O from/O PCSK9/B-Gene LOF/O variant/B-Var subjects/O points/O to/O a/O novel/B-PosReg role/I-PosReg for/O PCSK9/O in/O PBMC/O -/O adipose/O cell/O interactions/B-Interaction ./O
Atopic/O Dermatitis/O Susceptibility/O Variants/O in/O Filaggrin/O Hitchhike/O Hornerin/O Selective/O Sweep/O ./O
Human/O skin/O has/O evolved/O rapidly/O ,/O leaving/O evolutionary/O signatures/O in/O the/O genome/O ./O
The/O filaggrin/O (/B-Gene FLG/I-Gene )/I-Gene gene/O is/O widely/O studied/O for/O its/O skin/O -/O barrier/O function/O in/O humans/O ./O
The/O extensive/B-Var genetic/I-Var variation/I-Var in/O this/O gene/O ,/O especially/O common/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O mutations/B-Var ,/O has/O been/O established/O as/O primary/O risk/O factors/O for/O atopic/B-Disease dermatitis/I-Disease ./O
To/O investigate/O the/O evolution/O of/O this/O gene/O ,/O we/O analyzed/O 2,504/O human/O genomes/O and/O genotyped/O the/O copy/O number/O variation/O of/O filaggrin/O repeats/O within/O FLG/O in/O 126/O individuals/O from/O diverse/O ancestral/O backgrounds/O ./O
We/O were/O unable/O to/O replicate/O a/O recent/O study/O claiming/O that/O LoF/O of/O FLG/O is/O adaptive/O in/O northern/O latitudes/O with/O lower/O ultraviolet/O light/O exposure/O ./O
Instead/O ,/O we/O present/O multiple/O lines/O of/O evidence/O suggesting/O that/O FLG/O genetic/O variation/O ,/O including/O LoF/O variants/O ,/O have/O little/O or/O no/O effect/O on/O fitness/O in/O modern/O humans/O ./O
Haplotype/O -/O level/O scrutinization/O of/O the/O locus/O revealed/O signatures/O of/O a/O recent/O selective/O sweep/O in/O Asia/O ,/O which/O increased/O the/O allele/O frequency/O of/O a/O haplotype/O group/O (/O Huxian/O haplogroup/O )/O in/O Asian/O populations/O ./O
Functionally/O ,/O we/O found/O that/O the/O Huxian/O haplogroup/O carries/O dozens/O of/O functional/O variants/O in/O FLG/O and/O hornerin/O (/O HRNR/O )/O genes/O ,/O including/O those/O that/O are/O associated/O with/O atopic/O dermatitis/O susceptibility/O ,/O HRNR/O expression/O levels/O and/O microbiome/O diversity/O on/O the/O skin/O ./O
Our/O results/O suggest/O that/O the/O target/O of/O the/O adaptive/O sweep/O is/O HRNR/O gene/O function/O ,/O and/O the/O functional/O FLG/O variants/O that/O involve/O susceptibility/O to/O atopic/O dermatitis/O ,/O seem/O to/O hitchhike/O the/O selective/O sweep/O on/O HRNR/O ./O
Our/O study/O presents/O a/O novel/O case/O of/O a/O locus/O that/O harbors/O clinically/O relevant/O common/O genetic/O variation/O with/O complex/O evolutionary/O trajectories/O ./O
Variants/O of/O genes/O encoding/O collagens/O and/O matrix/O metalloproteinase/O system/O increased/O the/O risk/O of/O aortic/O dissection/O ./O
Aortic/O dissection/O (/O AD/O )/O is/O a/O devastating/O ,/O heterogeneous/O condition/O of/O aorta/O ./O
The/O homeostasis/O between/O collagens/O and/O matrix/O metalloproteases/O (/O MMPs)/tissue/O inhibitors/O of/O MMPs/O (/O TIMPs/O )/O system/O in/O the/O extracellular/O matrix/O plays/O an/O important/O role/O for/O structure/O and/O functions/O of/O aorta/O ./O
However/O ,/O our/O knowledge/O on/O association/O between/O variants/O of/O genes/O in/O this/O system/O and/O pathogenesis/O of/O AD/O is/O very/O limited/O ./O
We/O analyzed/O all/O yet/O known/O coding/O human/O genes/O of/O collagens/O (/O 45/O genes/O )/O ,/O MMPs/O //O TIMPs/O (/O 27/O genes/O )/O in/O 702/O sporadic/O AD/O patients/O and/O in/O 163/O matched/O healthy/O controls/O ,/O by/O using/O massively/O targeted/O next/O -/O generation/O and/O Sanger/O sequencing/O ./O
To/O define/O the/O pathogenesis/O of/O potential/O disease/O -/O causing/O candidate/O genes/O ,/O we/O performed/O transcriptome/O sequencing/O and/O pedigree/O co/O -/O segregation/O analysis/O in/O some/O genes/O and/O generated/O Col5a2/O knockout/O rats/O ./O
We/O identified/O 257/O pathogenic/O or/O likely/O pathogenic/O variants/O which/O involved/O 88.89/O %/O (/O 64/72/O )/O genes/O in/O collagens/O -/O MMPs/O //O TIMPs/O system/O and/O accounted/O for/O 31.05/O %/O (/O 218/702/O )/O sporadic/O AD/O patients/O ./O
In/O them/O ,/O 84.86/O %/O patients/O (/O 185/218/O )/O carried/O one/O variant/O ,/O 12.84/O %/O two/O variants/O and/O 2.30/O %/O more/O than/O two/O variants/O ./O
Importantly/O ,/O we/O identified/O 52/O novel/O probably/O pathogenic/O loss/O -/O of/O -/O function/O (/O LOF/O )/O variants/O (/O 20/O nonsense/O ,/O 16/O frameshift/O ,/O 14/O splice/O sites/O ,/O one/O stop/O -/O loss/O ,/O one/O initiation/O codon/O )/O in/O 11.06/O %/O (/O 50/452/O )/O AD/O patients/O ,/O which/O were/O absent/O in/O 163/O controls/O (/O P=2.5×10(-5/O )/O )/O ./O
Transcriptome/O sequencing/O revealed/O that/O identified/O variants/B-Var induced/O dyshomeostasis/B-Reg in/O expression/B-CPA of/I-CPA collagens/I-CPA -/I-CPA TIMPs/I-CPA //I-CPA MMPs/I-CPA systems/I-CPA ./O
The/O Col5a2/B-Gene (/O -/-/O )/O rats/O manifested/O growth/B-CPA retardation/I-CPA and/O aortic/B-CPA dysplasia/I-CPA ./O
Our/O study/O provides/O a/O first/O comprehensive/O map/O of/O genetic/O alterations/O in/O collagens/O -/O MMPs/O //O TIMPs/O system/O in/O sporadic/O AD/O patients/O and/O suggests/O that/O variants/O of/O these/O genes/O contribute/O largely/O to/O AD/O pathogenesis/O ./O
Alanine/O -/O scanning/O mutagenesis/O of/O human/O signal/O transducer/O and/O activator/O of/O transcription/O 1/O to/O estimate/O loss-/O or/O gain/O -/O of/O -/O function/O variants/O ./O
BACKGROUND/O :/O Germline/B-Var heterozygous/I-Var mutations/I-Var in/O human/O signal/B-Gene transducer/I-Gene and/O activator/B-Gene of/I-Gene transcription/I-Gene 1/I-Gene (/O STAT1/O )/O can/O cause/O loss/B-NegReg of/I-NegReg function/I-NegReg (/O LOF/O )/O ,/O as/O in/O patients/O with/O Mendelian/O susceptibility/O to/O mycobacterial/B-Disease diseases/I-Disease ,/O or/O gain/B-PosReg of/I-PosReg function/I-PosReg (/O GOF/O )/O ,/O as/O in/O patients/O with/O chronic/B-Disease mucocutaneous/I-Disease candidiasis/I-Disease ./O
LOF/O and/O GOF/O mutations/B-Var are/O equally/O rare/O and/O can/O affect/B-Reg the/O same/O domains/B-MPA of/O STAT1/B-Gene ,/O especially/O the/O coiled/B-MPA -/I-MPA coil/I-MPA domain/I-MPA (/O CCD/O )/O and/O DNA/B-MPA -/I-MPA binding/I-MPA domain/I-MPA (/O DBD/O )/O ./O
Moreover/O ,/O 6/O %/O of/O patients/O with/O chronic/O mucocutaneous/O candidiasis/O with/O a/O GOF/O STAT1/O mutation/O have/O mycobacterial/O disease/O ,/O obscuring/O the/O functional/O significance/O of/O the/O identified/O STAT1/O mutations/O ./O
Current/O computational/O approaches/O ,/O such/O as/O combined/O annotation/O -/O dependent/O depletion/O ,/O do/O not/O distinguish/O LOF/O and/O GOF/O variants/O ./O
OBJECTIVE/O :/O We/O estimated/O variations/O in/O the/O CCD/O //O DBD/O of/O STAT1/O ./O
METHODS/O :/O We/O mutagenized/O 342/O individual/O wild/O -/O type/O amino/O acids/O in/O the/O CCD/O //O DBD/O (/O 45.6/O %/O of/O full/O -/O length/O STAT1/O )/O to/O alanine/O and/O tested/O the/O mutants/O for/O STAT1/O transcriptional/O activity/O ./O
RESULTS/O :/O Of/O these/O 342/O mutants/O ,/O 201/O were/O neutral/O ,/O 30/O were/O LOF/O ,/O and/O 111/O were/O GOF/O mutations/O in/O a/O luciferase/O assay/O ./O
This/O assay/O system/O correctly/O estimated/O all/O previously/O reported/O LOF/O mutations/O (/O 100/O %/O )/O and/O slightly/O fewer/O GOF/O mutations/O (/O 78.1/O %/O )/O in/O the/O CCD/O //O DBD/O of/O STAT1/O ./O
We/O found/O that/O GOF/O alanine/O mutants/O occurred/O at/O the/O interface/O of/O the/O antiparallel/O STAT1/O dimer/O ,/O suggesting/O that/O they/O destabilize/O this/O dimer/O ./O
This/O assay/O also/O precisely/O predicted/O the/O effect/O of/O 2/O hypomorphic/O and/O dominant/O negative/O mutations/O ,/O E157/O K/O and/O G250E/O ,/O in/O the/O CCD/O of/O STAT1/O that/O we/O found/O in/O 2/O unrelated/O patients/O with/O Mendelian/O susceptibility/O to/O mycobacterial/O diseases/O ./O
CONCLUSION/O :/O The/O systematic/O alanine/O -/O scanning/O assay/O is/O a/O useful/O tool/O to/O estimate/O the/O GOF/O or/O LOF/O status/O and/O the/O effect/O of/O heterozygous/O missense/O mutations/O in/O STAT1/O identified/O in/O patients/O with/O severe/O infectious/O diseases/O ,/O including/O mycobacterial/O and/O fungal/O diseases/O ./O
Ruxolitinib/O reverses/O dysregulated/O T/O helper/O cell/O responses/O and/O controls/O autoimmunity/O caused/O by/O a/O novel/O signal/O transducer/O and/O activator/O of/O transcription/O 1/O (/O STAT1/O )/O gain/O -/O of/O -/O function/O mutation/O ./O
BACKGROUND/O :/O Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var in/O the/O human/B-Gene signal/I-Gene transducer/I-Gene and/I-Gene activator/I-Gene of/I-Gene transcription/I-Gene 1/I-Gene (/O STAT1/O )/O manifest/O in/O immunodeficiency/O and/O autoimmunity/O with/O impaired/B-NegReg TH17/B-CPA cell/I-CPA differentiation/I-CPA and/O exaggerated/B-PosReg responsiveness/B-Interaction to/I-Interaction type/I-Interaction I/I-Interaction and/I-Interaction II/I-Interaction interferons/I-Interaction ./O
Allogeneic/O bone/O marrow/O transplantation/O has/O been/O attempted/O in/O severely/O affected/O patients/O ,/O but/O outcomes/O have/O been/O poor/O ./O
OBJECTIVE/O :/O We/O sought/O to/O define/O the/O effect/O of/O increased/O STAT1/O activity/O on/O T/O helper/O cell/O polarization/O and/O to/O investigate/O the/O therapeutic/O potential/O of/O ruxolitinib/O in/O treating/O autoimmunity/O secondary/O to/O STAT1/O GOF/O mutations/O ./O
METHODS/O :/O We/O used/O in/O vitro/O polarization/O assays/O ,/O as/O well/O as/O phenotypic/O and/O functional/O analysis/O of/O STAT1-mutated/O patient/O cells/O ./O
RESULTS/O :/O We/O report/O a/O child/O with/O a/O novel/O mutation/B-Var in/I-Var the/I-Var linker/I-Var domain/I-Var of/O STAT1/B-Gene who/O had/O life/O -/O threatening/O autoimmune/O cytopenias/O and/O chronic/O mucocutaneous/O candidiasis/O ./O
Naive/O lymphocytes/O from/O the/O affected/O patient/O displayed/O increased/B-PosReg TH1/B-CPA and/I-CPA follicular/I-CPA T/I-CPA helper/I-CPA cell/I-CPA and/O suppressed/B-NegReg TH17/B-CPA cell/I-CPA responses/I-CPA ./O
The/O mutation/B-Var augmented/B-PosReg cytokine/B-MPA -/I-MPA induced/I-MPA STAT1/I-MPA phosphorylation/I-MPA without/O affecting/O dephosphorylation/O kinetics/O ./O
Treatment/O with/O the/O Janus/O kinase/O 1/2/O inhibitor/O ruxolitinib/O reduced/O hyperresponsiveness/O to/O type/O I/O and/O II/O interferons/O ,/O normalized/O TH1/O and/O follicular/O T/O helper/O cell/O responses/O ,/O improved/O TH17/O differentiation/O ,/O cured/O mucocutaneous/O candidiasis/O ,/O and/O maintained/O remission/O of/O immune/O -/O mediated/O cytopenias/O ./O
CONCLUSIONS/O :/O Autoimmunity/O and/O infection/O caused/O by/O STAT1/B-Gene GOF/B-PosReg mutations/B-Var are/O the/O result/O of/O dysregulated/O T/B-CPA helper/I-CPA cell/I-CPA responses/I-CPA ./O
Janus/O kinase/O inhibitor/O therapy/O could/O represent/O an/O effective/O targeted/O treatment/O for/O long/O -/O term/O disease/O control/O in/O severely/O affected/O patients/O for/O whom/O hematopoietic/O stem/O cell/O transplantation/O is/O not/O available/O ./O
Complexity/O of/O mechanisms/O among/O human/O proprotein/O convertase/O subtilisin/O -/O kexin/O type/O 9/O variants/O ./O
PURPOSE/O OF/O REVIEW/O :/O There/O are/O many/O reports/O of/O human/O variants/B-Var in/O proprotein/O convertase/O subtilisin/O -/O kexin/O type/O 9/O (/B-Gene PCSK9/I-Gene )/I-Gene that/O are/O either/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O or/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O ,/O with/O downstream/O effects/B-Reg on/O LDL/B-Disease cholesterol/I-Disease and/O cardiovascular/B-Disease disease/I-Disease (/O CVD/O )/O risk/O ./O
However/O ,/O data/O on/O particular/O mechanisms/O have/O only/O been/O minimally/O curated/O ./O
RECENT/O FINDINGS/O :/O GOF/B-PosReg variants/B-Var are/O individually/O ultrarare/O ,/O affect/B-Reg all/O domains/B-Protein of/I-Protein the/I-Protein protein/I-Protein ,/O act/O to/O reduce/B-NegReg LDL/B-Protein receptor/I-Protein expression/B-MPA through/O several/O mechanisms/O ,/O are/O a/O minor/O cause/B-Reg of/O familial/B-Disease hypercholesterolemia/I-Disease ,/O have/O been/O reported/O mainly/O within/O families/O ,/O have/O variable/O LDL/O cholesterol/O -/O raising/O effects/O ,/O and/O are/O associated/O with/O increased/O CVD/O risk/O mainly/O through/O observational/O studies/O in/O families/O and/O small/O cohorts/O ./O
In/O contrast/O ,/O LOF/B-NegReg variants/B-Var can/O be/O either/O ultrarare/O mutations/O or/O relatively/O more/O common/O polymorphisms/O seen/O in/O populations/O ,/O affect/B-Reg all/O domains/B-Protein of/I-Protein the/I-Protein protein/I-Protein ,/O act/O to/O increase/B-PosReg LDL/B-Protein receptor/I-Protein expression/B-MPA through/O several/O mechanisms/O ,/O have/O variable/O LDL/B-MPA cholesterol/B-NegReg -/I-NegReg lowering/I-NegReg effects/O ,/O and/O have/O been/O associated/O with/O decreased/B-NegReg CVD/B-Disease risk/O mainly/O through/O Mendelian/O randomization/O studies/O in/O epidemiologic/O populations/O ./O
SUMMARY/O :/O There/O is/O considerable/O complexity/O underlying/O the/O clinical/O concept/O of/O both/O LOF/O and/O GOF/O variants/O of/O PCSK9/O ./O
But/O despite/O the/O underlying/O mechanistic/O heterogeneity/O ,/O altered/O PCSK9/O secretion/O or/O function/O is/O ultimately/O correlated/O with/O plasma/O LDL/O cholesterol/O level/O ,/O which/O is/O also/O the/O driver/O of/O CVD/O outcomes/O ./O
Towards/O trans/O -/O diagnostic/O mechanisms/O in/O psychiatry/O :/O neurobehavioral/O profile/O of/O rats/O with/O a/O loss/O -/O of/O -/O function/O point/O mutation/O in/O the/O dopamine/O transporter/O gene/O ./O
The/O research/O domain/O criteria/O (/O RDoC/O )/O matrix/O has/O been/O developed/O to/O reorient/O psychiatric/O research/O towards/O measurable/O behavioral/O dimensions/O and/O underlying/O mechanisms/O ./O
Here/O ,/O we/O used/O a/O new/O genetic/O rat/O model/O with/O a/O loss/O -/O of/O -/O function/O point/O mutation/O in/O the/O dopamine/O transporter/O (/O DAT/O )/O gene/O (/O Slc6a3_N157/O K/O )/O to/O systematically/O study/O the/O RDoC/O matrix/O ./O
First/O ,/O we/O examined/O the/O impact/O of/O the/O Slc6a3_N157/O K/O mutation/O on/O monoaminergic/O signaling/O ./O
We/O then/O performed/O behavioral/O tests/O representing/O each/O of/O the/O five/O RDoC/O domains/O :/O negative/O and/O positive/O valence/O systems/O ,/O cognitive/O ,/O social/O and/O arousal/O //O regulatory/O systems/O ./O
The/O use/O of/O RDoC/O may/O be/O particularly/O helpful/O for/O drug/O development/O ./O
We/O studied/O the/O effects/O of/O a/O novel/O pharmacological/O approach/O metabotropic/O glutamate/O receptor/O mGluR2/3/O antagonism/O ,/O in/O DAT/O mutants/O in/O a/O comparative/O way/O with/O standard/O medications/O ./O
Loss/B-NegReg of/O DAT/B-Gene functionality/O in/O mutant/B-Var rats/O not/O only/O elevated/B-PosReg subcortical/B-MPA extracellular/I-MPA dopamine/I-MPA concentration/I-MPA but/O also/O altered/B-Reg the/O balance/B-MPA of/I-MPA monoaminergic/I-MPA transmission/I-MPA ./O
DAT/O mutant/O rats/O showed/O deficits/O in/O all/O five/O RDoC/O domains/O ./O
Thus/O ,/O mutant/O rats/O failed/O to/O show/O conditioned/O fear/O responses/O ,/O were/O anhedonic/O ,/O were/O unable/O to/O learn/O stimulus/O -/O reward/O associations/O ,/O showed/O impaired/O cognition/O and/O social/O behavior/O ,/O and/O were/O hyperactive/O ./O
Hyperactivity/O in/O mutant/O rats/O was/O reduced/O by/O amphetamine/O and/O atomoxetine/O ,/O which/O are/O well/O -/O established/O medications/O to/O reduce/O hyperactivity/O in/O humans/O ./O
The/O mGluR2/3/O antagonist/O LY341495/O also/O normalized/O hyperactivity/O in/O DAT/O mutant/O rats/O without/O affecting/O extracellular/O dopamine/O levels/O ./O
We/O systematically/O characterized/O an/O altered/O dopamine/O system/O within/O the/O context/O of/O the/O RDoC/O matrix/O and/O studied/O mGluR2/3/O antagonism/O as/O a/O new/O pharmacological/O strategy/O to/O treat/O mental/O disorders/O with/O underlying/O subcortical/O dopaminergic/O hyperactivity/O ./O
Conformational/O disruption/O of/O PI3Kδ/O regulation/O by/O immunodeficiency/O mutations/O in/O PIK3CD/O and/O PIK3R1/O ./O
Activated/B-Disease PI3/I-Disease K/I-Disease Delta/I-Disease Syndrome/I-Disease (/O APDS/O )/O is/O a/O primary/O immunodeficiency/O disease/O caused/B-Reg by/O activating/O mutations/B-Var in/O either/O the/O leukocyte/O -/O restricted/O p110δ/O catalytic/O (/B-Gene PIK3CD/I-Gene )/I-Gene subunit/O or/O the/O ubiquitously/O expressed/O p85α/O regulatory/O (/O PIK3R1/O )/O subunit/O of/O class/O IA/O phosphoinositide/O 3-kinases/O (/O PI3Ks/O )/O ./O
There/O are/O two/O classes/O of/O APDS/O :/O APDS1/O that/O arises/O from/O p110δ/O mutations/O that/O are/O analogous/O to/O oncogenic/O mutations/O found/O in/O the/O broadly/O expressed/O p110α/O subunit/O and/O APDS2/O that/O occurs/O from/O a/O splice/O mutation/O resulting/O in/O p85α/O with/O a/O central/O deletion/O (/O Δ434/O -/O 475/O )/O ./O
As/O p85/O regulatory/O subunits/O associate/O with/O and/O inhibit/O all/O class/O IA/O catalytic/O subunits/O ,/O APDS2/O mutations/O are/O expected/O to/O similarly/O activate/O p110α/O ,/O β/O ,/O and/O δ/O ,/O yet/O APDS2/O largely/O phenocopies/O APDS1/O without/O dramatic/O effects/O outside/O the/O immune/O system/O ./O
We/O have/O examined/O the/O molecular/O mechanism/O of/O activation/O of/O both/O classes/O of/O APDS/O mutations/O using/O a/O combination/O of/O biochemical/O assays/O and/O hydrogen/O -/O deuterium/O exchange/O mass/O spectrometry/O ./O
Intriguingly/O ,/O we/O find/O that/O an/O APDS2/B-Gene mutation/B-Var in/O p85α/O leads/O to/O substantial/O basal/O activation/B-PosReg of/O p110δ/B-MPA (/I-MPA >/I-MPA 300-fold/I-MPA )/I-MPA and/O disrupts/B-NegReg inhibitory/B-MPA interactions/I-MPA from/O the/O nSH2/O ,/O iSH2/O ,/O and/O cSH2/O domains/O of/O p85/O ,/O whereas/O p110α/O is/O only/O minimally/O basally/O activated/O (/O ∼2-fold/O )/O when/O associated/O with/O mutated/O p85α/O ./O
APDS1/O mutations/O in/O p110δ/O (/O N334/O K/O ,/O E525/O K/O ,/O E1021/O K/O )/O mimic/O the/O activation/O mechanisms/O previously/O discovered/O for/O oncogenic/O mutations/O in/O p110α/O ./O
All/O APDS/O mutations/O were/O potently/O inhibited/O by/O the/O Food/O and/O Drug/O Administration/O -/O approved/O p110δ/O inhibitor/O idelalisib/O ./O
Our/O results/O define/O the/O molecular/O basis/O of/O how/O PIK3CD/O and/O PIK3R1/O mutations/O result/O in/O APDS/O and/O reveal/O a/O potential/O path/O to/O treatment/O for/O all/O APDS/O patients/O ./O
N/O -/O cadherin/O Regulation/O of/O Bone/O Growth/O and/O Homeostasis/O Is/O Osteolineage/O Stage/O -/O Specific/O ./O
N/O -/O cadherin/O inhibits/O osteogenic/O cell/O differentiation/O and/O canonical/O Wnt/O //O β/O -/O catenin/O signaling/O in/O vitro/O ./O
However/O ,/O in/O vivo/O both/O conditional/O Cdh2/O ablation/O and/O overexpression/O in/O osteoblasts/O lead/O to/O low/O bone/O mass/O ./O
We/O tested/O the/O hypothesis/O that/O N/O -/O cadherin/O has/O different/O effects/O on/O osteolineage/O cells/O depending/O upon/O their/O differentiation/O stage/O ./O
Embryonic/O conditional/O osteolineage/O Cdh2/B-Gene deletion/B-Var in/O mice/O results/O in/O defective/B-NegReg growth/B-MPA ,/O low/B-NegReg bone/B-MPA mass/I-MPA ,/O and/O reduced/B-NegReg osteoprogenitor/B-MPA number/I-MPA ./O
These/O abnormalities/O are/O prevented/O by/O delaying/O Cdh2/O ablation/O until/O 1/O month/O of/O age/O ,/O thus/O targeting/O only/O committed/O and/O mature/O osteoblasts/O ,/O suggesting/O they/O are/O the/O consequence/O of/O N/O -/O cadherin/O deficiency/O in/O osteoprogenitors/O ./O
Indeed/O ,/O diaphyseal/O trabecularization/O actually/O increases/O when/O Cdh2/O is/O ablated/O postnatally/O ./O
The/O sclerostin/O -/O insensitive/O Lrp5(A214V/O )/O mutant/O ,/O associated/O with/O high/O bone/O mass/O ,/O does/O not/O rescue/O the/O growth/O defect/O ,/O but/O it/O overrides/O the/O low/O bone/O mass/O of/O embryonically/O Cdh2-deleted/O mice/O ,/O suggesting/O N/O -/O cadherin/O interacts/O with/O Wnt/O signaling/O to/O control/O bone/O mass/O ./O
Finally/O ,/O bone/O accrual/O and/O β/O -/O catenin/O accumulation/O after/O administration/O of/O an/O anti/O -/O Dkk1/O antibody/O are/O enhanced/O in/O N/O -/O cadherin/O -/O deficient/O mice/O ./O
Thus/O ,/O although/O lack/O of/O N/O -/O cadherin/O in/O embryonic/O and/O perinatal/O age/O is/O detrimental/O to/O bone/O growth/O and/O bone/O accrual/O ,/O in/O adult/O mice/O loss/O of/O N/O -/O cadherin/O in/O osteolineage/O cells/O favors/O bone/O formation/O ./O
Hence/O ,/O N/O -/O cadherin/O inhibition/O may/O widen/O the/O therapeutic/O window/O of/O osteoanabolic/O agents/O ./O
©/O 2017/O American/O Society/O for/O Bone/O and/O Mineral/O Research/O ./O
MAX/O inactivation/O is/O an/O early/O event/O in/O GIST/O development/O that/O regulates/O p16/O and/O cell/O proliferation/O ./O
KIT/B-Gene ,/O PDGFRA/B-Gene ,/O NF1/B-Gene and/O SDH/B-Gene mutations/B-Var are/O alternate/O initiating/O events/O ,/O fostering/B-Reg hyperplasia/O in/O gastrointestinal/B-MPA stromal/I-MPA tumours/I-MPA (/O GISTs/O )/O ,/O and/O additional/O genetic/O alterations/O are/O required/O for/O progression/O to/O malignancy/O ./O
The/O most/O frequent/O secondary/O alteration/O ,/O demonstrated/O in/O ∼70/O %/O of/O GISTs/O ,/O is/O chromosome/O 14q/O deletion/O ./O
Here/O we/O report/O hemizygous/O or/O homozygous/O inactivating/O mutations/O of/O the/O chromosome/O 14q/O MAX/O gene/O in/O 16/O of/O 76/O GISTs/O (/O 21/O %/O )/O ./O
We/O find/O MAX/O mutations/O in/O 17/O %/O and/O 50/O %/O of/O sporadic/O and/O NF1-syndromic/O GISTs/O ,/O respectively/O ,/O and/O we/O find/O loss/O of/O MAX/O protein/O expression/O in/O 48/O %/O and/O 90/O %/O of/O sporadic/O and/O NF1-syndromic/O GISTs/O ,/O respectively/O ,/O and/O in/O three/O of/O eight/O micro/O -/O GISTs/O ,/O which/O are/O early/O GISTs/O ./O
MAX/O genomic/O inactivation/O is/O associated/O with/O p16/O silencing/O in/O the/O absence/O of/O p16/O coding/O sequence/O deletion/O and/O MAX/O induction/O restores/O p16/O expression/O and/O inhibits/O GIST/O proliferation/O ./O
Hence/O ,/O MAX/O inactivation/O is/O a/O common/O event/O in/O GIST/O progression/O ,/O fostering/O cell/O cycle/O activity/O in/O early/O GISTs/O ./O
ATR/B-Gene Mutations/B-Var Promote/B-PosReg the/O Growth/B-MPA of/O Melanoma/B-Disease Tumors/I-Disease by/O Modulating/O the/O Immune/O Microenvironment/O ./O
Melanomas/O accumulate/O a/O high/O burden/O of/O mutations/B-Var that/O could/O potentially/O generate/B-Reg neoantigens/B-MPA ,/O yet/O somehow/O suppress/B-NegReg the/O immune/B-MPA response/I-MPA to/I-MPA facilitate/I-MPA continued/I-MPA growth/I-MPA ./O
In/O this/O study/O ,/O we/O identify/O a/O subset/O of/O human/O melanomas/O that/O have/O loss/O -/O of/O -/O function/O mutations/O in/O ATR/O ,/O a/O kinase/O that/O recognizes/O and/O repairs/O UV/O -/O induced/O DNA/O damage/O and/O is/O required/O for/O cellular/O proliferation/O ./O
ATR/B-Gene mutant/B-Var tumors/O exhibit/O both/O the/O accumulation/O of/O multiple/O mutations/O and/O the/O altered/O expression/O of/O inflammatory/O genes/O ,/O resulting/O in/O decreased/B-NegReg T/B-MPA cell/I-MPA recruitment/I-MPA and/O increased/B-PosReg recruitment/B-MPA of/I-MPA macrophages/I-MPA known/O to/O spur/O tumor/O invasion/O ./O
Taken/O together/O ,/O these/O studies/O identify/O a/O mechanism/O by/O which/O melanoma/O cells/O modulate/O the/O immune/O microenvironment/O to/O promote/O continued/O growth/O ./O
Regulation/O of/O endometrial/O cell/O proliferation/O by/O estrogen/O -/O induced/O BDNF/O signaling/O pathway/O ./O
Brain/O -/O derived/O neurotrophic/O factor/O (/O BDNF/O )/O is/O a/O member/O of/O the/O neurotrophin/O growth/O factors/O family/O ./O
Recent/O studies/O indicated/O that/O the/O level/O of/O BDNF/O in/O follicular/O fluid/O is/O a/O marker/O for/O oocyte/O quality/O and/O infertility/O ./O
Here/O ,/O we/O intend/O to/O further/O investigate/O the/O function/O of/O BDNF/O and/O its/O signaling/O pathway/O in/O the/O regulation/O of/O endometrial/O cells/O proliferation/O ./O
We/O found/O that/O BDNF/O is/O a/O critical/O growth/O factor/O in/O endometrial/O cells/O ./O
Activation/O of/O signal/O transducer/O and/O activator/O of/O transcription/O 3/O signaling/O pathway/O is/O required/O for/O BNDF/O -/O regulated/O endometrial/O cell/O proliferation/O ./O
Furthermore/O ,/O BDNF/O is/O an/O effector/O of/O estrogen/O in/O endometrial/O cells/O ./O
Finally/O ,/O we/O investigated/O the/O different/O role/O of/O Val66Met/O ,/O a/O single/O -/O nucleotide/O polymorphism/O of/O the/O BDNF/O gene/O ,/O in/O regulating/O endometrial/O cells/O proliferation/O ./O
The/O results/O showed/O that/O BDNF(V66/B-Gene M/I-Gene )/I-Gene polymorphism/B-Var is/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg polymorphism/B-Var in/O the/O regulation/B-MPA of/I-MPA endometrial/I-MPA cells/I-MPA growth/I-MPA ./O
Given/O the/O correlation/O between/O endometriosis/O and/O infertility/O ,/O it/O is/O important/O to/O understand/O the/O role/O of/O BDNF/O in/O regulating/O endometrial/O cells/O proliferation/O and/O to/O develop/O new/O therapeutic/O strategies/O for/O the/O treatment/O of/O endometriosis/O -/O related/O infertility/O ./O
Impact/O of/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O the/O low/O -/O density/O lipoprotein/O receptor/O -/O related/O protein/O 5/O (/B-Gene LRP5/I-Gene )/I-Gene on/O glucose/B-MPA and/I-MPA lipid/I-MPA homeostasis/I-MPA ./O
LRP5/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var have/O been/O shown/O to/O cause/O profound/B-MPA osteoporosis/I-MPA and/O have/O been/O associated/O with/O impaired/B-MPA insulin/I-MPA sensitivity/I-MPA and/O dysregulated/B-MPA lipid/I-MPA metabolism/I-MPA ./O
We/O hypothesized/O that/O gain/O -/O of/O -/O function/O mutations/O in/O LRP5/O would/O also/O affect/O these/O parameters/O ./O
We/O therefore/O studied/O individuals/O with/O LRP5/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var exhibiting/O high/O bone/O mass/O (/O HBM/O )/O phenotypes/O and/O found/O that/O while/O there/O was/O no/O detected/O change/O in/O insulin/O sensitivity/O ,/O there/O was/O a/O significant/O reduction/B-NegReg in/O serum/B-MPA LDL/I-MPA ./O
INTRODUCTION/O :/O Wnt/O signaling/O through/O LRP5/O represents/O a/O newly/O appreciated/O metabolic/O pathway/O ,/O which/O potentially/O represents/O a/O target/O for/O drug/O discovery/O in/O type/O 2/O diabetes/O and/O hyperlipidemia/O ./O
Studies/O in/O animal/O models/O suggest/O a/O physiologic/O link/O between/O LRP5/O and/O glucose/O and/O lipid/O homeostasis/O ;/O however/O ,/O whether/O it/O plays/O a/O similar/O role/O in/O humans/O is/O unclear/O ./O
As/O current/O literature/O links/O loss/O -/O of/O -/O function/O LRP5/O to/O impaired/O glucose/O and/O lipid/O metabolism/O ,/O we/O hypothesized/O that/O individuals/O with/O an/O HBM/O -/O causing/O mutation/O in/O LRP5/O would/O exhibit/O improved/O glucose/O and/O lipid/O homeostasis/O ./O
Since/O studies/O in/O animal/O models/O have/O suggested/O that/O Wnt/O signaling/O augments/O insulin/O secretion/O ,/O we/O also/O examined/O the/O effect/O of/O Wnt/O signaling/O on/O glucose/O -/O stimulated/O insulin/O secretion/O on/O human/O pancreatic/O islets/O ./O
METHODS/O :/O This/O was/O a/O matched/O case/O -/O control/O study/O ./O
We/O used/O several/O methods/O to/O assess/O glucose/O and/O lipid/O metabolism/O in/O 11/O individuals/O with/O HBM/O -/O causing/O mutations/O in/O LRP5/O ./O
Affected/O study/O participants/O were/O recruited/O from/O previously/O identified/O kindreds/O with/O HBM/O -/O causing/O LRP5/O mutations/O and/O included/O 9/O males/O and/O 2/O females/O ./O
Two/O subjects/O that/O were/O being/O treated/O with/O insulin/O for/O type/O 2/O diabetes/O were/O excluded/O from/O our/O analysis/O ,/O as/O this/O would/O have/O obscured/O our/O ability/O to/O determine/O the/O impact/O of/O gain/O -/O of/O -/O function/O LRP5/O mutations/O on/O glucose/O metabolism/O ./O
The/O mean/O age/O of/O the/O evaluated/O study/O subjects/O was/O 55/O ±/O 7/O with/O a/O mean/O BMI/O of/O 27.2/O ±/O 2.0/O ./O
Control/O subjects/O were/O matched/O and/O recruited/O from/O the/O general/O community/O at/O an/O equivalent/O ratio/O ,/O with/O 18/O males/O and/O 4/O females/O (/O mean/O age/O 56/O ±/O 4/O ;/O mean/O BMI/O 27.2/O ±/O 1.0/O )/O ./O
Study/O testing/O was/O conducted/O at/O an/O academic/O medical/O center/O ./O
RESULTS/O :/O There/O were/O no/O statistically/O significant/O differences/O between/O affected/O and/O matched/O control/O populations/O for/O HbA1c/O (/O p/O =/O 0.06/O )/O ,/O eAG/O (/O p/O =/O 0.06/O )/O ,/O insulin/O (/O p/O =/O 0.82/O )/O ,/O HOMA/O -/O B/O (/O p/O =/O 0.34/O )/O ,/O or/O HOMA/O -/O IR/O (/O p/O =/O 0.66/O )/O ./O
The/O mean/O Insulin/O Sensitivity/O Index/O (/O ISI/O )/O was/O also/O similar/O between/O control/O and/O affected/O individuals/O ./O
Total/O cholesterol/O (/O p/O =/O 0.43/O )/O ,/O triglycerides/O (/O TG/O )/O (/O p/O =/O 0.56/O )/O ,/O and/O HDL/O (/O p/O =/O 0.32/O )/O were/O not/O different/O between/O the/O same/O two/O groups/O ./O
In/O a/O small/O subset/O of/O studied/O subjects/O ,/O intramyocellular/O and/O hepatic/O lipid/O content/O were/O similar/O in/O the/O affected/O individuals/O and/O controls/O when/O quantified/O by/O proton/O magnetic/O resonance/O spectroscopy/O (/O MRS/O )/O ./O
However/O ,/O the/O mean/O value/O for/O serum/O LDL/O was/O significantly/O lower/O (/O p/O =/O 0.04/O )/O in/O affected/O individuals/O ./O
In/O primary/O human/O islets/O ,/O there/O were/O no/O differences/O between/O control/O and/O Wnt/O treatment/O groups/O for/O insulin/O secretion/O measured/O as/O area/O under/O the/O curve/O (/O AUC/O )/O for/O first/O phase/O (/O p/O =/O 0.17/O )/O or/O second/O phase/O (/O p/O =/O 0.33/O )/O insulin/O secretion/O ./O
CONCLUSIONS/O :/O Although/O our/O sample/O size/O was/O small/O ,/O our/O data/O do/O not/O support/O the/O hypothesis/O that/O HBM/O -/O causing/O LRP5/O mutations/O ,/O associated/O with/O increased/O Wnt/O signaling/O ,/O improve/O glucose/O metabolism/O in/O humans/O ./O
However/O ,/O it/O does/O appear/O that/O LRP5/B-Gene variants/B-Var may/O affect/B-Reg LDL/B-MPA metabolism/I-MPA ,/O a/O major/O risk/O factor/O for/O coronary/O artery/O disease/O ./O
The/O molecular/O mechanisms/O underpinning/O this/O effect/O warrant/O further/O study/O ./O
The/O Microtubule/O -/O Associated/O Protein/O MAP18/O Affects/O ROP2/O GTPase/O Activity/O during/O Root/O Hair/O Growth/O ./O
Establishment/O and/O maintenance/O of/O the/O polar/O site/O are/O important/O for/O root/O hair/O tip/O growth/O ./O
We/O previously/O reported/O that/O Arabidopsis/O (/O Arabidopsis/O thaliana/O )/O MICROTUBULE/O -/O ASSOCIATED/O PROTEIN18/O (/O MAP18/O )/O functions/O in/O controlling/O the/O direction/O of/O pollen/O tube/O growth/O and/O root/O hair/O elongation/O ./O
Additionally/O ,/O the/O Rop/O GTPase/O ROP2/O was/O reported/O as/O a/O positive/O regulator/O of/O both/O root/O hair/O initiation/O and/O tip/O growth/O in/O Arabidopsis/O ./O
Both/O loss/B-NegReg of/I-NegReg function/I-NegReg of/O ROP2/B-Gene and/O knockdown/B-Var of/O MAP18/B-Gene lead/O to/O a/O decrease/B-NegReg in/O root/B-MPA hair/I-MPA length/I-MPA ,/O whereas/O overexpression/O of/O either/O MAP18/O or/O ROP2/O causes/O multiple/O tips/O or/O a/O branching/O hair/O phenotype/O ./O
However/O ,/O it/O is/O unclear/O whether/O MAP18/O and/O ROP2/O coordinately/O regulate/O root/O hair/O growth/O ./O
In/O this/O study/O ,/O we/O demonstrate/O that/O MAP18/O and/O ROP2/O interact/O genetically/O and/O functionally/O ./O
MAP18/O interacts/O physically/O with/O ROP2/O in/O vitro/O and/O in/O vivo/O and/O preferentially/O binds/O to/O the/O inactive/O form/O of/O the/O ROP2/O protein/O ./O
MAP18/O promotes/O ROP2/O activity/O during/O root/O hair/O tip/O growth/O ./O
Further/O investigation/O revealed/O that/O MAP18/O competes/O with/O RhoGTPase/O GDP/O DISSOCIATION/O INHIBITOR1/O //O SUPERCENTIPEDE1/O for/O binding/O to/O ROP2/O ,/O in/O turn/O affecting/O the/O localization/O of/O active/O ROP2/O in/O the/O plasma/O membrane/O of/O the/O root/O hair/O tip/O ./O
These/O results/O reveal/O a/O novel/O function/O of/O MAP18/O in/O the/O regulation/O of/O ROP2/O activation/O during/O root/O hair/O growth/O ./O
A/O Ras/O GTPase/O associated/O protein/O is/O involved/O in/O the/O phototropic/O and/O circadian/O photobiology/O responses/O in/O fungi/O ./O
Light/O is/O an/O environmental/O signal/O perceived/O by/O most/O eukaryotic/O organisms/O and/O that/O can/O have/O major/O impacts/O on/O their/O growth/O and/O development/O ./O
The/O MadC/O protein/O in/O the/O fungus/O Phycomyces/O blakesleeanus/O (/O Mucoromycotina/O )/O has/O been/O postulated/O to/O form/O part/O of/O the/O photosensory/O input/O for/O phototropism/O of/O the/O fruiting/O body/O sporangiophores/O ,/O but/O the/O madC/O gene/O has/O remained/O unidentified/O since/O the/O 1960s/O when/O madC/O mutants/O were/O first/O isolated/O ./O
In/O this/O study/O the/O madC/O gene/O was/O identified/O by/O positional/O cloning/O ./O
All/O madC/O mutant/O strains/O contain/O loss/O -/O of/O -/O function/O point/O mutations/O within/O a/O gene/O predicted/O to/O encode/O a/O GTPase/O activating/O protein/O (/O GAP/O )/O for/O Ras/O ./O
The/O madC/O gene/O complements/O the/O Saccharomyces/O cerevisiae/O Ras/O -/O GAP/O ira1/O mutant/O and/O the/O encoded/O MadC/O protein/O interacts/O with/O P./O blakesleeanus/O Ras/O homologs/O in/O yeast/O two/O -/O hybrid/O assays/O ,/O indicating/O that/O MadC/O is/O a/O regulator/O of/O Ras/O signaling/O ./O
Deletion/B-Var of/O the/O homolog/O in/O the/O filamentous/O ascomycete/O Neurospora/O crassa/O affects/B-Reg the/O circadian/B-MPA clock/I-MPA output/I-MPA ,/O yielding/B-Reg a/O pattern/O of/O asexual/B-MPA conidiation/I-MPA similar/O to/O a/O ras-1/O mutant/O that/O is/O used/O in/O circadian/O studies/O in/O N./O crassa/O ./O
Thus/O ,/O MadC/O is/O unlikely/O to/O be/O a/O photosensor/O ,/O yet/O is/O a/O fundamental/O link/O in/O the/O photoresponses/O from/O blue/O light/O perceived/O by/O the/O conserved/O White/O Collar/O complex/O with/O Ras/O signaling/O in/O two/O distantly/O -/O related/O filamentous/O fungal/O species/O ./O
Paradoxical/O gain/O -/O of/O -/O function/O mutant/O of/O the/O G/O -/O protein/O -/O coupled/O receptor/O PROKR2/O promotes/O early/O puberty/O ./O
The/O human/O genome/O encodes/O ~750/O G/O -/O protein/O -/O coupled/O receptors/O (/O GPCRs/O )/O ,/O including/O prokineticin/O receptor/O 2/O (/O PROKR2/O )/O involved/O in/O the/O regulation/O of/O sexual/O maturation/O ./O
Previously/O reported/O pathogenic/O gain/O -/O of/O -/O function/O mutations/O of/O GPCR/O genes/O invariably/O encoded/O aberrant/O receptors/O with/O excessive/O signal/O transduction/O activity/O ./O
Although/O in/O vitro/O assays/O demonstrated/O that/O an/O artificially/O created/O inactive/O mutant/O of/O PROKR2/O exerted/O paradoxical/O gain/O -/O of/O -/O function/O effects/O when/O co/O -/O transfected/O with/O wild/O -/O type/O proteins/O ,/O such/O a/O phenomenon/O has/O not/O been/O observed/O in/O vivo/O ./O
Here/O ,/O we/O report/O a/O heterozygous/O frameshift/O mutation/O of/O PROKR2/O identified/O in/O a/O 3.5-year/O -/O old/O girl/O with/O central/O precocious/O puberty/O ./O
The/O mutant/B-Var mRNA/O escaped/B-NegReg nonsense/B-MPA -/I-MPA mediated/I-MPA decay/I-MPA and/O generated/O a/O GPCR/O lacking/B-NegReg two/B-MPA transmembrane/I-MPA domains/I-MPA and/O the/O carboxyl/O -/O terminal/O tail/O ./O
The/O mutant/O protein/O had/O no/O in/O vitro/O signal/O transduction/O activity/O ;/O however/O ,/O cells/O co/O -/O expressing/O the/O mutant/O and/O wild/O -/O type/O PROKR2/O exhibited/O markedly/O exaggerated/O ligand/O -/O induced/O Ca(2/O +/O )/O responses/O ./O
The/O results/O indicate/O that/O certain/O inactive/O PROKR2/B-Gene mutants/B-Var can/O cause/O early/O puberty/O by/O enhancing/B-PosReg the/O functional/B-MPA property/O of/O coexisting/O wild/O -/O type/O proteins/O ./O
Considering/O the/O structural/O similarity/O among/O GPCRs/O ,/O this/O paradoxical/O gain/O -/O of/O -/O function/O mechanism/O may/O underlie/O various/O human/O disorders/O ./O
The/O Tension/O -/O sensitive/O Ion/O Transport/O Activity/O of/O MSL8/O is/O Critical/O for/O its/O Function/O in/O Pollen/O Hydration/O and/O Germination/O ./O
All/O cells/O respond/O to/O osmotic/O challenges/O ,/O including/O those/O imposed/O during/O normal/O growth/O and/O development/O ./O
Mechanosensitive/O (/O MS/O )/O ion/O channels/O provide/O a/O conserved/O mechanism/O for/O regulating/O osmotic/O forces/O by/O conducting/O ions/O in/O response/O to/O increased/O membrane/O tension/O ./O
We/O previously/O demonstrated/O that/O the/O MS/O ion/O channel/O MscS/O -/O Like/O 8/O (/O MSL8/O )/O is/O required/O for/O pollen/O to/O survive/O multiple/O osmotic/O challenges/O that/O occur/O during/O the/O normal/O process/O of/O fertilization/O ,/O and/O that/O it/O can/O inhibit/O pollen/O germination/O ./O
However/O ,/O it/O remained/O unclear/O whether/O these/O physiological/O functions/O required/O ion/O flux/O through/O a/O mechanically/O gated/O channel/O provided/O by/O MSL8/O ./O
We/O introduced/O two/O point/O mutations/B-Var into/O the/O predicted/O pore/O -/O lining/O domain/O of/O MSL8/B-Gene that/O disrupted/B-NegReg normal/B-MPA channel/I-MPA function/I-MPA in/O different/O ways/O ./O
The/O Ile711Ser/B-Var mutation/O increased/B-PosReg the/O tension/B-MPA threshold/I-MPA of/O the/O MSL8/B-Gene channel/O while/O leaving/B-Reg conductance/B-MPA unchanged/I-MPA ,/O and/O the/O Phe720Leu/B-Var mutation/I-Var severely/O disrupted/B-NegReg the/O MSL8/B-Gene channel/B-Pathway ./O
Both/O of/O these/O mutations/B-Var impaired/B-NegReg the/O ability/B-MPA of/O MSL8/O to/O preserve/O pollen/O viability/O during/O hydration/O and/O to/O maintain/B-Reg the/O integrity/B-MPA of/O the/O pollen/O tube/O when/O expressed/O at/O endogenous/O levels/O ./O
When/O overexpressed/O in/O an/O msl8/O -/O 4/O null/O background/O ,/O MSL8I711S/O could/O partially/O rescue/O loss/O -/O of/O -/O function/O phenotypes/O ,/O while/O MSL8F720L/O could/O not/O ./O
When/O overexpressed/O in/O the/O wild/O -/O type/O Ler/O background/O ,/O MSL8I711S/O suppressed/O pollen/O germination/O ,/O similar/O to/O wild/O -/O type/O MSL8/O ./O
In/O contrast/O ,/O MSL8F720L/O failed/O to/O suppress/O pollen/O germination/O and/O increased/O pollen/O bursting/O ,/O thereby/O phenocopying/O the/O msl8/O -/O 4/O mutant/O ./O
Thus/O ,/O an/O intact/O MSL8/O channel/O is/O required/O for/O normal/O pollen/O function/O during/O hydration/O and/O germination/O ./O
These/O data/O establish/O MSL8/O as/O the/O first/O plant/O MS/O channel/O to/O fulfill/O previously/O established/O criteria/O for/O assignment/O as/O a/O mechanotransducer/O ./O
RACK1/O cooperates/O with/O NRAS(Q61/O K/O )/O to/O promote/O melanoma/O in/O vivo/O ./O
Melanoma/O is/O the/O deadliest/O skin/O cancer/O ./O
RACK1/O (/O Receptor/O for/O activated/O protein/O kinase/O C/O )/O protein/O was/O proposed/O as/O a/O biological/O marker/O of/O melanoma/O in/O human/O and/O domestic/O animal/O species/O harboring/O spontaneous/O melanomas/O ./O
As/O a/O scaffold/O protein/O ,/O RACK1/O is/O able/O to/O coordinate/O the/O interaction/O of/O key/O signaling/O molecules/O implicated/O in/O both/O physiological/O cellular/O functions/O and/O tumorigenesis/O ./O
A/O role/O for/O RACK1/O in/O rewiring/O ERK/O and/O JNK/O signaling/O pathways/O in/O melanoma/O cell/O lines/O had/O been/O proposed/O ./O
Here/O ,/O we/O used/O a/O genetic/O approach/O to/O test/O this/O hypothesis/O in/O vivo/O in/O the/O mouse/O ./O
We/O show/O that/O Rack1/B-Gene knock/B-Var -/I-Var down/I-Var in/O the/O mouse/O melanoma/O cell/O line/O B16/O reduces/B-NegReg invasiveness/B-MPA and/O induces/B-Reg cell/B-MPA differentiation/I-MPA ./O
We/O have/O developed/O the/O first/O mouse/O model/O for/O RACK1/O gain/O of/O function/O ,/O Tyr::Rack1-HA/O transgenic/O mice/O ,/O targeting/O RACK1/O to/O melanocytes/O in/O vivo/O ./O
RACK1/O overexpression/O was/O not/O sufficient/O to/O initiate/O melanomas/O despite/O activated/O ERK/O and/O AKT/O ./O
However/O ,/O in/O a/O context/O of/O melanoma/O predisposition/O ,/O RACK1/O overexpression/O reduced/O latency/O and/O increased/O incidence/O and/O metastatic/O rate/O ./O
In/O primary/O melanoma/O cells/O from/O Tyr::Rack1-HA/O ,/O Tyr::NRas(Q61/O K/O )/O mice/O ,/O activated/O JNK/O (/O c/O -/O Jun/O N/O -/O terminal/O kinase/O )/O and/O activated/O STAT3/O (/O signal/O transducer/O and/O activator/O of/O transcription/O 3/O )/O acted/O as/O RACK1/O oncogenic/O partners/O in/O tumoral/O progression/O ./O
A/O sequential/O and/O coordinated/O activation/O of/O ERK/O ,/O JNK/O and/O STAT3/O with/O RACK1/O is/O shown/O to/O accelerate/O aggressive/O melanoma/O development/O in/O vivo/O ./O
Identification/O and/O characterization/O of/O a/O novel/O DGAT1/O missense/O mutation/O associated/O with/O congenital/O diarrhea/O ./O
Acyl/O -/O CoA/O :/O diacylglycerol/O acyltransferase/O (/O DGAT)1/O and/O DGAT2/O catalyze/O triglyceride/O (/O TG/O )/O biosynthesis/O in/O humans/O ./O
Biallelic/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O human/O DGAT1/B-Gene result/O in/O severe/O congenital/B-Disease diarrhea/I-Disease and/O protein/B-Disease -/I-Disease losing/I-Disease enteropathy/I-Disease ./O
Additionally/O ,/O pharmacologic/O inhibition/O of/O DGAT1/O led/O to/O dose/O -/O related/O diarrhea/O in/O human/O clinical/O trials/O ./O
Here/O we/O identify/O a/O previously/O unknown/O DGAT1/O mutation/O in/O identical/O twins/O of/O South/O Asian/O descent/O ./O
These/O male/O patients/O developed/O watery/O diarrhea/O shortly/O after/O birth/O ,/O with/O protein/O -/O losing/O enteropathy/O and/O failure/O to/O thrive/O ./O
Exome/O sequencing/O revealed/O a/O homozygous/O recessive/O mutation/O in/O DGAT1/O ,/O c.314T/O >/O C/O ,/O p/O ./O L105P./O We/O show/O here/O that/O the/O p/B-Var ./I-Var L105P/I-Var DGAT1/B-Gene enzyme/O produced/O from/O the/O mutant/B-Var allele/O is/O less/B-NegReg abundant/O ,/O resulting/O in/O partial/O loss/B-NegReg of/O TG/B-MPA synthesis/I-MPA activity/I-MPA and/O decreased/B-NegReg formation/B-MPA of/I-MPA lipid/I-MPA droplets/I-MPA in/O patient/O -/O derived/O primary/O dermal/O fibroblasts/O ./O
Thus/O ,/O in/O contrast/O with/O complete/O loss/O -/O of/O -/O function/O alleles/O of/O DGAT1/O ,/O the/O p/B-Var ./I-Var L105P/I-Var missense/I-Var allele/O partially/O reduces/B-NegReg TG/B-MPA synthesis/I-MPA activity/I-MPA and/O causes/B-Reg a/O less/B-MPA severe/I-MPA clinical/I-MPA phenotype/I-MPA ./O
Our/O findings/O add/O to/O the/O growing/O recognition/O of/O DGAT1/B-Gene deficiency/B-Var as/O a/O cause/B-Reg of/O congenital/B-Disease diarrhea/I-Disease with/O protein/B-Disease -/I-Disease losing/I-Disease enteropathy/I-Disease and/O indicate/O that/O DGAT1/B-Gene mutations/B-Var result/B-Reg in/I-Reg a/O spectrum/B-Disease of/I-Disease diseases/I-Disease ./O
Hydrocephalus/B-Disease due/O to/O multiple/O ependymal/O malformations/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O MPDZ/B-Gene gene/O ./O
Congenital/O hydrocephalus/O is/O considered/O as/O either/O acquired/O due/O to/O haemorrhage/O ,/O infection/O or/O neoplasia/O or/O as/O of/O developmental/O nature/O and/O is/O divided/O into/O two/O subgroups/O ,/O communicating/O and/O obstructive/O ./O
Congenital/O hydrocephalus/O is/O either/O syndromic/O or/O non/O -/O syndromic/O ,/O and/O in/O the/O latter/O no/O cause/O is/O found/O in/O more/O than/O half/O of/O the/O patients/O ./O
In/O patients/O with/O isolated/B-Disease hydrocephalus/I-Disease ,/O L1CAM/B-Gene mutations/B-Var represent/O the/O most/O common/B-Reg aetiology/O ./O
More/O recently/O ,/O a/O founder/O mutation/O has/O also/O been/O reported/O in/O the/O MPDZ/O gene/O in/O foetuses/O presenting/O massive/O hydrocephalus/O ,/O but/O the/O neuropathology/O remains/O unknown/O ./O
We/O describe/O here/O three/O novel/O homozygous/O null/O mutations/O in/O the/O MPDZ/O gene/O in/O foetuses/O whose/O post/O -/O mortem/O examination/O has/O revealed/O a/O homogeneous/O phenotype/O characterized/O by/O multiple/O ependymal/O malformations/O along/O the/O aqueduct/O of/O Sylvius/O ,/O the/O third/O and/O fourth/O ventricles/O as/O well/O as/O the/O central/O canal/O of/O the/O medulla/O ,/O consisting/O in/O multifocal/O rosettes/O with/O immature/O cell/O accumulation/O in/O the/O vicinity/O of/O ependymal/O lining/O early/O detached/O from/O the/O ventricular/O zone/O ./O
MPDZ/O also/O named/O MUPP1/O is/O an/O essential/O component/O of/O tight/O junctions/O which/O are/O expressed/O from/O early/O brain/O development/O in/O the/O choroid/O plexuses/O and/O ependyma/O ./O
Alterations/O in/O the/O formation/O of/O tight/O junctions/O within/O the/O ependyma/O very/O likely/O account/O for/O the/O lesions/O observed/O and/O highlight/O for/O the/O first/O time/O that/O primary/O multifocal/O ependymal/O malformations/O of/O the/O ventricular/O system/O is/O genetically/O determined/O in/O humans/O ./O
Therefore/O ,/O MPDZ/O sequencing/O should/O be/O performed/O when/O neuropathological/O examination/O reveals/O multifocal/O ependymal/O rosette/O formation/O within/O the/O aqueduct/O of/O Sylvius/O ,/O of/O the/O third/O and/O fourth/O ventricles/O and/O of/O the/O central/O canal/O of/O the/O medulla/O ./O
Short/O hairpin/O RNA/O is/O more/O effective/O than/O long/O hairpin/O RNA/O in/O eliciting/O pointed/O loss/O -/O of/O -/O function/O phenotypes/O in/O Drosophila/O ./O
Pointed/O (/O Pnt/O )/O is/O a/O transcriptional/O activator/O that/O functions/O downstream/O of/O the/O highly/O conserved/O Receptor/O Tyrosine/O Kinase/O (/O RTK/O )/O signaling/O pathway/O ./O
Pnt/O is/O an/O ETS/O family/O transcription/O factor/O and/O encodes/O for/O two/O proteins/O ,/O PntP1/O and/O PntP2/O ./O
However/O ,/O while/O PntP1/O is/O constitutively/O active/O ,/O PntP2/O is/O only/O active/O after/O being/O phosphorylated/O by/O MAPK/O in/O the/O RTK/O pathway/O ./O
As/O mutations/B-Var in/O pnt/B-Gene perturb/B-Reg the/O development/B-CPA of/I-CPA several/I-CPA tissues/I-CPA ,/O we/O wanted/O to/O examine/O the/O effect/O and/O efficacy/O of/O using/O RNAi/O to/O target/O Pnt/O ./O
We/O have/O expressed/O pnt/O RNAi/O in/O the/O eyes/O ,/O oocyte/O ,/O and/O heart/O cells/O using/O three/O different/O RNAi/O lines/O :/O Valium20/O ,/O Valium10/O ,/O and/O VDRC/O ./O
Valium20/O is/O distinct/O since/O it/O generates/O a/O short/O hairpin/O RNA/O (/O shRNA/O )/O ,/O while/O Valium10/O and/O VDRC/O produce/O long/O hairpin/O dsRNA/O ./O
We/O found/O that/O for/O each/O tissue/O examined/O Valium20/O exhibited/O the/O strongest/O phenotype/O while/O the/O Valium10/O and/O VDRC/O lines/O produced/O varying/O levels/O of/O severity/O and/O that/O the/O long/O hairpin/O RNA/O produced/O by/O the/O Valium10/O and/O VDRC/O lines/O are/O unable/O to/O effectively/O knockdown/O pnt/O in/O embryonic/O tissues/O ./O
New/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var shows/O CACNA1D/B-Gene as/O recurrently/O mutated/O gene/O in/O autism/B-Disease spectrum/I-Disease disorders/I-Disease and/O epilepsy/B-Disease ./O
CACNA1D/O encodes/O the/O pore/O -/O forming/O α1-subunit/O of/O Cav1.3/O ,/O an/O L/O -/O type/O voltage/O -/O gated/O Ca2/O +/O -channel/O ./O
Despite/O the/O recent/O discovery/O of/O two/O de/O novo/O missense/O gain/O -/O of/O -/O function/O mutations/O in/O Cav1.3/O in/O two/O individuals/O with/O autism/O spectrum/O disorder/O (/O ASD/O )/O and/O intellectual/O disability/O CACNA1D/O has/O not/O been/O considered/O a/O prominent/O ASD/O -/O risk/O gene/O in/O large/O scale/O genetic/O analyses/O ,/O since/O such/O studies/O primarly/O focus/O on/O likely/O -/O disruptive/O genetic/O variants/O ./O
Here/O we/O report/O the/O discovery/O and/O characterization/O of/O a/O third/O de/O novo/O missense/O mutation/O in/O CACNA1D/O (/O V401L/O )/O in/O a/O patient/O with/O ASD/O and/O epilepsy/O ./O
For/O the/O functional/O characterization/O we/O introduced/O mutation/O V401L/O into/O two/O major/O C/O -/O terminal/O long/O and/O short/O Cav1.3/O splice/O variants/O ,/O expressed/O wild/O -/O type/O or/O mutant/O channel/O complexes/O in/O tsA-201/O cells/O and/O performed/O whole/O -/O cell/O patch/O -/O clamp/O recordings/O ./O
Mutation/O V401L/B-Var ,/O localized/O within/O the/O channel/O 's/O activation/O gate/O ,/O significantly/O enhanced/B-PosReg current/B-MPA densities/I-MPA ,/O shifted/O voltage/O dependence/O of/O activation/O and/O inactivation/O to/O more/O negative/O voltages/O and/O reduced/O channel/O inactivation/O in/O both/O Cav1.3/O splice/O variants/O ./O
Altogether/O these/O gating/O changes/B-Var are/O expected/O to/O result/O in/O enhanced/B-PosReg Ca2/B-MPA +/I-MPA -influx/I-MPA through/I-MPA the/I-MPA channel/I-MPA ,/O thus/O representing/O a/O strong/O gain/O -/O of/O -/O function/O phenotype/O ./O
Additionally/O ,/O we/O also/O found/O that/O mutant/O channels/O retained/O full/O sensitivity/O towards/O the/O clinically/O available/O Ca2/O +/O -channel/O blocker/O isradipine/O ./O
Our/O findings/O strengthen/O the/O evidence/O for/O CACNA1D/O as/O a/O novel/O candidate/O autism/O risk/O gene/O and/O encourage/O experimental/O therapy/O with/O available/O channel/O -/O blockers/O for/O this/O mutation/O ./O
The/O additional/O presence/O of/O seizures/O and/O neurological/O abnormalities/O in/O our/O patient/O define/O a/O novel/O phenotype/O partially/O overlapping/O with/O symptoms/O in/O two/O individuals/O with/O PASNA/O (/O congential/O primary/O aldosteronism/O ,/O seizures/O and/O neurological/O abnormalities/O )/O caused/O by/O similar/O Cav1.3/O gain/O -/O of/O -/O function/O mutations/O ./O
Proteomic/O analysis/O of/O filaggrin/O deficiency/O identifies/O molecular/O signatures/O characteristic/O of/O atopic/O eczema/O ./O
BACKGROUND/O :/O Atopic/B-Disease eczema/I-Disease (/O AE/O )/O is/O characterized/O by/O skin/O barrier/O and/O immune/O dysfunction/O ./O
Null/B-Var mutations/I-Var in/O filaggrin/O (/B-Gene FLG/I-Gene )/I-Gene ,/O a/O key/O epidermal/O barrier/O protein/O ,/O strongly/O predispose/B-Reg to/O AE/B-Disease ;/I-Disease however/O ,/O the/O precise/O role/O of/O FLG/O deficiency/O in/O AE/O pathogenesis/O remains/O incompletely/O understood/O ./O
OBJECTIVES/O :/O We/O sought/O to/O identify/O global/O proteomic/O changes/O downstream/O of/O FLG/O deficiency/O in/O human/O epidermal/O living/O skin/O -/O equivalent/O (/O LSE/O )/O models/O and/O validate/O findings/O in/O skin/O of/O patients/O with/O AE/O ./O
METHODS/O :/O Differentially/O expressed/O proteins/O from/O paired/O control/O (/O nontargeting/O control/O short/O hairpin/O RNA/O [/O shNT/O ]/O )/O and/O FLG/O knockdown/O (/O FLG/O knockdown/O short/O hairpin/O RNA/O [/O shFLG/O ]/O )/O LSEs/O were/O identified/O by/O means/O of/O proteomic/O analysis/O (/O liquid/O chromatography/O -/O mass/O spectrometry/O )/O and/O Ingenuity/O Pathway/O Analysis/O ./O
Expression/O of/O key/O targets/O was/O validated/O in/O independent/O LSE/O samples/O (/O quantitative/O RT/O -/O PCR/O and/O Western/O blotting/O )/O and/O in/O normal/O and/O AE/O skin/O biopsy/O specimens/O (/O immunofluorescence/O )/O ./O
RESULTS/O :/O Proteomic/O analysis/O identified/O 17/O (/O P/O ≤/O .05/O )/O differentially/O expressed/O proteins/O after/O FLG/O knockdown/O ,/O including/O kallikrein-7/O (/O KLK7/O ;/O 2.2-fold/O )/O ,/O cyclophilin/O A/O (/O PPIA/O ;/O 0.9-fold/O )/O ,/O and/O cofilin-1/O (/O CFL1/O ,/O 1.3-fold/O )/O ./O
Differential/O protein/O expression/O was/O confirmed/O in/O shNT/O //O shFLG/O LSEs/O ;/O however/O ,/O only/O KLK7/O was/O transcriptionally/O dysregulated/O ./O
Molecular/B-Pathway pathways/I-Pathway overrepresented/B-PosReg after/O FLG/B-Gene knockdown/B-Var included/O inflammation/O ,/O protease/O activity/O ,/O cell/O structure/O ,/O and/O stress/O ./O
Furthermore/O ,/O KLK7/O (/O 1.8-fold/O )/O and/O PPIA/O (/O 0.65-fold/O )/O proteins/O were/O differentially/O expressed/O in/O lesional/O biopsy/O specimens/O from/O patients/O with/O AE/O relative/O to/O normal/O skin/O ./O
CONCLUSIONS/O :/O For/O the/O first/O time/O ,/O we/O show/O that/O loss/B-Var of/O FLG/B-Gene in/O the/O absence/O of/O inflammation/O is/O sufficient/O to/O alter/B-Reg the/O expression/B-MPA level/I-MPA of/I-MPA proteins/I-MPA relevant/O to/O the/O pathogenesis/O of/O AE/O ./O
These/O include/O proteins/O regulating/O inflammatory/O ,/O proteolytic/O ,/O and/O cytoskeletal/O functions/O ./O
We/O identify/O PPIA/O as/O a/O novel/O protein/O with/O levels/O that/O are/O decreased/O in/O clinically/O active/O AE/O skin/O and/O show/O that/O the/O characteristic/O upregulation/O of/O KLK7/O expression/O in/O patients/O with/O AE/O occurs/O downstream/O of/O FLG/O loss/O ./O
Importantly/O ,/O we/O highlight/O disconnect/O between/O the/O epidermal/O proteome/O and/O transcriptome/O ,/O emphasizing/O the/O utility/O of/O global/O proteomic/O studies/O ./O
TREM2/O deficiency/O impairs/O chemotaxis/O and/O microglial/O responses/O to/O neuronal/O injury/O ./O
Sequence/O variations/B-Var in/O the/O triggering/O receptor/O expressed/O on/O myeloid/O cells/O 2/O (/B-Gene TREM2/I-Gene )/I-Gene have/O been/O linked/B-Reg to/I-Reg an/O increased/O risk/O for/O neurodegenerative/O disorders/O such/O as/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease and/O frontotemporal/B-Disease lobar/I-Disease degeneration/I-Disease ./O
In/O the/O brain/O ,/O TREM2/O is/O predominantly/O expressed/O in/O microglia/O ./O
Several/O disease/O -/O associated/O TREM2/B-Gene variants/B-Var result/O in/O a/O loss/O of/O function/O by/O reducing/B-NegReg microglial/B-CPA phagocytosis/I-CPA ,/O impairing/B-NegReg lipid/B-MPA sensing/I-MPA ,/O preventing/B-NegReg binding/B-Interaction of/O lipoproteins/B-Protein and/O affecting/B-Reg shielding/B-MPA of/I-MPA amyloid/I-MPA plaques/I-MPA ./O
We/O here/O investigate/O the/O consequences/O of/O TREM2/O loss/O of/O function/O on/O the/O microglia/O transcriptome/O ./O
Among/O the/O differentially/O expressed/O messenger/O RNAs/O in/O wild/O -/O type/O and/O Trem2(-/-/O )/O microglia/O ,/O gene/O clusters/O are/O identified/O which/O represent/O gene/O functions/O in/O chemotaxis/O ,/O migration/O and/O mobility/O ./O
Functional/O analyses/O confirm/O that/O loss/B-Var of/O TREM2/B-Gene impairs/B-NegReg appropriate/O microglial/B-CPA responses/I-CPA to/I-CPA injury/I-CPA and/I-CPA signals/I-CPA that/O normally/O evoke/O chemotaxis/O on/O multiple/O levels/O ./O
In/O an/O ex/O vivo/O organotypic/O brain/O slice/O assay/O ,/O absence/O of/O TREM2/O reduces/O the/O distance/O migrated/O by/O microglia/O ./O
Moreover/O ,/O migration/O towards/O defined/O chemo/O -/O attractants/O is/O reduced/O upon/O ablation/O of/O TREM2/O and/O can/O be/O rescued/O by/O TREM2/O re/O -/O expression/O ./O
In/O vivo/O ,/O microglia/O lacking/O TREM2/O migrate/O less/O towards/O injected/O apoptotic/O neurons/O ,/O and/O outgrowth/O of/O microglial/O processes/O towards/O sites/O of/O laser/O -/O induced/O focal/O CNS/O damage/O in/O the/O somatosensory/O cortex/O is/O slowed/O ./O
The/O apparent/O lack/O of/O chemotactic/O stimulation/O upon/O depletion/O of/O TREM2/O is/O consistent/O with/O a/O stable/O expression/O profile/O of/O genes/O characterizing/O the/O homoeostatic/O signature/O of/O microglia/O ./O
Novel/O loss/B-NegReg of/I-NegReg function/I-NegReg mutation/B-Var in/O KRIT1/B-Gene //I-Gene CCM1/I-Gene is/O associated/B-Reg with/I-Reg distinctly/O progressive/O cerebral/B-Disease and/I-Disease spinal/I-Disease cavernous/I-Disease malformations/I-Disease after/O radiochemotherapy/O for/O intracranial/O malignant/O germ/O cell/O tumor/O ./O
PURPOSE/O :/O Cerebrospinal/B-Disease cavernous/I-Disease malformations/I-Disease (/O CCMs/O )/O are/O vascular/O lesions/O characterized/O by/O dilated/O and/O leaky/O capillary/O caverns/O ./O
CCMs/O can/O cause/O seizures/O ,/O focal/O neurological/O deficits/O or/O acute/O intracranial/O hemorrhage/O ;/O however/O ,/O most/O patients/O are/O asymptomatic/O ./O
CCMs/O occur/O either/O sporadically/O or/O as/O a/O familial/O autosomal/O -/O dominant/O disorder/O ./O
We/O present/O a/O clinical/O and/O molecular/O study/O of/O a/O patient/O with/O distinctive/O cerebral/O and/O spinal/O cavernous/O malformations/O following/O radiochemotherapy/O for/O a/O malignant/O brain/O tumor/O ./O
METHODS/O :/O The/O patient/O had/O multiple/O magnet/O resonance/O imaging/O (/O MRI/O )/O examinations/O of/O his/O brain/O and/O spine/O following/O radiochemotherapy/O for/O a/O primary/O intracranial/O germ/O cell/O tumor/O (/O GCT/O )/O ,/O as/O part/O of/O his/O oncologic/O follow/O -/O up/O ./O
The/O MRI/O sequences/O included/O susceptibility/O -/O weighted/O imaging/O (/O SWI/O )/O ./O
The/O coding/O exons/O and/O their/O flanking/O intronic/O regions/O of/O KRIT1/O //O CCM1/O gene/O were/O analyzed/O for/O mutations/O by/O polymerase/O chain/O reaction/O (/O PCR/O )/O and/O direct/O sequencing/O ./O
RESULTS/O :/O MRI/O revealed/O numerous/O cerebral/O and/O spinal/O microhemorrhages/O and/O pronounced/O cavernous/O malformations/O that/O progressed/O with/O subsequent/O follow/O -/O up/O imaging/O ./O
Genetic/O analysis/O demonstrated/O a/O novel/O heterozygous/O KRIT1/B-Gene //I-Gene CCM1/I-Gene two/O base/O pair/O deletion/O (/B-Var c.1535_1536delTG/I-Var )/I-Var in/O exon/O 14/O ./O
This/O deletion/O leads/B-Reg to/I-Reg a/O frameshift/B-Var with/O a/O premature/B-MPA stop/I-MPA codon/I-MPA at/O nucleotide/O position/O 1553/O and/O a/O highly/O likely/O loss/B-NegReg of/I-NegReg function/I-NegReg of/O the/O KRIT1/B-Protein protein/I-Protein ./O
CONCLUSION/O :/O We/O describe/O a/O patient/O with/O a/O novel/O heterozygous/O germ/O line/O loss/B-NegReg of/I-NegReg function/I-NegReg mutation/B-Var in/O KRIT1/B-Gene ,/O which/O is/O associated/B-Reg with/I-Reg rapid/O -/O onset/O and/O highly/O progressive/O CCMs/B-Disease after/O radiochemotherapy/O for/O a/O malignant/O brain/O tumor/O ./O
Real/O -/O World/O Data/O on/O Prognostic/O Factors/O for/O Overall/O Survival/O in/O EGFR/B-Gene Mutation/B-Reg -/I-Reg Positive/I-Reg Advanced/O Non/B-Disease -/I-Disease Small/I-Disease Cell/I-Disease Lung/I-Disease Cancer/I-Disease Patients/O Treated/O with/O First/O -/O Line/O Gefitinib/O ./O
BACKGROUND/O :/O This/O study/O aimed/O to/O identify/O independent/O prognostic/O factors/O for/O overall/O survival/O (/O OS/O )/O of/O patients/O with/O advanced/O non/O -/O small/O cell/O lung/O cancer/O (/O NSCLC/O )/O harboring/O an/O activating/O epidermal/O growth/O factor/O receptor/O (/O EGFR/O )/O mutation/O and/O receiving/O gefitinib/O as/O first/O -/O line/O treatment/O in/O real/O -/O world/O practice/O ./O
MATERIALS/O AND/O METHODS/O :/O We/O enrolled/O 226/O patients/O from/O June/O 2011/O to/O May/O 2013/O ./O
During/O this/O period/O ,/O gefitinib/O was/O the/O only/O EGFR/O -/O tyrosine/O kinase/O inhibitor/O reimbursed/O by/O the/O Bureau/O of/O National/O Health/O Insurance/O of/O Taiwan/O ./O
RESULTS/O :/O The/O median/O progression/O -/O free/O survival/O and/O median/O OS/O were/O 11.9/O months/O (/O 95/O %/O confidence/O interval/O [/O CI/O ]/O :/O 9.7/O -/O 14.2/O )/O and/O 26.9/O months/O (/O 21.2/O -/O 32.5/O )/O ,/O respectively/O ./O
The/O Cox/O proportional/O hazards/O regression/O model/O revealed/O that/O postoperative/O recurrence/O ,/O performance/O status/O (/O Eastern/O Cooperative/O Oncology/O Grade/O [/O ECOG/O ]/O ≥2/O )/O ,/O smoking/O index/O (/O ≥20/O pack/O -/O years/O )/O ,/O liver/O metastasis/O at/O initial/O diagnosis/O ,/O and/O chronic/O hepatitis/O C/O virus/O (/O HCV/O )/O infection/O were/O independent/O prognostic/O factors/O for/O OS/O (/O hazard/O ratio/O [/O 95/O %/O CI/O ]/O 0.3/O [/O 0.11/O -/O 0.83/O ]/O ,/O p/O =/O .02/O ;/O 2.69/O [/O 1.60/O -/O 4.51/O ]/O ,/O p/O </O .001/O ;/O 1.92/O [/O 1.24/O -/O 2.97/O ]/O ,/O p/O =/O .003/O ;/O 2.26/O [/O 1.34/O -/O 3.82/O ]/O ,/O p/O =/O .002/O ;/O 3.38/O [/O 1.85/O -/O 7.78/O ]/O ,/O p/O </O .001/O ,/O respectively/O )/O ./O
However/O ,/O brain/O metastasis/O (/O BM/O )/O at/O initial/O diagnosis/O or/O intracranial/O progression/O during/O gefitinib/O treatment/O had/O no/O impact/O on/O OS/O (/O 1.266/O [/O 0.83/O -/O 1.93/O ]/O ,/O p/O =/O .275/O and/O 0.75/O [/O 0.48/O -/O 1.19/O ]/O ,/O p/O =/O .211/O ,/O respectively/O )/O ./O
CONCLUSION/O :/O HCV/O infection/O ,/O performance/O status/O (/O ECOG/O ≥2/O )/O ,/O newly/O diagnosed/O advanced/O NSCLC/O without/O prior/O operation/O ,/O and/O liver/O metastasis/O predicted/O poor/O OS/O in/O EGFR/O mutation/O -/O positive/O advanced/O NSCLC/O patients/O treated/O with/O first/O -/O line/O gefitinib/O ;/O however/O ,/O neither/O BM/O at/O initial/O diagnosis/O nor/O intracranial/O progression/O during/O gefitinib/O treatment/O had/O an/O impact/O on/O OS/O ./O
The/O Oncologist/O 2017;22:1/O -/O 9/O IMPLICATIONS/O FOR/O PRACTICE/O :/O The/O finding/O that/O chronic/O hepatitis/O C/O virus/O (/O HCV/O )/O infection/O might/O predict/O poor/O overall/O survival/O (/O OS/O )/O in/O epidermal/O growth/O factor/O receptor/O mutation/O -/O positive/O advanced/O non/O -/O small/O cell/O lung/O cancer/O (/O NSCLC/O )/O patients/O treated/O with/O first/O -/O line/O gefitinib/O may/O raise/O awareness/O of/O benefit/O from/O anti/O -/O HCV/O treatment/O in/O this/O patient/O population/O ./O
Brain/O metastasis/O in/O the/O initial/O diagnosis/O or/O intracranial/O progression/O during/O gefitinib/O treatment/O is/O not/O a/O prognostic/O factor/O for/O OS/O ./O
This/O study/O ,/O which/O enrolled/O a/O real/O -/O world/O population/O of/O NSCLC/O patients/O ,/O including/O sicker/O patients/O who/O were/O not/O eligible/O for/O a/O clinical/O trial/O ,/O may/O have/O impact/O on/O guiding/O usual/O clinical/O practice/O ./O
Loss/B-Var of/O the/O homologous/O recombination/O gene/O rad51/B-Gene leads/B-Reg to/O Fanconi/B-Disease anemia/I-Disease -/I-Disease like/I-Disease symptoms/I-Disease in/O zebrafish/O ./O
RAD51/O is/O an/O indispensable/O homologous/O recombination/O protein/O ,/O necessary/O for/O strand/O invasion/O and/O crossing/O over/O ./O
It/O has/O recently/O been/O designated/O as/O a/O Fanconi/B-Disease anemia/I-Disease (/O FA/O )/O gene/O ,/O following/O the/O discovery/O of/O two/O patients/O carrying/O dominant/O -/O negative/O mutations/O ./O
FA/O is/O a/O hereditary/O DNA/O -/O repair/O disorder/O characterized/O by/O various/O congenital/O abnormalities/O ,/O progressive/O bone/O marrow/O failure/O ,/O and/O cancer/O predisposition/O ./O
In/O this/O report/O ,/O we/O describe/O a/O viable/O vertebrate/O model/O of/O RAD51/O loss/O ./O
Zebrafish/O rad51/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutants/B-Var developed/O key/O features/O of/O FA/B-Disease ,/O including/O hypocellular/O kidney/O marrow/O ,/O sensitivity/O to/O cross/O -/O linking/O agents/O ,/O and/O decreased/O size/O ./O
We/O show/O that/O some/O of/O these/O symptoms/O stem/O from/O both/O decreased/O proliferation/O and/O increased/O apoptosis/O of/O embryonic/O hematopoietic/O stem/O and/O progenitor/O cells/O ./O
Comutation/O of/O p53/O was/O able/O to/O rescue/O the/O hematopoietic/O defects/O seen/O in/O the/O single/O mutants/O ,/O but/O led/O to/O tumor/O development/O ./O
We/O further/O demonstrate/O that/O prolonged/O inflammatory/O stress/O can/O exacerbate/O the/O hematological/O impairment/O ,/O leading/O to/O an/O additional/O decrease/O in/O kidney/O marrow/O cell/O numbers/O ./O
These/O findings/O strengthen/O the/O assignment/O of/O RAD51/O as/O a/O Fanconi/O gene/O and/O provide/O more/O evidence/O for/O the/O notion/O that/O aberrant/O p53/O signaling/O during/O embryogenesis/O leads/O to/O the/O hematological/O defects/O seen/O later/O in/O life/O in/O FA/O ./O
Further/O research/O on/O this/O zebrafish/O FA/O model/O will/O lead/O to/O a/O deeper/O understanding/O of/O the/O molecular/O basis/O of/O bone/O marrow/O failure/O in/O FA/O and/O the/O cellular/O role/O of/O RAD51/O ./O
Gene/O Co/O -/O Expression/O Network/O Analysis/O for/O Identifying/O Modules/O and/O Functionally/O Enriched/O Pathways/O in/O SCA2/O ./O
Spinocerebellar/B-Disease ataxia/I-Disease type/I-Disease 2/I-Disease (/O SCA2/O )/O is/O an/O autosomal/O dominant/O neurodegenerative/O disease/O caused/B-Reg by/I-Reg CAG/B-Var repeat/I-Var expansion/I-Var in/O the/O ATXN2/B-Gene gene/O ./O
The/O repeat/O resides/O in/O an/O encoded/O region/O of/O the/O gene/O resulting/O in/O polyglutamine/O (/O polyQ/O )/O expansion/O which/O has/O been/O assumed/O to/O result/O in/O gain/O of/O function/O ,/O predominantly/O ,/O for/O the/O ATXN2/O protein/O ./O
We/O evaluated/O temporal/O cerebellar/O expression/O profiles/O by/O RNA/O sequencing/O of/O ATXN2Q127/O mice/O vs/O wildtype/O littermates/O ./O
ATXN2Q127/O mice/O are/O characterized/O by/O a/O progressive/O motor/O phenotype/O onset/O ,/O and/O have/O progressive/O cerebellar/O molecular/O and/O neurophysiological/O (/O Purkinje/O cell/O firing/O frequency/O )/O phenotypes/O ./O
Our/O analysis/O revealed/O previously/O uncharacterized/O early/O and/O progressive/O abnormal/O patterning/O of/O cerebellar/O gene/O expression/O ./O
Weighted/O Gene/O Coexpression/O Network/O Analysis/O (/O WGCNA/O )/O revealed/O four/O gene/O modules/O that/O were/O significantly/O correlated/O with/O disease/O status/O ,/O composed/O primarily/O of/O genes/O associated/O with/O GTPase/O signaling/O ,/O calcium/O signaling/O ,/O and/O cell/O death/O ./O
Of/O these/O genes/O ,/O few/O overlapped/O with/O differentially/O expressed/O cerebellar/O genes/O that/O we/O identified/O in/O Atxn2-/-/O knockout/O mice/O vs/O wildtype/O littermates/O ,/O suggesting/O that/O loss/O -/O of/O -/O function/O is/O not/O a/O significant/O component/O of/O disease/O pathology/O ./O
We/O conclude/O that/O SCA2/O is/O a/O disease/O characterized/O by/O gain/O of/O function/O for/O ATXN2/O ./O
Exposure/O to/O phenols/O ,/O parabens/O and/O UV/O filters/O :/O Associations/O with/O loss/O -/O of/O -/O function/O mutations/O in/O the/O filaggrin/O gene/O in/O men/O from/O the/O general/O population/O ./O
BACKGROUND/O :/O Filaggrin/O is/O an/O epidermal/O protein/O that/O is/O important/O for/O normal/O skin/O barrier/O functions/O ./O
Up/O to/O 10/O %/O of/O Europeans/O and/O Asians/O carry/O filaggrin/O gene/O (/B-Gene FLG/I-Gene )/I-Gene loss/B-NegReg -/I-NegReg of/I-NegReg function/I-NegReg mutations/B-Var that/O appear/O to/O facilitate/B-PosReg trans/B-CPA -/I-CPA epidermal/I-CPA penetration/I-CPA of/O certain/O chemicals/O ./O
We/O previously/O showed/O that/O mutation/O carriers/O have/O higher/O internal/O exposure/O to/O certain/O phthalates/O ,/O compared/O to/O controls/O ,/O and/O hypothesized/O that/O they/O could/O have/O increased/O trans/O -/O epidermal/O penetration/O of/O other/O chemicals/O ./O
OBJECTIVES/O :/O We/O investigated/O exposure/O to/O non/O -/O persistent/O chemicals/O in/O young/O Danish/O men/O with/O and/O without/O FLG/O mutations/O ./O
METHODS/O :/O Concentrations/O of/O eight/O simple/O phenols/O ,/O six/O parabens/O and/O nine/O UV/O filters/O were/O analysed/O in/O urine/O from/O 65/O FLG/O loss/O -/O of/O -/O function/O mutation/O carriers/O and/O 130/O non/O -/O carriers/O (/O controls/O )/O ./O
Regression/O analyses/O ,/O controlling/O for/O urinary/O dilution/O and/O confounders/O ,/O were/O performed/O to/O estimate/O associations/O between/O FLG/O mutation/O status/O and/O chemical/O concentrations/O in/O urine/O ./O
RESULTS/O :/O FLG/O mutation/O carriers/O had/O 80/O %/O (/O 13/O -/O 180/O %/O )/O higher/O urinary/O concentrations/O of/O methyl/O paraben/O (/O MeP/O )/O and/O 91/O %/O (/O 13/O -/O 219/O %/O )/O higher/O concentrations/O of/O n/O -/O propyl/O paraben/O (/O n/O -/O PrP/O )/O than/O controls/O ./O
For/O 13/O compounds/O ,/O levels/O were/O higher/O in/O FLG/O mutation/O carriers/O ,/O although/O differences/O were/O only/O statistically/O significant/O for/O MeP/O and/O n/O -/O PrP./O Combined/O statistical/O analysis/O of/O concentrations/O of/O all/O the/O 18/O compounds/O that/O were/O detectable/O in/O >/O 10/O %/O of/O subjects/O ,/O suggested/O that/O concentrations/O were/O generally/O higher/O in/O mutation/O carriers/O (/O p=0.03/O )/O ./O
CONCLUSION/O :/O FLG/O loss/O -/O of/O -/O function/O mutation/O carriers/O have/O a/O higher/O internal/O exposure/O to/O some/O non/O -/O persistent/O chemicals/O ,/O independently/O of/O atopic/O dermatitis/O ./O
This/O may/O be/O due/O to/O increased/O trans/O -/O epidermal/O absorption/O and/or/O higher/O exposure/O ,/O and/O mutation/O carriers/O may/O constitute/O a/O group/O susceptible/O to/O increased/O absorption/O of/O chemicals/O and/O topical/O medication/O ./O
GRIN2B/O gain/O of/O function/O mutations/O are/O sensitive/O to/O radiprodil/O ,/O a/O negative/O allosteric/O modulator/O of/O GluN2B/O -/O containing/O NMDA/O receptors/O ./O
De/O novo/O gain/B-PosReg of/I-PosReg function/I-PosReg mutations/B-Var in/O GRIN2B/B-Gene encoding/O the/O GluN2B/O subunit/O of/O the/O N/O -/O methyl/O -/O d/O -/O aspartate/O (/O NMDA/O )/O receptor/O have/O been/O linked/O with/O epileptic/B-Disease encephalopathies/I-Disease ,/O including/O infantile/B-Disease spasms/I-Disease ./O
We/O investigated/O the/O effects/O of/O radiprodil/O ,/O a/O selective/O GluN2B/O negative/O allosteric/O modulator/O and/O other/O non/O -/O selective/O NMDA/O receptor/O inhibitors/O on/O glutamate/O currents/O mediated/O by/O NMDA/O receptors/O containing/O mutated/O GluN2B/O subunits/O ./O
The/O experiments/O were/O performed/O in/O Xenopus/O oocytes/O co/O -/O injected/O with/O the/O following/O human/O mRNAs/O :/O GRIN1/O //O GRIN2B/O ,/O GRIN1/O //O GRIN2B/O -/O R540H/O ,/O GRIN1/O //O GRIN2B/O -/O N615I/O and/O GRIN1/O //O GRIN2B/O -/O V618G./O Glutamate/O displayed/O slightly/O increased/O potency/O in/O the/O R540H/O variant/O ,/O but/O not/O in/O N615I/O and/O V618/O G/O variants/O ./O
However/O ,/O the/O inhibition/O by/O Mg(2/O +/O )/O was/O completely/O abolished/O in/O N615I/O and/O V618/O G/O variants/O ./O
In/O fact/O ,/O Mg(2/O +/O )/O enhanced/O glutamate/O responses/O in/O those/O variants/O ./O
The/O potency/O of/O radiprodil/O to/O block/O glutamate/O -/O evoked/O currents/O was/O not/O affected/O in/O any/O of/O the/O variants/O ,/O while/O the/O effects/O by/O non/O -/O selective/O NMDA/O inhibitors/O were/O greatly/O reduced/O in/O some/O of/O the/O variants/O ./O
Additionally/O ,/O in/O the/O Mg(2/O +/O )/O insensitive/O variants/O ,/O radiprodil/O blocked/O glutamate/O -/O activated/O currents/O with/O the/O same/O potency/O as/O in/O the/O absence/O of/O Mg(2/O +/O )/O ./O
The/O gain/O of/O function/O observed/O in/O the/O reported/O GRIN2B/O variants/O could/O be/O a/O key/O pathophysiological/O factor/O leading/O to/O neuronal/O hyper/O -/O excitability/O in/O epileptic/O encephalopathies/O ./O
The/O GluN2B/O -/O selective/O inhibitor/O radiprodil/O fully/O retained/O its/O pharmacological/O profile/O under/O these/O conditions/O ,/O while/O other/O non/O -/O selective/O NMDA/O receptor/O antagonists/O lost/O their/O potency/O ./O
Consequently/O ,/O our/O data/O suggest/O that/O radiprodil/O may/O be/O a/O valuable/O therapeutic/O option/O for/O treatment/O of/O pediatric/O epileptic/O encephalopathies/O associated/O with/O GRIN2B/O mutations/O ./O
PAI-1/O gain/O -/O of/O -/O function/O genotype/O ,/O factors/O increasing/O PAI-1/O levels/O ,/O and/O airway/O obstruction/O :/O The/O GALA/O II/O Cohort/O ./O
BACKGROUND/O :/O PAI-1/B-Gene gain/O -/O of/O -/O function/O variants/B-Var promote/B-PosReg airway/B-CPA fibrosis/I-CPA and/O are/O associated/B-Reg with/I-Reg asthma/B-Disease and/O with/O worse/O lung/O function/O in/O subjects/O with/O asthma/O ./O
OBJECTIVE/O :/O We/O sought/O to/O determine/O whether/O the/O association/O of/O a/O gain/O -/O of/O -/O function/O polymorphism/O in/O plasminogen/O activator/O inhibitor-1/O (/O PAI-1/O )/O with/O airway/O obstruction/O is/O modified/O by/O asthma/O status/O ,/O and/O whether/O any/O genotype/O effect/O persists/O after/O accounting/O for/O common/O exposures/O that/O increase/O PAI-1/O level/O ./O
METHODS/O :/O We/O studied/O 2070/O Latino/O children/O (/O 8/O -/O 21y/O )/O with/O genotypic/O and/O pulmonary/O function/O data/O from/O the/O GALA/O II/O cohort/O ./O
We/O estimated/O the/O relationship/O of/O the/O PAI-1/O risk/O allele/O with/O FEV1/O //O FVC/O by/O multivariate/O linear/O regression/O ,/O stratified/O by/O asthma/O status/O ./O
We/O examined/O the/O association/O of/O the/O polymorphism/O with/O asthma/O and/O airway/O obstruction/O within/O asthmatics/O via/O multivariate/O logistic/O regression/O ./O
We/O replicated/O associations/O in/O the/O SAPPHIRE/O cohort/O of/O African/O Americans/O (/O n=1056/O )/O ./O
Secondary/O analysis/O included/O the/O effect/O of/O the/O at/O -/O risk/O polymorphism/O on/O postbronchodilator/O lung/O function/O ./O
RESULTS/O :/O There/O was/O an/O interaction/O between/O asthma/O status/O and/O the/O PAI-1/O polymorphism/O on/O FEV1/O /FVC/O (/O P=.03/O )/O ./O
The/O gain/O -/O of/O -/O function/O variants/O ,/O genotypes/O (/O AA/O //O AG/O )/O ,/O were/O associated/O with/O lower/O FEV1/O /FVC/O in/O subjects/O with/O asthma/O (/O β=-1.25/O ,/O CI/O :/O -2.14,-0.35/O ,/O P=.006/O )/O ,/O but/O not/O in/O controls/O ./O
Subjects/O with/O asthma/O and/O the/O AA/O //O AG/O genotypes/O had/O a/O 5/O %/O decrease/O in/O FEV1/O /FVC/O (/O P<.001/O )/O ./O
In/O asthmatics/O ,/O the/O risk/O genotype/O (/O AA/O //O AG/O )/O was/O associated/O with/O a/O 39/O %/O increase/O in/O risk/O of/O clinically/O relevant/O airway/O obstruction/O (/O OR=1.39/O ,/O CI/O :/O 1.01/O ,/O 1.92/O ,/O P=.04/O )/O ./O
These/O associations/O persisted/O after/O exclusion/O of/O factors/O that/O increase/O PAI-1/O including/O tobacco/O exposure/O and/O obesity/O ./O
CONCLUSIONS/O AND/O CLINICAL/O RELEVANCE/O :/O The/O decrease/O in/O the/O FEV1/O /FVC/O ratio/O associated/O with/O the/O risk/O genotype/O was/O modified/O by/O asthma/O status/O ./O
The/O genotype/O increased/O the/O odds/O of/O airway/O obstruction/O by/O 75/O %/O within/O asthmatics/O only/O ./O
As/O exposures/O known/O to/O increase/O PAI-1/O levels/O did/O not/O mitigate/O this/O association/O ,/O PAI-1/O may/O contribute/O to/O airway/O obstruction/O in/O the/O context/O of/O chronic/O asthmatic/O airway/O inflammation/O ./O
Severe/O hypertriglyceridemia/B-Disease due/O to/O two/O novel/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg lipoprotein/B-Enzyme lipase/I-Enzyme gene/O mutations/O (/B-Var C310R/I-Var //I-Var E396V/I-Var )/I-Var in/O a/O Chinese/O family/O associated/B-Reg with/I-Reg recurrent/B-Disease acute/I-Disease pancreatitis/I-Disease ./O
Lipoprotein/O lipase/O (/O LPL/O )/O is/O widely/O expressed/O in/O skeletal/O muscles/O ,/O cardiac/O muscles/O as/O well/O as/O adipose/O tissue/O and/O involved/O in/O the/O catabolism/O of/O triglyceride/O ./O
Herein/O we/O have/O systematically/O characterized/O two/O novel/O loss/O -/O of/O -/O function/O mutations/O in/O LPL/O from/O a/O Chinese/O family/O in/O which/O afflicted/O members/O were/O manifested/O by/O severe/O hypertriglyceridemia/O and/O recurrent/O pancreatitis/O ./O
DNA/O sequencing/O revealed/O that/O the/O proband/O was/O a/O heterozygote/O carrying/O a/O novel/O c/O ./O
T928C/O (/O p/O ./O C310R/O )/O mutation/O in/O exon/O 6/O of/O the/O LPL/O gene/O ./O
Another/O member/O of/O the/O family/O was/O detected/O to/O be/O a/O compound/O heterozygote/O who/O along/O with/O the/O c/O ./O
T928C/O mutation/O also/O carried/O a/O novel/O missense/O mutation/O c/O ./O
A1187/O T/O (/O p/O ./O E396V/O )/O in/O exon/O 8/O of/O the/O LPL/O gene/O ./O
Furthermore/O ,/O COS-1/O cells/O were/O transfected/O with/O lentiviruses/O containing/O the/O mutant/O LPL/O genes/O ./O
While/O C310R/B-Var markedly/O reduced/B-NegReg the/O overall/O LPL/B-MPA protein/I-MPA level/I-MPA ,/O COS-1/O cells/O carrying/O E396V/O or/O double/O mutations/O contained/O similar/O overall/O LPL/O protein/O levels/O to/O the/O wild/O -/O type/O ./O
The/O specific/O activity/O of/O the/O LPL/O mutants/O remained/O at/O comparable/O magnitude/O to/O the/O wild/O -/O type/O ./O
However/O ,/O few/O LPL/O were/O detected/O in/O the/O culture/O medium/O for/O the/O mutants/O ,/O suggesting/O that/O both/O mutations/B-Var caused/B-Reg aberrant/O triglyceride/B-MPA catabolism/I-MPA ./O
More/O specifically/O ,/O E396V/B-Var and/O double/B-Var mutations/I-Var dampened/B-NegReg the/O transport/B-MPA of/I-MPA LPL/I-MPA to/I-MPA the/I-MPA cell/I-MPA surface/I-MPA ,/O while/O for/O the/O C310R/B-Var mutation/O ,/O reducing/B-NegReg LPL/B-MPA protein/I-MPA level/I-MPA might/O be/O involved/O ./O
By/O characterizing/O these/O two/O novel/O LPL/O mutations/O ,/O this/O study/O has/O expanded/O our/O understanding/O on/O the/O pathogenesis/O of/O familial/O hypertriglyceridemia/O (/O FHTG/O )/O ./O
WNT10A/B-Gene mutation/B-Var causes/B-Reg ectodermal/B-Disease dysplasia/I-Disease by/O impairing/B-NegReg progenitor/B-CPA cell/I-CPA proliferation/I-CPA and/O KLF4-mediated/B-CPA differentiation/I-CPA ./O
Human/O WNT10A/O mutations/O are/O associated/O with/O developmental/O tooth/O abnormalities/O and/O adolescent/O onset/O of/O a/O broad/O range/O of/O ectodermal/O defects/O ./O
Here/O we/O show/O that/O β/O -/O catenin/O pathway/O activity/O and/O adult/O epithelial/O progenitor/O proliferation/O are/O reduced/O in/O the/O absence/O of/O WNT10A/O ,/O and/O identify/O Wnt/O -/O active/O self/O -/O renewing/O stem/O cells/O in/O affected/O tissues/O including/O hair/O follicles/O ,/O sebaceous/O glands/O ,/O taste/O buds/O ,/O nails/O and/O sweat/O ducts/O ./O
Human/O and/O mouse/O WNT10A/O mutant/O palmoplantar/O and/O tongue/O epithelia/O also/O display/O specific/O differentiation/O defects/O that/O are/O mimicked/O by/O loss/O of/O the/O transcription/O factor/O KLF4/O ./O
We/O find/O that/O β/O -/O catenin/O interacts/O directly/O with/O region/O -/O specific/O LEF/O //O TCF/O factors/O ,/O and/O with/O KLF4/O in/O differentiating/O ,/O but/O not/O proliferating/O ,/O cells/O to/O promote/O expression/O of/O specialized/O keratins/O required/O for/O normal/O tissue/O structure/O and/O integrity/O ./O
Our/O data/O identify/O WNT10A/O as/O a/O critical/O ligand/O controlling/O adult/O epithelial/O proliferation/O and/O region/O -/O specific/O differentiation/O ,/O and/O suggest/O downstream/O β/O -/O catenin/O pathway/O activation/O as/O a/O potential/O approach/O to/O ameliorate/O regenerative/O defects/O in/O WNT10A/O patients/O ./O
Loss/B-Var of/I-Var function/I-Var in/O ROBO1/B-Gene is/O associated/B-Reg with/O tetralogy/B-Disease of/I-Disease Fallot/I-Disease and/O septal/B-Disease defects/I-Disease ./O
BACKGROUND/O :/O Congenital/O heart/O disease/O (/O CHD/O )/O is/O a/O common/O birth/O defect/O affecting/O approximately/O 1/O %/O of/O newborns/O ./O
Great/O progress/O has/O been/O made/O in/O elucidating/O the/O genetic/O aetiology/O of/O CHD/O with/O advances/O in/O genomic/O technology/O ,/O which/O we/O leveraged/O in/O recovering/O a/O new/O pathway/O affecting/O heart/O development/O in/O humans/O previously/O known/O to/O affect/O heart/O development/O in/O an/O animal/O model/O ./O
METHODS/O :/O Four/O hundred/O and/O sixteen/O individuals/O from/O Thailand/O and/O the/O USA/O diagnosed/O with/O CHD/O and/or/O congenital/O diaphragmatic/O hernia/O were/O evaluated/O with/O chromosomal/O microarray/O and/O whole/O exome/O sequencing/O ./O
The/O DECIPHER/O Consortium/O and/O medical/O literature/O were/O searched/O for/O additional/O patients/O ./O
Murine/O hearts/O from/O ENU/O -/O induced/O mouse/O mutants/O and/O transgenic/O mice/O were/O evaluated/O using/O both/O episcopic/O confocal/O histopathology/O and/O troponin/O I/O stained/O sections/O ./O
RESULTS/O :/O Loss/O of/O function/O ROBO1/O variants/O were/O identified/O in/O three/O families/O ;/O each/O proband/O had/O a/O ventricular/O septal/O defect/O ,/O and/O one/O proband/O had/O tetralogy/O of/O Fallot/O ./O
Additionally/O ,/O a/O microdeletion/O in/O an/O individual/O with/O CHD/O was/O found/O in/O the/O medical/O literature/O ./O
Mouse/O models/O showed/O perturbation/O of/O the/O Slit/O -/O Robo/O signalling/O pathway/O ,/O causing/O septation/O and/O outflow/O tract/O defects/O and/O craniofacial/O anomalies/O ./O
Two/O probands/O had/O variable/O facial/O features/O consistent/O with/O the/O mouse/O model/O ./O
CONCLUSION/O :/O Our/O findings/O identify/O Slit/O -/O Robo/O as/O a/O significant/O pathway/O in/O human/O heart/O development/O and/O CHD/O ./O
Human/O IκBα/O Gain/O of/O Function/O :/O a/O Severe/O and/O Syndromic/O Immunodeficiency/O ./O
Germline/O heterozygous/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var of/O NFKBIA/B-Gene ,/O encoding/O IκBα/O ,/O cause/O an/O autosomal/O dominant/O (/O AD/O )/O form/O of/O anhidrotic/B-Disease ectodermal/I-Disease dysplasia/I-Disease with/I-Disease immunodeficiency/I-Disease (/O EDA/O -/O ID/O )/O ./O
Fourteen/O unrelated/O patients/O have/O been/O reported/O since/O the/O identification/O of/O the/O first/O case/O in/O 2003/O ./O
All/O mutations/B-Var enhanced/B-PosReg the/O inhibitory/B-MPA activity/I-MPA of/O IκBα/B-Protein ,/O by/O preventing/B-NegReg its/O phosphorylation/B-MPA on/I-MPA serine/I-MPA 32/I-MPA or/I-MPA 36/I-MPA and/O its/O subsequent/O degradation/B-MPA ./O
The/O mutation/O certainly/O or/O probably/O occurred/O de/O novo/O in/O 13/O patients/O ,/O whereas/O it/O was/O inherited/O from/O a/O parent/O with/O somatic/O mosaicism/O in/O one/O patient/O ./O
Eleven/O mutations/O ,/O belonging/O to/O two/O groups/O ,/O were/O identified/O :/O (/O i/O )/O missense/O mutations/O affecting/O S32/O ,/O S36/O ,/O or/O neighboring/O residues/O (/O 8/O mutations/O ,/O 11/O patients/O )/O and/O (/O ii/O )/O nonsense/O mutations/O upstream/O from/O S32/O associated/O with/O the/O reinitiation/O of/O translation/O downstream/O from/O S36/O (/O 3/O mutations/O ,/O 3/O patients/O )/O ./O
Thirteen/O patients/O had/O developmental/O features/O of/O EDA/O ,/O the/O severity/O and/O nature/O of/O which/O differed/O between/O cases/O ./O
All/O patient/O cells/O tested/O displayed/O impaired/O NF/O -/O κB/O -/O mediated/O responses/O to/O the/O stimulation/O of/O various/O surface/O receptors/O involved/O in/O cell/O -/O intrinsic/O (/O fibroblasts/O )/O ,/O innate/O (/O monocytes/O )/O ,/O and/O adaptive/O (/O B/O and/O T/O cells/O )/O immunity/O ,/O including/O TLRs/O ,/O IL-1Rs/O ,/O TNFRs/O ,/O TCR/O ,/O and/O BCR/O ./O
All/O patients/O had/O profound/O B/O -/O cell/O deficiency/O ./O
Specific/O immunological/O features/O ,/O found/O in/O some/O ,/O but/O not/O all/O patients/O ,/O included/O a/O lack/O of/O peripheral/O lymph/O nodes/O ,/O lymphocytosis/O ,/O dysfunctional/O α/O //O β/O T/O cells/O ,/O and/O a/O lack/O of/O circulating/O γ/O //O δ/O T/O cells/O ./O
The/O patients/O had/O various/O pyogenic/O ,/O mycobacterial/O ,/O fungal/O ,/O and/O viral/O severe/O infections/O ./O
Patients/O with/O a/O missense/O mutation/O tended/O to/O display/O more/O severe/O phenotypes/O ,/O probably/O due/O to/O higher/O levels/O of/O GOF/O proteins/O ./O
In/O the/O absence/O of/O hematopoietic/O stem/O cell/O transplantation/O (/O HSCT/O )/O ,/O this/O condition/O cause/O death/O before/O the/O age/O of/O 1/O year/O (/O one/O child/O )/O ./O
Two/O survivors/O have/O been/O on/O prophylaxis/O (/O at/O 9/O and/O 22/O years/O )/O ./O
Six/O children/O died/O after/O HSCT/O ./O
Five/O survived/O ,/O four/O of/O whom/O have/O been/O on/O prophylaxis/O (/O 3/O to/O 21/O years/O post/O HSCT/O )/O ,/O whereas/O one/O has/O been/O well/O with/O no/O prophylaxis/O ./O
Heterozygous/O GOF/O mutations/O in/O IκBα/O underlie/O a/O severe/O and/O syndromic/O immunodeficiency/O ,/O the/O interindividual/O variability/O of/O which/O might/O partly/O be/O ascribed/O to/O the/O dichotomy/O of/O missense/O and/O nonsense/O mutations/O ,/O and/O the/O hematopoietic/O component/O of/O which/O can/O be/O rescued/O by/O HSCT/O ./O
ARX/B-Gene polyalanine/B-Var expansion/I-Var mutations/I-Var lead/B-Reg to/I-Reg migration/B-CPA impediment/I-CPA in/I-CPA the/I-CPA rostral/I-CPA cortex/I-CPA coupled/I-CPA with/O a/O developmental/B-CPA deficit/I-CPA of/I-CPA calbindin/I-CPA -/I-CPA positive/I-CPA cortical/I-CPA GABAergic/I-CPA interneurons/I-CPA ./O
The/O Aristaless/O -/O related/O homeobox/O gene/O (/O ARX/O )/O is/O indispensable/O for/O interneuron/O development/O ./O
Patients/O with/O ARX/O polyalanine/O expansion/O mutations/O of/O the/O first/O two/O tracts/O (/O namely/O PA1/O and/O PA2/O )/O suffer/O from/O intellectual/O disability/O of/O varying/O severity/O ,/O with/O seizures/O a/O frequent/O comorbidity/O ./O
The/O impact/O of/O PA1/O and/O PA2/O mutations/O on/O the/O brain/O development/O is/O unknown/O ,/O hindering/O the/O search/O for/O therapeutic/O interventions/O ./O
Here/O ,/O we/O characterized/O the/O disturbances/O to/O cortical/O interneuron/O development/O in/O mice/O modeling/O the/O two/O most/O common/O ARX/O polyalanine/O expansion/O mutations/O in/O human/O ./O
We/O found/O a/O consistent/O ∼40/O -/O 50/O %/O reduction/O of/O calbindin/O -/O positive/O interneurons/O ,/O but/O not/O Stt+/O or/O Cr+/O interneurons/O ,/O within/O the/O cortex/O of/O newborn/O hemizygous/O mice/O (/O p=0.024/O )/O for/O both/O mutant/O strains/O compared/O to/O wildtype/O (/O p=0.011/O )/O ./O
We/O demonstrate/O that/O this/O was/O a/O consequence/O of/O calbindin/O precursor/O cells/O being/O arrested/O or/O delayed/O at/O the/O ventral/O subpallium/O en/O route/O of/O tangential/O migration/O ./O
Ex/O -/O vivo/O assay/O validated/O this/O migration/O deficit/O in/O PA1/O cells/O (/O p=0.0002/O )/O suggesting/O that/O the/O defect/O is/O contributed/O by/O intrinsic/O loss/O of/O Arx/O function/O within/O migrating/O cells/O ./O
Both/O humans/O and/O mice/O with/O PA1/O mutations/O present/O with/O severe/O clinical/O features/O ,/O including/O intellectual/O disability/O and/O infantile/O spasms/O ./O
Our/O data/O further/O demonstrated/O the/O pathogenic/O mechanism/O was/O robustly/O shared/O between/O PA1/O and/O PA2/O mutations/O ,/O as/O previously/O reported/O including/O Arx/O protein/O reduction/O and/O overlapping/O transcriptome/O profiles/O within/O the/O developing/O mouse/O brains/O ./O
Data/O from/O our/O study/O demonstrated/O that/O cortical/B-CPA calbindin/I-CPA interneuron/I-CPA development/B-CPA and/O migration/B-CPA is/O negatively/B-NegReg affected/O by/O ARX/B-Gene polyalanine/B-Var expansion/I-Var mutations/I-Var ./O
Understanding/O the/O cellular/O pathogenesis/O contributing/O to/O disease/O manifestation/O is/O necessary/O to/O screen/O efficacy/O of/O potential/O therapeutic/O interventions/O ./O
Inducible/O activation/O of/O FGFR2/O in/O adult/O mice/O promotes/O bone/O formation/O after/O bone/O marrow/O ablation/O ./O
Apert/B-Disease syndrome/I-Disease is/O one/O of/O the/O most/O severe/O craniosynostoses/O ,/O resulting/O from/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O fibroblast/O growth/O factor/O receptor/O 2/O (/B-Gene FGFR2/I-Gene )/I-Gene ./O
Previous/O studies/O have/O shown/O that/O gain/O -/O of/O -/O function/O mutations/O of/O FGFR2/O (/O S252W/O or/O P253R/O )/O cause/O skull/O malformation/O of/O human/O Apert/O syndrome/O by/O affecting/O both/O chondrogenesis/O and/O osteogenesis/O ,/O underscoring/O the/O key/O role/O of/O FGFR2/O in/O bone/O development/O ./O
However/O ,/O the/O effects/O of/O FGFR2/O on/O bone/O formation/O at/O the/O adult/O stage/O have/O not/O been/O fully/O investigated/O ./O
To/O investigate/O the/O role/O of/O FGFR2/O in/O bone/O formation/O ,/O we/O generated/O mice/O with/O tamoxifen/O -/O inducible/O expression/O of/O mutant/O FGFR2/O (/O P253R/O )/O at/O the/O adult/O stage/O ./O
Mechanical/O bone/O marrow/O ablation/O (/O BMX/O )/O was/O performed/O in/O both/O wild/O -/O type/O and/O Fgfr2/B-Gene mutant/B-Var (/O MT/O )/O mice/O ./O
Changes/O in/O newly/O formed/O trabecular/O bone/O were/O assessed/O by/O micro/O -/O computed/O tomography/O and/O bone/O histomorphometry/O ./O
We/O found/O that/O MT/O mice/O exhibited/O increased/B-PosReg trabecular/B-CPA bone/I-CPA formation/I-CPA and/O decreased/B-NegReg bone/B-CPA resorption/I-CPA after/O BMX/O accompanied/O with/O a/O remarkable/O increase/B-PosReg in/O bone/B-CPA marrow/I-CPA stromal/I-CPA cell/I-CPA recruitment/B-CPA and/O proliferation/B-CPA ,/O osteoblast/B-CPA proliferation/B-CPA and/O differentiation/B-CPA ,/O and/O enhanced/B-PosReg Wnt/?-catenin/B-CPA activity/I-CPA ./O
Furthermore/O ,/O pharmacologically/O inhibiting/O Wnt/O //O β/O -/O catenin/O signaling/O can/O partially/O reverse/O the/O increased/O trabecular/O bone/O formation/O and/O decreased/O bone/O resorption/O in/O MT/O mice/O after/O BMX/O ./O
Our/O data/O demonstrate/O that/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O FGFR2/B-Gene exerts/B-MPA a/I-MPA Wnt/I-MPA //I-MPA β/I-MPA -/I-MPA catenin/I-MPA -/I-MPA dependent/I-MPA anabolic/I-MPA effect/I-MPA on/O trabecular/O bone/O by/O promoting/B-PosReg bone/B-CPA formation/I-CPA and/O inhibiting/B-NegReg bone/B-CPA resorption/I-CPA at/I-CPA the/I-CPA adult/I-CPA stage/I-CPA ./O
This/O article/O is/O protected/O by/O copyright/O ./O
All/O rights/O reserved/O ./O
Early/B-Disease -/I-Disease onset/I-Disease autoimmune/I-Disease disease/I-Disease due/O to/O a/O heterozygous/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var in/O TNFAIP3/B-Gene (/O A20/O )/O ./O
The/O moving/O junction/O protein/O RON4/O ,/O although/O not/O critical/O ,/O facilitates/O host/O cell/O invasion/O and/O stabilizes/O MJ/O members/O ./O
Toxoplasma/O gondii/O is/O an/O obligate/O intracellular/O parasite/O of/O phylum/O Apicomplexa/O ./O
To/O facilitate/O high/O -/O efficiency/O invasion/O of/O host/O cells/O ,/O T./O gondii/O secretes/O various/O proteins/O related/O to/O the/O moving/O junction/O (/O MJ/O )/O complex/O from/O rhoptries/O and/O micronemes/O into/O the/O interface/O between/O the/O parasite/O and/O host/O ./O
AMA1/O //O RON2/4/5/8/O is/O an/O important/O MJ/O complex/O ,/O but/O its/O mechanism/O of/O assembly/O remains/O unclear/O ./O
In/O this/O study/O ,/O we/O used/O the/O CRISPR/O -/O Cas9/O system/O to/O generate/O a/O derivative/O of/O T./O gondii/O strain/O RH/O with/O a/O null/B-Var mutation/I-Var in/O TgRON4/B-Gene ,/O thought/O to/O be/O an/O essential/O MJ/O component/O ./O
Deficiency/B-NegReg of/O TgRON4/B-Protein moderately/O decreased/B-NegReg invasion/B-CPA ability/I-CPA relative/O to/O that/O of/O the/O wild/O -/O type/O parasite/O ./O
In/O addition/O ,/O expression/B-MPA of/I-MPA the/I-MPA endogenous/I-MPA N/I-MPA -/I-MPA terminal/I-MPA fragment/I-MPA of/O RON5/B-Protein decreased/B-NegReg in/O the/O mutant/B-Var ./O
Together/O ,/O the/O results/O improve/O our/O understanding/O of/O the/O assembly/O mechanism/O of/O the/O MJ/O complex/O of/O T./O gondii/O and/O raise/O the/O possibility/O of/O developing/O new/O therapeutic/O drugs/O that/O target/O this/O complex/O ./O
Natural/O and/O induced/O loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var in/O SlMBP21/B-Gene MADS/O -/O box/O gene/O led/O to/O jointless-2/B-CPA phenotype/I-CPA in/O tomato/O ./O
Abscission/O is/O the/O mechanism/O by/O which/O plants/O disconnect/O unfertilized/O flowers/O ,/O ripe/O fruits/O ,/O senescent/O or/O diseased/O organs/O from/O the/O plant/O ./O
In/O tomato/O ,/O pedicel/O abscission/O is/O an/O important/O agronomic/O factor/O that/O controls/O yield/O and/O post/O -/O harvest/O fruit/O quality/O ./O
Two/O non/O -/O allelic/O mutations/O ,/O jointless/O (/O j/O )/O and/O jointless-2/O (/O j-2/O )/O ,/O controlling/O pedicel/O abscission/O zone/O formation/O have/O been/O documented/O but/O only/O j-2/O has/O been/O extensively/O used/O in/O breeding/O ./O
J/O was/O shown/O to/O encode/O a/O MADS/O -/O box/O protein/O ./O
Using/O a/O combination/O of/O physical/O mapping/O and/O gene/O expression/O analysis/O we/O identified/O a/O positional/O candidate/O ,/O Solyc12g038510/O ,/O associated/O with/O j-2/O phenotype/O ./O
Targeted/O knockout/O of/O Solyc12g038510/O ,/O using/O CRISPR/O //O Cas9/O system/O ,/O validated/O our/O hypothesis/O ./O
Solyc12g038510/O encodes/O the/O MADS/O -/O box/O protein/O SlMBP21/O ./O
Molecular/O analysis/O of/O j-2/O natural/O variation/O revealed/O two/O independent/O loss/O -/O of/O -/O function/O mutants/O ./O
The/O first/O results/O of/O an/O insertion/O of/O a/O Rider/O retrotransposable/O element/O ./O
The/O second/O results/O of/O a/O stop/O codon/O mutation/O that/O leads/O to/O a/O truncated/O protein/O form/O ./O
To/O bring/O new/O insights/O into/O the/O role/O of/O J/O and/O J-2/O in/O abscission/O zone/O formation/O ,/O we/O phenotyped/O the/O single/O and/O the/O double/O mutants/O and/O the/O engineered/O alleles/O ./O
We/O showed/O that/O J/O is/O epistatic/O to/O J-2/O and/O that/O the/O branched/O inflorescences/O and/O the/O leafy/O sepals/O observed/O in/O accessions/O harboring/O j-2/O alleles/O are/O likely/O the/O consequences/O of/O linkage/O drags/O ./O
Nephron/B-CPA development/I-CPA and/O extrarenal/B-CPA features/I-CPA in/O a/O child/O with/O congenital/O nephrotic/O syndrome/O caused/B-Reg by/I-Reg null/O LAMB2/B-Gene mutations/B-Var ./O
BACKGROUND/O :/O Congenital/O nephrotic/O syndrome/O (/O CNS/O )/O is/O a/O rare/O disorder/O caused/O by/O various/O structural/O and/O developmental/O defects/O of/O glomeruli/O ./O
It/O occurs/O typically/O as/O an/O isolated/O kidney/O disorder/O but/O associates/O sometimes/O with/O other/O systemic/O ,/O extrarenal/O manifestations/O ./O
CASE/O PRESENTATIONS/O :/O An/O infant/O presented/O with/O severe/O CNS/O ,/O which/O progressed/O rapidly/O to/O renal/O failure/O at/O age/O of/O 3/O months/O and/O death/O at/O 27/O months/O ./O
The/O clinical/O phenotypes/O and/O genetic/O causes/O were/O studied/O ,/O including/O the/O renal/O pathology/O at/O autopsy/O ./O
Besides/O the/O CNS/O ,/O the/O affected/O child/O had/O remarkable/O right/O -/O side/O predominant/O eye/O -/O ball/O hypoplasia/O with/O bilateral/O anterior/O chamber/O dysgenesis/O (/O microcoria/O )/O ./O
Brain/O MRI/O revealed/O grossly/O normal/O development/O in/O the/O cerebrum/O ,/O cerebellum/O ,/O and/O brain/O stem/O ./O
Auditory/O brainstem/O responses/O were/O bilaterally/O blunted/O ,/O suggesting/O a/O defective/O auditory/O system/O ./O
At/O autopsy/O ,/O both/O kidneys/O were/O mildly/O atrophied/O with/O persistent/O fetal/O lobulation/O ./O
Microscopic/O examination/O showed/O a/O diffuse/O global/O sclerosis/O ./O
However/O ,/O despite/O of/O the/O smaller/O size/O of/O glomeruli/O ,/O the/O nephron/O number/O remained/O similar/O to/O that/O of/O the/O age/O -/O matched/O control/O ./O
Whole/O -/O exome/O sequencing/O revealed/O that/O the/O affected/O child/O was/O compound/O heterozygous/O for/O novel/O truncating/O LAMB2/O mutations/O :/O a/O 4-bp/O insertion/O (/O p/O ./O Gly1693Alafs*8/O )/O and/O a/O splicing/O donor/O -/O site/O substitution/O (/O c.1225/O +/O 1/O G/O >/O A/O )/O ,/O presumably/O deleting/O the/O coiled/O -/O coil/O domains/O that/O form/O the/O laminin/O 5/O -/O 2/O -/O 1/O heterotrimer/O complex/O ./O
CONCLUSIONS/O :/O Our/O case/O represents/O a/O variation/O of/O Pierson/O syndrome/O that/O accompanies/O CNS/O with/O unilateral/O ocular/O hypoplasia/O ./O
The/O average/O number/O but/O smaller/O glomeruli/O could/O reflect/O either/O mal/O -/O development/O or/O glomerulosclerosis/O ./O
Heterogeneous/O clinical/O expression/O of/O LAMB2/O defects/O may/O associate/O with/O the/O difference/O in/O fetal/O β1/O subtype/O compensation/O among/O affected/O tissues/O ./O
Further/O study/O is/O necessary/O to/O evaluate/O incidence/O and/O features/O of/O auditory/O defect/O under/O LAMB2/O deficiency/O ./O
Exome/O sequencing/O reveals/O independent/O SGCD/B-Gene deletions/B-Var causing/B-Reg limb/B-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease in/O Boston/O terriers/O ./O
BACKGROUND/O :/O Limb/O -/O girdle/O muscular/O dystrophies/O (/O LGMDs/O )/O are/O a/O heterogeneous/O group/O of/O inherited/O autosomal/O myopathies/O that/O preferentially/O affect/O voluntary/O muscles/O of/O the/O shoulders/O and/O hips/O ./O
LGMD/O has/O been/O clinically/O described/O in/O several/O breeds/O of/O dogs/O ,/O but/O the/O responsible/O mutations/O are/O unknown/O ./O
The/O clinical/O presentation/O in/O dogs/O is/O characterized/O by/O marked/O muscle/O weakness/O and/O atrophy/O in/O the/O shoulder/O and/O hips/O during/O puppyhood/O ./O
METHODS/O :/O Following/O clinical/O evaluation/O ,/O the/O identification/O of/O the/O dystrophic/O histological/O phenotype/O on/O muscle/O histology/O ,/O and/O demonstration/O of/O the/O absence/O of/O sarcoglycan/O -/O sarcospan/O complex/O by/O immunostaining/O ,/O whole/O exome/O sequencing/O was/O performed/O on/O five/O Boston/O terriers/O :/O one/O affected/O dog/O and/O its/O three/O family/O members/O and/O one/O unrelated/O affected/O dog/O ./O
RESULTS/O :/O Within/O sarcoglycan/O -/O δ/O (/B-Gene SGCD/I-Gene )/I-Gene ,/O a/O two/O base/O pair/O deletion/O segregating/O with/O LGMD/O in/O the/O family/O was/O discovered/O ,/O and/O a/O deletion/O encompassing/O exons/O 7/O and/O 8/O was/O found/O in/O the/O unrelated/O dog/O ./O
Both/O mutations/B-Var are/O predicted/O to/O cause/O an/O absence/B-NegReg of/O SGCD/B-Gene protein/B-Protein ,/O confirmed/O by/O immunohistochemistry/O ./O
The/O mutations/O are/O private/O to/O each/O family/O ./O
CONCLUSIONS/O :/O Here/O ,/O we/O describe/O the/O first/O cases/O of/O canine/O LGMD/O characterized/O at/O the/O molecular/O level/O with/O the/O classification/O of/O LGMD2F./O Calcium/O pumps/O and/O interacting/O BON1/O protein/O modulate/O calcium/O signature/O ,/O stomatal/O closure/O ,/O and/O plant/O immunity/O ./O
Calcium/O signaling/O is/O essential/O for/O environmental/O responses/O including/O immune/O responses/O ./O
Here/O we/O provide/O evidence/O that/O the/O evolutionarily/O conserved/O protein/O BONZAI1/O (/O BON1/O )/O functions/O together/O with/O autoinhibited/O calcium/O ATPase/O 10/O (/O ACA10/O )/O and/O ACA8/O to/O regulate/O calcium/O signals/O in/O Arabidopsis/O ./O
BON1/O is/O a/O plasma/O membrane/O localized/O protein/O that/O negatively/O regulates/O the/O expression/O of/O immune/O receptor/O genes/O and/O positively/O regulates/O stomatal/O closure/O ./O
We/O found/O that/O BON1/O interacts/O with/O the/O autoinhibitory/O domains/O of/O ACA10/O and/O ACA8/O ,/O and/O the/O aca10/B-Gene loss/B-NegReg of/I-NegReg function/I-NegReg (/O LOF/O )/O mutants/B-Var have/O an/O autoimmune/O phenotype/O similar/O to/O that/O of/O the/O bon1/B-Gene LOF/B-NegReg mutants/B-Var ./O
Genetic/O evidences/O indicate/O that/O BON1/O positively/O regulates/O the/O activities/O of/O ACA10/O and/O ACA8/O ./O
Consistent/O with/O this/O idea/O ,/O the/O steady/B-MPA level/I-MPA of/I-MPA calcium/I-MPA concentration/I-MPA is/O increased/B-PosReg in/O both/O aca10/B-Gene and/O bon1/B-Gene mutants/B-Var ./O
Most/O strikingly/O ,/O cytosolic/O calcium/O oscillation/O imposed/O by/O external/O calcium/O treatment/O was/O altered/O in/O aca10/O ,/O aca8/O ,/O and/O bon1/O mutants/O in/O guard/O cells/O ./O
In/O addition/O ,/O calcium/B-CPA and/I-CPA pathogen/I-CPA induced/I-CPA stomatal/I-CPA closure/I-CPA was/O compromised/B-NegReg in/O the/O aca10/B-Gene and/O bon1/B-Gene mutants/B-Var ./O
Taken/O together/O ,/O this/O study/O indicates/O that/O ACA10/8/O and/O BON1/O physically/O interact/O on/O plasma/O membrane/O and/O function/O in/O the/O generation/O of/O cytosol/O calcium/O signatures/O that/O are/O critical/O for/O stomatal/O movement/O and/O impact/O plant/O immunity/O ./O
Extracellular/O inhibitors/O can/O attenuate/O tumorigenic/O Wnt/O pathway/O activity/O in/O adenomatous/O polyposis/O coli/O mutants/O :/O Predictions/O of/O a/O validated/O mathematical/O model/O ./O
BACKGROUND/O :/O Despite/O considerable/O investigational/O efforts/O ,/O no/O method/O to/O overcome/O the/O pathogenesis/O caused/O by/O loss/O of/O function/O (/O LoF/O )/O mutations/O in/O tumor/O suppressor/O genes/O has/O been/O successfully/O translated/O to/O the/O clinic/O ./O
The/O most/O frequent/O LoF/B-NegReg mutation/B-Var in/O human/O cancers/O is/O Adenomatous/B-Gene polyposis/I-Gene coli/I-Gene (/O APC/O )/O ,/O causing/O aberrant/O activation/B-PosReg of/O the/O Wnt/B-Pathway pathway/I-Pathway ./O
In/O nearly/O all/O colon/B-Disease cancer/I-Disease tumors/I-Disease ,/O the/O APC/B-Protein protein/I-Protein is/O truncated/O ,/O but/O still/O retains/B-NegReg partial/I-NegReg binding/B-Interaction abilities/B-MPA ./O
OBJECTIVE/O &/O METHODS/O :/O Here/O ,/O we/O tested/O the/O hypothesis/O that/O extracellular/O inhibitors/O of/O the/O Wnt/O pathway/O ,/O although/O acting/O upstream/O of/O the/O APC/O mutation/O ,/O can/O restore/O normal/O levels/O of/O pathway/O activity/O in/O colon/O cancer/O cells/O ./O
To/O this/O end/O ,/O we/O developed/O and/O simulated/O a/O mathematical/O model/O for/O the/O Wnt/O pathway/O in/O different/O APC/O mutants/O ,/O with/O or/O without/O the/O effects/O of/O the/O extracellular/O inhibitors/O ,/O Secreted/O Frizzled/O -/O Related/O Protein1/O (/O sFRP1/O )/O and/O Dickhopf1/O (/O Dkk1/O )/O ./O
We/O compared/O our/O model/O predictions/O to/O experimental/O data/O in/O the/O literature/O ./O
RESULTS/O :/O Our/O model/O accurately/O predicts/O T/O -/O cell/O factor/O (/O TCF/O )/O activity/O in/O mutant/O cells/O that/O vary/O in/O APC/O mutation/O ./O
Model/O simulations/O suggest/O that/O both/O sFRP1/O and/O DKK1/O can/O reduce/O TCF/O activity/O in/O APC1638N/1572/O T/O and/O Apcmin/O //O min/O mutants/O ,/O but/O restoration/O of/O normal/O activity/O levels/O is/O possible/O only/O in/O the/O former/O ./O
When/O applied/O in/O combination/O ,/O synergism/O between/O the/O two/O inhibitors/O can/O reduce/O their/O effective/O doses/O to/O one/O -/O fourth/O of/O the/O doses/O required/O under/O single/O inhibitor/O application/O ./O
Overall/O ,/O re/O -/O establishment/O of/O normal/O Wnt/O pathway/O activity/O is/O predicted/O for/O every/O APC/O mutant/O in/O whom/O TCF/O activity/O is/O increased/O by/O up/O to/O 11/O fold/O ./O
CONCLUSIONS/O :/O Our/O work/O suggests/O that/O extracellular/O inhibitors/O can/O effectively/O restore/O normal/O Wnt/O pathway/O activity/O in/O APC/O -/O truncated/O cancer/O cells/O ,/O even/O though/O these/O LoF/O mutations/O occur/O downstream/O of/O the/O inhibitory/O action/O ./O
The/O insufficient/O activity/O of/O the/O truncated/O APC/O can/O be/O quantitatively/O balanced/O by/O the/O upstream/O intervention/O ./O
This/O new/O concept/O of/O upstream/O intervention/O to/O control/O the/O effects/O of/O downstream/O mutations/O may/O be/O considered/O also/O for/O other/O partial/O LoF/O mutations/O in/O other/O signaling/O pathways/O ./O
A/O case/O of/O hypocholesterolemia/B-Disease and/O steatosis/B-Disease in/O a/O carrier/O of/O a/O PCSK9/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var and/O polymorphisms/O predisposing/O to/O nonalcoholic/O fatty/O liver/O disease/O ./O
We/O report/O a/O new/O case/O of/O hypobetalipoproteinemia/O in/O a/O 44-year/O -/O old/O man/O of/O Peruvian/O origin/O exhibiting/O a/O heterozygous/O PCSK9/O missense/O mutation/O (/B-Var c.946/I-Var G/I-Var >/I-Var T/I-Var ,/O p./O Gly316Cys/O )/O ./O
In/O vitro/O functional/O studies/O demonstrated/O that/O this/O mutation/O leads/O to/O a/O loss/B-NegReg of/I-NegReg function/I-NegReg of/O PCSK9/B-Gene on/O low/B-MPA -/I-MPA density/I-MPA lipoprotein/I-MPA receptor/I-MPA degradation/I-MPA ./O
This/O patient/O exhibited/O liver/O steatosis/O ;/O he/O was/O neither/O diabetic/O ,/O nor/O obese/O or/O alcoholic/O ,/O but/O is/O a/O carrier/O of/O 2/O polymorphisms/O ,/O p/O ./O Ile148Met/O (/O rs738409/O )/O and/O p/O ./O Glu167Lys/O (/O rs58542926/O )/O on/O PNPLA3/O and/O TM6SF2/O gene/O ,/O respectively/O ,/O previously/O shown/O to/O be/O associated/O with/O nonalcoholic/O steatosis/O and/O fibrosis/O evolution/O ./O
These/O data/O suggested/O that/O if/O a/O resistance/O to/O hepatic/O steatosis/O mediated/O by/O the/O PCSK9/O deficiency/O exists/O ,/O as/O demonstrated/O in/O mice/O ,/O it/O is/O not/O sufficient/O to/O prevent/O hepatic/O fatty/O accumulation/O in/O the/O case/O of/O genetic/O factors/O predisposing/O to/O nonalcoholic/O fatty/O liver/O disease/O ./O
Ovarian/B-Protein aromatase/I-Protein loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutant/B-Var medaka/O undergo/B-Reg ovary/B-CPA degeneration/I-CPA and/O partial/B-CPA female/I-CPA -/I-CPA to/I-CPA -/I-CPA male/I-CPA sex/I-CPA reversal/I-CPA after/O puberty/O ./O
Although/O estrogens/O have/O been/O generally/O considered/O to/O play/O a/O critical/O role/O in/O ovarian/O differentiation/O in/O non/O -/O mammalian/O vertebrates/O ,/O the/O specific/O functions/O of/O estrogens/O during/O ovarian/O differentiation/O remain/O unclear/O ./O
We/O isolated/O two/O mutants/O with/O premature/O stops/O in/O the/O ovarian/O aromatase/O (/B-Gene cyp19a1/I-Gene )/I-Gene gene/O from/O an/O N/O -/O ethyl/O -/O N/O -/O nitrosourea/O -/O based/O gene/O -/O driven/O mutagenesis/O library/O of/O the/O medaka/O ,/O Oryzias/O latipes/O ./O
In/O XX/O mutants/O ,/O gonads/O first/O differentiated/O into/O normal/O ovaries/O containing/O many/O ovarian/O follicles/O that/O failed/O to/O accumulate/O yolk/O ./O
Subsequently/O ,/O ovarian/O tissues/O underwent/O extensive/O degeneration/O ,/O followed/O by/O the/O appearance/O of/O testicular/O tissues/O on/O the/O dorsal/O side/O of/O ovaries/O ./O
In/O the/O newly/O formed/O testicular/O tissue/O ,/O strong/O expression/O of/O gsdf/O was/O detected/O in/O sox9a2-positive/O somatic/O cells/O surrounding/O germline/O stem/O cells/O suggesting/O that/O gsdf/O plays/O an/O important/O role/O in/O testicular/O differentiation/O during/O estrogen/O -/O depleted/O female/O -/O to/O -/O male/O sex/O reversal/O ./O
We/O conclude/O that/O endogenous/O estrogens/O synthesized/O after/O fertilization/O are/O not/O essential/O for/O early/O ovarian/O differentiation/O but/O are/O critical/O for/O the/O maintenance/O of/O adult/O ovaries/O ./O
Refining/O genotype/O -/O phenotype/O correlation/O in/O Alström/O syndrome/O through/O study/O of/O primary/O human/O fibroblasts/O ./O
BACKGROUND/O :/O Alström/B-Disease syndrome/I-Disease (/O AS/O )/O ,/O featuring/O retinal/O dystrophy/O ,/O neuronal/O deafness/O ,/O cardiomyopathy/O ,/O metabolic/O syndrome/O ,/O and/O diffuse/O fibrosis/O ,/O is/O caused/O by/O biallelic/O mutations/O in/O the/O centrosomal/O protein/O ALMS1/O ./O
Genotype/O -/O phenotype/O correlation/O has/O been/O suggested/O without/O assessment/O of/O ALMS1/O expression/O ./O
METHODS/O :/O ALMS1/O expression/O (/O real/O -/O time/O PCR/O and/O immunocytochemistry/O )/O and/O cilia/O formation/O (/O immunocytochemistry/O )/O were/O assessed/O in/O fibroblasts/O from/O deeply/O phenotyped/O volunteers/O diagnosed/O with/O AS/O recruited/O from/O a/O dedicated/O AS/O Service/O ./O
Exome/O sequencing/O was/O used/O in/O two/O participants/O without/O convincing/O biallelic/O ALMS1/O mutations/O ,/O and/O BBS2/O (/O Bardet/O -/O Biedl/O syndrome/O 2/O )/O protein/O expression/O was/O assessed/O in/O one/O patient/O with/O biallelic/O BBS2/O mutations/O ./O
Hedgehog/O -/O induced/O GLI1/O expression/O and/O PDGFA/O signaling/O was/O assessed/O using/O quantitative/O real/O -/O time/O PCR/O ,/O immunoblotting/O ,/O or/O immunostaining/O of/O fixed/O cells/O after/O stimulation/O ./O
RESULTS/O :/O In/O 16/O of/O the/O patient/O cell/O lines/O examined/O ,/O ALMS1/B-Gene protein/B-Protein was/O undetectable/B-NegReg (/O 14/O with/O biallelic/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O mutations/B-Var )/I-Var ,/O and/O in/O two/O ,/O ALMS1/O staining/O was/O equivocal/O (/O one/O with/O biallelic/O LoF/O mutations/O )/O ./O
In/O five/O lines/O ,/O ALMS1/O expression/O was/O normal/O using/O at/O least/O one/O fixation/O method/O (/O one/O with/O biallelic/O LoF/O mutations/O )/O ./O
These/O differences/O were/O not/O accounted/O for/O by/O major/O differences/O in/O ALMS1/O mRNA/O expression/O ./O
Exome/O sequencing/O of/O two/O participants/O with/O normal/O ALMS1/O expression/O identified/O biallelic/O LoF/O BBS2/O mutations/O in/O one/O ./O
No/O second/O ,/O known/O ciliopathy/O mutation/O was/O found/O in/O the/O other/O patient/O ,/O who/O had/O one/O LoF/O ALMS1/O mutation/O ./O
Phenotypes/O were/O milder/O or/O atypical/O in/O participants/O with/O preserved/O ALMS1/O immunostaining/O ,/O even/O when/O two/O with/O likely/O alternative/O genetic/O diagnoses/O were/O excluded/O ./O
All/O cells/O studied/O developed/O normal/O cilia/O ,/O ALMS1/O and/O BBS2/O mutant/O cells/O showed/O normal/O Hedgehog/O -/O induced/O upregulation/O of/O GLI1/O expression/O ,/O and/O PDGFA/O signaling/O was/O normal/O in/O ALMS1-deficient/O cells/O ./O
CONCLUSION/O :/O Milder/O or/O atypical/O presentations/O of/O AS/O should/O prompt/O genetic/O evaluation/O for/O alternative/O ,/O clinically/O overlapping/O ciliopathies/O ./O
A/O subgroup/O of/O patients/O with/O bona/O fide/O ALMS1/O defects/O have/O milder/O phenotypes/O due/O to/O residual/O ALMS1/O expression/O ,/O which/O may/O be/O more/O important/O than/O mutation/O site/O ./O
Small/O chaperons/O and/O autophagy/O protected/O neurons/O from/O necrotic/O cell/O death/O ./O
Neuronal/O necrosis/O occurs/O during/O early/O phase/O of/O ischemic/O insult/O ./O
However/O ,/O our/O knowledge/O of/O neuronal/O necrosis/O is/O still/O inadequate/O ./O
To/O study/O the/O mechanism/O of/O neuronal/O necrosis/O ,/O we/O previously/O established/O a/O Drosophila/O genetic/O model/O of/O neuronal/O necrosis/O by/O calcium/O overloading/O through/O expression/O of/O a/O constitutively/O opened/O cation/O channel/O mutant/O ./O
Here/O ,/O we/O performed/O further/O genetic/O screens/O and/O identified/O a/O suppressor/O of/O neuronal/O necrosis/O ,/O CG17259/O ,/O which/O encodes/O a/O seryl/O -/O tRNA/O synthetase/O ./O
We/O found/O that/O loss/B-Var -/I-Var of/I-Var -/I-Var function/I-Var (/O LOF/O )/O CG17259/B-Gene activated/B-PosReg eIF2α/B-Protein phosphorylation/B-CPA and/O subsequent/O up/B-PosReg -/I-PosReg regulation/I-PosReg of/O chaperons/B-CPA (/B-Protein Hsp26/I-Protein and/O Hsp27/B-Protein )/I-Protein and/O autophagy/B-CPA ./O
Genetically/O ,/O down/B-NegReg -/I-NegReg regulation/I-NegReg of/O eIF2α/B-Protein phosphorylation/B-CPA ,/O Hsp26/B-Protein //I-Protein Hsp27/I-Protein or/O autophagy/B-CPA reduced/B-NegReg the/O protective/B-CPA effect/I-CPA of/O LOF/B-Var CG17259/B-Gene ,/O indicating/O they/O function/O downstream/O of/O CG17259/O ./O
The/O protective/O effect/O of/O these/O protein/O degradation/O pathways/O indicated/O activation/O of/O a/O toxic/O protein/O during/O neuronal/O necrosis/O ./O
Our/O data/O indicated/O that/O p53/O was/O likely/O one/O such/O protein/O ,/O because/O p53/O was/O accumulated/O in/O the/O necrotic/O neurons/O and/O down/O -/O regulation/O of/O p53/O rescued/O necrosis/O ./O
In/O the/O SH/O -/O SY5Y/O human/O cells/O ,/O tunicamycin/O (/O TM/O )/O ,/O a/O PERK/O activator/O ,/O promoted/O transcription/O of/O hsp27/O ;/O and/O necrosis/O induced/O by/O glutamate/O could/O be/O rescued/O by/O TM/O ,/O associated/O with/O reduced/O p53/O accumulation/O ./O
In/O an/O ischemic/O stroke/O model/O in/O rats/O ,/O p53/O protein/O was/O also/O increased/O ,/O and/O TM/O treatment/O could/O reduce/O the/O p53/O accumulation/O and/O brain/O damage/O ./O
In/O vivo/O CRISPR/O screening/O identifies/O Ptpn2/O as/O a/O cancer/O immunotherapy/O target/O ./O
Immunotherapy/O with/O PD-1/O checkpoint/O blockade/O is/O effective/O in/O only/O a/O minority/O of/O patients/O with/O cancer/O ,/O suggesting/O that/O additional/O treatment/O strategies/O are/O needed/O ./O
Here/O we/O use/O a/O pooled/O in/O vivo/O genetic/O screening/O approach/O using/O CRISPR/O -/O Cas9/O genome/O editing/O in/O transplantable/O tumours/O in/O mice/O treated/O with/O immunotherapy/O to/O discover/O previously/O undescribed/O immunotherapy/O targets/O ./O
We/O tested/O 2,368/O genes/O expressed/O by/O melanoma/O cells/O to/O identify/O those/O that/O synergize/O with/O or/O cause/O resistance/O to/O checkpoint/O blockade/O ./O
We/O recovered/O the/O known/O immune/O evasion/O molecules/O PD/O -/O L1/O and/O CD47/O ,/O and/O confirmed/O that/O defects/O in/O interferon/O -/O γ/O signalling/O caused/O resistance/O to/O immunotherapy/O ./O
Tumours/O were/O sensitized/O to/O immunotherapy/O by/O deletion/O of/O genes/O involved/O in/O several/O diverse/O pathways/O ,/O including/O NF/O -/O κB/O signalling/O ,/O antigen/O presentation/O and/O the/O unfolded/O protein/O response/O ./O
In/O addition/O ,/O deletion/B-Var of/O the/O protein/O tyrosine/O phosphatase/O PTPN2/B-Gene in/O tumour/O cells/O increased/B-PosReg the/O efficacy/B-CPA of/I-CPA immunotherapy/I-CPA by/O enhancing/B-PosReg interferon/B-MPA -/I-MPA γ/I-MPA -/I-MPA mediated/I-MPA effects/I-MPA on/I-MPA antigen/I-MPA presentation/I-MPA and/O growth/B-CPA suppression/I-CPA ./O
In/O vivo/O genetic/O screens/O in/O tumour/O models/O can/O identify/O new/O immunotherapy/O targets/O in/O unanticipated/O pathways/O ./O
A/O patient/O with/O germ/O -/O line/O gain/O -/O of/O -/O function/O PDGFRB/O p/O ./O N666H/O mutation/O and/O marked/O clinical/O response/O to/O imatinib/O ./O
PurposeHeterozygous/O germ/O -/O line/O activating/O mutations/B-Var in/O PDGFRB/B-Gene cause/B-Reg Kosaki/B-Disease and/I-Disease Penttinen/I-Disease syndromes/I-Disease and/O myofibromatosis/B-Disease ./O
We/O describe/O a/O 10-year/O -/O old/O child/O with/O a/O germ/O -/O line/O PDGFRB/B-Gene p/B-Var ./I-Var N666H/I-Var mutation/O who/O responded/B-MPA to/I-MPA the/I-MPA tyrosine/I-MPA kinase/I-MPA inhibitor/I-MPA imatinib/I-MPA by/O inhibition/B-NegReg of/O PDGFRB.MethodsThe/B-Gene impact/O of/O p/O ./O N666H/O on/O PDGFRB/O function/O and/O sensitivity/O to/O imatinib/O was/O studied/O in/O cell/O culture/O ./O
ResultsCells/O expressing/O the/O p/O ./O N666H/O mutation/O showed/O constitutive/O PDGFRB/O tyrosine/O phosphorylation/O ./O
PDGF/O -/O independent/O proliferation/O was/O abolished/O by/O imatinib/O at/O 1/O μM/O concentration/O ./O
Patient/O fibroblasts/O showed/O constitutive/O receptor/O tyrosine/O phosphorylation/O that/O was/O also/O abrogated/O by/O imatinib/O with/O reduced/O proliferation/O of/O treated/O cells/O ./O
This/O led/O to/O patient/O treatment/O with/O imatinib/O at/O 400/O mg/O daily/O (/O 340/O mg/O //O m(2/O )/O )/O for/O a/O year/O with/O objective/O improvement/O of/O debilitating/O hand/O and/O foot/O contractures/O ,/O reduced/O facial/O coarseness/O ,/O and/O significant/O improvement/O in/O quality/O of/O life/O ./O
New/O small/O subcutaneous/O nodules/O developed/O ,/O but/O remained/O stable/O ./O
Transient/O leukopenia/O ,/O neutropenia/O ,/O and/O fatigue/O resolved/O without/O intervention/O ;/O however/O ,/O mildly/O decreased/O growth/O velocity/O resulted/O in/O reducing/O imatinib/O dose/O to/O 200/O mg/O daily/O (/O 170/O mg/O //O m(2/O )/O )/O ./O
The/O patient/O continues/O treatment/O with/O ongoing/O clinical/O response/O ./O
ConclusionTo/O our/O knowledge/O ,/O this/O is/O one/O of/O the/O first/O personalized/O treatments/O of/O a/O congenital/O disorder/O caused/O by/O a/O germ/O -/O line/O PDGF/O receptor/O mutation/O with/O a/O PDGFRB/O inhibitor/O ./O
GENETICS/O in/O MEDICINE/O advance/O online/O publication/O ,/O 20/O July/O 2017/O ;/O doi:10.1038/O //O gim.2017.104/O ./O
Genetic/O Diseases/O of/O PIEZO1/O and/O PIEZO2/O Dysfunction/O ./O
Mutations/O in/O the/O genes/O encoding/O the/O mechanosensitive/O cation/O channels/O PIEZO1/O and/O PIEZO2/O are/O responsible/O for/O multiple/O hereditary/O human/O diseases/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O human/O PIEZO1/B-Gene gene/O cause/O autosomal/B-Disease recessive/I-Disease congenital/I-Disease lymphatic/I-Disease dysplasia/I-Disease ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O the/O human/O PIEZO1/B-Gene gene/O cause/O the/O autosomal/B-Disease dominant/I-Disease hemolytic/I-Disease anemia/I-Disease ,/O hereditary/B-Disease xerocytosis/I-Disease (/O also/O known/O as/O dehydrated/B-Disease stomatocytosis/I-Disease )/I-Disease ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O human/O PIEZO2/B-Gene gene/O cause/O an/O autosomal/B-Disease recessive/I-Disease syndrome/I-Disease of/I-Disease muscular/I-Disease atrophy/I-Disease with/O perinatal/O respiratory/O distress/O ,/O arthrogryposis/B-Disease ,/O and/O scoliosis/B-Disease ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O the/O human/O PIEZO2/B-Gene gene/O cause/O three/O clinical/O types/O of/O autosomal/B-Disease dominant/I-Disease distal/I-Disease arthrogryposis/I-Disease ./O
This/O chapter/O will/O review/O the/O hereditary/O diseases/O caused/O by/O mutations/O in/O the/O PIEZO/O genes/O and/O will/O discuss/O additional/O physiological/O systems/O in/O which/O PIEZO/O channel/O dysfunction/O may/O contribute/O to/O human/O disease/O pathophysiology/O ./O
Differential/O calcium/O sensitivity/O in/O NaV/O 1.5/O mixed/O syndrome/O mutants/O ./O
KEY/O POINTS/O :/O SCN5a/B-Gene mutations/B-Var may/O express/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/B-Disease Long/I-Disease QT/I-Disease Syndrome-3/I-Disease )/I-Disease ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/B-Disease Brugada/I-Disease Syndrome/I-Disease 1/I-Disease )/I-Disease or/O both/O (/O mixed/O syndromes/O )/O ,/O depending/O on/O the/O mutation/O and/O environmental/O triggers/O ./O
One/O such/O trigger/O may/O be/O an/O increase/O in/O cytosolic/O calcium/O ,/O accompanying/O exercise/O ./O
Many/O mixed/O syndromes/O mutants/O ,/O including/O ∆KPQ/O ,/O E1784/O K/O ,/O 1795insD/O and/O Q1909R/O ,/O are/O found/O in/O calcium/O -/O sensitive/O regions/O ./O
Elevated/O cytosolic/O calcium/O attenuates/O gain/O -/O of/O -/O function/O properties/O in/O ∆KPQ/O ,/O 1795insD/O and/O Q1909R/O ,/O but/O not/O in/O E1784K./O By/O contrast/O ,/O elevated/O cytosolic/O calcium/O further/O exacerbates/O gain/O -/O of/O -/O function/O in/O E1784/O K/O by/O destabilizing/O slow/O inactivation/O ./O
Action/O potential/O modelling/O ,/O using/O a/O modified/O O'Hara/O Rudy/O model/O ,/O suggests/O that/O elevated/O heart/O rate/O rescues/O action/O potential/O duration/O in/O ∆KPQ/O ,/O 1795insD/O and/O Q1909R/O ,/O but/O not/O in/O E1784K./O Action/O potential/O simulations/O suggest/O that/O E1784/O K/O carriers/O have/O an/O increased/O intracellular/O sodium/O -/O to/O -/O calcium/O ratio/O under/O bradycardia/O and/O tachycardia/O conditions/O ./O
Elevated/O cytosolic/O calcium/O ,/O which/O is/O common/O during/O high/O heart/O rates/O ,/O ameliorates/O or/O exacerbates/O the/O mixed/O syndrome/O phenotype/O depending/O on/O the/O genetic/O signature/O ./O
ABSTRACT/O :/O Inherited/O arrhythmias/O may/O arise/O from/O mutations/O in/O the/O gene/O for/O SCN5a/O ,/O which/O encodes/O the/O cardiac/O voltage/O -/O gated/O sodium/O channel/O ,/O NaV/O 1.5/O ./O
Mutants/O in/O NaV/O 1.5/O result/O in/O Brugada/O Syndrome/O (/O BrS1/O )/O ,/O Long/O -/O QT/O Syndrome/O (/O LQT3/O )/O or/O mixed/O syndromes/O (/O an/O overlap/O of/O BrS1/O //O LQT3/O )/O ./O
Exercise/O is/O a/O potential/O arrhythmogenic/O trigger/O in/O mixed/O syndromes/O ./O
We/O aimed/O to/O determine/O the/O effects/O of/O elevated/O cytosolic/O calcium/O ,/O which/O is/O common/O during/O exercise/O ,/O in/O mixed/O syndrome/O NaV/O 1.5/O mutants/O ./O
We/O used/O whole/O -/O cell/O patch/O clamp/O to/O assess/O the/O biophysical/O properties/O of/O NaV/O 1.5/O wild/O -/O type/O (/O WT/O )/O ,/O ∆KPQ/O ,/O E1784/O K/O ,/O 1795insD/O and/O Q1909R/O mutants/O in/O human/O embryonic/O kidney/O 293/O cells/O transiently/O transfected/O with/O the/O NaV/O 1.5/O α/O subunit/O (/O WT/O or/O mutants/O )/O ,/O β1/O subunit/O and/O enhanced/O green/O fluorescent/O protein/O ./O
Voltage/O -/O dependence/O and/O kinetics/O were/O measured/O at/O cytosolic/O calcium/O levels/O of/O approximately/O 0/O ,/O 500/O and/O 2500/O nm/O ./O
In/O silico/O ,/O action/O potential/O (/O AP/O )/O model/O simulations/O were/O performed/O using/O a/O modified/O O'Hara/O Rudy/O model/O ./O
Elevated/O cytosolic/O calcium/O attenuates/O the/O late/O sodium/O current/O in/O ∆KPQ/O ,/O 1795insD/O and/O Q1909R/O ,/O but/O not/O in/O E1784K./O Elevated/O cytosolic/O calcium/O restores/O steady/O -/O state/O slow/O inactivation/O (/O SSSI/O )/O to/O the/O WT/O -/O form/O in/O Q1909R/O ,/O but/O depolarized/O SSSI/O in/O E1784K./O Our/O AP/O simulations/O showed/O a/O frequency/O -/O dependent/O reduction/O of/O AP/O duration/O in/O ∆KPQ/O ,/O 1795insD/O and/O Q1909R/O carriers/O ./O
In/O E1784/O K/O ,/O AP/O duration/O is/O relatively/O prolonged/O at/O both/O low/O and/O high/O heart/O rates/O ,/O resulting/O in/O a/O sodium/O overload/O ./O
Cellular/O perturbations/O during/O exercise/O may/O affect/O BrS1/O //O LQT3/O patients/O differently/O depending/O on/O their/O individual/O genetic/O signature/O ./O
Thus/O ,/O exercise/O may/O be/O therapeutic/O or/O may/O be/O an/O arrhythmogenic/O trigger/O in/O some/O SCN5a/O patients/O ./O
D242N/O ,/O a/O KV7.1/O LQTS/O mutation/O uncovers/O a/O key/O residue/O for/O IKs/O voltage/O dependence/O ./O
KV7.1/O and/O KCNE1/O co/O -/O assemble/O to/O give/O rise/O to/O the/O IKs/O current/O ,/O one/O of/O the/O most/O important/O repolarizing/O currents/O of/O the/O cardiac/O action/O potential/O ./O
Its/O relevance/O is/O underscored/O by/O the/O identification/O of/O >/O 500/O mutations/B-Var in/O KV7.1/B-Gene and/O ,/O at/O least/O ,/O 36/O in/O KCNE1/B-Gene ,/O that/O cause/B-Reg Long/B-Disease QT/I-Disease Syndrome/I-Disease (/O LQTS/O )/O ./O
The/O aim/O of/O this/O study/O was/O to/O characterize/O the/O biophysical/O and/O cellular/O consequences/O of/O the/O D242N/B-Var KV7.1/B-Gene mutation/O associated/B-Reg with/O the/O LQTS/B-Disease ./O
The/O mutation/B-Var is/O located/O in/O the/O S4/O transmembrane/O segment/O ,/O within/O the/O voltage/O sensor/O of/O the/O KV7.1/O channel/O ,/O disrupting/B-NegReg the/O conserved/B-MPA charge/I-MPA balance/I-MPA of/I-MPA this/I-MPA region/I-MPA ./O
Perforated/O patch/O -/O clamp/O experiments/O show/O that/O ,/O unexpectedly/O ,/O the/O mutation/B-Var did/O not/O disrupt/O the/O voltage/O -/O dependent/O activation/O but/O it/O removed/B-NegReg the/O inactivation/B-MPA and/O slowed/B-NegReg the/O activation/B-MPA kinetics/I-MPA of/O D242N/B-MPA KV7.1/I-MPA channels/I-MPA ./O
Biotinylation/O of/O cell/O -/O surface/O protein/O and/O co/O -/O immunoprecipitation/O experiments/O revealed/O that/O neither/O plasma/O membrane/O targeting/O nor/O co/O -/O assembly/O between/O KV7.1/O and/O KCNE1/O was/O altered/O by/O the/O mutation/O ./O
However/O ,/O the/O association/O of/O D242N/O KV7.1/O with/O KCNE1/O strongly/O shifted/O the/O voltage/O dependence/O of/O activation/O to/O more/O depolarized/O potentials/O (/O +50mV/O )/O ,/O hindering/O IKs/O current/O at/O physiologically/O relevant/O membrane/O potentials/O ./O
Both/O functional/O and/O computational/O analysis/O suggest/O that/O the/O clinical/O phenotype/O of/O the/O LQTS/O patients/O carrying/O the/O D242N/B-Var mutation/O is/O due/O to/O impaired/B-NegReg action/B-MPA potential/I-MPA adaptation/I-MPA to/I-MPA exercise/I-MPA and/O ,/O in/O particular/O ,/O to/O increase/B-PosReg in/O heart/B-MPA rate/I-MPA ./O
Moreover/O ,/O our/O data/O identify/O D242/O aminoacidic/O position/O as/O a/O potential/O residue/O involved/O in/O the/O KCNE1-mediated/O regulation/O of/O the/O voltage/O dependence/O of/O activation/O of/O the/O KV7.1/O channel/O ./O
A/O Gene/O Implicated/O in/O Activation/O of/O Retinoic/O Acid/O Receptor/O Targets/O is/O a/O Novel/O Renal/O Agenesis/O Gene/O in/O Humans/O ./O
Renal/B-Disease agenesis/I-Disease (/O RA/O )/O is/O one/O of/O the/O more/O extreme/O examples/O of/O congenital/O anomalies/O of/O the/O kidney/O and/O urinary/O tract/O (/O CAKUT/O )/O ./O
Bilateral/O renal/O agenesis/O is/O almost/O invariably/O fatal/O at/O birth/O ,/O and/O unilateral/O renal/O agenesis/O can/O lead/O to/O future/O health/O issues/O including/O end/O stage/O renal/O disease/O ./O
Genetic/O investigations/O have/O identified/O several/O gene/O variants/B-Var which/O cause/B-Reg RA/B-Disease ,/O including/O EYA1/O ,/O LHX1/O ,/O and/O WT1/O However/O ,/O whereas/O compound/O null/O mutations/O of/O genes/O encoding/O α/O and/O γ/O retinoic/O acid/O receptors/O (/O RARs/O )/O cause/O RA/O in/O mice/O ,/O to/O date/O there/O have/O been/O no/O reports/O of/O variants/O in/O RAR/O genes/O causing/O RA/O in/O humans/O ./O
In/O this/O study/O ,/O we/O carried/O out/O whole/O exome/O sequence/O analysis/O of/O two/O families/O showing/O inheritance/O of/O an/O RA/O phenotype/O ,/O and/O in/O both/O identified/O a/O single/O candidate/O gene/O ,/O GREB1L/O Analysis/O of/O a/O zebrafish/O greb1l/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutant/B-Var revealed/O defects/O in/O the/O pronephric/B-MPA kidney/I-MPA just/I-MPA prior/I-MPA to/I-MPA death/I-MPA ,/O and/O F0/O CRISPR/O //O Cas9/O mutagenesis/B-Var of/O Greb1l/O in/O the/O mouse/O revealed/B-Reg kidney/B-MPA agenesis/I-MPA phenotypes/I-MPA ,/O implicating/O Greb1l/O in/O this/O disorder/O ./O
GREB1L/O resides/O in/O a/O chromatin/O complex/O with/O RAR/O members/O ,/O and/O our/O data/O implicate/O GREB1L/O as/O a/O coactivator/O for/O RARs/O ./O
This/O study/O is/O the/O first/O to/O associate/O a/O component/O of/O the/O RAR/O pathway/O with/O renal/O agenesis/O in/O humans/O ./O
Equivalent/O missense/B-Var variant/I-Var in/O the/O FOXP2/B-Gene and/O FOXP1/B-Gene transcription/O factors/O causes/B-Reg distinct/O neurodevelopmental/B-Disease disorders/I-Disease ./O
The/O closely/O related/O paralogues/O FOXP2/O and/O FOXP1/O encode/O transcription/O factors/O with/O shared/O functions/O in/O the/O development/O of/O many/O tissues/O ,/O including/O the/O brain/O ./O
However/O ,/O while/O mutations/B-Var in/O FOXP2/B-Gene lead/B-Reg to/I-Reg a/O speech/O //O language/O disorder/O characterized/O by/O childhood/B-Disease apraxia/I-Disease of/I-Disease speech/I-Disease (/O CAS/O )/O ,/O the/O clinical/O profile/O of/O FOXP1/B-Gene variants/B-Var includes/B-Reg a/O broader/O neurodevelopmental/O phenotype/O with/O global/B-Disease developmental/I-Disease delay/I-Disease ,/O intellectual/B-Disease disability/I-Disease ,/O and/O speech/B-Disease //I-Disease language/I-Disease impairment/I-Disease ./O
Using/O clinical/O whole/O -/O exome/O sequencing/O ,/O we/O report/O an/O identical/O de/O novo/O missense/O FOXP1/O variant/O identified/O in/O three/O unrelated/O patients/O ./O
The/O variant/O ,/O p/O ./O R514H/O ,/O is/O located/O in/O the/O forkhead/O -/O box/O DNA/O -/O binding/O domain/O and/O is/O equivalent/O to/O the/O well/O -/O studied/O p/O ./O R553H/O FOXP2/O variant/O that/O cosegregates/O with/O CAS/O in/O a/O large/O UK/O family/O ./O
We/O present/O here/O for/O the/O first/O time/O a/O direct/O comparison/O of/O the/O molecular/O and/O clinical/O consequences/O of/O the/O same/O mutation/O affecting/O the/O equivalent/O residue/O in/O FOXP1/O and/O FOXP2/O ./O
Detailed/O functional/O characterization/O of/O the/O two/O variants/O in/O cell/O model/O systems/O revealed/O very/O similar/O molecular/O consequences/O ,/O including/O aberrant/O subcellular/O localization/O ,/O disruption/O of/O transcription/O factor/O activity/O ,/O and/O deleterious/O effects/O on/O protein/O interactions/O ./O
Nonetheless/O ,/O clinical/O manifestations/O were/O broader/O and/O more/O severe/O in/O the/O three/O cases/O carrying/O the/O p/O ./O R514H/O FOXP1/O variant/O than/O in/O individuals/O with/O the/O p/O ./O R553H/O variant/O related/O to/O CAS/O ,/O highlighting/O divergent/O roles/O of/O FOXP2/O and/O FOXP1/O in/O neurodevelopment/O ./O
Novel/O PRPS1/O gain/O -/O of/O -/O function/O mutation/O in/O a/O patient/O with/O congenital/O hyperuricemia/O and/O facial/O anomalies/O ./O
Phosphoribosylpyrophosphate/O synthetase/O (/O PRPPS/O )/O superactivity/O (/O OMIM/O 300661/O )/O is/O a/O rare/O inborn/O error/O of/O purine/O metabolism/O that/O is/O caused/O by/O gain/O -/O of/O -/O function/O mutations/O in/O the/O X/O -/O chromosomal/O gene/O PRPS1/O (/O Xq22.3/O )/O ./O
Clinical/O characteristics/O include/O congenital/O hyperuricemia/O and/O hyperuricosuria/O ,/O gouty/O arthritis/O ,/O urolithiasis/O ,/O developmental/O delay/O ,/O hypotonia/O ,/O recurrent/O infections/O ,/O short/O stature/O ,/O and/O hearing/O loss/O ./O
Only/O eight/O families/O with/O PRPPS/O superactivity/O and/O PRPS1/O gain/O -/O of/O -/O function/O mutations/O have/O been/O reported/O to/O date/O ./O
We/O report/O on/O a/O 7-year/O -/O old/O boy/O with/O congenital/O hyperuricemia/O ,/O urolithiasis/O ,/O developmental/O delay/O ,/O short/O stature/O ,/O hypospadias/O ,/O and/O facial/O dysmorphisms/O ./O
His/O mother/O also/O suffered/O from/O hyperuricemia/O that/O was/O diagnosed/O at/O age/O 13/O years/O ./O
A/O novel/O PRPS1/O missense/O mutation/O (/O c.573G/O >/O C/O ,/O p.[Leu191Phe/O ]/O )/O was/O detected/O in/O the/O proband/O and/O his/O mother/O ./O
Enzyme/O activity/O analysis/O confirmed/O superactivity/O of/O PRPP/O synthetase/O ./O
Analysis/O of/O the/O crystal/O structure/O of/O human/O PRPPS/O suggests/O that/O the/O Leu191Phe/B-Gene mutation/B-Var affects/B-Reg the/O architecture/B-MPA of/O both/O allosteric/O sites/O ,/O thereby/O preventing/B-NegReg the/O allosteric/B-MPA inhibition/I-MPA of/O the/O enzyme/B-Enzyme ./O
The/O family/O reported/O here/O broadens/O the/O clinical/O spectrum/O of/O PRPPS/O superactivity/O and/O indicates/O that/O this/O rare/O metabolic/O disorder/O might/O be/O associated/O with/O a/O recognizable/O facial/O gestalt/O ./O
Naturally/O -/O Segregating/O Variation/B-Var at/O Ugt86Dd/B-Gene Contributes/B-Reg to/O Nicotine/B-MPA Resistance/I-MPA in/I-MPA Drosophila/I-MPA melanogaster/I-MPA ./O
Identifying/O the/O sequence/O polymorphisms/O underlying/O complex/O trait/O variation/O is/O a/O key/O goal/O of/O genetics/O research/O ,/O since/O knowing/O the/O precise/O causative/O molecular/O events/O allows/O insight/O into/O the/O pathways/O governing/O trait/O variation/O ./O
Genetic/O analysis/O of/O complex/O traits/O in/O model/O systems/O regularly/O starts/O by/O constructing/O QTL/O maps/O ,/O but/O generally/O fails/O to/O identify/O causative/O sequence/O polymorphisms/O ./O
Previously/O we/O mapped/O a/O series/O of/O QTL/O contributing/O to/O resistance/O to/O nicotine/O in/O a/O Drosophila/O melanogaster/O multiparental/O mapping/O resource/O ,/O and/O here/O use/O a/O battery/O of/O functional/O tests/O to/O resolve/O QTL/O to/O the/O molecular/O level/O ./O
One/O large/O -/O effect/O QTL/O resided/O over/O a/O cluster/O of/O UDP/O -/O glucuronosyltransferases/O ,/O and/O quantitative/O complementation/O tests/O using/O deficiencies/O eliminating/O subsets/O of/O these/O detoxification/O genes/O revealed/O allelic/O variation/O impacting/O resistance/O ./O
RNAseq/O showed/O that/O Ugt86Dd/O had/O significantly/O higher/O expression/O in/O genotypes/O that/O are/O more/O resistant/O to/O nicotine/O ,/O and/O anterior/O midgut/O -/O specific/O RNAi/O of/O this/O gene/O reduced/O resistance/O ./O
We/O discovered/O a/O segregating/O 22-bp/O frameshift/B-Var deletion/I-Var in/O Ugt86Dd/B-Gene ,/O and/O accounting/O for/O the/O InDel/O during/O mapping/O largely/O eliminates/B-NegReg the/O QTL/B-MPA ,/O implying/O the/O event/O explains/O the/O bulk/O of/O the/O effect/O of/O the/O mapped/O locus/O ./O
CRISPR/O //O Cas9/O editing/O a/O relatively/O resistant/O genotype/O to/O generate/O lesions/B-Var in/O Ugt86Dd/B-Gene that/O recapitulate/O the/O naturally/O -/O occurring/O putative/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg allele/O leads/O to/O a/O large/O reduction/B-NegReg in/O resistance/B-MPA ./O
Despite/O this/O major/O effect/O of/O the/O deletion/O ,/O the/O allele/O appears/O to/O be/O very/O rare/O in/O wild/O -/O caught/O populations/O ,/O and/O likely/O explains/O only/O a/O small/O fraction/O of/O the/O natural/O variation/O for/O the/O trait/O ./O
Nonetheless/O ,/O this/O putatively/O causative/O coding/O InDel/O can/O be/O a/O launchpad/O for/O future/O mechanistic/O exploration/O of/O xenobiotic/O detoxification/O ./O
Sequence/B-Var exchange/I-Var between/O R/B-Gene genes/O converts/B-Reg virus/O resistance/O into/O nematode/B-MPA resistance/I-MPA ,/O and/O vice/O versa/O ./O
Plants/O have/O evolved/O a/O limited/O repertoire/O of/O NB/O -/O LRR/O disease/O resistance/O (/O R/O )/O genes/O to/O protect/O themselves/O against/O a/O myriad/O of/O pathogens/O ./O
This/O limitation/O is/O thought/O to/O be/O counterbalanced/O by/O the/O rapid/O evolution/O of/O NB/O -/O LRR/O proteins/O ,/O as/O only/O few/O sequence/O changes/B-Var have/O been/O shown/O to/O be/O sufficient/O to/O alter/B-Reg resistance/B-MPA specificities/I-MPA towards/I-MPA novel/I-MPA strains/I-MPA of/I-MPA a/I-MPA pathogen/I-MPA ./O
However/O ,/O little/O is/O known/O about/O the/O flexibility/O of/O NB/O -/O LRR/O genes/O to/O switch/O resistance/O specificities/O between/O phylogenetically/O unrelated/O pathogens/O ./O
To/O investigate/O this/O ,/O we/O created/O domain/O swaps/O between/O the/O close/O homologs/O Gpa2/O and/O Rx1/O ,/O which/O confer/O resistance/O in/O potato/O to/O the/O cyst/O nematode/O Globodera/O pallida/O and/O Potato/O virus/O X/O (/O PVX/O )/O ,/O respectively/O ./O
The/O genetic/O fusion/O of/O the/O CC/O -/O NB/O -/O ARC/O of/O Gpa2/O with/O the/O LRR/O of/O Rx1/O (/O Gpa2CN/O //O Rx1L/O )/O resulted/O in/O autoactivity/O ,/O but/O lowering/O the/O protein/O levels/O restored/O its/O specific/O activation/O response/O including/O extreme/O resistance/O to/O PVX/O in/O potato/O shoots/O ./O
The/O reciprocal/O construct/O (/O Rx1CN/O //O Gpa2L/O )/O showed/O a/O loss/O -/O of/O -/O function/O phenotype/O ,/O but/O exchange/B-Var of/O the/O first/O 3/O LRR/O repeats/O of/O Rx1/B-Gene was/O sufficient/O to/O regain/B-PosReg a/O wild/B-MPA type/I-MPA resistance/I-MPA response/I-MPA to/I-MPA G./I-MPA pallida/I-MPA in/I-MPA the/I-MPA roots/I-MPA ./O
These/O data/O demonstrate/O that/O exchanging/B-Var the/O recognition/O moiety/O in/O the/O LRR/O is/O sufficient/O to/O convert/B-Reg extreme/O virus/O resistance/O in/O the/O leaves/O into/O mild/B-MPA nematode/I-MPA resistance/I-MPA in/I-MPA the/I-MPA roots/I-MPA ,/O and/O vice/O versa/O ./O
In/O addition/O ,/O we/O show/O that/O the/O CC/O -/O NB/O -/O ARC/O can/O operate/O independently/O of/O the/O recognition/O specificities/O defined/O by/O the/O LRR/O domain/O ,/O either/O above/O or/O belowground/O ./O
These/O data/O show/O the/O versatility/O of/O NB/O -/O LRR/O genes/O to/O generate/O resistances/O to/O unrelated/O pathogens/O with/O completely/O different/O lifestyles/O and/O routes/O of/O invasion/O ./O
Lethal/O digenic/O mutations/B-Var in/O the/O K(+/O )/O channels/O Kir4.1/O (/B-Gene KCNJ10/I-Gene )/I-Gene and/O SLACK/O (/B-Gene KCNT1/I-Gene )/I-Gene associated/B-Reg with/O severe/O -/O disabling/O seizures/B-Disease and/O neurodevelopmental/B-Disease delay/I-Disease ./O
A/O 2-year/O -/O old/O boy/O presented/O profound/O developmental/O delay/O ,/O failure/O to/O thrive/O ,/O ataxia/O ,/O hypotonia/O and/O tonic/O -/O clonic/O seizures/O that/O caused/O the/O death/O of/O the/O patient/O ./O
Targeted/O and/O whole/O -/O exome/O sequencing/O revealed/O two/O heterozygous/O missense/O variants/O :/O a/O novel/O mutation/O in/O KCNJ10/O gene/O that/O encodes/O for/O the/O inwardly/O -/O rectifying/O K(+/O )/O channel/O Kir4.1/O and/O another/O previously/O characterized/O mutation/O in/O KCNT1/O that/O encodes/O for/O the/O Na(+)-activated/O K(+/O )/O channel/O known/O as/O Slo2.2/O or/O SLACK/O ./O
The/O objectives/O of/O this/O study/O were/O to/O perform/O the/O clinical/O and/O genetic/O characterization/O of/O the/O proband/O and/O his/O family/O and/O to/O examine/O the/O functional/O consequence/O of/O the/O Kir4.1/O mutation/O ./O
The/O mutant/O and/O wild/O -/O type/O KCNJ10/O constructs/O were/O generated/O and/O heterologously/O expressed/O in/O Xenopus/O laevis/O oocytes/O ,/O and/O whole/O -/O cell/O K(+/O )/O currents/O were/O measured/O using/O the/O two/O -/O electrode/O voltage/O -/O clamp/O technique/O ./O
The/O KCNJ10/B-Gene mutation/B-Var c.652C/O >/O T/O resulted/B-Reg in/I-Reg a/O p/O ./O L218F/O substitution/B-Var at/O a/O highly/O conserved/O residue/O site/O ./O
Wild/O -/O type/O KCNJ10/O expression/O yielded/O robust/O Kir/O currents/O ,/O while/O currents/O from/O oocytes/O expressing/O the/O mutation/O were/O reduced/O ./O
Western/O Blot/O analysis/O revealed/O reduced/B-NegReg protein/B-MPA expression/I-MPA by/O the/O mutation/B-Var ./O
Kir5.1/O subunits/O display/O selective/O heteromultimerization/O with/O Kir4.1/O constituting/O channels/O with/O unique/O kinetics/O ./O
The/O effect/O of/O the/O mutation/O on/O Kir4.1/5.1/O channel/O activity/O was/O twofold/O :/O a/O reduction/O in/O current/O amplitudes/O and/O an/O increase/O in/O the/O pH/O -/O dependent/O inhibition/O ./O
We/O thus/O report/O a/O novel/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var in/O Kir4.1/O found/O in/O a/O patient/O with/O a/O co/O -/O exiting/O mutation/B-Var in/O SLACK/O channels/O that/O results/B-Reg in/I-Reg a/O fatal/B-Disease disease/I-Disease ./O
Allelic/O Complexity/O in/O Long/O QT/O Syndrome/O :/O A/O Family/O -/O Case/O Study/O ./O
Congenital/O long/B-Disease QT/I-Disease syndrome/I-Disease (/O LQTS/O )/O is/O associated/O with/O high/O genetic/O and/O allelic/O heterogeneity/O ./O
In/O some/O cases/O ,/O more/O than/O one/O genetic/O variant/O is/O identified/O in/O the/O same/O (/O compound/O heterozygosity/O )/O or/O different/O (/O digenic/O heterozygosity/O )/O genes/O ,/O and/O subjects/O with/O multiple/O pathogenic/O mutations/O may/O have/O a/O more/O severe/O disease/O ./O
Standard/O -/O of/O -/O care/O clinical/O genetic/O testing/O for/O this/O and/O other/O arrhythmia/O susceptibility/O syndromes/O improves/O the/O identification/O of/O complex/O genotypes/O ./O
Therefore/O ,/O it/O is/O important/O to/O distinguish/O between/O pathogenic/O mutations/O and/O benign/O rare/O variants/O ./O
We/O identified/O four/O genetic/O variants/O (/O KCNQ1-p/O ./O
R583H/O ,/O KCNH2-p/O ./O
C108Y/O ,/O KCNH2-p/O ./O
K897/O T/O ,/O and/O KCNE1-p/O ./O
G38S/O )/O in/O an/O LQTS/O family/O ./O
On/O the/O basis/O of/O in/O silico/O analysis/O ,/O clinical/O data/O from/O our/O family/O ,/O and/O the/O evidence/O from/O previous/O studies/O ,/O we/O analyzed/O two/O mutated/O channels/O ,/O KCNQ1-p/O ./O
R583H/O and/O KCNH2-p/O ./O
C108Y/O ,/O using/O the/O whole/O -/O cell/O patch/O clamp/O technique/O ./O
We/O found/O that/O KCNQ1-p/O ./O
R583H/O was/O not/O associated/O with/O a/O severe/O functional/O impairment/O ,/O whereas/O KCNH2-p/B-Var ./I-Var
C108Y/I-Var ,/O a/O novel/O variant/O ,/O encoded/B-Reg a/O non/B-Pathway -/I-Pathway functional/I-Pathway channel/I-Pathway that/O exerts/O dominant/B-NegReg -/I-NegReg negative/I-NegReg effects/B-MPA on/O the/O wild/O -/O type/O ./O
Notably/O ,/O the/O common/O variants/O KCNH2-p/O ./O
K897/O T/O and/O KCNE1-p/O ./O
G38S/O were/O previously/O reported/O to/O produce/O more/O severe/O phenotypes/O when/O combined/O with/O disease/O -/O causing/O alleles/O ./O
Our/O results/O indicate/O that/O the/O novel/O KCNH2-C108Y/B-Var variant/O can/O be/O a/O pathogenic/B-Reg LQTS/B-Disease mutation/O ,/O whereas/O KCNQ1-p/O ./O
R583H/O ,/O KCNH2-p/O ./O
K897/O T/O ,/O and/O KCNE1-p/O ./O
G38S/O could/O be/O LQTS/O modifiers/O ./O
POSITIVE/O REGULATOR/O OF/O IRON/O HOMEOSTASIS/O 1/O (/O OsPRI1/O )/O positively/O regulates/O iron/O homeostasis/O in/O rice/O ./O
OsHRZ1/O is/O a/O potential/O iron/O -/O binding/O sensor/O ./O
However/O ,/O it/O is/O unclear/O how/O OsHRZ1/O transmits/O signals/O ./O
In/O this/O study/O ,/O we/O reveal/O that/O OsPRI1/O interacts/O with/O OsHRZ1/O ./O
A/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var to/O OsPRI1/B-Gene increased/B-PosReg the/O sensitivity/B-MPA of/O plants/O to/O Fe/O -/O deficient/O conditions/O and/O downregulated/B-NegReg the/O expression/B-MPA of/O Fe/O -/O deficiency/O -/O responsive/O genes/O ./O
Yeast/O one/O -/O hybrid/O and/O electrophoretic/O mobility/O shift/O assay/O results/O suggested/O that/O OsPRI1/O binds/O to/O the/O OsIRO2/O and/O OsIRO3/O promoters/O ./O
In/O vitro/O ubiquitination/O experiments/O indicated/O that/O OsPRI1/O is/O ubiquitinated/O by/O OsHRZ1/O ./O
Cell/O -/O free/O degradation/O assays/O revealed/O that/O the/O stability/B-MPA of/O OsPRI1/O decreased/O in/O wild/O type/O roots/O ,/O but/O increased/B-PosReg in/O the/O hrz1/B-Gene -/I-Gene 2/I-Gene mutant/B-Var ,/O suggesting/O OsHRZ1/O is/O responsible/O for/O the/O instability/O of/O OsPRI1/O ./O
The/O hrz1/O -/O 2/O seedlings/O were/O insensitive/O to/O Fe/O -/O deficient/O conditions/O ./O
When/O the/O pri1/B-Gene -/I-Gene 1/I-Gene mutation/B-Var was/O introduced/B-Interaction into/O hrz1/B-Gene -/I-Gene 2/I-Gene mutants/B-Var ,/O the/O pri1hrz1/O double/O mutant/O was/O more/B-PosReg sensitive/B-MPA to/I-MPA Fe/I-MPA deficiency/I-MPA than/O the/O hrz1/O -/O 2/O mutant/O ./O
Additionally/O ,/O the/O expression/O levels/O of/O Fe/O -/O deficiency/O -/O responsive/O genes/O were/O lower/O in/O the/O hrz1pri1/O double/O mutant/O than/O in/O the/O hrz1/O -/O 2/O mutant/O ./O
Collectively/O ,/O these/O results/O imply/O that/O OsPRI1/O ,/O which/O is/O ubiquitinated/O by/O OsHRZ1/O ,/O mediates/O rice/O responses/O to/O Fe/O -/O deficiency/O by/O positively/O regulating/O OsIRO2/O and/O OsIRO3/O expression/O as/O part/O of/O the/O OsHRZ1-OsPRI1-OsIRO2/3/O signal/O transduction/O cascade/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg but/O not/O dominant/O -/O negative/O intragenic/O IKZF1/B-Gene deletions/B-Var are/O associated/O with/O an/O adverse/O prognosis/O in/O adult/O BCR/O -/O ABL/O -/O negative/O acute/B-Disease lymphoblastic/I-Disease leukemia/I-Disease ./O
Genetic/O alterations/O of/O the/O transcription/O factor/O IKZF1/O (/O "/O IKAROS/O "/O )/O are/O detected/O in/O around/O 15/O -/O 30/O %/O of/O cases/O of/O BCR/O -/O ABL/O -/O negative/O B/O -/O cell/O precursor/O acute/O lymphoblastic/O leukemia/O (/O ALL/O )/O ./O
Different/O types/O of/O intragenic/O deletions/B-Var have/O been/O observed/O ,/O resulting/O in/O a/O functionally/B-MPA inactivated/I-MPA allele/I-MPA (/B-NegReg "/I-NegReg loss/I-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg "/I-NegReg )/I-NegReg or/O in/O "/B-NegReg dominant/I-NegReg -/I-NegReg negative/I-NegReg "/I-NegReg isoforms/B-MPA ./O
The/O prognostic/O impact/O of/O these/O alterations/O especially/O in/O adult/O acute/O lymphoblastic/O leukemia/O is/O not/O well/O defined/O ./O
We/O analyzed/O 482/O well/O -/O characterized/O cases/O of/O adult/O BCR/O -/O ABL/O -/O negative/O B/O -/O precursor/O acute/O lymphoblastic/O leukemia/O uniformly/O treated/O in/O the/O framework/O of/O the/O GMALL/O studies/O and/O detected/O IKZF1/O alterations/O in/O 128/O cases/O (/O 27/O %/O )/O ./O
In/O 20/O %/O ,/O the/O IKZF1/O alteration/O was/O present/O in/O a/O large/O fraction/O of/O leukemic/O cells/O (/O "/O high/O deletion/O load/O "/O )/O while/O in/O 7/O %/O it/O was/O detected/O only/O in/O small/O subclones/O (/O "/O low/O deletion/O load/O "/O )/O ./O
Some/O patients/O showed/O more/O than/O one/O IKZF1/O alteration/O (/O 8/O %/O )/O ./O
Patients/O exhibiting/O a/O loss/O -/O of/O -/O function/O isoform/O with/O high/B-Var deletion/I-Var load/I-Var had/O a/O shorter/B-NegReg overall/B-MPA survival/I-MPA (/O OS/O at/O 5/O years/O 28/O %/O vs./O 59/O %/O ,/O p<0.0001/O )/O ,/O also/O significant/O in/O a/O subgroup/O analysis/O of/O standard/O risk/O patients/O according/O to/O GMALL/O classification/O (/O OS/O at/O 5/O years/O 37/O %/O vs./O 68/O %/O ,/O p=0.0002/O )/O ./O
Low/O deletion/O load/O or/O dominant/O -/O negative/O IKZF1/O alterations/O had/O no/O prognostic/O impact/O ./O
The/O results/O thus/O suggest/O that/O there/O is/O a/O clear/O distinction/O between/O loss/O -/O of/O -/O function/O and/O dominant/O -/O negative/O IKZF1/O deletions/O ./O
Affected/O patients/O should/O thus/O be/O monitored/O for/O minimal/O residual/O disease/O carefully/O to/O detect/O incipient/O relapses/O at/O an/O early/O stage/O and/O they/O are/O potential/O candidates/O for/O alternative/O or/O intensified/O treatment/O regimes/O ./O
Registered/O at/O http://www.clinicaltrials.gov/O :/O NCT00199056/O ,/O NCT00198991/O ./O
Stress/O -/O Induced/O Sleep/O After/O Exposure/O to/O Ultraviolet/O Light/O Is/O Promoted/O by/O p53/O in/O Caenorhabditis/O elegans/O ./O
Stress/O -/O induced/O sleep/O (/O SIS/O )/O in/O C./O elegans/O is/O important/O for/O restoration/O of/O cellular/O homeostasis/O and/O is/O a/O useful/O model/O to/O study/O the/O function/O and/O regulation/O of/O sleep/O ./O
SIS/O is/O triggered/O when/O epidermal/O growth/O factor/O (/O EGF/O )/O activates/O the/O ALA/O neuron/O ,/O which/O then/O releases/O neuropeptides/O to/O promote/O sleep/O ./O
To/O further/O understand/O this/O behavior/O ,/O we/O established/O a/O new/O model/O of/O stress/O -/O induced/O sleep/O using/O irradiation/O by/O ultraviolet/O C/O (/O UVC/O )/O light/O ./O
While/O UVC/O irradiation/O requires/O ALA/O signaling/O and/O leads/O to/O a/O sleep/O state/O similar/O to/O that/O induced/O by/O heat/O and/O other/O stressors/O ,/O it/O does/O not/O induce/O the/O proteostatic/O stress/O seen/O with/O heat/O exposure/O ./O
Based/O on/O the/O known/O genotoxic/O effects/O of/O UVC/O irradiation/O ,/O we/O tested/O two/O genes/O -/O atl-1/O and/O cep-1-which/O encode/O proteins/O that/O act/O in/O the/O DNA/O damage/O response/O pathway/O ./O
Loss/O of/O function/O mutants/O of/O atl-1/O had/O no/O defect/O in/O UVC/O induced/O SIS/O but/O a/O partial/O loss/B-NegReg of/I-NegReg function/I-NegReg mutant/B-Var of/O cep-1/B-Gene ,/O gk138/O ,/O had/O decreased/B-NegReg movement/B-MPA quiescence/I-MPA following/O UVC/O irradiation/O ./O
Germline/O ablation/O experiments/O and/O tissue/O -/O specific/O RNA/O interference/O experiments/O showed/O that/O cep-1/O is/O required/O somatically/O in/O neurons/O for/O its/O effect/O on/O SIS/O ./O
The/O cep-1(gk138/B-Gene )/I-Gene mutant/B-Var suppressed/B-NegReg body/B-MPA movement/I-MPA quiescence/I-MPA controlled/I-MPA by/I-MPA EGF/I-MPA ,/O indicating/O that/O CEP-1/O acts/O downstream/O or/O in/O parallel/O to/O ALA/O activation/O to/O promote/O quiescence/O in/O response/O to/O ultraviolet/O light/O ./O
PCSK9/B-Gene deficiency/B-Var results/O in/O increased/B-PosReg ectopic/B-MPA fat/I-MPA accumulation/I-MPA in/O experimental/O models/O and/O in/O humans/O ./O
Background/O Proprotein/O convertase/O subtilisin/O kexin/O type/O 9/O (/O PCSK9/O )/O regulates/O low/O -/O density/O lipoprotein/O and/O very/O low/O -/O density/O lipoprotein/O receptor/O expression/O in/O several/O tissues/O ./O
Here/O we/O evaluated/O whether/O PCSK9/O may/O modulate/O the/O handling/O of/O triglycerides/O in/O the/O liver/O and/O peripheral/O tissues/O ./O
Methods/O Subjects/O from/O the/O PLIC/O cohort/O were/O genotyped/O for/O the/O loss/O -/O of/O -/O function/O PCSK9/O R46L/O variant/O and/O characterized/O for/O clinical/O and/O biochemical/O parameters/O ,/O total/O and/O android/O fat/O mass/O ,/O hepatic/O steatosis/O and/O epicardial/O fat/O thickness/O ./O
Visceral/O adipose/O tissue/O and/O subcutaneous/O adipose/O tissue/O in/O PCSK9/O KO/O and/O wild/O type/O mice/O were/O quantified/O by/O nuclear/O magnetic/O resonance/O imaging/O ./O
Results/O Carriers/O of/O the/O R46L/O variant/O (/O n/O =/O 13/O )/O had/O lower/O low/O -/O density/O lipoprotein/O cholesterol/O levels/O ,/O higher/O body/O mass/O index/O and/O increased/O percentage/O of/O total/O and/O android/O fat/O masses/O compared/O with/O non/O -/O carriers/O (/O n/O =/O 521/O )/O ./O
R46L/B-Gene variant/B-Var associated/O with/O a/O two/O -/O fold/O increase/B-PosReg prevalence/O of/O hepatic/B-MPA steatosis/I-MPA and/I-MPA higher/I-MPA epicardial/I-MPA fat/I-MPA thickness/I-MPA ./O
These/O observations/O were/O replicated/O in/O PCSK9/O KO/O mice/O ,/O which/O showed/O increased/O visceral/O adipose/O tissue/O (/O but/O not/O subcutaneous/O adipose/O tissue/O )/O when/O fed/O chow/O or/O high/O -/O fat/O diet/O for/O 20/O weeks/O ,/O compared/O with/O wild/O type/O mice/O ./O
Conclusions/O These/O data/O suggest/O that/O genetically/O determined/O PCSK9/B-Gene deficiency/B-Var might/O be/O associated/B-Reg with/O ectopic/B-MPA fat/I-MPA accumulation/I-MPA ./O
A/O Braf/B-Gene kinase/O -/O inactive/O mutant/B-Var induces/B-Reg lung/B-Disease adenocarcinoma/I-Disease ./O
The/O initiating/O oncogenic/O event/O in/O almost/O half/O of/O human/O lung/O adenocarcinomas/O is/O still/O unknown/O ,/O a/O fact/O that/O complicates/O the/O development/O of/O selective/O targeted/O therapies/O ./O
Yet/O these/O tumours/O harbour/O a/O number/O of/O alterations/O without/O obvious/O oncogenic/O function/O including/O BRAF/O -/O inactivating/O mutations/O ./O
Inactivating/O BRAF/O mutants/O in/O lung/O predominate/O over/O the/O activating/O V600E/O mutant/O that/O is/O frequently/O observed/O in/O other/O tumour/O types/O ./O
Here/O we/O demonstrate/O that/O the/O expression/O of/O an/O endogenous/O Braf(D631A/O )/O kinase/O -/O inactive/O isoform/O in/O mice/O (/O corresponding/O to/O the/O human/O BRAF(D594A/O )/O mutation/O )/O triggers/O lung/O adenocarcinoma/O in/O vivo/O ,/O indicating/O that/O BRAF/O -/O inactivating/O mutations/O are/O initiating/O events/O in/O lung/O oncogenesis/O ./O
Moreover/O ,/O inactivating/O BRAF/O mutations/O have/O also/O been/O identified/O in/O a/O subset/O of/O KRAS/O -/O driven/O human/O lung/O tumours/O ./O
Co/O -/O expression/O of/O Kras(G12V/B-Var )/I-Var and/O Braf(D631A/B-Var )/I-Var in/O mouse/O lung/O cells/O markedly/O enhances/B-PosReg tumour/B-MPA initiation/I-MPA ,/O a/O phenomenon/O mediated/O by/O Craf/O kinase/O activity/O ,/O and/O effectively/O accelerates/O tumour/O progression/O when/O activated/O in/O advanced/O lung/O adenocarcinomas/O ./O
We/O also/O report/O a/O key/O role/O for/O the/O wild/O -/O type/O Braf/O kinase/O in/O sustaining/O Kras(G12V)/Braf(D631A)-driven/O tumours/O ./O
Ablation/O of/O the/O wild/O -/O type/O Braf/O allele/O prevents/O the/O development/O of/O lung/O adenocarcinoma/O by/O inducing/O a/O further/O increase/O in/O MAPK/O signalling/O that/O results/O in/O oncogenic/O toxicity/O ;/O this/O effect/O can/O be/O abolished/O by/O pharmacological/O inhibition/O of/O Mek/O to/O restore/O tumour/O growth/O ./O
However/O ,/O the/O loss/B-Var of/O wild/O -/O type/O Braf/B-Gene also/O induces/B-Reg transdifferentiation/B-CPA of/O club/O cells/O ,/O which/O leads/B-Reg to/I-Reg the/O rapid/B-MPA development/I-MPA of/I-MPA lethal/I-MPA intrabronchiolar/I-MPA lesions/I-MPA ./O
These/O observations/O indicate/O that/O the/O signal/O intensity/O of/O the/O MAPK/O pathway/O is/O a/O critical/O determinant/O not/O only/O in/O tumour/O development/O ,/O but/O also/O in/O dictating/O the/O nature/O of/O the/O cancer/O -/O initiating/O cell/O and/O ultimately/O the/O resulting/O tumour/O phenotype/O ./O
Enpp1/O is/O an/O anti/O -/O aging/O factor/O that/O regulates/O Klotho/O under/O phosphate/O overload/O conditions/O ./O
Control/O of/O phosphate/O metabolism/O is/O crucial/O to/O regulate/O aging/O in/O mammals/O ./O
Klotho/O is/O a/O well/O -/O known/O anti/O -/O aging/O factor/O that/O regulates/O phosphate/O metabolism/O :/O mice/O mutant/O or/O deficient/O in/O Klotho/O exhibit/O phenotypes/O resembling/O human/O aging/O ./O
Here/O we/O show/O that/O ectonucleotide/O pyrophosphatase/O //O phosphodiesterase/O 1/O (/O Enpp1/O )/O is/O required/O for/O Klotho/O expression/O under/O phosphate/O overload/O conditions/O ./O
Loss/B-Var -/I-Var of/I-Var -/I-Var function/I-Var Enpp1/B-Gene (/O ttw/O //O ttw/O )/O mice/O under/O phosphate/O overload/O conditions/O exhibited/B-Reg phenotypes/O resembling/O human/O aging/O and/O Klotho/O mutants/O ,/O such/O as/O short/O life/O span/O ,/O arteriosclerosis/B-Disease and/O osteoporosis/B-Disease ,/O with/O elevated/B-PosReg serum/B-MPA 1,25(OH)2D3/I-MPA levels/I-MPA ./O
Enpp1/O (/O ttw/O //O ttw/O )/O mice/O also/O exhibited/O significantly/O reduced/O renal/O Klotho/O expression/O under/O phosphate/O overload/O conditions/O ,/O and/O aging/O phenotypes/O in/O these/O mice/O were/O rescued/O by/O Klotho/O overexpression/O ,/O a/O low/O vitamin/O D/O diet/O or/O vitamin/O D/O receptor/O knockout/O ./O
These/O findings/O indicate/O that/O Enpp1/O plays/O a/O crucial/O role/O in/O regulating/O aging/O via/O Klotho/O expression/O under/O phosphate/O overload/O conditions/O ./O
Characterization/O of/O the/O autophagy/O -/O related/O gene/O BmATG8/O in/O Bipolaris/O maydis/O ./O
Autophagy/O is/O involved/O in/O cellular/O development/O and/O the/O maintenance/O of/O viability/O under/O nutrient/O deprivation/O in/O a/O wide/O range/O of/O eukaryotes/O ./O
A/O filamentous/O ascomycete/O Bipolaris/O maydis/O ,/O responsible/O for/O southern/O corn/O leaf/O blight/O ,/O is/O also/O studied/O as/O a/O model/O fungus/O for/O sexual/O reproduction/O in/O filamentous/O ascomycetes/O that/O form/O filiform/O ascospores/O ./O
In/O order/O to/O clarify/O the/O roles/O of/O autophagy/O in/O various/O stages/O of/O the/O life/O cycle/O of/O B./O maydis/O ,/O we/O constructed/O null/O mutants/O of/O BmATG8/O ,/O an/O orthologue/O of/O the/O Saccharomyces/O cerevisiae/O autophagy/O gene/O ATG8/O in/O B./O maydis/O ./O
Deletion/B-Var of/O BmATG8/B-Gene impaired/B-NegReg localization/B-MPA of/O cytosolic/O components/O to/O the/O vacuole/O under/O nitrogen/O starvation/O ,/O suggesting/O that/O autophagy/B-CPA was/O deficient/B-NegReg in/O the/O null/O mutants/O ./O
Additionally/O ,/O fluorescent/O microscopic/O observations/O on/O a/O eGFP/O -/O fused/O BmATG8/O expressing/O strain/O showed/O that/O BmATG8/O is/O associated/O with/O autophagy/O -/O related/O structures/O ./O
In/O vegetative/O growth/O ,/O ΔBmATG8/B-Gene strains/O showed/O a/O reduction/B-NegReg in/O conidiation/B-CPA and/I-CPA aerial/I-CPA mycelial/I-CPA growth/I-CPA ./O
Interestingly/O ,/O the/O mutant/O conidia/O indicated/O loss/O of/O the/O germination/O rate/O under/O starvation/O conditions/O and/O affected/O longevity/O ./O
However/O ,/O germinated/O mutant/O conidia/O were/O still/O capable/O of/O infecting/O the/O host/O plant/O via/O appressoria/O ./O
In/O sexual/O reproduction/O ,/O ascospores/O with/O ΔBmATG8/O genetic/O background/O were/O aborted/O ./O
Our/O results/O revealed/O that/O autophagy/O plays/O a/O crucial/O role/O in/O the/O function/O of/O conidia/O ,/O not/O in/O host/O infection/O via/O appressoria/O in/O B./O maydis/O ./O
In/O addition/O ,/O conservation/O of/O the/O importance/O of/O autophagy/O in/O ascospore/O development/O is/O suggested/O among/O ascomycetes/O including/O species/O that/O form/O bitunicate/O ascus/O ./O
Impairment/O of/O different/O protein/O domains/O causes/O variable/O clinical/O presentation/O within/O Pitt/O -/O Hopkins/O syndrome/O and/O suggests/O intragenic/O molecular/O syndromology/O of/O TCF4/O ./O
Pitt/B-Disease -/I-Disease Hopkins/I-Disease syndrome/I-Disease is/O a/O neurodevelopmental/O disorder/O characterized/O by/O severe/O intellectual/O disability/O and/O a/O distinctive/O facial/O gestalt/O ./O
It/O is/O caused/B-Reg by/I-Reg haploinsufficiency/B-Var of/O the/O TCF4/B-Gene gene/O ./O
The/O TCF4/O protein/O has/O different/O functional/O domains/O ,/O with/O the/O NLS/O (/O nuclear/O localization/O signal/O )/O domain/O coded/O by/O exons/O 7/O -/O 8/O and/O the/O bHLH/O (/O basic/O Helix/O -/O Loop/O -/O Helix/O )/O domain/O coded/O by/O exon/O 18/O ./O
Several/O alternatively/O spliced/O TCF4/O variants/O have/O been/O described/O ,/O allowing/O for/O translation/O of/O variable/O protein/O isoforms/O ./O
Typical/O PTHS/O patients/O have/O impairment/O of/O at/O least/O the/O bHLH/O domain/O ./O
To/O which/O extent/O impairment/O of/O the/O remaining/O domains/O contributes/O to/O the/O final/O phenotype/O is/O not/O clear/O ./O
There/O is/O recent/O evidence/O that/O certain/O loss/O -/O of/O -/O function/O variants/B-Var disrupting/B-NegReg TCF4/B-Gene are/O associated/O with/O mild/B-Disease ID/I-Disease ,/O but/O not/O with/O typical/O PTHS/O ./O
We/O describe/O a/O frameshift/B-Reg -/I-Reg causing/I-Reg partial/B-Var gene/I-Var deletion/I-Var encompassing/O exons/O 4/O -/O 6/O of/O TCF4/B-Gene in/O an/O adult/O patient/O with/B-Reg mild/B-Disease ID/I-Disease and/O nonspecific/O facial/O dysmorphisms/O but/O without/O the/O typical/O features/O of/O PTHS/O ,/O and/O a/O c.520C/B-Var >/I-Var T/I-Var nonsense/O variant/O within/O exon/O 8/O in/O a/O child/O presenting/O with/B-Reg a/O severe/O phenotype/O largely/O mimicking/O PTHS/B-Disease ,/O but/O lacking/O the/O typical/O facial/O dysmorphism/O ./O
Investigation/O on/O mRNA/O ,/O along/O with/O literature/O review/O ,/O led/O us/O to/O suggest/O a/O preliminary/O phenotypic/O map/O of/O loss/O -/O of/O -/O function/O variants/O affecting/O TCF4/O ./O
An/O intragenic/O phenotypic/O map/O of/O loss/O -/O of/O -/O function/O variants/O in/O TCF4/O is/O suggested/O here/O for/O the/O first/O time/O :/O variants/O within/O exons/O 1/O -/O 4/O and/O exons/O 4/O -/O 6/O give/O rise/O to/O a/O recurrent/O phenotype/O with/O mild/O ID/O not/O in/O the/O spectrum/O of/O Pitt/O -/O Hopkins/O syndrome/O (/O biallelic/O preservation/O of/O both/O the/O NLS/O and/O bHLH/O domains/O )/O ;/O variants/O within/O exons/O 7/O -/O 8/O cause/O a/O severe/O phenotype/O resembling/O PTHS/O but/O in/O absence/O of/O the/O typical/O facial/O dysmorphism/O (/O impairment/O limited/O to/O the/O NLS/O domain/O )/O ;/O variants/O within/O exons/O 9/O -/O 19/O cause/O typical/O Pitt/O -/O Hopkins/O syndrome/O (/O impairment/O of/O at/O least/O the/O bHLH/O domain/O )/O ./O
Understanding/O the/O TCF4/O molecular/O syndromology/O can/O allow/O for/O proper/O nosology/O in/O the/O current/O era/O of/O whole/O genomic/O investigations/O ./O
ARHGAP29/O Mutation/O Is/O Associated/O with/O Abnormal/O Oral/O Epithelial/O Adhesions/O ./O
Nonsyndromic/B-Disease cleft/I-Disease lip/I-Disease and/or/I-Disease palate/I-Disease (/O NSCL/O //O P/O )/O is/O a/O prevalent/O birth/O defect/O of/O complex/O etiology/O ./O
Previous/O studies/O identified/O mutations/B-Var in/O ARHGAP29/B-Gene associated/B-Reg with/O an/O increased/O risk/O for/O NSCL/B-Disease //I-Disease P./I-Disease To/O investigate/O the/O effects/O of/O ARHGAP29/O in/O vivo/O ,/O we/O generated/O a/O novel/O murine/O allele/O by/O inserting/O a/O point/O mutation/O identified/O in/O a/O patient/O with/O NSCL/O //O P./O This/O single/B-Var -/I-Var nucleotide/I-Var variation/I-Var of/O ARHGAP29/B-Gene translates/O to/O an/O early/O nonsense/O mutation/O (/B-Var K326X/I-Var )/I-Var ,/O presumably/O resulting/O in/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O ./O
Embryos/O from/O Arhgap29(K326X/+/O )/O intercrosses/O were/O harvested/O at/O various/O time/O points/O ./O
No/O homozygous/O Arhgap29(K326X/O )/O animals/O were/O found/O in/O the/O 45/O analyzed/O litters/O ,/O assessed/O as/O early/O as/O embryonic/O day/O 8.5/O (/O e8.5/O )/O ./O
Coronal/O sectioning/O of/O e13.5/O and/O e14.5/O heads/O revealed/O that/O 59/O %/O of/O Arhgap29(K326X/+/O )/O mice/O (/O n/O =/O 37/O )/O exhibited/O improper/O epithelial/O contact/O between/O developing/O oral/O structures/O ,/O while/O none/O were/O observed/O in/O wild/O types/O (/O n/O =/O 10/O )/O ./O
In/O addition/O ,/O Arhgap29(K326X/+/O )/O embryos/O exhibited/O a/O significantly/O higher/O percentage/O of/O maxillary/O epithelium/O in/O contact/O with/O mandibular/O epithelium/O ./O
Immunofluorescent/O analyses/O of/O the/O periderm/O and/O oral/O adhesions/O revealed/O the/O presence/O of/O Arhgap29/O in/O periderm/O cells/O ./O
These/O cells/O were/O p63/O negative/O ,/O keratin/O 17/O positive/O ,/O and/O keratin/O 6/O positive/O and/O present/O at/O sites/O of/O adhesion/O ,/O although/O occasionally/O disorganized/O ./O
Oral/O adhesions/O did/O not/O appear/O to/O impair/O palatogenesis/O ,/O as/O all/O analyzed/O Arhgap29(K326X/+/O )/O embryos/O showed/O confluent/O palatal/O mesenchyme/O and/O epithelium/O at/O e18.5/O (/O n/O =/O 16/O )/O ,/O and/O no/O mice/O were/O found/O with/O a/O cleft/O at/O birth/O ./O
Collectively/O ,/O our/O data/O demonstrate/O that/O ARHGAP29/O is/O required/O for/O embryonic/O survival/O and/O that/O heterozygosity/O for/O LoF/B-NegReg variants/B-Var of/O Arhgap29/B-Gene increases/B-PosReg the/O incidence/B-CPA and/I-CPA length/I-CPA of/I-CPA oral/I-CPA adhesions/I-CPA at/I-CPA a/I-CPA critical/I-CPA time/I-CPA point/I-CPA during/I-CPA orofacial/I-CPA development/I-CPA ./O
In/O conclusion/O ,/O we/O validate/O the/O LoF/B-NegReg nature/O of/O the/O human/O K326X/B-Var mutation/I-Var in/O vivo/O and/O reveal/O a/O previously/O unknown/O effect/O of/O Arhgap29/B-Gene in/O murine/O craniofacial/B-CPA development/I-CPA ./O
Deciphering/O the/O molecular/O basis/O of/O ferroportin/O resistance/O to/O hepcidin/O :/O Structure/O //O function/O analysis/O of/O rare/O SLC40A1/B-Gene missense/B-Var mutations/I-Var found/B-Reg in/O suspected/O hemochromatosis/B-Disease type/I-Disease 4/I-Disease patients/O ./O
Genetic/O medicine/O applied/O to/O the/O study/O of/O hemochromatosis/O has/O identified/O the/O systemic/O loop/O controlling/O iron/O homeostasis/O ,/O centered/O on/O hepcidin/O -/O ferroportin/O interaction/O ./O
Current/O challenges/O are/O to/O dissect/O the/O molecular/O pathways/O underlying/O liver/O hepcidin/O synthesis/O in/O response/O to/O circulatory/O iron/O ,/O HFE/O ,/O TFR2/O ,/O HJV/O ,/O TMPRSS6/O and/O BMP6/O functions/O ,/O and/O to/O define/O the/O major/O structural/O elements/O of/O hepcidin/O -/O ferroportin/O interaction/O ./O
We/O built/O a/O first/O 3D/O model/O of/O human/O ferroportin/O structure/O ,/O using/O the/O crystal/O structure/O of/O EmrD/O ,/O a/O bacterial/O drug/O efflux/O transporter/O of/O the/O Major/O Facilitator/O Superfamily/O ,/O as/O template/O ./O
The/O model/O enabled/O study/O of/O disease/O -/O associated/O mutations/O ,/O and/O guided/O mutagenesis/O experiments/O to/O determine/O the/O role/O of/O conserved/O residues/O in/O protein/O stability/O and/O iron/O transport/O ./O
Results/O revealed/O novel/O amino/O acids/O that/O are/O critical/O for/O the/O iron/O export/O function/O and/O the/O hepcidin/O -/O mediated/O inhibition/O mechanism/O :/O for/O example/O ,/O tryptophan/O 42/O ,/O localized/O in/O the/O extracellular/O end/O of/O the/O ferroportin/O pore/O and/O involved/O in/O both/O biological/O functions/O ./O
Here/O ,/O we/O propose/O a/O strategy/O that/O is/O not/O limited/O to/O structure/O analysis/O ,/O but/O integrates/O information/O from/O different/O sources/O ,/O including/O human/O disease/O -/O associated/O mutations/O and/O functional/O in/O vitro/O assays/O ./O
The/O first/O major/O hypothesis/O of/O this/O PhD/O thesis/O is/O that/O ferroportin/O resistance/O to/O hepcidin/O relies/O on/O different/O molecular/O mechanisms/O that/O are/O critical/O for/O ferroportin/O endocytosis/O ,/O and/O include/O at/O least/O three/O fundamental/O steps/O :/O (/O i/O )/O hepcidin/O binding/O to/O ferroportin/O ,/O (/O ii/O )/O structural/O reorganization/O of/O the/O N-/O and/O C/O -/O ter/O ferroportin/O lobes/O ,/O and/O (/O iii/O )/O ferroportin/O ubiquitination/O ./O
Loss/O -/O of/O -/O function/O mutations/O in/O filaggrin/O gene/O and/O malignant/O melanoma/O :/O a/O case/O control/O study/O ./O
BACKGROUND/O :/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O filaggrin/O gene/O (/B-Gene FLG/I-Gene )/I-Gene have/O been/O suggested/O to/O increase/O the/O susceptibility/O of/O skin/B-Disease malignancies/I-Disease due/O to/O reduced/B-NegReg levels/B-MPA of/I-MPA epidermal/I-MPA filaggrin/I-MPA and/O its/O degradation/B-MPA products/I-MPA ,/O urocanic/B-MPA acid/I-MPA ,/O which/O may/O be/O protective/O against/O ultraviolet/O irradiation/O ./O
OBJECTIVE/O :/O We/O aimed/O to/O investigate/O the/O association/O between/O FLG/O mutation/O status/O and/O the/O occurrence/O of/O malignant/O melanoma/O (/O MM/O )/O in/O Danish/O adults/O ./O
METHODS/O :/O The/O prevalence/O of/O FLG/O mutations/O in/O a/O sample/O of/O MM/O biopsies/O was/O compared/O with/O a/O FLG/O genotyped/O cohort/O from/O two/O general/O population/O studies/O ./O
Pearson/O 's/O chi/O -/O square/O and/O Fisher/O 's/O exact/O tests/O were/O used/O to/O compare/O the/O two/O groups/O ./O
RESULTS/O :/O A/O total/O of/O 867/O MM/O biopsies/O and/O 9965/O general/O population/O controls/O were/O genotyped/O ,/O respectively/O ./O
In/O the/O MM/O sample/O 2/O (/O 0.23/O %/O )/O individuals/O were/O homozygous/O and/O 80/O (/O 9.4/O %/O )/O heterozygous/O mutation/O carriers/O ./O
In/O the/O general/O population/O controls/O the/O prevalence/O of/O FLG/O mutations/O was/O 18/O (/O 0.18/O %/O )/O and/O 835/O (/O 8.4/O %/O )/O for/O homozygous/O and/O heterozygous/O mutations/O ,/O respectively/O ./O
Fisher/O 's/O exact/O test/O and/O Pearson/O 's/O chi/O square/O test/O yielded/O non/O -/O significant/O p/O -/O values/O when/O the/O groups/O were/O compared/O ./O
CONCLUSION/O :/O FLG/O mutation/O was/O not/O associated/O with/O MM/O in/O the/O studied/O populations/O ./O
This/O finding/O indicates/O that/O epidermal/O deficiency/O of/O filaggrin/O and/O its/O degradation/O products/O do/O not/O influence/O the/O risk/O of/O MM/O significantly/O ./O
This/O article/O is/O protected/O by/O copyright/O ./O
All/O rights/O reserved/O ./O
A/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O TNFRSF13B/B-Gene is/O a/O candidate/O for/O predisposition/O to/O familial/B-Disease or/I-Disease sporadic/I-Disease immune/I-Disease thrombocytopenia/I-Disease ./O
BACKGROUND/O :/O Most/O immune/B-Disease thrombocytopenia/I-Disease (/O ITP/O )/O is/O sporadic/O but/O a/O positive/O family/O history/O of/O ITP/O in/O some/O patients/O suggests/O that/O hereditary/O forms/O exist/O ./O
Due/O to/O the/O rarity/O of/O familial/O ITP/O families/O available/O for/O study/O and/O the/O heterogeneity/O of/O sporadic/O ITP/O ,/O family/O linkage/O analysis/O or/O genome/O wide/O association/O studies/O are/O limited/O ./O
OBJECTIVES/O :/O Based/O on/O one/O ITP/O pedigree/O ,/O we/O try/O to/O identify/O the/O predisposing/O gene/O in/O familial/O or/O sporadic/O ITP/O and/O reveal/O the/O way/O in/O which/O it/O causes/O thrombocytopenia/O ./O
METHODS/O :/O Gene/O expression/O profiling/O analysis/O and/O whole/O -/O exome/O sequencing/O was/O performed/O on/O samples/O from/O familial/O ITP/O members/O ,/O sporadic/O ITP/O cases/O and/O healthy/O individuals/O ./O
We/O also/O evaluated/O the/O influence/O of/O potential/O pathogenic/O mutation/O on/O immune/O function/O and/O megakaryocyte/O apoptosis/O ./O
RESULTS/O :/O Whole/O -/O exome/O sequencing/O identified/O a/O potential/O pathologic/B-Reg p/B-Var ./I-Var G76S/I-Var heterozygous/O mutation/O on/O the/O TNFRSF13B/B-Gene gene/O in/O familial/B-Disease ITP/I-Disease patients/O ./O
ITP/O patients/O harboring/O G76S/B-Var mutation/O displayed/O upregulated/B-PosReg "/B-MPA cytokine/I-MPA -/I-MPA cytokine/I-MPA receptor/I-MPA interaction/I-MPA "/I-MPA signal/I-MPA ,/O increased/B-PosReg serum/B-MPA TNFα/I-MPA ,/O IL-17α/I-MPA ,/O IFNγ/I-MPA and/I-MPA BAFF/I-MPA levels/I-MPA ,/O and/O enhanced/B-PosReg binding/B-Interaction capacity/I-Interaction of/I-Interaction APRIL/I-Interaction ligand/I-Interaction to/I-Interaction B/I-Interaction cells/I-Interaction ./O
Additionally/O ,/O EBV/O -/O transformed/O B/O cells/O with/O the/O G76S/B-Var mutation/O could/O induce/B-PosReg human/B-CPA megakaryocyte/I-CPA line/I-CPA (/I-CPA Meg-01/I-CPA )/I-CPA apoptosis/I-CPA significantly/O ./O
CONCLUSION/O :/O p/B-Var ./I-Var G76S/I-Var mutation/O on/O TNFRSF13B/B-Gene gene/O is/O responsible/B-Reg for/O ITP/B-Disease ,/O and/O is/O a/O genetic/O predisposing/O factor/O for/O familial/O or/O sporadic/O ITP/O ./O
This/O article/O is/O protected/O by/O copyright/O ./O
All/O rights/O reserved/O ./O
A/O single/O active/O site/O mutation/O in/O the/O pikromycin/O thioesterase/O generates/O a/O more/O effective/O macrocyclization/O catalyst/O ./O
Macrolactonization/O of/O natural/O product/O analogs/O presents/O a/O significant/O challenge/O to/O both/O biosynthetic/O assembly/O and/O synthetic/O chemistry/O ./O
In/O the/O preceding/O paper/O ,/O we/O identified/O a/O thioesterase/O (/O TE/O )/O domain/O catalytic/O bottleneck/O in/O the/O processing/O of/O un/O -/O natural/O substrates/O in/O the/O pikromycin/O (/O Pik/O )/O system/O ,/O preventing/O the/O formation/O of/O epimerized/O macrolactones/O ./O
Here/O ,/O we/O perform/O molecular/O dynamics/O (/O MD/O )/O simulations/O showing/O the/O epimerized/O hexaketide/O was/O accommodated/O within/O the/O Pik/O TE/O active/O site/O ;/O however/O ,/O intrinsic/O conformational/O preferences/O of/O the/O substrate/O resulted/O in/O predominately/O unproductive/O conformations/O ,/O in/O agreement/O with/O the/O observed/O hydrolysis/O ./O
Accordingly/O ,/O we/O engineered/O the/O stereospecific/O Pik/O TE/O to/O yield/O a/O variant/O (/O TES148C/O )/O with/O improved/O reaction/O kinetics/O and/O gain/O -/O of/O -/O function/O processing/O of/O an/O unnatural/O ,/O epimerized/O hexaketide/O ./O
Quantum/O mechanical/O (/O QM/O )/O comparison/O of/O model/O TES148C/O and/O TEWT/O reaction/O coordinate/O diagrams/O revealed/O a/O change/O in/O mechanism/O from/O a/O stepwise/O addition/O -/O elimination/O (/O TEWT/O )/O to/O a/O lower/O energy/O concerted/O acyl/O substitution/O (/O TES148C/O )/O ,/O accounting/O for/O the/O gain/O -/O of/O -/O function/O and/O improved/O reaction/O kinetics/O ./O
Finally/O ,/O we/O introduced/O the/O S148C/B-Var mutation/O into/O a/O polyketide/O synthase/O module/O (/O PikAIII/O -/O TE/O )/O to/O impart/O increased/B-PosReg substrate/B-MPA flexibility/I-MPA ,/O enabling/B-PosReg the/O production/B-MPA of/I-MPA diastereomeric/I-MPA macrolactones/I-MPA ./O
A/O comprehensive/O functional/O assessment/O of/O carboxylesterase/O 1/O nonsynonymous/O polymorphisms/O ./O
Carboxylesterase/O 1/O (/O CES1/O )/O is/O the/O predominant/O human/O hepatic/O hydrolase/O responsible/O for/O the/O metabolism/O of/O many/O clinically/O important/O medications/O ./O
CES1/O expression/O and/O activity/O vary/O markedly/O among/O individuals/O ;/O and/O genetic/O variation/O is/O a/O major/O contributing/O factor/O to/O CES1/O interindividual/O variability/O ./O
In/O the/O present/O study/O ,/O we/O comprehensively/O examined/O the/O functions/O of/O CES1/O nonsynonymous/O single/O nucleotide/O polymorphisms/O (/O nsSNPs/O )/O and/O haplotypes/O using/O transfected/O cell/O lines/O and/O individual/O human/O liver/O tissues/O ./O
The/O 20/O candidate/O variants/O include/O CES1/O nsSNPs/O with/O a/O minor/O allele/O frequency/O (/O MAF/O )/O >/O 0.5/O %/O in/O a/O given/O population/O or/O located/O in/O close/O proximity/O to/O the/O CES1/O active/O site/O ./O
Five/O nsSNPs/O including/O L40Ter/O (/B-Var rs151291296/I-Var )/I-Var ,/O G142E/O (/B-Var rs121912777/I-Var )/I-Var ,/O G147C/O (/B-Var rs146456965/I-Var )/I-Var ,/O Y170D/O (/B-Var rs148947808/I-Var )/I-Var ,/O and/O R171C/O (/B-Var rs201065375/I-Var )/I-Var were/O found/O to/O be/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/O for/O metabolizing/B-MPA the/O CES1/B-Enzyme substrates/O clopidogrel/O ,/O enalapril/O ,/O and/O sacubitril/O ./O
Additionally/O ,/O the/O A158V/O (/B-Var rs202121317/I-Var )/I-Var ,/O R199H/O (/B-Var rs2307243/I-Var )/I-Var ,/O E220/O G/O (/B-Var rs200707504/I-Var )/I-Var ,/O and/O T290/O M/O (/B-Var rs202001817/I-Var )/I-Var decreased/B-NegReg CES1/B-Enzyme activity/B-MPA to/O a/O lesser/O extent/O in/O a/O substrate/O -/O dependent/O manner/O ./O
Several/O nsSNPs/O including/O the/O L40Ter/O (/B-Var rs151291296/I-Var )/I-Var ,/O G147C/O (/B-Var rs146456965/I-Var )/I-Var ,/O Y170D/O (/B-Var rs148947808/I-Var )/I-Var ,/O and/O R171C/O (/B-Var rs201065375/I-Var )/I-Var significantly/O reduced/B-NegReg CES1/B-Protein protein/I-Protein and/or/O mRNA/B-MPA expressions/I-MPA in/O the/O transfected/O cells/O ./O
Functions/O of/O the/O common/O nonsynonymous/O haplotypes/O D203E/O -/O A269S/O and/O S75N/O -/O D203E/O -/O A269S/O were/O evaluated/O using/O cells/O stably/O expressing/O the/O haplotypes/O and/O a/O large/O set/O of/O human/O livers/O ./O
Neither/O CES1/O expression/O nor/O activity/O were/O affected/O by/O the/O two/O haplotypes/O ./O
In/O sum/O ,/O the/O study/O revealed/O several/O functional/O nsSNPs/O with/O impaired/O activity/O on/O the/O metabolism/O of/O CES1/O substrate/O drugs/O ./O
Clinical/O investigations/O are/O warranted/O to/O determine/O whether/O these/O nsSNPs/O can/O serve/O as/O biomarkers/O for/O the/O prediction/O of/O therapeutic/O outcomes/O of/O drugs/O metabolized/O by/O CES1/O ./O
Progranulin/B-Protein haploinsufficiency/B-Var reduces/B-NegReg amyloid/B-MPA beta/I-MPA deposition/I-MPA in/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease model/O mice/O ./O
Granulin/O (/O Grn/O )/O mutations/O were/O identified/O in/O familial/O frontotemporal/B-Disease lobar/I-Disease degeneration/I-Disease (/O FTLD/O )/O patients/O with/O TAR/O DNA/O -/O binding/O protein/O of/O 43/O kd/O (/O TDP-43/O )/O pathology/O ./O
Grn/B-Protein transcript/O haploinsufficiency/B-Var is/O proposed/O as/O a/O disease/O mechanism/O that/O leads/O to/O the/O loss/B-NegReg of/I-NegReg functional/I-NegReg progranulin/O (/B-Protein PGRN/I-Protein )/I-Protein protein/O ./O
Thus/O ,/O these/O mutations/B-Var are/O strongly/O involved/B-Reg in/O FTLD/B-Disease pathogenesis/O ./O
Moreover/O ,/O recent/O findings/O indicate/O that/O Grn/B-Protein mutations/B-Var are/O associated/B-Reg with/O other/O neurodegenerative/O disorders/O with/O tau/O pathology/O ,/O including/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease ./O
To/O investigate/O the/O influence/O of/O PGRN/O on/O amyloid/O beta/O (/O Aβ/O )/O accumulation/O ,/O amyloid/O precursor/O protein/O (/O APP/O )/O transgenic/O mice/O were/O interbred/O with/O Grn/O -/O deficient/O mice/O ,/O producing/O APP/O transgenic/O mice/O harboring/O the/O Grn/O hemizygote/O (/O APP/O //O Grn+/-/O )/O ./O
Brains/O were/O collected/O from/O 16/O -/O 18-month/O -/O old/O APP/O and/O APP/O //O Grn+/-/O mice/O and/O sequential/O extraction/O of/O proteins/O ,/O immunoblotting/O and/O immunohistochemical/O analysis/O were/O performed/O ./O
Immunohistochemical/O analysis/O showed/O that/O the/O number/O and/O area/O of/O Aβ/O plaque/O was/O significantly/O decreased/O in/O APP/O //O Grn+/-/O mice/O as/O compared/O to/O APP/O mice/O ./O
Immunoblotting/O analysis/O revealed/O that/O Aβ/O was/O reduced/O in/O the/O sarkosyl/O -/O insoluble/O fraction/O of/O 16/O -/O 18-month/O -/O old/O APP/O //O Grn+/-/O mice/O as/O compared/O with/O that/O of/O APP/O transgenic/O mice/O ./O
Our/O data/O suggest/O that/O PGRN/B-Protein haploinsufficiency/B-Var may/O decrease/B-NegReg accumulation/B-MPA of/I-MPA Aβ/I-MPA ./O
Identification/O of/O distinct/O mutational/O patterns/O and/O new/O driver/O genes/O in/O oesophageal/O squamous/O cell/O carcinomas/O and/O adenocarcinomas/O ./O
OBJECTIVES/O :/O Oesophageal/B-Disease squamous/I-Disease cell/I-Disease carcinoma/I-Disease (/O OSCC/O )/O and/O adenocarcinoma/O (/O OAC/O )/O are/O distinct/O cancers/O in/O terms/O of/O a/O number/O of/O clinical/O and/O epidemiological/O characteristics/O ,/O complicating/O the/O design/O of/O clinical/O trials/O and/O biomarker/O developments/O ./O
We/O analysed/O 1048/O oesophageal/O tumour/O -/O germline/O pairs/O from/O both/O subtypes/O ,/O to/O characterise/O their/O genomic/O features/O ,/O and/O biological/O and/O clinical/O significance/O ./O
DESIGN/O :/O Previously/O exome/O -/O sequenced/O samples/O were/O re/O -/O analysed/O to/O identify/O significantly/O mutated/O genes/O (/O SMGs/O )/O and/O mutational/O signatures/O ./O
The/O biological/O functions/O of/O novel/O SMGs/O were/O investigated/O using/O cell/O line/O and/O xenograft/O models/O ./O
We/O further/O performed/O whole/O -/O genome/O bisulfite/O sequencing/O and/O chromatin/O immunoprecipitation/O (/O ChIP)-seq/O to/O characterise/O epigenetic/O alterations/O ./O
RESULTS/O :/O OSCC/O and/O OAC/O displayed/O nearly/O mutually/O exclusive/O sets/O of/O driver/O genes/O ,/O indicating/O that/O they/O follow/O independent/O developmental/O paths/O ./O
The/O combined/O sample/O size/O allowed/O the/O statistical/O identification/O of/O a/O number/O of/O novel/O subtype/O -/O specific/O SMGs/O ,/O mutational/O signatures/O and/O prognostic/O biomarkers/O ./O
Particularly/O ,/O we/O identified/O a/O novel/O mutational/O signature/O similar/O to/O Catalogue/O Of/O Somatic/O Mutations/O In/O Cancer/O (/O COSMIC)signature/O 16/O ,/O which/O has/O prognostic/O value/O in/O OSCC/O ./O
Two/O newly/O discovered/O SMGs/O ,/O CUL3/O and/O ZFP36L2/O ,/O were/O validated/O as/O important/O tumour/O -/O suppressors/O specific/O to/O the/O OSCC/O subtype/O ./O
We/O further/O identified/O their/O additional/O loss/O -/O of/O -/O function/O mechanisms/O ./O
CUL3/B-Gene was/O homozygously/O deleted/B-Var specifically/O in/B-Reg OSCC/B-Disease and/O other/O squamous/B-Disease cell/I-Disease cancers/I-Disease (/O SCCs/O )/O ./O
Notably/O ,/O ZFP36L2/O is/O associated/O with/O super/O -/O enhancer/O in/O healthy/O oesophageal/O mucosa/O ;/O DNA/O hypermethylation/O in/O its/O super/O -/O enhancer/O reduced/O active/O histone/O markers/O in/O squamous/O cancer/O cells/O ,/O suggesting/O an/O epigenetic/O inactivation/O of/O a/O super/O -/O enhancer/O -/O associated/O SCC/O suppressor/O ./O
CONCLUSIONS/O :/O These/O data/O comprehensively/O contrast/O differences/O between/O OSCC/O and/O OAC/O at/O both/O genomic/O and/O epigenomic/O levels/O ,/O and/O reveal/O novel/O molecular/O features/O for/O further/O delineating/O the/O pathophysiological/O mechanisms/O and/O treatment/O strategies/O for/O these/O cancers/O ./O
Gait/O disturbance/O and/O lower/O limb/O pain/O in/O a/O patient/O with/O PIK3CA/O -/O related/O disorder/O ./O
Post/O -/O zygotic/O activating/O mutations/O in/O PIK3CA/O and/O other/O genes/O encoding/O members/O of/O PI3K/O -/O AKT/O -/O mTOR/O pathway/O have/O been/O found/O in/O various/O overgrowth/O syndromes/O that/O have/O been/O grouped/O together/O as/O PIK3CA/O -/O related/O overgrowth/O spectrum/O (/O PROS/O )/O ./O
We/O report/O a/O female/O patient/O with/O gait/O disturbance/O ,/O leg/O pain/O ,/O isolated/O macrodactyly/O of/O the/O foot/O ,/O and/O mild/O intellectual/O disability/O ./O
Imaging/O of/O the/O lower/O limb/O showed/O a/O lipoblastoma/O of/O the/O right/O thigh/O ./O
A/O mosaic/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O in/O the/O catalytic/O domain/O of/O PIK3CA/B-Gene (/B-Var c.3140/I-Var A/I-Var >/I-Var G/I-Var ;/I-Var p/B-Var ./I-Var His1047Arg/I-Var )/I-Var was/O detected/O in/O the/O adipose/O tissue/O and/O in/O skin/O cultured/O fibroblasts/O from/O the/O macrodactyly/O but/O not/O in/O blood/O ./O
The/O leg/O pain/O and/O the/O severe/O walking/O disturbance/O improved/O slightly/O over/O time/O and/O serial/O MRI/O of/O the/O lower/O limbs/O suggested/O that/O the/O size/O of/O the/O lipoblastoma/O relative/O to/O the/O lower/O limb/O muscles/O or/O to/O the/O whole/O lower/O limb/O was/O unchanged/O as/O consequence/O of/O limb/O growth/O ./O
This/O case/O report/O illustrates/O that/O pain/O and/O gait/O disturbance/O can/O be/O features/O of/O PROS/O and/O highlights/O the/O need/O of/O better/O knowledge/O about/O the/O natural/O history/O of/O the/O disease/O ./O
Loss/O -/O of/O -/O Function/O GRHL3/O Variants/O Detected/O in/O African/O Patients/O with/O Isolated/O Cleft/O Palate/O ./O
In/O contrast/O to/O the/O progress/O that/O has/O been/O made/O toward/O understanding/O the/O genetic/O etiology/O of/O cleft/O lip/O with/O or/O without/O cleft/O palate/O ,/O relatively/O little/O is/O known/O about/O the/O genetic/O etiology/O for/O cleft/B-Disease palate/I-Disease only/I-Disease (/O CPO/O )/O ./O
A/O common/O coding/O variant/O of/O grainyhead/O like/O transcription/O factor/O 3/O (/O GRHL3/O )/O was/O recently/O shown/O to/O be/O associated/O with/O risk/O for/O CPO/O in/O Europeans/O ./O
Mutations/O in/O this/O gene/O were/O also/O reported/O in/O families/O with/O Van/O der/O Woude/O syndrome/O ./O
To/O identify/O rare/O mutations/O in/O GRHL3/O that/O might/O explain/O the/O missing/O heritability/O for/O CPO/O ,/O we/O sequenced/O GRHL3/O in/O cases/O of/O CPO/O from/O Africa/O ./O
We/O recruited/O participants/O from/O Ghana/O ,/O Ethiopia/O ,/O and/O Nigeria/O ./O
This/O cohort/O included/O case/O -/O parent/O trios/O ,/O cases/O and/O other/O family/O members/O ,/O as/O well/O as/O controls/O ./O
We/O sequenced/O exons/O of/O this/O gene/O in/O DNA/O from/O a/O total/O of/O 134/O nonsyndromic/O cases/O ./O
When/O possible/O ,/O we/O sequenced/O them/O in/O parents/O to/O identify/O de/O novo/O mutations/O ./O
Five/O novel/O mutations/O were/O identified/O :/O 2/O missense/O (/O c.497C/O >/O A/O ;/O p/O ./O Pro166His/O and/O c.1229A/O >/O G/O ;/O p/O ./O Asp410Gly/O )/O ,/O 1/O splice/O site/O (/O c.1282A/O >/O C/O p/O ./O Ser428Arg/O )/O ,/O 1/O frameshift/O (/O c.470delC/O ;/O p/O ./O Gly158Alafster55/O )/O ,/O and/O 1/O nonsense/O (/O c.1677C/O >/O A/O ;/O p/O ./O Tyr559Ter/O )/O ./O
These/O mutations/O were/O absent/O from/O 270/O sequenced/O controls/O and/O from/O all/O public/O exome/O and/O whole/O genome/O databases/O ,/O including/O the/O 1000/O Genomes/O database/O (/O which/O includes/O data/O from/O Africa/O )/O ./O
However/O ,/O 4/O of/O the/O 5/O mutations/O were/O present/O in/O unaffected/O mothers/O ,/O indicating/O that/O their/O penetrance/O is/O incomplete/O ./O
Interestingly/O ,/O 1/O mutation/B-Var damaged/B-NegReg a/O predicted/O sumoylation/B-MPA site/I-MPA ,/O and/O another/O disrupted/B-NegReg a/O predicted/O CK1/B-MPA phosphorylation/I-MPA site/O ./O
Overexpression/O assays/O in/O zebrafish/O and/O reporter/O assays/O in/O vitro/O indicated/O that/O 4/O variants/O were/O functionally/O null/O or/O hypomorphic/O ,/O while/O 1/O was/O dominant/O negative/O ./O
This/O study/O provides/O evidence/O that/O ,/O as/O in/O Caucasian/O populations/O ,/O mutations/B-Var in/O GRHL3/B-Gene contribute/O to/O the/O risk/B-Reg of/O nonsyndromic/O CPO/B-Disease in/O the/O African/O population/O ./O
The/O apolipoprotein/B-Protein C/I-Protein -/I-Protein III/I-Protein (/B-Var Gln38Lys/I-Var )/I-Var variant/O associated/O with/O human/B-Disease hypertriglyceridemia/I-Disease is/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O ./O
Recent/O cell/O culture/O and/O animal/O studies/O have/O suggested/O that/O expression/O of/O human/O apo/O C/O -/O III/O in/O the/O liver/O has/O a/O profound/O impact/O on/O the/O triacylglycerol/O (/O TAG)-rich/O VLDL1/O production/O under/O lipid/O -/O rich/O conditions/O ./O
The/O apoC/O -/O III/O Gln38Lys/O variant/O was/O identified/O in/O subjects/O of/O Mexican/O origin/O with/O moderate/O hypertriglyceridemia/O ./O
We/O postulated/O that/O Gln38Lys/O (/O C3QK/O )/O ,/O being/O a/O gain/O -/O of/O -/O function/O mutation/O ,/O promotes/O hepatic/O VLDL1/O assembly/O //O secretion/O ./O
To/O test/O this/O hypothesis/O ,/O we/O expressed/O C3QK/O in/O McA/O -/O RH7777/O cells/O and/O apoc3-null/O mice/O to/O contrast/O its/O effect/O with/O WT/O apoC/O -/O III/O (/O C3WT/O )/O ./O
In/O both/O model/O systems/O ,/O C3QK/O expression/O increased/O the/O secretion/O of/O VLDL1-TAG/O (/O by/O 230/O %/O )/O under/O lipid/O -/O rich/O conditions/O ./O
Metabolic/O labeling/O experiments/O with/O C3QK/O cells/O showed/O an/O increase/O in/O de/B-MPA novo/I-MPA lipogenesis/I-MPA (/O DNL/O )/O ./O
Fasting/O plasma/O concentration/O of/O TAG/O ,/O cholesterol/O ,/O cholesteryl/O ester/O ,/O and/O FA/O were/O increased/O in/O C3QK/O mice/O as/O compared/O with/O C3WT/O mice/O ./O
Liver/O of/O C3QK/B-Var mice/O also/O displayed/O an/O increase/B-PosReg in/O DNL/B-MPA and/O expression/B-MPA of/O lipogenic/B-Gene genes/I-Gene as/O compared/O with/O that/O in/O C3WT/O mice/O ./O
These/O results/O suggest/O that/O C3QK/B-Var variant/O is/O a/O gain/O -/O of/O -/O function/O mutation/O that/O can/O stimulate/B-PosReg VLDL1/B-MPA production/I-MPA ,/O through/O enhanced/B-PosReg DNL/B-MPA ./O
The/O Impact/O of/O Heterozygous/O KCNK3/O Mutations/O Associated/O With/O Pulmonary/O Arterial/O Hypertension/O on/O Channel/O Function/O and/O Pharmacological/O Recovery/O ./O
BACKGROUND/O :/O Heterozygous/O loss/O of/O function/O mutations/B-Var in/O the/O KCNK3/B-Gene gene/O cause/B-Reg hereditary/O pulmonary/B-Disease arterial/I-Disease hypertension/I-Disease (/O PAH/O )/O ./O
KCNK3/O encodes/O an/O acid/O -/O sensitive/O potassium/O channel/O ,/O which/O contributes/O to/O the/O resting/O potential/O of/O human/O pulmonary/O artery/O smooth/O muscle/O cells/O ./O
KCNK3/O is/O widely/O expressed/O in/O the/O body/O ,/O and/O dimerizes/O with/O other/O KCNK3/O subunits/O ,/O or/O the/O closely/O related/O ,/O acid/O -/O sensitive/O KCNK9/O channel/O ./O
METHODS/O AND/O RESULTS/O :/O We/O engineered/O homomeric/O and/O heterodimeric/O mutant/O and/O nonmutant/O KCNK3/O channels/O associated/O with/O PAH/O ./O
Using/O whole/O -/O cell/O patch/O -/O clamp/O electrophysiology/O in/O human/O pulmonary/O artery/O smooth/O muscle/O and/O COS7/O cell/O lines/O ,/O we/O determined/O that/O homomeric/O and/O heterodimeric/O mutant/O channels/O in/O heterozygous/O KCNK3/O conditions/O lead/O to/O mutation/O -/O specific/O severity/O of/O channel/O dysfunction/O ./O
Both/O wildtype/O and/O mutant/O KCNK3/O channels/O were/O activated/O by/O ONO/O -/O RS-082/O (/O 10/O μmol/O //O L/O )/O ,/O causing/O cell/O hyperpolarization/O ./O
We/O observed/O robust/O gene/O expression/O of/O KCNK3/O in/O healthy/O and/O familial/O PAH/O patient/O lungs/O ,/O but/O no/O quantifiable/O expression/O of/O KCNK9/O ,/O and/O demonstrated/O in/O functional/O studies/O that/O KCNK9/O minimizes/O the/O impact/O of/O select/O KCNK3/O mutations/O when/O the/O 2/O channel/O subunits/O co/O -/O assemble/O ./O
CONCLUSIONS/O :/O Heterozygous/O KCNK3/B-Gene mutations/B-Var in/O PAH/O lead/O to/O variable/O loss/B-NegReg of/O channel/B-MPA function/I-MPA via/O distinct/O mechanisms/O ./O
Homomeric/O and/O heterodimeric/O mutant/O KCNK3/O channels/O represent/O novel/O therapeutic/O substrates/O in/O PAH/O ./O
Pharmacological/O and/O pH/O -/O dependent/O activation/O of/O wildtype/O and/O mutant/O KCNK3/O channels/O in/O pulmonary/O artery/O smooth/O muscle/O cells/O leads/O to/O membrane/O hyperpolarization/O ./O
Co/O -/O assembly/O of/O KCNK3/O with/O KCNK9/O subunits/O may/O provide/O protection/O against/O KCNK3/O loss/O of/O function/O in/O tissues/O where/O both/O KCNK9/O and/O KCNK3/O are/O expressed/O ,/O contributing/O to/O the/O lung/O -/O specific/O phenotype/O observed/O clinically/O in/O patients/O with/O PAH/O because/O of/O KCNK3/O mutations/O ./O
Modifiers/O of/O GRN/O -/O Associated/O Frontotemporal/O Lobar/O Degeneration/O ./O
Heterozygous/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O mutations/B-Var in/O the/O human/O progranulin/O gene/O (/B-Gene GRN/I-Gene )/I-Gene cause/O frontotemporal/B-Disease lobar/I-Disease degeneration/I-Disease (/O FTLD/O )/O by/O a/O mechanism/O of/O haploinsufficiency/O ./O
Patients/O present/O most/O frequently/O with/O frontotemporal/O dementia/O ,/O which/O is/O the/O second/O most/O common/O neurodegenerative/O dementia/O at/O young/O age/O ./O
Currently/O ,/O no/O disease/O -/O modifying/O therapies/O are/O available/O for/O these/O patients/O ./O
Stimulating/O GRN/O protein/O expression/O or/O inhibiting/O its/O breakdown/O is/O an/O obvious/O therapeutic/O strategy/O ,/O and/O is/O indeed/O the/O focus/O of/O current/O preclinical/O research/O and/O clinical/O trials/O ./O
Multiple/O studies/O have/O demonstrated/O the/O heterogeneity/O in/O clinical/O presentation/O and/O wide/O variability/O in/O age/O of/O onset/O in/O patients/O carrying/O a/O GRN/O LOF/O mutation/O ./O
Recently/O ,/O this/O heterogeneity/O became/O an/O opportunity/O to/O identify/O disease/O modifiers/O ,/O considering/O that/O these/O might/O constitute/O suitable/O targets/O for/O developing/O disease/O -/O modifying/O or/O disease/O -/O delaying/O therapies/O ./O
De/O novo/O SETD5/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variant/B-Var as/O a/O cause/O for/O intellectual/B-Disease disability/I-Disease in/O a/O 10-year/O old/O boy/O with/O an/O aberrant/O blind/O ending/O bronchus/O ./O
Although/O rare/O ,/O 3p/O microdeletion/O cases/O have/O been/O well/O described/O in/O the/O clinical/O literature/O ./O
The/O clinical/O phenotype/O includes/O ;/O intellectual/O disability/O (/O ID/O )/O ,/O growth/O retardation/O ,/O facial/O dysmorphism/O ,/O and/O cardiac/O malformations/O ./O
Advances/O in/O chromosome/O microarray/O (/O CMA/O )/O testing/O narrowed/O the/O 3p25/O critical/O region/O to/O a/O 124/O kb/O region/O ,/O and/O recent/O Whole/O Exome/O Sequencing/O (/O WES/O )/O studies/O have/O suggested/O that/O the/O SETD5/O gene/O contributes/O significantly/O to/O the/O 3p25/O phenotype/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg (/O LoF/O )/O variants/B-Var in/O SETD5/B-Gene are/O now/O considered/O a/O likely/O cause/O of/O ID/B-Disease ./O
We/O report/O here/O a/O patient/O with/O a/O frameshift/O LoF/O variant/O in/O exon/O 12/O of/O SETD5/O ./O
This/O patient/O has/O features/O overlapping/O with/O other/O patients/O described/O with/O LoF/O SETD5/O variants/O to/O include/O ;/O similar/O facial/O morphology/O ,/O feeding/O difficulties/O ,/O ID/O ,/O behavioral/O abnormalities/O and/O leg/O length/O discrepancy/O ./O
In/O addition/O ,/O he/O presents/O with/O an/O aberrant/O blind/O ending/O bronchus/O ./O
This/O report/O adds/O to/O publications/O describing/O intragenic/O mutations/O in/O SETD5/O and/O supports/O the/O assertion/O that/O de/O novo/O LoF/O mutations/O in/O SETD5/O present/O with/O an/O overlapping/O but/O distinct/O phenotype/O in/O comparison/O with/O 3p25/O microdeletion/O syndromes/O ./O
Signal/O transducer/O and/O activator/O of/O transcription/O gain/O -/O of/O -/O function/O primary/O immunodeficiency/O //O immunodysregulation/O disorders/O ./O
PURPOSE/O OF/O REVIEW/O :/O To/O describe/O primary/B-Disease immunodeficiencies/I-Disease caused/O by/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutations/B-Var of/O signal/O transducer/O and/O activator/O of/O transcription/O (/B-Gene STAT/I-Gene )/I-Gene genes/O ,/O a/O group/O of/O genetically/O determined/O disorders/O characterized/O by/O susceptibility/O to/O infections/O and/O ,/O in/O many/O cases/O ,/O autoimmune/O manifestations/O ./O
RECENT/O FINDINGS/O :/O GOF/O mutations/B-Var affecting/O STAT1/B-Gene result/O in/O increased/B-PosReg STAT/B-MPA tyrosine/I-MPA phosphorylation/I-MPA and/O secondarily/O increased/B-PosReg response/B-MPA to/I-MPA STAT1-signaling/I-MPA cytokines/I-MPA ,/O such/O as/O interferons/O ./O
In/O contrast/O ,/O STAT3/O hyperactivity/O is/O not/O usually/O related/O to/O hyperphosphorylation/O but/O rather/O to/O increased/O STAT3-mediated/O transcriptional/O activity/O ./O
In/O both/O cases/O ,/O heterozygous/O STAT1/O and/O STAT3/O GOF/O mutations/O trigger/O a/O distinct/O set/O of/O genes/O in/O target/O cells/O that/O lead/O to/O abnormal/O functioning/O of/O antimicrobial/O response/O and/or/O autoimmunity/O and/O result/O in/O autosomal/O dominant/O diseases/O ./O
SUMMARY/O :/O Clinical/O manifestations/O of/O patients/O with/O STAT1/O GOF/O are/O characterized/O by/O mucocutaneous/O candidiasis/O and/O recurrent/O lower/O tract/O respiratory/O infections/O ./O
In/O addition/O ,/O many/O patients/O have/O thyroiditis/O ,/O type/O 1/O diabetes/O mellitus/O ,/O autoimmune/O cytopenias/O ,/O cancer/O or/O aneurysms/O ./O
Patients/O with/O germline/O STAT3/O GOF/O mutations/O have/O an/O increased/O frequency/O of/O early/O -/O onset/O multiorgan/O autoimmunity/O (/O i.e./O autoimmune/O enteropathy/O ,/O type/O 1/O diabetes/O mellitus/O ,/O autoimmune/O interstitial/O lung/O disease/O and/O autoimmune/O cytopenias/O )/O ,/O lymphoproliferation/O ,/O short/O stature/O and/O ,/O less/O frequently/O ,/O severe/O recurrent/O infections/O ./O
Treatment/O options/O range/O from/O antimicrobial/O therapy/O ,/O intravenous/O or/O subcutaneous/O immunoglobulin/O and/O immunosuppressive/O drugs/O ./O
Some/O patients/O with/O STAT1/O GOF/O disorder/O have/O undergone/O hematopoietic/O stem/O cell/O transplantation/O ,/O although/O these/O have/O been/O difficult/O because/O of/O the/O underlying/O proinflammatory/O milieu/O from/O the/O mutation/O ./O
GNPTAB/O missense/O mutations/O cause/O loss/O of/O GlcNAc-1-phosphotransferase/O activity/O in/O mucolipidosis/O type/O II/O through/O distinct/O mechanisms/O ./O
Mucolipidoses/O (/O ML/O )/O II/O and/O III/O alpha/O //O beta/O are/O lysosomal/O storage/O diseases/O caused/O by/O pathogenic/O mutations/O in/O GNPTAB/O encoding/O the/O α⁄β/O -/O subunit/O precursor/O of/O GlcNAc-1-phosphotransferase/O ./O
To/O determine/O genotype/O -/O phenotype/O correlation/O and/O functional/O analysis/O of/O mutant/O GlcNAc-1-phosphotransferase/O ,/O 13/O Brazilian/O patients/O clinically/O and/O biochemical/O diagnosed/O for/O MLII/O or/O III/O alpha/O //O beta/O were/O studied/O ./O
By/O sequencing/O of/O genomic/O GNPTAB/B-Gene of/O the/O MLII/O and/O MLIII/O alpha/O //O beta/O patients/O we/O identified/O six/O novel/O mutations/O :/O p/B-Var ./I-Var D76/I-Var G/I-Var ,/O p/B-Var ./I-Var S385L/I-Var ,/O p/B-Var ./I-Var Q278Kfs*3/I-Var ,/O p/B-Var ./I-Var H588Qfs*27/I-Var ,/O p/B-Var ./I-Var N642Lfs*10/I-Var and/O p/B-Var ./I-Var Y1111/I-Var */I-Var ./O
Expression/O analysis/O by/O western/O blotting/O and/O immunofluorescence/O microscopy/O revealed/O that/O the/O mutant/O α⁄β/O -/O subunit/O precursor/O p/B-Var ./I-Var D76/I-Var G/I-Var is/O retained/O in/O the/O endoplasmic/O reticulum/O whereas/O the/O mutant/O p/B-Var ./I-Var S385L/I-Var is/O correctly/O transported/O to/O the/O cis/O -/O Golgi/O apparatus/O and/O proteolytically/O processed/O ./O
Both/O mutations/O lead/O to/O complete/O loss/B-NegReg of/O GlcNAc-1-phosphotransferase/B-Enzyme activity/B-MPA ,/O consistent/O with/O the/O severe/O clinical/O MLII/O phenotype/O of/O the/O patients/O ./O
Our/O study/O expands/O the/O genotypic/O spectrum/O of/O MLII/O and/O provides/O novel/O insights/O into/O structural/O requirements/O to/O ensure/O GlcNAc-1-phosphotransferase/O activity/O ./O
Altered/O Cav1.2/O function/O in/O the/O Timothy/O syndrome/O mouse/O model/O produces/O ascending/O serotonergic/O abnormalities/O ./O
Polymorphism/O in/O the/O gene/O CACNA1C/O ,/O encoding/O the/O pore/O -/O forming/O subunit/O of/O Cav1.2/O L/O -/O type/O calcium/O channels/O ,/O has/O one/O of/O the/O strongest/O genetic/O linkages/O to/O schizophrenia/O ,/O bipolar/O disorder/O and/O major/O depressive/O disorder/O :/O psychopathologies/O in/O which/O serotonin/O signaling/O has/O been/O implicated/O ./O
Additionally/O ,/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O CACNA1C/B-Gene is/O responsible/O for/O the/O neurodevelopmental/O disorder/O Timothy/B-Disease syndrome/I-Disease that/O presents/O with/O prominent/O behavioral/O features/O on/O the/O autism/O spectrum/O ./O
Given/O an/O emerging/O role/O for/O serotonin/O in/O the/O etiology/O of/O autism/O spectrum/O disorders/O (/O ASD/O )/O ,/O we/O investigate/O the/O relationship/O between/O Cav1.2/O and/O the/O ascending/O serotonin/O system/O in/O the/O Timothy/O syndrome/O type/O 2/O (/O TS2-neo/O )/O mouse/O ,/O which/O displays/O behavioral/O features/O consistent/O with/O the/O core/O triad/O of/O ASD/O ./O
We/O find/O that/O TS2-neo/O mice/O exhibit/O enhanced/O serotonin/O tissue/O content/O and/O axon/O innervation/O of/O the/O dorsal/O striatum/O ,/O as/O well/O as/O decreased/O serotonin/O turnover/O in/O the/O amygdala/O ./O
These/O regionally/O specific/O alterations/O are/O accompanied/O by/O an/O enhanced/O active/O coping/O response/O during/O acute/O stress/O (/O forced/O swim/O )/O ,/O serotonin/O neuron/O Fos/O activity/O in/O the/O caudal/O dorsal/O raphe/O ,/O and/O serotonin/O type/O 1A/O receptor/O -/O dependent/O feedback/O inhibition/O of/O the/O rostral/O dorsal/O raphe/O nuclei/O ./O
Collectively/O ,/O these/O results/O suggest/O that/O the/O global/O gain/O -/O of/O -/O function/O Cav1.2/O mutation/O associated/O with/O Timothy/O syndrome/O has/O pleiotropic/O effects/O on/O the/O ascending/O serotonin/O system/O including/O neuroanatomical/O changes/O ,/O regional/O differences/O in/O forebrain/O serotonin/O metabolism/O and/O feedback/O regulatory/O control/O mechanisms/O within/O the/O dorsal/O raphe/O ./O
Altered/O activity/O of/O the/O ascending/O serotonin/O system/O continues/O to/O emerge/O as/O a/O common/O neural/O signature/O across/O several/O ASD/O mouse/O models/O ,/O and/O the/O capacity/O for/O Cav1.2/O L/O -/O type/O calcium/O channels/O to/O impact/O both/O serotonin/O structure/O and/O function/O has/O important/O implications/O for/O several/O neuropsychiatric/O conditions/O ./O
Localization/O of/O Cdc7/O Protein/O Kinase/O During/O DNA/O Replication/O in/O Saccharomyces/O cerevisiae/O ./O
DDK/O ,/O a/O conserved/O serine/O -/O threonine/O protein/O kinase/O composed/O of/O a/O regulatory/O subunit/O ,/O Dbf4/O ,/O and/O a/O catalytic/O subunit/O ,/O Cdc7/O ,/O is/O essential/O for/O DNA/O replication/O initiation/O during/O S/O phase/O of/O the/O cell/O cycle/O through/O MCM2/O -/O 7/O helicase/O phosphorylation/O ./O
The/O biological/O significance/O of/O DDK/O is/O well/O characterized/O ,/O but/O the/O full/O mechanism/O of/O how/O DDK/O associates/O with/O substrates/O remains/O unclear/O ./O
Cdc7/O is/O bound/O to/O chromatin/O in/O the/O Saccharomyces/O cerevisiae/O genome/O throughout/O the/O cell/O cycle/O ,/O but/O there/O is/O little/O empirical/O evidence/O as/O to/O specific/O Cdc7/O binding/O locations/O ./O
Using/O biochemical/O and/O genetic/O techniques/O ,/O this/O study/O investigated/O the/O specific/O localization/O of/O Cdc7/O on/O chromatin/O ./O
The/O Calling/O Cards/O method/O ,/O using/O Ty5/O retrotransposons/O as/O a/O marker/O for/O DNA/O -/O protein/O binding/O ,/O suggests/O Cdc7/O kinase/O is/O preferentially/O bound/O to/O genomic/O DNA/O known/O to/O replicate/O early/O in/O S/O phase/O ,/O including/O centromeres/O and/O origins/O of/O replication/O ./O
We/O also/O discovered/O Cdc7/O binding/O throughout/O the/O genome/O ,/O which/O may/O be/O necessary/O to/O initiate/O other/O cellular/O processes/O ,/O including/O meiotic/O recombination/O and/O translesion/O synthesis/O ./O
A/O kinase/O dead/O Cdc7/B-Gene point/B-Var mutation/I-Var increases/B-PosReg the/O Ty5/B-MPA retrotransposon/I-MPA integration/I-MPA efficiency/I-MPA and/O a/O 55-amino/B-MPA acid/I-MPA C/I-MPA -/I-MPA terminal/I-MPA truncation/I-MPA of/O Cdc7/B-Gene ,/O unable/B-NegReg to/O bind/B-Interaction Dbf4/B-Gene ,/O reduces/B-NegReg Cdc7/B-Gene binding/B-Interaction suggesting/O a/O requirement/O for/O Dbf4/O to/O stabilize/O Cdc7/O on/O chromatin/O during/O S/O phase/O ./O
Chromatin/O immunoprecipitation/O demonstrates/O that/O Cdc7/O binding/O near/O specific/O origins/O changes/O during/O S/O phase/O ./O
Our/O results/O suggest/O a/O model/O where/O Cdc7/O is/O loosely/O bound/O to/O chromatin/O during/O G1/O At/O the/O G1/O //O S/O transition/O ,/O Cdc7/O binding/O to/O chromatin/O is/O increased/O and/O stabilized/O ,/O preferentially/O at/O sites/O that/O may/O become/O origins/O ,/O in/O order/O to/O carry/O out/O a/O variety/O of/O cellular/O processes/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O PTPN11/B-Gene in/O histiocytic/B-Disease sarcomas/I-Disease of/O Bernese/O Mountain/O Dogs/O ./O
Histiocytic/O sarcoma/O (/O HS/O )/O is/O an/O aggressive/O malignant/O neoplasm/O of/O dendritic/O cell/O origin/O that/O is/O common/O in/O certain/O breeds/O of/O dogs/O ./O
High/O prevalence/O of/O fatal/O ,/O disseminated/O HS/O has/O been/O described/O in/O Bernese/O Mountain/O Dogs/O (/O BMDs/O )/O ./O
Support/O for/O genetic/O predisposition/O to/O develop/O HS/O has/O been/O presented/O in/O several/O studies/O ,/O but/O to/O date/O ,/O causative/O genetic/O events/O have/O not/O been/O reported/O ./O
In/O addition/O ,/O no/O driver/O mutations/O have/O been/O identified/O in/O tumours/O ./O
Recently/O ,/O E76/B-Var K/I-Var gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O in/O SHP2/O encoded/O by/O the/O PTPN11/B-Gene gene/O has/O been/O described/O in/O human/O histiocytic/B-Disease malignancies/I-Disease ./O
In/O our/O study/O ,/O we/O identified/O the/O PTPN11E76/O K/O in/O HS/O of/O BMDs/O ./O
Amplification/O of/O exon/O 3/O of/O the/O PTPN11/O gene/O followed/O by/O Sanger/O sequencing/O was/O used/O to/O detect/O the/O mutation/O and/O estimate/O the/O prevalence/O in/O HS/O from/O 30/O BMDs/O ,/O 13/O Golden/O Retrievers/O and/O 10/O other/O dog/O breeds/O ./O
The/O overall/O prevalence/O of/O PTPN11E76/O K/O in/O HS/O of/O BMDs/O was/O 36.67/O %/O compared/O with/O 8.69/O %/O in/O other/O breeds/O ./O
No/O mutation/O was/O identified/O in/O normal/O tissues/O from/O 10/O BMDs/O with/O HS/O that/O carried/O the/O mutation/O and/O 12/O control/O dogs/O with/O no/O neoplastic/O disease/O ,/O including/O 6/O BMDs/O ./O
Increased/O immunoreactivity/O for/O AKT/O ,/O phosphorylated/O ERK1/2/O and/O phosphorylated/O AKT/O in/O a/O small/O subset/O of/O BMDs/O with/O PTPN11E76/O K/O suggests/O that/O a/O gain/O -/O of/O -/O function/O might/O be/O mediated/O by/O the/O ERK/O and/O AKT/O pathways/O ./O
These/O data/O suggest/O PTPN11E76/O K/O as/O an/O important/O driver/O mutation/O of/O HS/O in/O BMDs/O ./O
This/O information/O may/O not/O only/O aid/O in/O unravelling/O the/O tumourigenic/O events/O associated/O with/O HS/O in/O BMDs/O ,/O but/O also/O help/O in/O identifying/O more/O promising/O therapeutic/O strategies/O ./O
Homozygous/O KIDINS220/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/B-Var in/O fetuses/O with/O cerebral/B-CPA ventriculomegaly/I-CPA and/O limb/B-CPA contractures/I-CPA ./O
Heterozygous/B-Var mutations/I-Var in/O KIDINS220/B-Gene were/O recently/O suggested/O a/O cause/B-Reg of/O spastic/B-Disease paraplegia/I-Disease ,/O intellectual/B-Disease disability/I-Disease ,/O nystagmus/B-Disease and/O obesity/B-Disease ./O
All/O patients/O carried/O terminal/O nonsense/O de/O novo/O mutations/O that/O seemed/O to/O escape/O nonsense/O -/O mediated/O mRNA/O decay/O ./O
The/O mechanism/O for/O pathogenicity/O is/O yet/O unexplained/O ,/O as/O it/O seems/O that/O heterozygous/O loss/O -/O of/O -/O function/O variants/O of/O KIDINS220/O are/O generally/O well/O tolerated/O ./O
We/O present/O a/O consanguineous/O couple/O who/O experienced/O four/O pregnancy/O terminations/O due/O to/O repeated/O findings/O in/O the/O fetuses/O comprising/O enlarged/O cerebral/O ventricles/O and/O limb/O contractures/O ./O
Exome/O sequencing/O in/O two/O of/O the/O aborted/O fetuses/O revealed/O a/O shared/O homozygous/O frameshift/O variant/O in/O exon/O 24/O in/O KIDINS220/O ./O
Sanger/O sequencing/O of/O the/O variant/O in/O available/O family/O members/O showed/O complete/O segregation/O with/O the/O affection/O status/O ,/O resulting/O in/O a/O LOD/O score/O of/O 2.5/O under/O an/O autozygous/O inheritance/O model/O ./O
mRNA/O studies/O revealed/O destruction/O of/O the/O original/O splice/O site/O ,/O resulting/O in/O an/O out/O -/O of/O -/O frame/O transcript/O and/O introduction/O of/O a/O premature/O termination/O codon/O in/O exon/O 25/O ./O
Premature/O termination/O codons/O in/O this/O position/O are/O likely/O to/O cause/O activation/O of/O nonsense/O -/O mediated/O mRNA/O decay/O and/O result/O in/O complete/O absence/O of/O KIDINS220/O protein/O in/O individuals/O homozygous/O for/O the/O variant/O ./O
The/O phenotype/O of/O the/O presented/O fetuses/O overlaps/O with/O findings/O in/O functional/O studies/O of/O knockout/O Kidins220/O mice/O embryos/O that/O are/O non/O -/O viable/O with/O enlarged/O cerebral/O ventricles/O ./O
The/O human/O fetuses/O also/O exhibit/O several/O similarities/O to/O the/O milder/O phenotype/O described/O in/O patients/O with/O heterozygous/O KIDINS220/O mutations/O ./O
We/O hence/O propose/O that/O the/O identified/O homozygous/O loss/O -/O of/O -/O function/O variant/O in/O KIDINS220/O causes/O the/O phenotype/O in/O the/O presented/O fetuses/O ,/O and/O that/O this/O represents/O a/O hitherto/O undescribed/O severe/O autosomal/O recessive/O neurodevelopmental/O disorder/O ./O
The/O GNASR201C/O mutation/O associated/O with/O clonal/O hematopoiesis/O supports/O transplantable/O hematopoietic/O stem/O cell/O activity/O ./O
Genome/O sequencing/O efforts/O have/O identified/O virtually/O all/O of/O the/O important/O mutations/O in/O adult/O myeloid/O malignancies/O ./O
More/O recently/O ,/O population/O studies/O have/O identified/O cancer/O -/O associated/O variants/O in/O the/O blood/O of/O otherwise/O healthy/O individuals/O as/O they/O age/O ,/O a/O phenomenon/O termed/O clonal/O hematopoiesis/O of/O indeterminate/O potential/O (/O CHIP/O )/O ./O
This/O suggests/O that/O these/O mutations/O may/O occur/O in/O hematopoietic/O stem/O cells/O (/O HSCs/O )/O long/O before/O any/O clinical/O presentation/O but/O are/O not/O necessarily/O harbingers/O of/O transformation/O because/O only/O a/O fraction/O of/O individuals/O with/O CHIP/O develop/O hematopoietic/O pathologies/O ./O
Delineation/O between/O CHIP/O variants/O that/O predispose/O for/O disease/O versus/O those/O that/O are/O more/O benign/O could/O be/O used/O as/O a/O prognostic/O factor/O to/O identify/O individuals/O at/O greater/O risk/O for/O transformation/O ./O
To/O achieve/O this/O ,/O the/O biological/O impact/O of/O CHIP/O variants/O on/O HSC/O function/O must/O be/O validated/O ./O
One/O variant/O that/O has/O been/O identified/O recurrently/O in/O CHIP/B-CPA is/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg missense/B-Var mutation/I-Var in/O the/O imprinted/O gene/O GNAS/B-Gene (/O Guanine/O Nucleotide/O Binding/O Protein/O ,/O Alpha/O Stimulating/O )/O ./O
In/O this/O study/O ,/O we/O examined/O the/O effect/O of/O the/O GNASR201C/O variant/O on/O HSC/O function/O ./O
Ectopic/O expression/O of/O GNASR201C/B-Var supported/B-PosReg transplantable/B-CPA HSC/I-CPA activity/I-CPA and/O improved/B-PosReg lymphoid/B-CPA output/I-CPA in/O secondary/O recipients/O ./O
Because/O declining/O lymphoid/O output/O is/O a/O hallmark/O of/O aging/O ,/O GNASR201C/O mutations/O may/O sustain/O lymphoid/O -/O biased/O HSCs/O over/O time/O and/O maintain/O them/O in/O a/O developmental/O state/O favorable/O for/O transformation/O ./O
N1366S/O mutation/O of/O human/O skeletal/O muscle/O sodium/O channel/O causes/O paramyotonia/O congenita/O ./O
KEY/O POINTS/O :/O Paramyotonia/B-Disease congenita/I-Disease is/O a/O hereditary/O channelopathy/O caused/B-Reg by/O missense/B-Var mutations/I-Var in/O the/O SCN4A/B-Gene gene/O ,/O which/O encodes/O the/O α/O subunit/O of/O the/O human/O skeletal/O muscle/O voltage/O -/O gated/O sodium/O channel/O NaV1.4/O ./O
Affected/O individuals/O suffered/O from/O myotonia/O and/O paralysis/O of/O muscles/O ,/O which/O were/O aggravated/O by/O exposure/O to/O cold/O ./O
We/O report/O a/O three/O -/O generation/O Chinese/O family/O with/O patients/O presenting/O paramyotonia/O congenita/O and/O identify/O a/O novel/O N1366S/O mutation/O of/O NaV1.4/O ./O
Whole/O -/O cell/O electrophysiological/O recordings/O of/O the/O N1366S/O channel/O reveal/O a/O gain/O -/O of/O -/O function/O change/O of/O gating/O in/O response/O to/O cold/O ./O
Modelling/O and/O molecular/O dynamic/O simulation/O data/O suggest/O that/O an/O arginine/O -/O to/O -/O serine/O substitution/O at/O position/O 1366/O increases/O the/O distance/O from/O N1366/O to/O R1454/O and/O disrupts/O the/O hydrogen/O bond/O formed/O between/O them/O at/O low/O temperature/O ./O
We/O demonstrate/O that/O N1366S/O is/O a/O disease/O -/O causing/O mutation/O and/O that/O the/O temperature/O -/O sensitive/O alteration/O of/O N1366S/O channel/O activity/O may/O be/O responsible/O for/O the/O pronounced/O paramyotonia/O congenita/O symptoms/O of/O these/O patients/O ./O
ABSTRACT/O :/O Paramyotonia/B-Disease congenita/I-Disease is/O an/O autosomal/O dominant/O skeletal/O muscle/O channelopathy/O caused/B-Reg by/O missense/B-Var mutations/I-Var in/O SCN4A/B-Gene ,/O the/O gene/O encoding/O the/O α/O subunit/O of/O the/O human/O skeletal/O muscle/O voltage/O -/O gated/O sodium/O channel/O NaV1.4/O ./O
We/O report/O a/O three/O -/O generation/O family/O in/O which/O six/O members/O present/O clinical/O symptoms/O of/O paramyotonia/O congenita/O characterized/O by/O a/O marked/O worsening/O of/O myotonia/O by/O cold/O and/O by/O the/O presence/O of/O clear/O episodes/O of/O paralysis/O ./O
We/O identified/O a/O novel/O mutation/O in/O SCN4A/O (/O Asn1366Ser/O ,/O N1366S/O )/O in/O all/O patients/O in/O the/O family/O but/O not/O in/O healthy/O relatives/O or/O in/O 500/O normal/O control/O subjects/O ./O
Functional/O analysis/O of/O the/O channel/O protein/O expressed/O in/O HEK293/O cells/O by/O whole/O -/O cell/O patch/O clamp/O recording/O revealed/O that/O the/O N1366S/O mutation/O led/O to/O significant/O alterations/O in/O the/O gating/O process/O of/O the/O NaV1.4/O channel/O ./O
The/O N1366S/B-Var mutant/O displayed/O a/O cold/O -/O induced/O hyperpolarizing/O shift/O in/O the/O voltage/O dependence/O of/O activation/O and/O a/O depolarizing/O shift/O in/O fast/O inactivation/O ,/O as/O well/O as/O a/O reduced/B-NegReg rate/B-MPA of/O fast/B-MPA inactivation/I-MPA and/O accelerated/B-PosReg recovery/B-MPA from/O fast/B-MPA inactivation/I-MPA ./O
In/O addition/O ,/O homology/O modelling/O and/O molecular/O dynamic/O simulation/O of/O N1366S/O and/O wild/O -/O type/O NaV1.4/O channels/O indicated/O that/O the/O arginine/O -/O to/O -/O serine/O substitution/O disrupted/O the/O hydrogen/O bond/O formed/O between/O N1366/O and/O R1454/O ./O
Together/O ,/O our/O results/O suggest/O that/O N1366S/B-Var is/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O of/O NaV1.4/O at/O low/O temperature/O and/O the/O mutation/O may/O be/O responsible/O for/O the/O clinical/O symptoms/O of/O paramyotonia/B-Disease congenita/I-Disease in/O the/O affected/O family/O and/O constitute/O a/O basis/O for/O studies/O into/O its/O pathogenesis/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/B-Var in/O NFIA/B-Gene provide/O further/O support/O that/O NFIA/O is/O a/O critical/O gene/O in/O 1p32-p31/B-Disease deletion/I-Disease syndrome/I-Disease :/I-Disease A/O four/O patient/O series/O ./O
The/O association/O between/O 1p32-p31/O contiguous/O gene/O deletions/O and/O a/O distinct/O phenotype/O that/O includes/O anomalies/O of/O the/O corpus/O callosum/O ,/O ventriculomegaly/O ,/O developmental/O delay/O ,/O seizures/O ,/O and/O dysmorphic/O features/O has/O been/O long/O recognized/O and/O described/O ./O
Recently/O ,/O the/O observation/O of/O overlapping/O phenotypes/O in/O patients/O with/O chromosome/O translocations/O that/O disrupt/O NFIA/O (/O Nuclear/O factor/O I/O //O A/O )/O ,/O a/O gene/O within/O this/O deleted/O region/O ,/O and/O NFIA/O intragenic/O deletions/O has/O led/O to/O the/O hypothesis/O that/O NFIA/O is/O a/O critical/O gene/O within/O this/O region/O ./O
The/O wide/O application/O and/O increasing/O accessibility/O of/O whole/O exome/O sequencing/O (/O WES/O )/O has/O helped/O identify/O new/O cases/O to/O support/O this/O hypothesis/O ./O
Here/O ,/O we/O describe/O four/O patients/O with/O loss/O -/O of/O -/O function/O variants/O in/O the/O NFIA/O gene/O identified/O through/O WES/O ./O
The/O clinical/O presentation/O of/O these/O patients/O significantly/O overlaps/O with/O the/O phenotype/O described/O in/O previously/O reported/O cases/O of/O 1p32-p31/O deletion/O syndrome/O ,/O NFIA/O gene/O disruptions/O and/O intragenic/O NFIA/O deletions/O ./O
Our/O cohort/O includes/O a/O mother/O and/O daughter/O as/O well/O as/O an/O unrelated/O individual/O who/O share/O the/O same/O nonsense/O variant/O (/O c.205C/O >/O T/O ,/O p/O ./O Arg69Ter/O ;/O NM_001145512.1/O )/O ./O
We/O also/O report/O a/O patient/O with/O a/O frameshift/O NFIA/O variant/O (/O c.159_160dupCC/O ,/O p/O ./O Gln54ProfsTer49/O )/O ./O
We/O have/O compared/O published/O cases/O of/O 1p32-p31/O microdeletion/O syndrome/O ,/O translocations/O resulting/O in/O NFIA/O gene/O disruption/O ,/O intragenic/O deletions/O ,/O and/O loss/O -/O of/O -/O function/O mutations/O (/O including/O our/O four/O patients/O )/O to/O reveal/O that/O abnormalities/O of/O the/O corpus/O callosum/O ,/O ventriculomegaly/O //O hydrocephalus/O ,/O macrocephaly/O ,/O Chiari/O I/O malformation/O ,/O dysmorphic/O features/O ,/O developmental/O delay/O ,/O hypotonia/O ,/O and/O urinary/O tract/O defects/O are/O common/O findings/O ./O
The/O consistent/O overlap/O in/O clinical/O presentation/O provides/O further/O evidence/O of/O the/O critical/O role/O of/O NFIA/O haploinsufficiency/O in/O the/O development/O of/O the/O 1p32-p31/O microdeletion/O syndrome/O phenotype/O ./O
Clcn7F318L/+/O as/O a/O new/O mouse/O model/O of/O Albers/O -/O Schönberg/O disease/O ./O
Dominant/O negative/B-NegReg mutations/B-Var in/O CLCN7/B-Gene ,/O which/O encodes/O a/O homodimeric/O chloride/O channel/O needed/O for/O matrix/O acidification/O by/O osteoclasts/O ,/O cause/O Albers/B-Disease -/I-Disease Schönberg/I-Disease disease/I-Disease (/O also/O known/O as/O autosomal/O dominant/O osteopetrosis/O type/O 2/O )/O ./O
More/O than/O 25/O different/O CLCN7/O mutations/O have/O been/O identified/O in/O patients/O affected/O with/O Albers/O -/O Schönberg/O disease/O ,/O but/O only/O one/O mutation/O (/O Clcn7G213R/O )/O has/O been/O introduced/O in/O mice/O to/O create/O an/O animal/O model/O of/O this/O disease/O ./O
Here/O we/O describe/O a/O mouse/O with/O a/O different/O osteopetrosis/O -/O causing/O mutation/O (/O Clcn7F318L/O )/O ./O
Compared/O to/O Clcn7+/+/O mice/O ,/O 12-week/O -/O old/O Clcn7F318L/+/O mice/O have/O significantly/O increased/B-PosReg trabecular/B-CPA bone/I-CPA volume/I-CPA ,/O consistent/O with/O Clcn7F318L/B-Var acting/O as/O a/O dominant/O negative/B-NegReg mutation/O ./O
Clcn7F318L/O //O F318L/O and/O Clcn7F318L/O //O G213R/O mice/O die/O by/O 1month/O of/O age/O and/O resemble/O Clcn7/O knockout/O mice/O ,/O which/O indicate/O that/O p/B-Var ./I-Var F318L/I-Var mutant/O protein/B-Protein is/O non/B-MPA -/I-MPA functional/I-MPA and/O p/O ./O F318L/O and/O p/O ./O G213R/O mutant/O proteins/O do/O not/O complement/O one/O another/O ./O
Since/O it/O has/O been/O reported/O that/O treatment/O with/O interferon/O gamma/O (/O IFN/O -/O G/O )/O improves/O bone/O properties/O in/O Clcn7G213R/+/O mice/O ,/O we/O treated/O Clcn7F318L/+/O mice/O with/O IFN/O -/O G/O and/O observed/O a/O decrease/O in/O osteoclast/O number/O and/O mineral/O apposition/O rate/O ,/O but/O no/O overall/O improvement/O in/O bone/O properties/O ./O
Our/O results/O suggest/O that/O the/O benefits/O of/O IFN/O -/O G/O therapy/O in/O patients/O with/O Albers/O -/O Schönberg/O disease/O may/O be/O mutation/O -/O specific/O ./O
Highlighting/O Interleukin-36/O Signalling/O in/O Plaque/O Psoriasis/O and/O Pustular/O Psoriasis/O ./O
Plaque/O psoriasis/O and/O pustular/O psoriasis/O are/O overlapping/O ,/O but/O distinct/O ,/O disorders/O ./O
The/O therapeutic/O response/O to/O biologics/O supports/O the/O pivotal/O role/O of/O the/O tumour/O necrosis/O alpha/O (/O TNF-?)//O interleukin/O (/O IL)-23/O //O IL-17/O //O IL-22/O axis/O in/O the/O pathogenesis/O of/O these/O disorders/O ./O
Recently/O ,/O functional/O activation/O of/O the/O IL-36/O receptor/O (/O IL-36R/O )/O was/O discovered/O to/O be/O another/O driving/O force/O in/O the/O pathogenesis/O of/O psoriasis/O ./O
This/O was/O first/O highlighted/O by/O the/O discovery/O that/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var of/O the/O IL-36R/O antagonist/O (/B-Gene IL-36Ra/I-Gene )/I-Gene causes/O pustular/B-Disease psoriasis/I-Disease ./O
Although/O the/O TNF-?/IL-23/O //O IL-17/O //O IL-22/O axis/O and/O the/O functional/O activation/O of/O IL-36R/O are/O fundamentally/O involved/O in/O plaque/O psoriasis/O and/O pustular/O psoriasis/O ,/O respectively/O ,/O the/O 2/O pathways/O are/O closely/O related/O and/O mutually/O reinforced/O ,/O resulting/O in/O full/O -/O blown/O clinical/O manifestations/O ./O
This/O review/O summarizes/O current/O topics/O on/O how/O IL-36/O agonists/O (/O IL-36/O ?/O ,/O IL-36/O ?/O ,/O IL-36/O ?/O )/O signal/O IL-36R/O ,/O the/O pathological/O expression/O of/O IL-36/O agonists/O and/O IL-36Ra/O in/O plaque/O and/O pustular/O psoriatic/O lesions/O ,/O and/O the/O cross/O -/O talk/O between/O the/O TNF-?/IL-23/O //O IL-17/O //O IL-22/O axis/O and/O the/O functional/O activation/O of/O IL-36R/O in/O the/O epidermal/O milieu/O ./O
CCR5Δ32/O (/O rs333/O )/O polymorphism/O is/O associated/O with/O decreased/O risk/O of/O chronic/O and/O aggressive/O periodontitis/O :/O A/O case/O -/O control/O analysis/O based/O in/O disease/O resistance/O and/O susceptibility/O phenotypes/O ./O
Chronic/O and/O aggressive/O periodontitis/O are/O infectious/O diseases/O characterized/O by/O the/O irreversible/O destruction/O of/O periodontal/O tissues/O ,/O which/O is/O mediated/O by/O the/O host/O inflammatory/O immune/O response/O triggered/O by/O periodontal/O infection/O ./O
The/O chemokine/O receptor/O CCR5/O play/O an/O important/O role/O in/O disease/O pathogenesis/O ,/O contributing/O to/O pro/O -/O inflammatory/O response/O and/O osteoclastogenesis/O ./O
CCR5Δ32/O (/B-Var rs333/I-Var )/I-Var is/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/O in/O the/O CCR5/B-Gene gene/O ,/O which/O can/O potentially/O modulate/B-Reg the/O host/B-CPA response/I-CPA and/O ,/O consequently/O periodontitis/O outcome/O ./O
Thus/O ,/O we/O investigated/O the/O effect/O of/O the/O CCR5Δ32/O mutation/O over/O the/O risk/O to/O suffer/O periodontitis/O in/O a/O cohort/O of/O Brazilian/O patients/O (/O total/O N=699/O )/O ,/O representative/O of/O disease/O susceptibility/O (/O chronic/O periodontitis/O ,/O N=197/O ;/O and/O aggressive/O periodontitis/O ,/O N=91/O )/O or/O resistance/O (/O chronic/O gingivitis/O ,/O N=193/O )/O phenotypes/O ,/O and/O healthy/O subjects/O (/O N=218/O )/O ./O
Additionally/O ,/O we/O assayed/O the/O influence/O of/O CCR5Δ32/O in/O the/O expression/O of/O the/O biomarkers/O TNFα/O ,/O IL-1β/O ,/O IL-10/O ,/O IL-6/O ,/O IFN/O -/O γ/O and/O T/O -/O bet/O ,/O and/O key/O periodontal/O pathogens/O P./O gingivalis/O ,/O T./O forsythia/O ,/O and/O T./O denticola/O ./O
In/O the/O association/O analysis/O of/O resistant/O versus/O susceptible/O subjects/O ,/O CCR5Δ32/O mutant/O allele/O -/O carriers/O proved/O significantly/O protected/O against/O chronic/O (/O OR/O 0.49/O ;/O 95/O %/O CI/O 0.29/O -/O 0.83/O ;/O p/O -/O value/O 0.01/O )/O and/O aggressive/O (/O OR/O 0.46/O ;/O 95/O %/O CI/O 0.22/O -/O 0.94/O ;/O p/O -/O value/O 0.03/O )/O periodontitis/O ./O
Further/O ,/O heterozygous/O subjects/O exhibited/O significantly/O decreased/B-NegReg expression/B-MPA of/O TNFα/B-Protein in/O periodontal/O tissues/O ,/O pointing/O to/O a/O functional/O effect/O of/O the/O mutation/B-Var in/O periodontal/O tissues/O during/O the/O progression/O of/O the/O disease/O ./O
Conversely/O ,/O no/O significant/O changes/O were/O observed/O in/O the/O presence/O or/O quantity/O of/O the/O periodontal/O pathogens/O P./O gingivalis/O ,/O T./O forsythia/O ,/O and/O T./O denticola/O in/O the/O subgingival/O biofilm/O that/O could/O be/O attributable/O to/O the/O mutant/O genotype/O ./O
Tacrolimus/O rescues/O the/O signaling/O and/O gene/O expression/O signature/O of/O endothelial/O ALK1/O loss/O -/O of/O -/O function/O and/O improves/O HHT/O vascular/O pathology/O ./O
Hereditary/B-Disease hemorrhagic/I-Disease telangiectasia/I-Disease (/O HHT/O )/O is/O a/O highly/O debilitating/O and/O life/O -/O threatening/O genetic/O vascular/O disorder/O arising/O from/O endothelial/O cell/O (/O EC/O )/O proliferation/O and/O hypervascularization/O ,/O for/O which/O no/O cure/O exists/O ./O
Because/O HHT/B-Disease is/O caused/O by/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O bone/O morphogenetic/O protein/O 9/O (/B-MPA BMP9)-ALK1-Smad1/5/8/I-MPA signaling/I-MPA ,/O interventions/O aimed/O at/O activating/O this/O pathway/O are/O of/O therapeutic/O value/O ./O
We/O interrogated/O the/O whole/O -/O transcriptome/O in/O human/O umbilical/O vein/O ECs/O (/O HUVECs/O )/O and/O found/O that/O ALK1/O signaling/O inhibition/O was/O associated/O with/O a/O specific/O pro/O -/O angiogenic/O gene/O expression/O signature/O ,/O which/O included/O a/O significant/O elevation/O of/O DLL4/O expression/O ./O
By/O screening/O the/O NIH/O clinical/O collections/O of/O FDA/O -/O approved/O drugs/O ,/O we/O identified/O tacrolimus/O (/O FK-506/O )/O as/O the/O most/O potent/O activator/O of/O ALK1/O signaling/O in/O BMP9-challenged/O C2C12/O reporter/O cells/O ./O
In/O HUVECs/O ,/O tacrolimus/O activated/O Smad1/5/8/O and/O opposed/O the/O pro/O -/O angiogenic/O gene/O expression/O signature/O associated/O with/O ALK1/O loss/O -/O of/O -/O function/O ,/O by/O notably/O reducing/O Dll4/O expression/O ./O
In/O these/O cells/O ,/O tacrolimus/O also/O inhibited/O Akt/O and/O p38/O stimulation/O by/O vascular/O endothelial/O growth/O factor/O ,/O a/O major/O driver/O of/O angiogenesis/O ./O
In/O the/O BMP9/10-immunodepleted/O postnatal/O retina/O -/O a/O mouse/O model/O of/O HHT/O vascular/O pathology/O -/O tacrolimus/O activated/O endothelial/O Smad1/5/8/O and/O prevented/O the/O Dll4/O overexpression/O and/O hypervascularization/O associated/O with/O this/O model/O ./O
Finally/O ,/O tacrolimus/O stimulated/O Smad1/5/8/O signaling/O in/O C2C12/O cells/O expressing/O BMP9-unresponsive/O ALK1/O HHT/O mutants/O and/O in/O HHT/O patient/O blood/O outgrowth/O ECs/O ./O
Tacrolimus/O repurposing/O has/O therefore/O therapeutic/O potential/O in/O HHT/O ./O
Zebrafish/O cdc6/O hypomorphic/O mutation/O causes/O Meier/O -/O Gorlin/O syndrome/O -/O like/O phenotype/O ./O
Cell/O Division/O Cycle/O 6/O (/O Cdc6/O )/O is/O a/O component/O of/O pre/O -/O replicative/O complex/O (/O preRC/O )/O forming/O on/O DNA/O replication/O origins/O in/O eukaryotes/O ./O
Recessive/O mutations/B-Var in/O ORC1/B-Gene ,/O ORC4/B-Gene ,/O ORC6/B-Gene ,/O CDT1/B-Gene or/O CDC6/B-Gene of/O the/O preRC/O in/O human/O cause/B-Reg Meier/B-Disease -/I-Disease Gorlin/I-Disease syndrome/I-Disease (/O MGS/O )/O that/O is/O characterized/O by/O impaired/O post/O -/O natal/O growth/O ,/O short/O stature/O and/O microcephaly/O ./O
However/O ,/O vertebrate/O models/O of/O MGS/O have/O not/O been/O reported/O ./O
Through/O N/O -/O ethyl/O -/O N/O -/O nitrosourea/O mutagenesis/O and/O Cas9/O knockout/O ,/O we/O generate/O several/O cdc6/O mutant/O lines/O in/O zebrafish/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var of/O cdc6/B-Gene ,/O as/O manifested/O by/O cdc6tsu4305/O and/O cdc6tsu7cd/O mutants/O ,/O lead/O to/O embryonic/B-CPA lethality/I-CPA due/O to/O cell/B-CPA cycle/I-CPA arrest/I-CPA at/I-CPA the/I-CPA S/I-CPA phase/I-CPA and/O extensive/O apoptosis/B-CPA ./O
Embryos/O homozygous/O for/O a/O cdc6/O hypomorphic/O mutation/O ,/O cdc6tsu21cd/O ,/O develop/O normally/O during/O embryogenesis/O ./O
Later/O on/O ,/O compared/O with/O their/O wild/O -/O type/O (/O WT/O )/O siblings/O ,/O cdc6tsu21cd/B-Var mutant/I-Var fish/O show/O growth/O retardation/O ,/O and/O their/O body/B-CPA weight/I-CPA and/I-CPA length/I-CPA in/O adulthood/O are/O greatly/O reduced/B-NegReg ,/O which/O resemble/O human/O MGS/O ./O
Surprisingly/O ,/O cdc6tsu21cd/B-Var mutant/I-Var fish/O become/O males/O with/O a/O short/O life/O and/O fail/O to/O mate/O with/O WT/O females/O ,/O suggesting/O defective/B-NegReg reproduction/B-CPA ./O
Overexpression/O of/O Cdc6/O mutant/O forms/O ,/O which/O mimic/O human/O CDC6(T323R/B-Gene )/I-Gene mutation/B-Var found/O in/O a/O MGS/O patient/O ,/O in/O zebrafish/O cdc6tsu4305/O mutant/O embryos/O partially/O represses/B-NegReg cell/B-CPA death/I-CPA phenotype/I-CPA ,/O suggesting/O that/O the/O human/O CDC6(T323R/O )/O mutation/O is/O a/O hypomorph/O ./O
cdc6tsu21cd/O mutant/O fish/O will/O be/O useful/O to/O detect/O more/O tissue/O defects/O and/O develop/O medical/O treatment/O strategies/O for/O MGS/O patients/O ./O
Three/O Cases/O of/O KCNT1/O Mutations/O :/O Malignant/O Migrating/O Partial/O Seizures/O in/O Infancy/O with/O Massive/O Systemic/O to/O Pulmonary/O Collateral/O Arteries/O ./O
KCNT1/B-Gene mutations/B-Var are/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/O in/O potassium/O channels/O resulting/O in/O severe/O infantile/B-Disease epilepsy/I-Disease ./O
Herein/O we/O describe/O 3/O infants/O with/O malignant/O migrating/O partial/O seizures/O with/O KCNT1/O mutations/O accompanied/O by/O massive/O systemic/O to/O pulmonary/O collateral/O arteries/O with/O life/O -/O threatening/O hemoptysis/O and/O heart/O failure/O ./O
Homozygous/B-Var indel/I-Var mutation/I-Var in/O CDH11/B-Gene as/O the/O probable/O cause/B-Reg of/O Elsahy/B-Disease -/I-Disease Waters/I-Disease syndrome/I-Disease ./O
Two/O sisters/O from/O a/O consanguineous/O couple/O were/O seen/O in/O genetics/O department/O for/O facial/O dysmorphic/O features/O and/O glaucoma/O ./O
They/O both/O had/O broad/O foreheads/O ,/O hypertelorism/O ,/O megalocorneas/O ,/O thick/O eyebrows/O with/O synophrys/O ,/O flat/O malar/O regions/O ,/O broad/O and/O bulbous/O noses/O ,/O and/O mild/O prognathism/O ./O
Both/O had/O glaucoma/O ,/O younger/O one/O also/O had/O cataracts/O and/O phthisis/O bulbi/O ./O
Other/O findings/O included/O bilateral/O partial/O cutaneous/O syndactyly/O of/O 2nd/O and/O 3rd/O fingers/O ,/O history/O of/O impacted/O teeth/O with/O dentigerous/O cyst/O in/O the/O elder/O one/O ,/O and/O intellectual/O disability/O (/O mild/O and/O borderline/O )/O ./O
The/O sisters/O were/O considered/O to/O have/O Elsahy/O -/O Waters/O syndrome/O ./O
In/O order/O to/O elucidate/O the/O underlying/O molecular/O cause/O ,/O sisters/O and/O their/O healthy/O parents/O were/O genotyped/O by/O SNP/O arrays/O ,/O followed/O by/O homozygosity/O mapping/O ./O
Homozygous/O regions/O were/O further/O analyzed/O by/O exome/O sequencing/O in/O one/O affected/O individual/O ./O
A/O homozygous/O indel/O variant/O segregating/O with/O the/O condition/O was/O detected/O in/O CDH11/O (/O c.1116_1117delinsGATCATCAG/O ,/O p.(Ile372MetfsTer9/O )/O )/O ,/O which/O was/O then/O validated/O by/O using/O Sanger/O sequencing/O ./O
CDH11/O encodes/O cadherin/O 11/O (/O osteo/O -/O cadherin/O )/O that/O regulates/O cell/O -/O cell/O adhesion/O ,/O cell/O polarization/O and/O migration/O ,/O as/O well/O as/O osteogenic/O differentiation/O ./O
Further/O experiments/O revealed/O that/O CDH11/O expression/O was/O decreased/O in/O patient/O -/O derived/O fibroblasts/O as/O compared/O to/O the/O heterozygous/O parent/O and/O another/O healthy/O donor/O ./O
Immunostaining/O showed/O absence/O of/O the/O protein/O expression/O in/O patient/O fibroblasts/O ./O
In/O addition/O ,/O cell/B-CPA proliferation/I-CPA rate/I-CPA was/O slow/B-NegReg and/O osteogenic/B-CPA differentiation/I-CPA potential/I-CPA was/O delayed/B-NegReg ./O
We/O consider/O that/O this/O study/O reveals/O loss/O -/O of/O -/O function/O mutations/B-Var in/O CDH11/B-Gene as/O a/O probable/O cause/O of/O this/O phenotype/O ./O
Next/O generation/O sequencing/O in/O further/O patients/O would/O both/O prove/O this/O gene/O as/O causative/O ,/O and/O finely/O delineate/O this/O clinical/O spectrum/O further/O contributing/O in/O identification/O of/O other/O possibly/O involved/O gene(s/O )/O ./O
Effect/B-Reg of/O Mutant/B-Var p53/B-Gene Proteins/B-Protein on/O Glycolysis/B-MPA and/O Mitochondrial/B-MPA Metabolism/I-MPA ./O
TP53/O is/O one/O of/O the/O most/O commonly/O mutated/O genes/O in/O human/O cancers/O ./O
Unlike/O other/O tumor/O suppressors/O that/O are/O frequently/O deleted/O or/O acquire/O loss/O -/O of/O -/O function/O mutations/O ,/O the/O majority/O of/O TP53/B-Gene mutations/B-Var in/O tumors/O are/O missense/B-Var substitutions/I-Var ,/O which/O lead/O to/O the/O expression/B-MPA of/O full/O -/O length/O mutant/B-Var proteins/B-Protein that/O accumulate/B-PosReg in/O cancer/O cells/O and/O may/O confer/O unique/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O activities/B-MPA to/O promote/B-PosReg tumorigenic/B-CPA events/I-CPA ./O
Recently/O ,/O mutant/B-Var p53/B-Gene proteins/B-Protein have/O been/O shown/O to/O mediate/O metabolic/B-CPA changes/I-CPA as/O a/O novel/O GOF/B-PosReg to/O promote/B-PosReg tumor/B-CPA development/I-CPA ./O
There/O is/O a/O strong/O rationale/O that/O the/O GOF/O activities/O ,/O including/O alterations/O in/O cellular/O metabolism/O ,/O might/O vary/O between/O the/O different/O p53/O mutants/O ./O
Accordingly/O ,/O the/O effect/O of/O different/O mutant/O p53/O proteins/O on/O cancer/O cell/O metabolism/O is/O largely/O unknown/O ./O
In/O this/O study/O ,/O we/O have/O metabolically/O profiled/O several/O individual/O frequently/O occurring/O p53/O mutants/O in/O cancers/O ,/O focusing/O on/O glycolytic/O and/O mitochondrial/O oxidative/O phosphorylation/O pathways/O ./O
Our/O investigation/O highlights/O the/O diversity/O of/O different/O p53/O mutants/O in/O terms/O of/O their/O effect/O on/O metabolism/O ,/O which/O might/O provide/O a/O foundation/O for/O the/O development/O of/O more/O effective/O targeted/O pharmacological/O approaches/O toward/O variants/O of/O mutant/O p53/O ./O
The/O Roles/O of/O the/O Sole/O Activator/O -/O Type/O Auxin/O Response/O Factor/O in/O Pattern/O Formation/O of/O Marchantia/O polymorpha/O ./O
Cell/O division/O patterning/O is/O important/O to/O determine/O body/O shape/O in/O plants/O ./O
Nuclear/O auxin/O signaling/O mediated/O by/O AUXIN/O RESPONSE/O FACTOR/O (/O ARF/O )/O transcription/O factors/O affects/O plant/O growth/O and/O development/O through/O regulation/O of/O cell/O division/O ,/O elongation/O and/O differentiation/O ./O
The/O evolutionary/O origin/O of/O the/O ARF/O -/O mediated/O pathway/O dates/O back/O to/O at/O least/O the/O common/O ancestor/O of/O bryophytes/O and/O other/O land/O plants/O ./O
The/O liverwort/O Marchantia/O polymorpha/O has/O three/O phylogenetically/O distinct/O ARFs/O :/O MpARF1/O ,/O the/O sole/O '/O activator/O '/O ARF/O ;/O and/O MpARF2/O and/O MpARF3/O ,/O two/O '/O repressor/O '/O ARFs/O ./O
Genetic/O screens/O for/O auxin/O -/O resistant/O mutants/O revealed/O that/O loss/O of/O MpARF1/O function/O conferred/O auxin/O insensitivity/O ./O
Mparf1/B-Gene mutants/B-Var showed/O reduced/B-NegReg auxin/B-Gene -/I-Gene inducible/I-Gene gene/I-Gene expression/B-MPA and/O various/O developmental/B-CPA defects/I-CPA ,/O including/O thallus/O twisting/O and/O gemma/O malformation/O ./O
We/O further/O investigated/O the/O role/O of/O MpARF1/O in/O gemma/O development/O ,/O which/O is/O traceable/O at/O the/O cellular/O level/O ./O
In/O wild/O -/O type/O plants/O ,/O a/O gemma/O initial/O first/O undergoes/O several/O transverse/O divisions/O to/O generate/O a/O single/O -/O celled/O stalk/O and/O a/O gemma/O proper/O ,/O followed/O by/O rather/O synchronous/O longitudinal/O divisions/O in/O the/O latter/O ./O
Mparf1/O mutants/O often/O contained/O multicelled/O stalks/O and/O showed/O defects/O in/O the/O execution/O and/O timing/O of/O the/O longitudinal/O divisions/O ./O
While/O wild/O -/O type/O gemmae/O finally/O generate/O two/O meristem/O notches/O ,/O Mparf1/O gemmae/O displayed/O various/O numbers/O of/O ectopic/O meristems/O ./O
These/O results/O suggest/O that/O MpARF1/O regulates/O formative/O cell/O divisions/O and/O axis/O formation/O through/O auxin/O responses/O ./O
The/O mechanism/O for/O activator/O ARF/O regulation/O of/O pattern/O formation/O may/O be/O shared/O in/O land/O plants/O and/O therefore/O important/O for/O the/O general/O acquisition/O of/O three/O -/O dimensional/O body/O plans/O ./O
Loss/O of/O the/O nutrient/O sensor/O TAS1R3/O leads/O to/O reduced/O bone/O resorption/O ./O
The/O taste/O receptor/O type/O 1/O (/O TAS1R/O )/O family/O of/O heterotrimeric/O G/O protein/O -/O coupled/O receptors/O participates/O in/O monitoring/O energy/O and/O nutrient/O status/O ./O
TAS1R/O member/O 3/O (/O TAS1R3/O )/O is/O a/O bi/O -/O functional/O protein/O that/O recognizes/O amino/O acids/O such/O as/O L/O -/O glycine/O and/O L/O -/O glutamate/O or/O sweet/O molecules/O such/O as/O sucrose/O and/O fructose/O when/O dimerized/O with/O TAS1R/O member/O 1/O (/O TAS1R1/O )/O or/O TAS1R/O member/O 2/O (/O TAS1R2/O )/O ,/O respectively/O ./O
It/O was/O recently/O reported/O that/O deletion/B-Var of/O TAS1R3/B-Gene expression/O in/O Tas1R3/O mutant/O mice/O leads/O to/O increased/B-PosReg cortical/B-CPA bone/I-CPA mass/I-CPA but/O the/O underlying/O cellular/O mechanism/O leading/O to/O this/O phenotype/O remains/O unclear/O ./O
Here/O ,/O we/O independently/O corroborate/O the/O increased/B-PosReg thickness/B-CPA of/I-CPA cortical/I-CPA bone/I-CPA in/O femurs/O of/O 20-week/O -/O old/O male/O Tas1R3/B-Gene mutant/B-Var mice/O and/O confirm/O that/O Tas1R3/O is/O expressed/O in/O the/O bone/O environment/O ./O
Tas1R3/O is/O expressed/O in/O undifferentiated/O bone/O marrow/O stromal/O cells/O (/O BMSCs/O )/O in/O vitro/O and/O its/O expression/O is/O maintained/O during/O BMP2-induced/O osteogenic/O differentiation/O ./O
However/O ,/O levels/O of/O the/O bone/O formation/O marker/O procollagen/O type/O I/O N/O -/O terminal/O propeptide/O (/O PINP/O )/O are/O unchanged/O in/O the/O serum/O of/O 20-week/O -/O old/O Tas1R3/O mutant/O mice/O as/O compared/O to/O controls/O ./O
In/O contrast/O ,/O levels/B-MPA of/I-MPA the/I-MPA bone/I-MPA resorption/I-MPA marker/I-MPA collagen/I-MPA type/I-MPA I/I-MPA C/I-MPA -/I-MPA telopeptide/I-MPA are/O reduced/B-NegReg greater/O than/O 60/O %/O in/O Tas1R3/B-Gene mutant/B-Var mice/O ./O
Consistent/O with/O this/O ,/O Tas1R3/O and/O its/O putative/O signaling/O partner/O Tas1R2/O are/O expressed/O in/O primary/O osteoclasts/O and/O their/O expression/O levels/O positively/O correlate/O with/O differentiation/O status/O ./O
Collectively/O ,/O these/O findings/O suggest/O that/O high/B-PosReg bone/B-CPA mass/I-CPA in/O Tas1R3/B-Gene mutant/B-Var mice/O is/O due/O to/O uncoupled/O bone/O remodeling/O with/O reduced/B-NegReg osteoclast/B-CPA function/I-CPA and/O provide/O rationale/O for/O future/O experiments/O examining/O the/O cell/O -/O type/O -/O dependent/O role/O for/O TAS1R/O family/O members/O in/O nutrient/O sensing/O in/O postnatal/O bone/O remodeling/O ./O
Molecular/O characterization/O of/O the/O llama/O FGF5/O gene/O and/O identification/O of/O putative/O loss/O of/O function/O mutations/O ./O
Llama/O ,/O the/O most/O numerous/O domestic/O camelid/O in/O Argentina/O ,/O has/O good/O fiber/O -/O production/O ability/O ./O
Although/O a/O few/O genes/O related/O to/O other/O productive/O traits/O have/O been/O characterized/O ,/O the/O molecular/O genetic/O basis/O of/O fiber/O growth/O control/O in/O camelids/O is/O still/O poorly/O understood/O ./O
Fibroblast/O growth/O factor/O 5/O (/O FGF5/O )/O is/O a/O secreted/O signaling/O protein/O that/O controls/O hair/O growth/O in/O humans/O and/O other/O mammals/O ./O
Mutations/O in/O the/O FGF5/O gene/O have/O been/O associated/O with/O long/O -/O hair/O phenotypes/O in/O several/O species/O ./O
Here/O ,/O we/O sequenced/O the/O llama/O FGF5/O gene/O ,/O which/O consists/O of/O three/O exons/O encoding/O 813/O bp/O ./O
cDNA/O analysis/O from/O hair/O follicles/O revealed/O the/O expression/O of/O two/O FGF5/O alternative/O spliced/O transcripts/O ,/O in/O one/O of/O which/O exon/O 2/O is/O absent/O ./O
DNA/O variation/O analysis/O showed/O four/O polymorphisms/O in/O the/O coding/O region/O :/O a/O synonymous/O SNP/O (/O c.210A/O >/O G/O )/O ,/O a/O single/O base/O deletion/O (/B-Var c.348delA/I-Var )/I-Var ,/O a/O 12-bp/O insertion/O (/O c.351_352insCATATAACATAG/O )/O and/O a/O non/O -/O sense/O mutation/O (/O c.499C/O >/O T/O )/O ./O
The/O deletion/O was/O always/O found/O together/O with/O the/O insertion/O forming/O a/O haplotype/O and/O producing/O a/O putative/O truncated/O protein/O of/O 123/O amino/O acids/O ./O
The/O c.499C/B-Var >/I-Var T/I-Var mutation/O also/O leads/O to/O a/O premature/O stop/O codon/O at/O position/O 168/O ./O
In/O both/O cases/O ,/O critical/B-MPA functional/I-MPA domains/I-MPA of/O FGF5/B-Gene ,/O including/O one/O heparin/B-MPA binding/I-MPA site/I-MPA ,/O are/O lost/B-NegReg ./O
All/O animals/O analyzed/O were/O homozygous/O for/O one/O of/O the/O deleterious/O mutations/O or/O compound/O heterozygous/O for/O both/O (/O i.e./O c.348delA/O ,/O c.351_352insCATATAACATAG/O //O c.499/O T/O )/O ./O
Sequencing/O of/O guanaco/O samples/O showed/O that/O the/O FGF5/O gene/O encodes/O a/O full/O -/O length/O 270-amino/O acid/O protein/O ./O
These/O results/O suggest/O that/O FGF5/O is/O likely/O functional/O in/O short/O -/O haired/O wild/O species/O and/O non/O -/O functional/O in/O the/O domestic/O fiber/O -/O producing/O species/O ,/O the/O llama/O ./O
Differential/O regulation/O of/O two/O FLNA/O transcripts/O explains/O some/O of/O the/O phenotypic/O heterogeneity/O in/O the/O loss/O -/O of/O -/O function/O filaminopathies/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O X/O -/O linked/O gene/O FLNA/B-Gene can/O lead/O to/O abnormal/B-CPA neuronal/I-CPA migration/I-CPA ,/O vascular/B-CPA and/I-CPA cardiac/I-CPA defects/I-CPA ,/O and/O congenital/B-Disease intestinal/I-Disease pseudo/I-Disease -/I-Disease obstruction/I-Disease (/O CIPO/O )/O ,/O the/O latter/O characterized/O by/O anomalous/O intestinal/O smooth/O muscle/O layering/O ./O
Survival/O in/O male/O hemizygotes/O for/O such/O mutations/O is/O dependent/O on/O retention/O of/O residual/O FLNA/O function/O but/O it/O is/O unclear/O why/O a/O subgroup/O of/O males/O with/O mutations/O in/O the/O 5/O '/O end/O of/O the/O gene/O can/O present/O with/O CIPO/O alone/O ./O
Here/O ,/O we/O demonstrate/O evidence/O for/O the/O presence/O of/O two/O FLNA/O isoforms/O differing/O by/O 28/O residues/O at/O the/O N/O -/O terminus/O initiated/O at/O ATG+1/O and/O ATG+82/O ./O
A/O male/O with/O CIPO/O (/O c.18_19del/O )/O exclusively/O expressed/O FLNA/O ATG+82/O ,/O implicating/O the/O longer/O protein/O isoform/O (/O ATG+1/O )/O in/O smooth/O muscle/O development/O ./O
In/O contrast/O ,/O mutations/O leading/O to/O reduction/O of/O both/O isoforms/O are/O associated/O with/O compound/O phenotypes/O affecting/O the/O brain/O ,/O heart/O ,/O and/O intestine/O ./O
RNA/O -/O seq/O data/O revealed/O three/O distinct/O transcription/O start/O sites/O ,/O two/O of/O which/O produce/O a/O protein/O isoform/O utilizing/O ATG+1/O while/O the/O third/O utilizes/O ATG+82/O ./O
Transcripts/O sponsoring/O translational/O initiation/O at/O ATG+1/O predominate/O in/O intestinal/O smooth/O muscle/O ,/O and/O are/O more/O abundant/O compared/O with/O the/O level/O measured/O in/O fibroblasts/O ./O
Together/O these/O observations/O describe/O a/O new/O mechanism/O of/O tissue/O -/O specific/O regulation/O of/O FLNA/O that/O could/O reflect/O the/O differing/O mechanical/O requirements/O of/O these/O cell/O types/O during/O development/O ./O
A/O disulfide/O bond/O A/O -/O like/O oxidoreductase/O is/O a/O strong/O candidate/O gene/O for/O self/O -/O incompatibility/O in/O apricot/O (/O Prunus/O armeniaca/O )/O pollen/O ./O
S/O -/O RNase/O based/O gametophytic/O self/O -/O incompatibility/O (/O SI/O )/O is/O a/O widespread/O prezygotic/O reproductive/O barrier/O in/O flowering/O plants/O ./O
In/O the/O Solanaceae/O ,/O Plantaginaceae/O and/O Rosaceae/O gametophytic/O SI/O is/O controlled/O by/O the/O pistil/O -/O specific/O S/O -/O RNases/O and/O the/O pollen/O S/O -/O locus/O F/O -/O box/O proteins/O but/O non/O -/O S/O -/O specific/O factors/O ,/O namely/O modifiers/O ,/O are/O also/O required/O ./O
In/O apricot/O ,/O Prunus/O armeniaca/O (/O Rosaceae/O )/O ,/O we/O previously/O mapped/O two/O pollen/O -/O part/O mutations/B-Var that/O confer/B-Reg self/B-MPA -/I-MPA compatibility/I-MPA in/O cultivars/O Canino/O and/O Katy/O at/O the/O distal/O end/O of/O chromosome/O 3/O (/O M/O -/O locus/O )/O unlinked/O to/O the/O S/O -/O locus/O ./O
Here/O ,/O we/O used/O high/O -/O resolution/O mapping/O to/O identify/O the/O M/O -/O locus/O with/O an/O ~134/O kb/O segment/O containing/O ParM-1/O -/O 16/O genes/O ./O
Gene/O expression/O analysis/O identified/O four/O genes/O preferentially/O expressed/O in/O anthers/O as/O modifier/O gene/O candidates/O ,/O ParM-6/O ,/O -7/O ,/O -9/O and/O -14/O ./O
Variant/O calling/O of/O WGS/O Illumina/O data/O from/O Canino/O ,/O Katy/O ,/O and/O 10/O self/O -/O incompatible/O cultivars/O detected/O a/O 358/O bp/O miniature/O inverted/O -/O repeat/O transposable/O element/O (/O MITE/O )/O insertion/O in/O ParM-7/O shared/O only/O by/O self/O -/O compatible/O apricots/O ,/O supporting/O ParM-7/O as/O strong/O candidate/O gene/O required/O for/O SI/O ./O
ParM-7/O encodes/O a/O disulfide/O bond/O A/O -/O like/O oxidoreductase/O protein/O ,/O which/O we/O named/O ParMDO/O ./O
The/O MITE/B-Gene insertion/B-Var truncates/B-NegReg the/O ParMDO/B-MPA ORF/I-MPA and/O produces/O a/O loss/B-NegReg of/O SI/B-MPA function/I-MPA ,/O suggesting/O that/O pollen/O rejection/O in/O Prunus/O is/O dependent/O on/O redox/O regulation/O ./O
Based/O on/O phylogentic/O analyses/O we/O also/O suggest/O that/O ParMDO/O may/O have/O originated/O from/O a/O tandem/O duplication/O followed/O by/O subfunctionalization/O and/O pollen/O -/O specific/O expression/O ./O
The/O Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg Function/I-PosReg Integrin/O β3/O Pro33/O Variant/B-Var Alters/O the/O Serotonin/B-MPA System/I-MPA in/O the/O Mouse/O Brain/O ./O
Engagement/O of/O integrins/O by/O the/O extracellular/O matrix/O initiates/O signaling/O cascades/O that/O drive/O a/O variety/O of/O cellular/O functions/O ,/O including/O neuronal/O migration/O and/O axonal/O pathfinding/O in/O the/O brain/O ./O
Multiple/O lines/O of/O evidence/O link/O the/O ITGB3/O gene/O encoding/O the/O integrin/O β3/O subunit/O with/O the/O serotonin/O (/O 5-HT/O )/O system/O ,/O likely/O via/O its/O modulation/O of/O the/O 5-HT/O transporter/O (/O SERT/O )/O ./O
The/O ITGB3/B-Gene coding/O polymorphism/O Leu33Pro/B-Var (/O rs5918/O ,/O PlA2/O )/O produces/O hyperactive/B-PosReg αvβ3/B-Protein receptors/I-Protein that/O influence/B-Reg whole/B-MPA -/I-MPA blood/I-MPA 5-HT/I-MPA levels/I-MPA and/O may/O influence/B-Reg the/O risk/O for/O autism/B-Disease spectrum/I-Disease disorder/I-Disease (/O ASD/O )/O ./O
Using/O a/O phenome/O -/O wide/O scan/O of/O psychiatric/O diagnoses/O ,/O we/O found/O significant/O ,/O male/O -/O specific/O associations/O between/O the/O Pro33/O allele/O and/O attention/O -/O deficit/O hyperactivity/O disorder/O and/O ASDs/O ./O
Here/O ,/O we/O used/O knock/O -/O in/O (/O KI/O )/O mice/O expressing/O an/O Itgb3/B-Gene variant/B-Var that/O phenocopies/O the/O human/O Pro33/O variant/O to/O elucidate/O the/O consequences/O of/O constitutively/O enhanced/B-PosReg αvβ3/B-MPA signaling/I-MPA to/I-MPA the/I-MPA 5-HT/I-MPA system/I-MPA in/O the/O brain/O ./O
KI/O mice/O displayed/O deficits/O in/O multiple/O behaviors/O ,/O including/O anxiety/O ,/O repetitive/O ,/O and/O social/O behaviors/O ./O
Anatomical/O studies/O revealed/O a/O significant/O decrease/O in/O 5-HT/O synapses/O in/O the/O midbrain/O ,/O accompanied/O by/O decreases/O in/O SERT/O activity/O and/O reduced/O localization/O of/O SERTs/O to/O integrin/O adhesion/O complexes/O in/O synapses/O of/O KI/O mice/O ./O
Inhibition/O of/O focal/O adhesion/O kinase/O (/O FAK/O )/O rescued/O SERT/O function/O in/O synapses/O of/O KI/O mice/O ,/O demonstrating/O that/O constitutive/O active/O FAK/O signaling/O downstream/O of/O the/O Pro32Pro33/O integrin/O αvβ3/O suppresses/O SERT/O activity/O ./O
Our/O studies/O identify/O a/O complex/O regulation/O of/O 5-HT/O homeostasis/O and/O behaviors/O by/O integrin/O αvβ3/O ,/O revealing/O an/O important/O role/O for/O integrins/O in/O modulating/O risk/O for/O neuropsychiatric/O disorders/O ./O
SIGNIFICANCE/O STATEMENT/O The/O integrin/O β3/O Leu33Pro/O coding/O polymorphism/O has/O been/O associated/O with/O autism/O spectrum/O disorders/O (/O ASDs/O )/O within/O a/O subgroup/O of/O patients/O with/O elevated/O blood/O 5-HT/O levels/O ,/O linking/O integrin/O β3/O ,/O 5-HT/O ,/O and/O ASD/O risk/O ./O
We/O capitalized/O on/O these/O interactions/O to/O demonstrate/O that/O the/O Pro33/O coding/O variation/O in/O the/O murine/O integrin/O β3/O recapitulates/O the/O sex/O -/O dependent/O neurochemical/O and/O behavioral/O attributes/O of/O ASD/O ./O
Using/O state/O -/O of/O -/O the/O -/O art/O techniques/O ,/O we/O show/O that/O presynaptic/O 5-HT/O function/O is/O altered/O in/O these/O mice/O ,/O and/O that/O the/O localization/O of/O 5-HT/O transporters/O to/O specific/O compartments/O within/O the/O synapse/O ,/O disrupted/O by/O the/O integrin/O β3/O Pro33/O mutation/O ,/O is/O critical/O for/O appropriate/O reuptake/O of/O 5-HT/O ./O
Our/O studies/O provide/O fundamental/O insight/O into/O the/O genetic/O network/O regulating/O 5-HT/O neurotransmission/O in/O the/O CNS/O that/O is/O also/O associated/O with/O ASD/O risk/O ./O
Parkin/B-Gene absence/B-Var accelerates/B-PosReg microtubule/B-MPA aging/I-MPA in/I-MPA dopaminergic/I-MPA neurons/I-MPA ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg caused/O by/O mutations/B-Var in/O the/O parkin/O gene/O (/B-Gene PARK2/I-Gene )/I-Gene lead/O to/O early/B-Disease -/I-Disease onset/I-Disease familial/I-Disease Parkinson/I-Disease 's/I-Disease disease/I-Disease ./O
Recently/O ,/O mechanistic/O studies/O proved/O the/O ability/O of/O parkin/O in/O regulating/O mitochondria/O homeostasis/O and/O microtubule/O (/O MT/O )/O stability/O ./O
Looking/O at/O these/O systems/O during/O aging/O of/O PARK2/O knockout/O mice/O ,/O we/O found/O that/O loss/B-Var of/O parkin/B-Gene induced/O an/O accelerated/B-PosReg (/B-MPA over)acetylation/I-MPA of/O MT/O system/O both/O in/O dopaminergic/O neuron/O cell/O bodies/O and/O fibers/O ,/O localized/O in/O the/O substantia/O nigra/O and/O corpus/O striatum/O ,/O respectively/O ./O
Interestingly/O ,/O in/O PARK2/O knockout/O mice/O ,/O changes/O of/O MT/O stability/O preceded/O the/O alteration/O of/O mitochondria/O transport/O ./O
Moreover/O ,/O in/O -/O cell/O experiments/O confirmed/O that/O loss/B-Var of/O parkin/B-Gene affects/B-Reg mitochondria/B-MPA mobility/I-MPA and/O showed/O that/O this/O defect/O depends/O on/O MT/O system/O as/O it/O is/O rescued/O by/O paclitaxel/O ,/O a/O well/O -/O known/O MT/O -/O targeted/O agent/O ./O
Furthermore/O ,/O both/O in/O PC12/O neuronal/O cells/O and/O in/O patients/O '/O induced/O pluripotent/O stem/O cell/O -/O derived/O midbrain/O neurons/O ,/O we/O observed/O that/O parkin/O deficiencies/O cause/O the/O fragmentation/O of/O stable/O MTs/O ./O
Therefore/O ,/O we/O suggest/O that/O parkin/O acts/O as/O a/O regulator/O of/O MT/O system/O during/O neuronal/O aging/O ,/O and/O we/O endorse/O the/O hypothesis/O that/O MT/O dysfunction/O may/O be/O crucial/O in/O the/O pathogenesis/O of/O Parkinson/O 's/O disease/O ./O
Parkinson/B-Disease 's/I-Disease Disease/I-Disease -/I-Disease Associated/I-Disease LRRK2/B-Gene Hyperactive/O Kinase/O Mutant/B-Var Disrupts/B-NegReg Synaptic/B-MPA Vesicle/I-MPA Trafficking/I-MPA in/I-MPA Ventral/I-MPA Midbrain/I-MPA Neurons/I-MPA ./O
Parkinson/O 's/O disease/O (/O PD/O )/O is/O characterized/O pathologically/O by/O the/O selective/O loss/O of/O substantia/O nigra/O (/O SN/O )/O dopaminergic/O (/O DAergic/O )/O neurons/O ./O
Recent/O evidence/O has/O suggested/O a/O role/O of/O LRRK2/O ,/O linked/O to/O the/O most/O frequent/O familial/O PD/O ,/O in/O regulating/O synaptic/O vesicle/O (/O SV/O )/O trafficking/O ./O
However/O ,/O the/O mechanism/O whereby/O LRRK2/B-Gene mutants/B-Var contribute/B-Reg to/O nigral/B-MPA vulnerability/I-MPA remains/O unclear/O ./O
Here/O we/O show/O that/O the/O most/O common/O PD/O mutation/B-Var LRRK2/B-Gene G2019S/O impairs/B-NegReg SV/B-MPA endocytosis/I-MPA in/I-MPA ventral/I-MPA midbrain/I-MPA (/I-MPA MB/I-MPA )/I-MPA neurons/I-MPA ,/O including/I-MPA DA/I-MPA neurons/I-MPA ,/O and/O the/O slowed/O endocytosis/O can/O be/O rescued/O by/O inhibition/O of/O LRRK2/O kinase/O activity/O ./O
A/O similar/O endocytic/O defect/O ,/O however/O ,/O was/O not/O observed/O in/O LRRK2/O mutant/O neurons/O from/O the/O neocortex/O (/O hereafter/O ,/O cortical/O neurons/O )/O or/O the/O hippocampus/O ,/O suggesting/O a/O brain/O region/O -/O specific/O vulnerability/O to/O the/O G2019S/O mutation/O ./O
Additionally/O ,/O we/O found/O MB/O -/O specific/O impairment/B-NegReg of/O SV/B-MPA endocytosis/I-MPA in/I-MPA neurons/I-MPA carrying/O heterozygous/O deletion/B-Var of/O SYNJ1/B-Gene (/O PARK20/O )/O ,/O a/O gene/O that/O is/O associated/O with/O recessive/O Parkinsonism/O ./O
Combining/O SYNJ1+/-/B-Var and/O LRRK2/B-Var G2019S/I-Var does/O not/O exacerbate/O SV/O endocytosis/O but/O impairs/B-NegReg sustained/B-MPA exocytosis/I-MPA in/I-MPA MB/I-MPA neurons/I-MPA and/O alters/B-Reg specific/B-MPA motor/I-MPA functions/I-MPA of/O 1-year/O -/O old/O male/O mice/O ./O
Interestingly/O ,/O we/O show/O that/O LRRK2/B-Var directly/O phosphorylates/O synaptojanin1/O in/O vitro/O ,/O resulting/B-Reg in/I-Reg the/O disruption/B-MPA of/I-MPA endophilin/I-MPA -/I-MPA synaptojanin1/I-MPA interaction/I-MPA required/I-MPA for/I-MPA SV/I-MPA endocytosis/I-MPA ./O
Our/O work/O suggests/O a/O merge/O of/O LRRK2/O and/O SYNJ1/O pathogenic/O pathways/O in/O deregulating/O SV/O trafficking/O in/O MB/O neurons/O as/O an/O underlying/O molecular/O mechanism/O of/O early/O PD/O pathogenesis/O ./O
SIGNIFICANCE/O STATEMENT/O Understanding/O midbrain/O dopaminergic/O (/O DAergic/O )/O neuron/O -/O selective/O vulnerability/O in/O PD/O is/O essential/O for/O the/O development/O of/O targeted/O therapeutics/O ./O
We/O report/O ,/O for/O the/O first/O time/O ,/O a/O nerve/O terminal/O impairment/O in/O SV/O trafficking/O selectively/O in/O MB/O neurons/O but/O not/O cortical/O neurons/O caused/O by/O two/O PARK/O genes/O :/O LRRK2/O (/O PARK8/O )/O and/O SYNJ1/O (/O PARK20/O )/O ./O
We/O demonstrate/O that/O the/O enhanced/B-PosReg kinase/B-MPA activity/I-MPA resulting/O from/O the/O most/O frequent/O G2019S/B-Var mutation/O in/O LRRK2/B-Gene is/O the/O key/O to/O this/O impairment/O ./O
We/O provide/O evidence/O suggesting/O that/O LRRK2/B-Gene G2019S/B-Var and/O SYNJ1/B-Gene loss/B-NegReg of/I-NegReg function/I-NegReg share/O a/O similar/O pathogenic/O pathway/O in/O deregulating/B-MPA DAergic/I-MPA neuron/I-MPA SV/I-MPA endocytosis/I-MPA and/O that/O they/O play/B-Reg additive/I-Reg roles/I-Reg in/O facilitating/O each/O other/O 's/O pathogenic/O functions/O in/O PD/B-Disease ./O
From/O mutational/O inactivation/O to/O aberrant/O gain/O -/O of/O -/O function/O :/O Unraveling/O the/O structural/O basis/O of/O mutant/O p53/O oncogenic/O transition/O ./O
Various/O evidence/O has/O revealed/O that/O mutations/B-Var in/O p53/B-Gene exert/O activities/O that/O go/O beyond/O simply/O inactivation/B-NegReg of/O wildtype/B-MPA functions/I-MPA but/O rather/O elicits/B-Reg downstream/O interactions/B-Interaction that/O promote/B-PosReg malignancy/B-Disease described/O as/O mutant/B-Var p53/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O ./O
Here/O we/O report/O the/O first/O account/O of/O the/O dynamics/O of/O mutation/O -/O induced/O structural/O transition/O of/O native/O p53/O to/O an/O aberrant/O gain/O -/O of/O -/O function/O state/O ,/O studying/O the/O wildtype/O (/O WT/O )/O and/O high/O incidence/O contact/O (/B-Var R273C/I-Var )/I-Var and/O structural/O (/B-Var R175H/I-Var )/I-Var mutant/O p53/B-Gene (/O mutp53/O )/O through/O molecular/O dynamics/O simulation/O ./O
Result/O analysis/O revealed/O that/O both/O mutants/O exhibited/B-Reg structural/B-Var distortion/I-Var and/O reduced/B-NegReg flexibility/B-MPA ,/O indicative/O of/O rigidity/O and/O kinetic/O stability/O ./O
In/O addition/O ,/O surface/O analysis/O revealed/O an/O increase/O in/O the/O accessible/O surface/O area/O in/O the/O p53/O mutants/O ./O
This/O suggests/O that/O the/O GOF/O transition/O involves/O protein/O unfolding/O and/O exposure/O of/O buried/O hydrophobic/O surface/O essential/O for/O interaction/O with/O HSF-1/O oncogenic/O partner/O and/O wildtype/O p63/O ,/O and/O p73/O homologs/O ./O
Further/O validation/O revealed/O binding/O cavities/O ,/O similar/O in/O the/O mutants/O but/O dissimilar/O to/O the/O WT/O ./O
Taken/O together/O ,/O this/O study/O complements/O experimental/O findings/O and/O reveals/O the/O interplay/O between/O mutation/B-Reg -/I-Reg induced/I-Reg structural/B-Var distortion/I-Var ,/O loss/B-NegReg of/O flexibility/B-MPA ,/O rigidity/B-MPA ,/O enhanced/B-PosReg stability/B-MPA ,/O protein/O unfolding/O and/O ultimately/O ,/O exposure/O of/O binding/O surfaces/O as/O conformational/O attributes/O that/O characterize/O mutP53/O structure/O -/O GOF/O activities/O ./O
This/O insight/O is/O ,/O therefore/O ,/O of/O great/O importance/O as/O it/O opens/O up/O a/O novel/O therapeutic/O approach/O toward/O the/O structure/O based/O targeting/O of/O mutP53/O oncogenic/O involvement/O beyond/O wildtype/O inactivation/O ./O
Furthermore/O ,/O "/O exposed/O "/O binding/O site/O information/O obtained/O from/O this/O study/O can/O be/O explored/O for/O structure/O -/O based/O design/O of/O substances/O best/O described/O as/O "/O destabilizers/O "/O to/O disrupt/O the/O GOF/O interaction/O of/O mutp53/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg HCN2/B-Gene variants/B-Var in/O genetic/O epilepsy/B-Disease ./O
Genetic/O generalized/O epilepsy/O (/O GGE/O )/O is/O a/O common/O epilepsy/O syndrome/O that/O encompasses/O seizure/O disorders/O characterized/O by/O spike/O -/O and/O -/O wave/O discharges/O (/O SWDs/O )/O ./O
Pacemaker/O hyperpolarization/O -/O activated/O cyclic/O nucleotide/O -/O gated/O channels/O (/O HCN/O )/O are/O considered/O integral/O to/O SWD/O genesis/O ,/O making/O them/O an/O ideal/O gene/O candidate/O for/O GGE/O ./O
We/O identified/O HCN2/O missense/O variants/O from/O a/O large/O cohort/O of/O 585/O GGE/O patients/O ,/O recruited/O by/O the/O Epilepsy/O Phenome/O -/O Genome/O Project/O (/O EPGP/O )/O ,/O and/O performed/O functional/O analysis/O using/O two/O -/O electrode/O voltage/O clamp/O recordings/O from/O Xenopus/O oocytes/O ./O
The/O p/O ./O S632W/O variant/O was/O identified/O in/O a/O patient/O with/O idiopathic/O photosensitive/O occipital/O epilepsy/O and/O segregated/O in/O the/O family/O ./O
This/O variant/O was/O also/O independently/O identified/O in/O an/O unrelated/O patient/O with/O childhood/O absence/O seizures/O from/O a/O European/O cohort/O of/O 238/O familial/O GGE/O cases/O ./O
The/O p/O ./O V246/O M/O variant/O was/O identified/O in/O a/O patient/O with/O photo/O -/O sensitive/O GGE/O and/O his/O father/O diagnosed/O with/O juvenile/O myoclonic/O epilepsy/O ./O
Functional/O studies/O revealed/O that/O both/O p/B-Var ./I-Var S632W/I-Var and/O p/B-Var ./I-Var V246/I-Var M/I-Var had/O an/O identical/O functional/O impact/O including/O a/O depolarizing/B-MPA shift/I-MPA in/I-MPA the/I-MPA voltage/I-MPA dependence/I-MPA of/O activation/B-PosReg that/O is/O consistent/O with/O a/O gain/O -/O of/O -/O function/O ./O
In/O contrast/O ,/O no/O biophysical/O changes/O resulted/O from/O the/O introduction/O of/O common/O population/O variants/O ,/O p/O ./O E280/O K/O and/O p/O ./O A705/O T/O ,/O and/O the/O p/O ./O R756C/O variant/O from/O EPGP/O that/O did/O not/O segregate/O with/O disease/O ./O
Our/O data/O suggest/O that/O HCN2/B-Gene variants/B-Var can/O confer/O susceptibility/B-MPA to/O GGE/O via/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mechanism/O ./O
Polymorphism/O of/O glutathione/O S/O -/O transferase/O M1/O and/O T1/O genes/O and/O susceptibility/O to/O psoriasis/O disease/O :/O A/O study/O from/O North/O India/O ./O
BACKGROUND/O :/O Increased/O oxidative/O stress/O and/O resulting/O inflammation/O has/O been/O emphasized/O as/O a/O factor/O in/O the/O pathogenesis/O of/O many/O diseases/O including/O psoriasis/O ./O
Glutathione/O S/O -/O transferases/O (/O GSTs/O )/O protect/O against/O oxidative/O stress/O ,/O inflammation/O ,/O and/O genotoxicity/O ./O
Polymorphisms/B-Var in/O the/O GST/B-Gene genes/O may/O lead/B-Reg to/I-Reg an/O imbalance/B-MPA in/I-MPA pro-/I-MPA and/I-MPA antioxidant/I-MPA systems/I-MPA resulting/O in/O the/O increased/B-PosReg production/B-MPA of/I-MPA reactive/I-MPA oxygen/I-MPA species/I-MPA that/O could/O influence/B-Reg the/O pathogenesis/O of/O psoriasis/B-Disease ./O
AIM/O :/O The/O aim/O of/O this/O study/O was/O to/O investigate/O the/O association/O between/O GSTs/O (/O GSTM1/O and/O GSTT1/O )/O gene/O polymorphism/O in/O patients/O with/O chronic/O plaque/O psoriasis/O as/O a/O factor/O in/O the/O susceptibility/O and/O development/O of/O psoriasis/O ./O
MATERIALS/O AND/O METHODS/O :/O We/O assessed/O 128/O patients/O with/O psoriasis/O and/O 250/O age-/O and/O sex/O -/O matched/O healthy/O controls/O ./O
Genomic/O DNA/O was/O extracted/O from/O peripheral/O blood/O by/O the/O phenol/O chloroform/O method/O ./O
The/O null/O GSTT1/O and/O GSTM1/O genotypes/O were/O identified/O by/O multiplex/O polymerase/O chain/O reaction/O (/O PCR/O )/O method/O ./O
RESULTS/O :/O The/O null/O genotype/O of/O GSTM1/O and/O GSTT1/O was/O seen/O in/O 45.3/O %/O and/O 40.6/O %/O in/O psoriasis/O patients/O whereas/O in/O the/O controls/O it/O was/O 34.4/O %/O and/O 20.0/O %/O ,/O respectively/O ./O
A/O significant/O association/O was/O seen/O between/O the/O null/O alleles/O of/O the/O GSTT1/O (/O OR/O =/O 2.74/O )/O and/O GSTM1/O (/O OR/O =/O 1.58/O )/O alone/O or/O in/O combination/O with/O tobacco/O use/O (/O P/O </O 0.001/O )/O and/O psoriasis/O risk/O ./O
The/O presence/B-Var of/O both/O null/O genotypes/O of/O GSTM1/B-Gene and/O GSTT1/B-Gene further/O increased/B-PosReg the/O risk/O of/O psoriasis/B-Disease (/O OR/O =/O 3.52/O )/O when/O compared/O with/O the/O positive/O genotypes/O of/O GSTM1/O and/O GSTT1/O ./O
LIMITATIONS/O :/O A/O major/O limitation/O of/O this/O study/O was/O the/O small/O sample/O size/O ./O
A/O large/O epidemiological/O study/O is/O necessary/O to/O confirm/O these/O findings/O ./O
CONCLUSIONS/O :/O The/O null/O genotype/O of/O GSTT1/O is/O a/O strong/O predisposing/O factor/O for/O psoriasis/O in/O North/O India/O ./O
Loss/O -/O of/O -/O function/O of/O ASPARTIC/O PEPTIDASE/O NODULE/O -/O INDUCED/O 1/O (/O APN1/O )/O in/O Lotus/O japonicus/O restricts/O efficient/O nitrogen/O -/O fixing/O symbiosis/O with/O specific/O Mesorhizobium/O loti/O strains/O ./O
The/O nitrogen/O -/O fixing/O symbiosis/O of/O legumes/O and/O Rhizobium/O bacteria/O is/O established/O by/O complex/O interactions/O between/O the/O two/O symbiotic/O partners/O ./O
Legume/O Fix-/O mutants/O form/O apparently/O normal/O nodules/O with/O endosymbiotic/O rhizobia/O but/O fail/O to/O induce/O rhizobial/O nitrogen/O fixation/O ./O
These/O mutants/O are/O useful/O for/O identifying/O the/O legume/O genes/O involved/O in/O the/O interactions/O essential/O for/O symbiotic/O nitrogen/O fixation/O ./O
We/O describe/O here/O a/O Fix-/O mutant/O of/O Lotus/O japonicus/O ,/O apn1/O ,/O which/O showed/O a/O very/O specific/O symbiotic/O phenotype/O ./O
It/O formed/O ineffective/O nodules/O when/O inoculated/O with/O the/O Mesorhizobium/O loti/O strain/O TONO/O ./O
In/O these/O nodules/O ,/O infected/O cells/O disintegrated/O and/O successively/O became/O necrotic/O ,/O indicating/B-Reg premature/B-MPA senescence/I-MPA typical/O of/O Fix-/B-Var mutants/I-Var ./O
However/O ,/O it/O formed/O effective/O nodules/O when/O inoculated/O with/O the/O M./O loti/O strain/O MAFF303099/O ./O
Among/O nine/O different/O M./O loti/O strains/O tested/O ,/O four/O formed/O ineffective/O nodules/O and/O five/O formed/O effective/O nodules/O on/O apn1/O roots/O ./O
The/O identified/O causal/O gene/O ,/O ASPARTIC/O PEPTIDASE/O NODULE/O -/O INDUCED/O 1/O (/O LjAPN1/O )/O ,/O encodes/O a/O nepenthesin/O -/O type/O aspartic/O peptidase/O ./O
The/O well/O characterized/O Arabidopsis/O aspartic/O peptidase/O CDR1/O could/O complement/O the/O strain/O -/O specific/O Fix-/O phenotype/O of/O apn1/O ./O
LjAPN1/O is/O a/O typical/O late/O nodulin/O ;/O its/O gene/O expression/O was/O exclusively/O induced/O during/O nodule/O development/O ./O
LjAPN1/O was/O most/O abundantly/O expressed/O in/O the/O infected/O cells/O in/O the/O nodules/O ./O
Our/O findings/O indicate/O that/O LjAPN1/O is/O required/O for/O the/O development/O and/O persistence/O of/O functional/O (/O nitrogen/O -/O fixing/O )/O symbiosis/O in/O a/O rhizobial/O strain/O -/O dependent/O manner/O ,/O and/O thus/O determines/O compatibility/O between/O M./O loti/O and/O L./O japonicus/O at/O the/O level/O of/O nitrogen/O fixation/O ./O
[/O FILAGGRIN/O GENE/O NULL/O -/O MUTATIONS/O AND/O ATOPIC/O DISEASES/O ]/O ./O
Null/B-Var -/I-Var mutations/I-Var which/O cause/O loss/B-NegReg of/I-NegReg function/I-NegReg of/O the/O gene/O encoding/O filaggrin/O (/B-Gene FLG/I-Gene )/I-Gene have/O been/O strongly/O linked/B-Reg to/O the/O development/O of/O atopic/O disorders/O ,/O predominantly/O atopic/B-Disease eczema/I-Disease //I-Disease dermatitis/I-Disease syndrome/I-Disease (/O AEDS/O )/O ./O
Filaggrin/O plays/O a/O key/O role/O in/O epidermal/O barrier/O function/O by/O upholding/O epidermal/O structure/O and/O moisturization/O ./O
Up/O to/O now/O ,/O around/O 40/O variants/O of/O FLG/O null/O -/O mutations/O have/O been/O genotyped/O among/O different/O world/O populations/O ./O
FLG/O null/O -/O mutations/O are/O present/O in/O up/O to/O 10/O %/O of/O the/O Caucasian/O population/O in/O Western/O Europe/O and/O North/O America/O ,/O with/O R05X/O and/O 2282del4/O as/O the/O most/O common/O null/O -/O mutations/O ./O
Epidemiological/O studies/O conducted/O in/O Europe/O indicate/O a/O latitude/O dependent/O distribution/O of/O common/O FLG/O null/O -/O mutations/O with/O a/O decreasing/O north/O -/O south/O gradient/O of/O R501X/O and/O 2282del4/O mutation/O frequencies/O ./O
FLG/B-Gene null/B-Var -/I-Var mutation/I-Var carriers/O are/O prone/O to/O develop/B-PosReg unspecific/B-Disease skin/I-Disease symptoms/I-Disease related/O to/O atopic/O and/O non/O -/O atopic/O skin/O disorders/O due/O to/O their/O defect/O of/O epidermal/O barrier/O function/O ,/O which/O allows/O greater/O skin/O penetration/O of/O various/O hazards/O ./O
Epidemiological/O studies/O indicate/O an/O association/B-Interaction of/O FLG/B-Gene null/B-Var -/I-Var mutations/I-Var with/O AEDS/B-Disease ,/O whereas/O results/O regarding/O an/O association/O of/O FLG/O null/O -/O mutations/O with/O sensitization/O to/O common/O inhalant/O allergens/O and/O development/O of/O rhinitis/O and/O asthma/O are/O incoherent/O ./O
A/O study/O conducted/O in/O Croatia/O found/O a/O low/O frequency/O of/O FLG/O null/O -/O mutations/O in/O general/O population/O (/O 2.6/O %/O )/O and/O did/O not/O confirm/O FLG/O null/O -/O mutations/O as/O an/O etiological/O factor/O for/O atopy/O and/O atopic/O disease/O in/O the/O studied/O population/O ./O
FGF/O -/O FGFR/O Mediates/O the/O Activity/O -/O Dependent/O Dendritogenesis/O of/O Layer/O IV/O Neurons/O during/O Barrel/O Formation/O ./O
Fibroblast/O growth/O factors/O (/O FGFs/O )/O and/O FGF/O receptors/O (/O FGFRs/O )/O are/O known/O for/O their/O potent/O effects/O on/O cell/O proliferation/O //O differentiation/O and/O cortical/O patterning/O in/O the/O developing/O brain/O ./O
However/O ,/O little/O is/O known/O regarding/O the/O roles/O of/O FGFs/O //O FGFRs/O in/O cortical/O circuit/O formation/O ./O
Here/O we/O show/O that/O Fgfr1/2/3/O and/O Fgf7/9/10/22/O mRNAs/O are/O expressed/O in/O the/O developing/O primary/O somatosensory/O (/O S1/O )/O barrel/O cortex/O ./O
Barrel/O cortex/O layer/O IV/O spiny/O stellate/O cells/O (/O bSCs/O )/O are/O the/O primary/O recipients/O of/O ascending/O sensory/O information/O via/O thalamocortical/O axons/O (/O TCAs/O )/O ./O
Detail/O quantification/O revealed/O distinctive/O phases/O for/O bSC/O dendritogenesis/O :/O orienting/O dendrites/O toward/O TCAs/O ,/O adding/O de/O novo/O dendritic/O segments/O ,/O and/O elongating/O dendritic/O length/O ,/O while/O maintaining/O dendritic/O patterns/O ./O
Deleting/O Fgfr1/2/3/O in/O bSCs/O had/O minimal/O impact/O on/O dendritic/O polarity/O but/O transiently/O increased/O the/O number/O of/O dendritic/O segments/O ./O
However/O ,/O 6/O d/O later/O ,/O FGFR1/2/3/O loss/O of/O function/O reduced/O dendritic/O branch/O numbers/O ./O
These/O data/O suggest/O that/O FGFs/O //O FGFRs/O have/O a/O role/O in/O stabilizing/O dendritic/O patterning/O ./O
Depolarization/O of/O cultured/O mouse/O cortical/O neurons/O upregulated/O the/O levels/O of/O several/O Fgf/O //O Fgfr/O mRNAs/O within/O 2/O h./O In/O vivo/O ,/O within/O 6/O h/O of/O systemic/O kainic/O acid/O administration/O at/O postnatal/O day/O 6/O ,/O mRNA/O levels/O of/O Fgf9/O ,/O Fgf10/O ,/O Fgfr2c/O ,/O and/O Fgfr3b/O in/O S1/O cortices/O were/O enhanced/O ,/O and/O this/O was/O accompanied/O by/O exuberant/O dendritogenesis/O of/O bSCs/O by/O 24/O h./O Deleting/O Fgfr1/2/3/O abolished/O kainic/O acid/O -/O induced/O bSC/O dendritic/O overgrowth/O ./O
Finally/O ,/O FGF9/10/O gain/O of/O function/O also/O resulted/O in/O extensive/O dendritogenesis/O ./O
Together/O ,/O our/O data/O suggest/O that/O FGFs/O //O FGFRs/O can/O be/O regulated/O by/O glutamate/O transmission/O to/O modulate/O //O stabilize/O bSC/O dendritic/O complexity/O ./O
Both/O male/O and/O female/O mice/O were/O used/O for/O our/O study/O ./O
SIGNIFICANCE/O STATEMENT/O Glutamatergic/O transmission/O plays/O critical/O roles/O in/O cortical/O circuit/O formation/O ./O
Its/O dysregulation/O has/O been/O proposed/O as/O a/O core/O factor/O in/O the/O etiology/O of/O many/O neurological/O diseases/O ./O
We/O found/O that/O excessive/O glutamate/O transmission/O upregulated/O mRNA/O expression/O of/O Fgfrs/O and/O their/O ligands/O Fgfs/O Deleting/B-Var Fgfr1/2/3/B-Gene not/O only/O impaired/B-NegReg bSC/B-MPA dendritogenesis/I-MPA but/O also/O abolished/B-NegReg glutamate/B-MPA transmission/I-MPA -/I-MPA induced/I-MPA dendritic/I-MPA overgrowth/I-MPA ./O
Overexpressing/O FGF9/O or/O FGF10/O in/O cortical/O glutamatergic/O neurons/O results/O in/O excessive/O dendritic/O outgrowth/O within/O 24/O h/O ,/O resembling/O the/O changes/O induced/O by/O excessive/O glutamate/O transmission/O ./O
Our/O findings/O provide/O strong/O evidence/O for/O the/O physiological/O role/O of/O fibroblast/O growth/O factors/O (/O FGFs/O )/O and/O FGF/O receptors/O (/O FGFRs/O )/O in/O establishing/O and/O maintaining/O cortical/O circuits/O ./O
Perturbing/O the/O expression/O levels/O of/O FGFs/O //O FGFRs/O by/O excessive/O glutamatergic/O neurotransmission/O could/O lead/O to/O abnormal/O neuronal/O circuits/O ,/O which/O may/O contribute/O to/O neurological/O and/O psychiatric/O disease/O ./O
Why/O are/O there/O hotspot/O mutations/O in/O the/O TP53/O gene/O in/O human/O cancers/O ?/O The/O p53/O gene/O contains/O homozygous/O mutations/O in/O ~50/O -/O 60/O %/O of/O human/O cancers/O ./O
About/O 90/O %/O of/O these/O mutations/O encode/O missense/O mutant/O proteins/O that/O span/O ~190/O different/O codons/O localized/O in/O the/O DNA/O -/O binding/O domain/O of/O the/O gene/O and/O protein/O ./O
These/O mutations/B-Var produce/O a/O protein/O with/O a/O reduced/O capacity/O to/O bind/O to/O a/O specific/O DNA/O sequence/O that/O regulates/B-Reg the/O p53/B-Pathway transcriptional/I-Pathway pathway/I-Pathway ./O
Eight/O of/O these/O mutations/O are/O localized/O in/O codons/O that/O account/O for/O ~28/O %/O of/O the/O total/O p53/O mutations/O and/O these/O alleles/O appear/O to/O be/O selected/O for/O preferentially/O in/O human/O cancers/O of/O many/O tissue/O types/O ./O
This/O article/O explores/O the/O question/O '/O Why/O are/O there/O hotspot/O mutations/O in/O the/O p53/O gene/O in/O human/O cancers/O ?/O '/O Four/O possible/O reasons/O for/O this/O are/O considered/O ;/O (/O 1/O )/O the/O hotspot/O mutant/B-Var alleles/O produce/O a/O protein/O that/O has/O a/O highly/O altered/B-Reg structure/B-MPA ,/O (/O 2/O )/O environmental/O mutagens/O produce/O allele/O -/O specific/O changes/O in/O the/O p53/O gene/O ,/O (/O 3/O )/O these/O mutations/O arise/O at/O selected/O sites/O in/O the/O gene/O due/O to/O a/O specific/O DNA/O sequence/O ,/O such/O as/O a/O methylated/O cytosine/O residue/O in/O a/O CpG/O dinucleotide/O ,/O which/O has/O a/O higher/O mutation/O rate/O changing/O C/O to/O T/O nucleotides/O ,/O (/O 4/O )/O along/O with/O the/O observed/O change/O in/O mutant/O p53/O proteins/O ,/O which/O produce/O a/O loss/O of/O function/O (/O DNA/O binding/O and/O transcription/O )/O ,/O some/O mutant/B-Var proteins/B-Protein have/O an/O allele/O -/O specific/O gain/B-PosReg of/I-PosReg function/I-PosReg that/O promotes/O cancer/B-Disease ./O
Evidence/O is/O presented/O that/O demonstrates/O the/O first/O three/O possibilities/O all/O contribute/O some/O property/O to/O this/O list/O of/O hotspot/O mutations/O ./O
The/O fourth/O possibility/O remains/O to/O be/O tested/O ./O
Mutant/O p53/O partners/O in/O crime/O ./O
Mutant/B-Var p53/B-Gene proteins/B-Protein impart/O changes/B-Reg in/O cellular/B-MPA behavior/I-MPA and/O function/B-MPA through/O interactions/B-Interaction with/O proteins/B-Protein that/O alter/O gene/O expression/O ./O
The/O milieu/O of/O intracellular/O proteins/O available/O to/O interact/O with/O mutant/O p53/O is/O context/O specific/O and/O changes/O with/O disease/O ,/O cell/O type/O ,/O and/O environmental/O conditions/O ./O
Varying/O conformations/O of/O mutant/B-Var p53/B-Gene largely/O dictate/B-Reg protein/B-MPA -/I-MPA protein/I-MPA interactions/I-MPA as/O different/O point/O mutations/O within/O protein/O -/O coding/O regions/O greatly/O alter/O the/O extent/O and/O array/O of/O gain/O -/O of/O -/O function/O (/O GOF/O )/O activities/O ./O
Given/O such/O variables/O ,/O how/O can/O knowledge/O regarding/O p53/O missense/O mutations/O be/O translated/O into/O predicting/O or/O altering/O biologic/O activity/O for/O therapy/O ?/O How/O may/O knowledge/O regarding/O mutant/O p53/O functions/O within/O certain/O disease/O contexts/O be/O harnessed/O to/O blunt/O or/O ablate/O mutant/O p53/O GOF/O for/O therapy/O ?/O In/O this/O article/O ,/O we/O review/O known/O proteins/O that/O interact/O with/O mutant/B-Var p53/B-Gene and/O result/O in/O the/O activation/B-PosReg of/O genes/B-Gene that/O contribute/O to/O p53/O GOF/O with/O particular/O emphasis/O on/O context/O dependency/O and/O an/O evolving/O appreciation/O of/O GOF/O mechanisms/O ./O
Exceptional/O Response/O to/O Temsirolimus/O in/O a/O Metastatic/O Clear/O Cell/O Renal/O Cell/O Carcinoma/O With/O an/O Early/O Novel/O MTOR/O -/O Activating/O Mutation/O ./O
mTOR/O pathway/O inhibitors/O are/O important/O drugs/O for/O the/O treatment/O of/O advanced/O renal/O cell/O carcinoma/O (/O RCC/O )/O ./O
However/O ,/O no/O valid/O predictive/O markers/O have/O been/O identified/O to/O guide/O treatment/O selection/O and/O identify/O patients/O who/O are/O sensitive/O to/O these/O drugs/O ./O
Mutations/O activating/O the/O mTOR/O pathway/O have/O been/O suggested/O to/O predict/O response/O ;/O however/O ,/O their/O predictive/O value/O is/O still/O unclear/O ./O
Here/O ,/O we/O present/O the/O genomic/O and/O functional/O characterization/O of/O a/O patient/O with/O metastatic/O clear/O cell/O RCC/O (/O ccRCC/O )/O who/O experienced/O a/O partial/O response/O to/O temsirolimus/O after/O a/O poor/O response/O to/O 2/O previous/O lines/O of/O treatment/O ./O
At/O the/O time/O of/O publication/O ,/O the/O patient/O was/O disease/O -/O free/O 8/O years/O after/O temsirolimus/O treatment/O ./O
Multiregion/O whole/O -/O exome/O sequencing/O (/O WES/O )/O on/O 3/O regions/O of/O the/O primary/O tumor/O ,/O 1/O metastasis/O ,/O and/O blood/O revealed/O tumor/O mutations/O in/O driver/O genes/O in/O ccRCC/O :/O a/O missense/O mutation/O in/O VHL/O (/O p/O ./O W88L/O )/O ,/O a/O loss/O -/O of/O -/O function/O mutation/O in/O BAP1/O (/O p/O ./O E454Rfs*15/O )/O ,/O and/O a/O novel/O missense/O mutation/O in/O MTOR/O (/O p/O ./O Y1974H/O )/O ./O
The/O MTOR/O mutation/O was/O present/O in/O all/O tumor/O regions/O ,/O with/O similar/O allele/O frequency/O as/O the/O VHL/O mutation/O ,/O and/O in/O vitro/O functional/O assessment/O of/O the/O MTOR/B-Gene variant/B-Var demonstrated/O that/O it/O increased/B-PosReg mTORC1/B-MPA activity/I-MPA ./O
Consistently/O ,/O immunohistochemistry/O in/O the/O tumor/O samples/O demonstrated/O increased/O levels/O of/O phospho/O -/O S6/O ./O
In/O conclusion/O ,/O multiregion/O WES/O identified/O a/O novel/O MTOR/B-Gene mutation/B-Var acquired/O early/O during/O tumor/O development/O as/O the/O event/O leading/B-Reg to/I-Reg a/O high/B-MPA sensitivity/I-MPA to/I-MPA temsirolimus/I-MPA treatment/I-MPA ./O
This/O study/O supports/O tumor/O multiregion/O sequencing/O to/O detect/O truncal/O mutations/O in/O the/O mTOR/O pathway/O to/O identify/O patients/O sensitive/O to/O mTOR/O inhibitors/O ./O
Loss/O of/O function/O JAK1/O mutations/O occur/O at/O high/O frequency/O in/O cancers/O with/O microsatellite/O instability/O and/O are/O suggestive/O of/O immune/O evasion/O ./O
Immune/O evasion/O is/O a/O well/O -/O recognized/O hallmark/O of/O cancer/O and/O recent/O studies/O with/O immunotherapy/O agents/O have/O suggested/O that/O tumors/O with/O increased/O numbers/O of/O neoantigens/O elicit/O greater/O immune/O responses/O ./O
We/O hypothesized/O that/O the/O immune/O system/O presents/O a/O common/O selective/O pressure/O on/O high/O mutation/O burden/O tumors/O and/O therefore/O immune/O evasion/O mutations/O would/O be/O enriched/O in/O high/O mutation/O burden/O tumors/O ./O
The/O JAK/O family/O of/O kinases/O is/O required/O for/O the/O signaling/O of/O a/O host/O of/O immune/O modulators/O in/O tumor/O ,/O stromal/O ,/O and/O immune/O cells/O ./O
Therefore/O ,/O we/O analyzed/O alterations/O in/O this/O family/O for/O the/O hypothesized/O signature/O of/O an/O immune/O evasion/O mutation/O ./O
Here/O ,/O we/O searched/O a/O database/O of/O 61,704/O unique/O solid/O tumors/O for/O alterations/O in/O the/O JAK/O family/O kinases/O (/O JAK1/2/3/O ,/O TYK2/O )/O ./O
We/O used/O The/O Cancer/O Genome/O Atlas/O and/O Cancer/O Cell/O Line/O Encyclopedia/O data/O to/O confirm/O and/O extend/O our/O findings/O by/O analyzing/O gene/O expression/O patterns/O ./O
Recurrent/O frameshift/B-Var mutations/I-Var in/O JAK1/B-Gene were/O associated/B-Reg with/O high/B-MPA mutation/I-MPA burden/I-MPA and/O microsatellite/B-MPA instability/I-MPA ./O
These/O mutations/B-Var occurred/B-Reg in/O multiple/O tumor/O types/O including/O endometrial/B-Disease ,/O colorectal/B-Disease ,/O stomach/B-Disease ,/O and/O prostate/B-Disease carcinomas/B-Disease ./O
Analyzing/O gene/O expression/O signatures/O in/O endometrial/O and/O stomach/O adenocarcinomas/O revealed/O that/O tumors/O with/O a/O JAK1/O frameshift/O exhibited/O reduced/O expression/O of/O interferon/O response/O signatures/O and/O multiple/O anti/O -/O tumor/O immune/O signatures/O ./O
Importantly/O ,/O endometrial/O cancer/O cell/O lines/O exhibited/O similar/O gene/O expression/O changes/O that/O were/O expected/O to/O be/O tumor/O cell/O intrinsic/O (/O e.g./O interferon/O response/O )/O but/O not/O those/O expected/O to/O be/O tumor/O cell/O extrinsic/O (/O e.g./O NK/O cells/O )/O ./O
From/O these/O data/O ,/O we/O derive/O two/O primary/O conclusions/O :/O 1/O )/O JAK1/O frameshifts/O are/O loss/O of/O function/O alterations/O that/O represent/O a/O potential/O pan/O -/O cancer/O adaptation/O to/O immune/O responses/O against/O tumors/O with/O microsatellite/O instability/O ;/O 2/O )/O The/O mechanism/O by/O which/O JAK1/B-Var loss/B-NegReg of/I-NegReg function/I-NegReg contributes/O to/O tumor/B-MPA immune/I-MPA evasion/I-MPA is/O likely/O associated/O with/O loss/O of/O the/O JAK1-mediated/O interferon/O response/O ./O
Gain/B-PosReg of/I-PosReg function/I-PosReg of/O TMEM16E/B-Gene //I-Gene ANO5/I-Gene scrambling/B-MPA activity/I-MPA caused/O by/O a/O mutation/B-Var associated/O with/O gnathodiaphyseal/B-Disease dysplasia/I-Disease ./O
Mutations/B-Var in/O the/O human/O TMEM16E/B-Gene (/O ANO5/O )/O gene/O are/O associated/B-Reg both/O with/O the/O bone/B-Disease disease/I-Disease gnathodiaphyseal/B-Disease dysplasia/I-Disease (/O GDD/O ;/O OMIM/O :/O 166260/O )/O and/O muscle/B-Disease dystrophies/I-Disease (/O OMIM/O :/O 611307/O ,/O 613319/O )/O ./O
However/O ,/O the/O physiological/O function/O of/O TMEM16E/O has/O remained/O unclear/O ./O
We/O show/O here/O that/O human/O TMEM16E/O ,/O when/O overexpressed/O in/O mammalian/O cell/O lines/O ,/O displayed/O partial/O plasma/O membrane/O localization/O and/O gave/O rise/O to/O phospholipid/O scrambling/O (/O PLS/O )/O as/O well/O as/O non/O -/O selective/O ionic/O currents/O with/O slow/O time/O -/O dependent/O activation/O at/O highly/O depolarized/O membrane/O potentials/O ./O
While/O the/O activity/O of/O wild/O -/O type/O TMEM16E/O depended/O on/O elevated/O cytosolic/O Ca2/O +/O levels/O ,/O a/O mutant/O form/O carrying/O the/O GDD/O -/O causing/O T513I/O substitution/O showed/O PLS/O and/O large/O time/O -/O dependent/O ion/O currents/O even/O at/O low/O cytosolic/O Ca2/O +/O concentrations/O ./O
Contrarily/O ,/O mutation/O of/O the/O homologous/O position/O in/O the/O Ca2/O +/O -activated/O Cl-/O channel/O TMEM16B/O paralog/O hardly/O affected/O its/O function/O ./O
In/O summary/O ,/O these/O data/O provide/O the/O first/O direct/O demonstration/O of/O Ca2/O +/O -dependent/O PLS/O activity/O for/O TMEM16E/O and/O suggest/O a/O gain/O -/O of/O -/O function/O phenotype/O related/O to/O a/O GDD/O mutation/O ./O
Multiple/O Legionella/O pneumophila/O effector/O virulence/O phenotypes/O revealed/O through/O high/O -/O throughput/O analysis/O of/O targeted/O mutant/O libraries/O ./O
Legionella/O pneumophila/O is/O the/O causative/O agent/O of/O a/O severe/O pneumonia/O called/O Legionnaires/O '/O disease/O ./O
A/O single/O strain/O of/O L./O pneumophila/O encodes/O a/O repertoire/O of/O over/O 300/O different/O effector/O proteins/O that/O are/O delivered/O into/O host/O cells/O by/O the/O Dot/O //O Icm/O type/O IV/O secretion/O system/O during/O infection/O ./O
The/O large/O number/O of/O L./O pneumophila/O effectors/O has/O been/O a/O limiting/O factor/O in/O assessing/O the/O importance/O of/O individual/O effectors/O for/O virulence/O ./O
Here/O ,/O a/O transposon/O insertion/O sequencing/O technology/O called/O INSeq/O was/O used/O to/O analyze/O replication/O of/O a/O pool/O of/O effector/O mutants/O in/O parallel/O both/O in/O a/O mouse/O model/O of/O infection/O and/O in/O cultured/O host/O cells/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O genes/O encoding/O effector/O proteins/O resulted/O in/O host/B-MPA -/I-MPA specific/I-MPA or/O broad/B-MPA virulence/I-MPA phenotypes/I-MPA ./O
Screen/O results/O were/O validated/O for/O several/O effector/O mutants/O displaying/O different/O virulence/O phenotypes/O using/O genetic/O complementation/O studies/O and/O infection/O assays/O ./O
Specifically/O ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O gene/O encoding/O LegC4/B-Gene resulted/O in/O enhanced/B-PosReg L./B-CPA pneumophila/I-CPA in/O the/O lungs/O of/O infected/O mice/O but/O not/O within/O cultured/O host/O cells/O ,/O which/O indicates/O LegC4/B-Var augments/B-PosReg bacterial/B-CPA clearance/I-CPA by/O the/O host/O immune/O system/O ./O
The/O effector/O proteins/O RavY/O and/O Lpg2505/O were/O important/O for/O efficient/O replication/O within/O both/O mammalian/O and/O protozoan/O hosts/O ./O
Further/O analysis/O of/O Lpg2505/O revealed/O that/O this/O protein/O functions/O as/O a/O metaeffector/O that/O counteracts/O host/O cytotoxicity/O displayed/O by/O the/O effector/O protein/O SidI./O Thus/O ,/O this/O study/O identified/O a/O large/O cohort/O of/O effectors/O that/O contribute/O to/O L./O pneumophila/O virulence/O positively/O or/O negatively/O and/O has/O demonstrated/O regulation/O of/O effector/O protein/O activities/O by/O cognate/O metaeffectors/O as/O being/O critical/O for/O host/O pathogenesis/O ./O
A/O Partial/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg Variant/B-Var in/O AKT2/B-Gene Is/O Associated/O With/O Reduced/B-NegReg Insulin/B-CPA -/I-CPA Mediated/I-CPA Glucose/I-CPA Uptake/I-CPA in/O Multiple/O Insulin/O -/O Sensitive/O Tissues/O :/O A/O Genotype/O -/O Based/O Callback/O Positron/O Emission/O Tomography/O Study/O ./O
Rare/O fully/O penetrant/O mutations/O in/O AKT2/O are/O an/O established/O cause/O of/O monogenic/O disorders/O of/O glucose/O metabolism/O ./O
Recently/O ,/O a/O novel/O partial/O loss/O -/O of/O -/O function/O AKT2/O coding/O variant/O (/O p/O ./O Pro50Thr/O )/O was/O identified/O that/O is/O nearly/O specific/O to/O Finns/O (/O frequency/O 1.1/O %/O )/O ,/O with/O the/O low/O -/O frequency/O allele/O associated/O with/O an/O increase/O in/O fasting/O plasma/O insulin/O level/O and/O risk/O of/O type/O 2/O diabetes/O ./O
The/O effects/O of/O the/O p/O ./O Pro50Thr/O AKT2/O variant/O (/O p/O ./O P50T/O //O AKT2/O )/O on/O insulin/O -/O stimulated/O glucose/O uptake/O (/O GU/O )/O in/O the/O whole/O body/O and/O in/O different/O tissues/O have/O not/O previously/O been/O investigated/O ./O
We/O identified/O carriers/O (/O N/O =/O 20/O )/O and/O matched/O noncarriers/O (/O N/O =/O 25/O )/O for/O this/O allele/O in/O the/O population/O -/O based/O Metabolic/O Syndrome/O in/O Men/O (/O METSIM)study/O and/O invited/O these/O individuals/O back/O for/O positron/O emission/O tomography/O study/O with/O [/O 18F]-fluorodeoxyglucose/O during/O euglycemic/O hyperinsulinemia/O ./O
When/O we/O compared/O p/O ./O P50T/O //O AKT2/O carriers/O to/O noncarriers/O ,/O we/O found/O a/O 39.4/O %/O reduction/O in/O whole/O -/O body/O GU/O (/O P/O =/O 0.006/O )/O and/O a/O 55.6/O %/O increase/O in/O the/O rate/O of/O endogenous/O glucose/O production/O (/O P/O =/O 0.038/O )/O ./O
We/O found/O significant/O reductions/O in/O GU/O in/O multiple/O tissues/O -/O skeletal/O muscle/O (/O 36.4/O %/O )/O ,/O liver/O (/O 16.1/O %/O )/O ,/O brown/O adipose/O (/O 29.7/O %/O )/O ,/O and/O bone/O marrow/O (/O 32.9%)-and/O increases/O of/O 16.8/O -/O 19.1/O %/O in/O seven/O tested/O brain/O regions/O ./O
These/O data/O demonstrate/O that/O the/O p/B-Var ./I-Var P50/I-Var T/I-Var substitution/O of/O AKT2/B-Gene influences/B-Reg insulin/B-MPA -/I-MPA mediated/I-MPA GU/I-MPA in/O multiple/O insulin/O -/O sensitive/O tissues/O and/O may/O explain/O ,/O at/O least/O in/O part/O ,/O the/O increased/O risk/O of/O type/O 2/O diabetes/O in/O p/O ./O P50T/O //O AKT2/O carriers/O ./O
Common/O and/O rare/O TBK1/B-Gene variants/B-Var in/B-Reg early/B-Disease -/I-Disease onset/I-Disease Alzheimer/I-Disease disease/I-Disease in/O a/O European/O cohort/O ./O
TANK/O -/O binding/O kinase/O 1/O (/B-Gene TBK1/I-Gene )/I-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LoF/O )/O mutations/B-Var are/O known/O to/O cause/O frontotemporal/B-Disease dementia/I-Disease (/O FTD/O )/O and/O amyotrophic/B-Disease lateral/I-Disease sclerosis/I-Disease (/O ALS/O )/O ,/O often/O combined/O with/O memory/O deficits/O early/O in/O the/O disease/O course/O ./O
We/O performed/O targeted/O resequencing/O of/O TBK1/O in/O 1253/O early/O onset/O Alzheimer/O 's/O disease/O (/O EOAD/O )/O patients/O from/O 8/O European/O countries/O to/O investigate/O whether/O pathogenic/O TBK1/O mutations/O are/O enriched/O among/O patients/O with/O clinical/O diagnosis/O of/O EOAD/O ./O
Variant/O frequencies/O were/O compared/O against/O 2117/O origin/O -/O matched/O controls/O ./O
We/O identified/O only/O 1/O LoF/O mutation/O (/O p/O ./O Thr79del/O )/O in/O a/O patient/O clinically/O diagnosed/O with/O Alzheimer/O 's/O disease/O and/O a/O positive/O family/O history/O of/O ALS/O ./O
We/O did/O not/O observe/O enrichment/O of/O rare/O variants/O in/O EOAD/O patients/O compared/O to/O controls/O ,/O nor/O of/O rare/O variants/O affecting/O NFκB/O induction/O ./O
Of/O 3/O common/O coding/O variants/O ,/O rs7486100/O showed/O evidence/O of/O association/O (/O OR/O 1.46/O [/O 95/O %/O CI/O 1.13/O -/O 1.9/O ]/O ;/O p/O -/O value/O 0.01/O )/O ./O
Homozygous/O carriers/O of/O the/O risk/O allele/O showed/O reduced/O expression/O of/O TBK1/O (/O p/O -/O value/O 0.03/O )/O ./O
Our/O findings/O are/O not/O indicative/O of/O a/O significant/O role/O for/O TBK1/O mutations/O in/O EOAD/O ./O
The/O association/O between/O common/O variants/O in/O TBK1/O ,/O disease/O risk/O and/O reduced/O TBK1/O expression/O warrants/O follow/O -/O up/O in/O FTD/O //O ALS/O cohorts/O ./O
Polymorphisms/O in/O inflammasome/O genes/O and/O risk/O of/O asthma/O in/O Brazilian/O children/O ./O
Considering/O its/O role/O in/O inflammation/O and/O recently/O described/O "/O alternative/O "/O roles/O in/O epithelial/O homeostasis/O and/O Th1/O //O Th2/O balance/O ,/O we/O hypothesize/O that/O inflammasome/O genetics/O could/O contribute/O to/O the/O development/O of/O asthma/O ./O
Selected/O functional/O polymorphisms/O in/O inflammasome/O genes/O are/O evaluated/O in/O a/O cohort/O of/O asthmatic/O children/O and/O their/O families/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg NLRP1/B-Gene variants/B-Var rs11651270/B-Var ,/O rs12150220/B-Var and/O rs2670660/B-Var resulted/O significantly/O associated/O to/O asthma/B-Disease in/O trios/O (/O TDT/O )/O analysis/O ;/O and/O rs11651270/B-Var and/O rs2670660/B-Var also/O with/B-Reg asthma/B-Disease severity/O and/O total/O IgE/B-MPA level/I-MPA in/O asthmatic/O children/O ./O
NLRP1/O activators/O in/O humans/O are/O still/O unknown/O ,/O however/O we/O hypothesized/O that/O individuals/O with/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg SNPs/B-Var in/O NLRP1/B-Gene could/O be/O more/O prone/B-PosReg in/O activating/B-MPA inflammasome/I-MPA in/O the/O presence/O of/O asthma/O -/O related/O cell/O stressors/O (/O i.e./O ER/O stress/O or/O ROS/O )/O ,/O and/O this/O activation/O contribute/O to/O exacerbate/B-PosReg inflammatory/B-CPA response/I-CPA and/O asthma/B-CPA development/I-CPA ./O
Gain/O -/O of/O -/O function/O IL1A/B-Gene rs17561/B-Var resulted/O significantly/O associated/O with/O a/O reduced/B-NegReg pulmonary/B-CPA capacity/I-CPA in/O asthmatic/O children/O ./O
IL18/B-Gene rs5744256/B-Var which/O lead/O to/O lower/B-NegReg serum/B-MPA level/I-MPA of/I-MPA IL-18/I-MPA appeared/O to/O be/O associated/O to/O a/O worse/O response/O to/O bronchodilators/O ./O
Concluding/O ,/O this/O work/O provides/O evidences/O about/O the/O contribution/O of/O inflammasome/O genetics/O in/O the/O development/O of/O paediatric/O asthma/O ,/O both/O considering/O its/O inflammatory/O role/O in/O alveolar/O macrophages/O (/O i.e./O :/O NLRP1/O )/O or/O its/O homeostatic/O role/O in/O lung/O epithelial/O cells/O (/O i.e./O :/O IL1A/O ,/O IL18/O )/O ./O
MED13L/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/B-Var in/O two/O patients/O with/O syndromic/O Pierre/B-Disease Robin/I-Disease sequence/I-Disease ./O
We/O report/O two/O unrelated/O patients/O with/O Pierre/O Robin/O sequence/O (/O PRS/O )/O and/O a/O strikingly/O similar/O combination/O of/O associated/O features/O ./O
Whole/O exome/O sequencing/O was/O performed/O for/O both/O patients/O ./O
No/O single/O gene/O containing/O likely/O pathogenic/O point/O mutations/O in/O both/O patients/O could/O be/O identified/O ,/O but/O the/O finding/O of/O an/O essential/O splice/O site/O mutation/O in/O mediator/O complex/O subunit/O 13/O like/O (/O MED13L/O )/O in/O one/O patient/O prompted/O the/O investigation/O of/O copy/O number/O variants/O in/O MED13L/O in/O the/O other/O ,/O leading/O to/O the/O identification/O of/O an/O intragenic/O deletion/O ./O
Disruption/B-Var of/O MED13L/B-Gene ,/O encoding/O a/O component/O of/O the/O Mediator/O complex/O ,/O is/O increasingly/O recognized/O as/O the/O cause/B-Reg of/O an/O intellectual/B-Disease disability/I-Disease syndrome/I-Disease with/O associated/O facial/B-Disease dysmorphism/I-Disease ./O
Our/O findings/O suggest/O that/O MED13L/O -/O related/O disorders/O are/O a/O possible/O differential/O diagnosis/O for/O syndromic/O PRS/O ./O
Loss/B-Var -/I-Var of/I-Var -/I-Var activity/I-Var -/I-Var mutation/I-Var in/O the/O cardiac/B-MPA chloride/I-MPA -/I-MPA bicarbonate/I-MPA exchanger/I-MPA AE3/I-MPA causes/O short/B-Disease QT/I-Disease syndrome/I-Disease ./O
Patients/O with/O short/O QT/O syndrome/O (/O SQTS/O )/O may/O present/O with/O syncope/O ,/O ventricular/O fibrillation/O or/O sudden/O cardiac/O death/O ./O
Six/O SQTS/O susceptibility/O genes/O ,/O encoding/O cation/O channels/O ,/O explain/O </O 25/O %/O of/O SQTS/O cases/O ./O
Here/O we/O identify/O a/O missense/B-Var mutation/I-Var in/O the/O anion/O exchanger/O (/O AE3)-encoding/O SLC4A3/B-Gene gene/O in/O two/O unrelated/O families/O with/O SQTS/O ./O
The/O mutation/O causes/O reduced/B-NegReg surface/B-MPA expression/I-MPA of/I-MPA AE3/I-MPA and/O reduced/B-NegReg membrane/B-MPA bicarbonate/I-MPA transport/I-MPA ./O
Slc4a3/O knockdown/O in/O zebrafish/O causes/O increased/O cardiac/O pHi/O ,/O short/O QTc/O ,/O and/O reduced/O systolic/O duration/O ,/O which/O is/O rescued/O by/O wildtype/O but/O not/O mutated/O SLC4A3/O ./O
Mechanistic/O analyses/O suggest/O that/O an/O increase/O in/O pHi/O and/O decrease/O in/O [/O Cl-]i/O shortened/O the/O action/O potential/O duration/O ./O
However/O ,/O other/O mechanisms/O may/O also/O play/O a/O role/O ./O
Altered/O anion/O transport/O represents/O a/O mechanism/O for/O development/O of/O arrhythmia/O and/O may/O provide/O new/O therapeutic/O possibilities/O ./O
In/O Silico/O Approach/O to/O Investigate/O the/O Structural/O and/O Functional/O Attributes/O of/O Familial/O Hypercholesterolemia/O Variants/O Reported/O in/O the/O Saudi/O Population/O ./O
Familial/B-Disease hypercholesterolemia/I-Disease (/O FH/O )/O is/O a/O metabolic/O disorder/O that/O leads/O primarily/O to/O premature/O cardiovascular/O diseases/O ,/O the/O main/O cause/O of/O mortality/O in/O Saudi/O Arabia/O (/O SA/O )/O ./O
FH/O is/O underreported/O and/O underdiagnosed/O in/O SA/O with/O statistical/O evidence/O of/O high/O expected/O prevalence/O in/O such/O a/O consanguineous/O community/O ./O
Lacking/O knowledge/O of/O which/O and/O how/O these/O alterations/O are/O actually/O impacting/O lipid/O metabolism/O is/O one/O of/O the/O main/O reasons/O why/O FH/O is/O insufficiently/O diagnosed/O in/O the/O region/O ./O
The/O aim/O of/O this/O study/O was/O to/O develop/O a/O fast/O prediction/O approach/O using/O an/O integrated/O bioinformatics/O method/O for/O future/O screening/O of/O the/O potential/O causative/O variants/O from/O national/O registries/O ./O
A/O total/O of/O 21/O variants/O were/O detected/O with/O majority/O rate/O in/O LDLR/O (/O 81/O %/O )/O ./O
Variants/O were/O classified/O based/O on/O the/O type/O of/O mutation/O ./O
Missense/O variants/O resulting/O in/O amino/O acid/O changes/O ,/O c.1429G/B-Var >/I-Var A/I-Var (/O p/O ./O D477N/O )/O ,/O c.1474G/B-Var >/I-Var A/I-Var (/O p/O ./O D492N/O )/O ,/O c.1731G/B-Var >/I-Var T/I-Var (/O p/O ./O W577C/O )/O ,/O and/O c.1783C/B-Var >/I-Var T/I-Var (/O p/O ./O R595W/O )/O in/O LDLR/B-Gene gene/O ,/O in/O addition/O to/O c.9835A/B-Var >/I-Var G/I-Var (/O p/O ./O S3279/O G/O )/O in/O APOB/B-Gene ,/O were/O shown/O to/O be/O deleterious/O by/O concordant/O analysis/O ./O
Furthermore/O ,/O functional/B-Interaction interaction/I-Interaction deformities/B-Reg showed/O a/O significant/O loss/B-NegReg and/O gain/B-PosReg of/O energies/B-MPA in/I-MPA the/I-MPA mutated/I-MPA proteins/I-MPA ./O
These/O findings/O will/O help/O in/O distinguishing/O the/O most/O harmful/O mutations/O needed/O to/O be/O screened/O for/O clinically/O diagnosed/O FH/O patients/O in/O SA/O ./O
Such/O computational/O research/O is/O necessary/O to/O avoid/O time/O consumption/O and/O the/O usage/O of/O expensive/O biological/O experiments/O ./O
This/O can/O be/O a/O fast/O track/O to/O facilitate/O the/O future/O filtering/O and/O screening/O of/O causative/O mutations/O from/O national/O registries/O ./O
Effects/O of/O null/O mutation/O of/O the/O heat/O -/O shock/O gene/O htpG/O on/O the/O production/O of/O virulence/O factors/O by/O Pseudomonas/O aeruginosa/O ./O
AIM/O :/O Pseudomonas/O aeruginosa/O is/O one/O of/O the/O most/O clinically/O important/O opportunistic/O pathogen/O in/O humans/O ./O
The/O aim/O of/O the/O project/O was/O to/O study/O effects/O of/O HtpG/O on/O the/O selected/O virulence/O factors/O responsible/O for/O pathogenesis/O and/O biofilm/O formation/O of/O P./O aeruginosa/O ./O
METHODOLOGY/O :/O By/O characterizing/O a/O htpG/O null/O mutant/O of/O P./O aeruginosa/O ,/O we/O have/O identified/O the/O role/O of/O HtpG/O in/O the/O production/O of/O selected/O factors/O ./O
RESULTS/O :/O We/O showed/O that/O ΔhtpG/B-Gene mutant/B-Var affects/O many/O physiological/O processes/O containing/O :/O decreased/B-NegReg activity/B-MPA of/O the/O LasA/B-Enzyme protease/I-Enzyme ,/O reduction/B-NegReg of/O biofilm/B-MPA formation/I-MPA ,/O decreased/B-NegReg motility/B-CPA ,/O and/O diminished/B-NegReg amount/B-MPA of/I-MPA rhamnolipids/I-MPA and/I-MPA pyoverdine/I-MPA //I-MPA pyocyanin/I-MPA ./O
These/O defects/O were/O most/O evident/O when/O the/O ΔhtpG/O strain/O was/O cultured/O at/O 42/O °/O C/O ./O
CONCLUSION/O :/O Our/O findings/O demonstrate/O the/O unexplored/O role/O of/O HtpG/O in/O the/O pathogenicity/O of/O P./O aeruginosa/O ,/O and/O indicate/O potential/O targets/O for/O antibacterial/O therapeutics/O ./O
[/O Formula/O :/O see/O text/O ]/O ./O
Molecular/O and/O cellular/O issues/O of/O KMT2A/B-Gene variants/B-Var involved/B-Reg in/I-Reg Wiedemann/B-Disease -/I-Disease Steiner/I-Disease syndrome/I-Disease ./O
Variants/B-Var in/O KMT2A/B-Gene ,/O encoding/O the/O histone/O methyltransferase/O KMT2A/O ,/O are/O a/O growing/O cause/B-Reg of/O intellectual/B-Disease disability/I-Disease (/O ID/O )/O ./O
Up/O to/O now/O ,/O the/O majority/O of/O KMT2A/B-Gene variants/B-Var are/O non/B-Var -/I-Var sense/I-Var and/O frameshift/B-Var variants/O causing/B-Reg a/O typical/O form/O of/O Wiedemann/B-Disease -/I-Disease Steiner/I-Disease syndrome/I-Disease ./O
We/O studied/O KMT2A/O gene/O in/O a/O cohort/O of/O 200/O patients/O with/O unexplained/O syndromic/O and/O non/O -/O syndromic/O ID/O and/O identified/O four/O novel/O variants/O ,/O one/O splice/O and/O three/O missense/O variants/O ,/O possibly/O deleterious/O ./O
We/O used/O primary/O cells/O from/O the/O patients/O and/O molecular/O approaches/O to/O determine/O the/O deleterious/O effects/B-Reg of/O those/O variants/B-Var on/O KMT2A/B-Gene expression/B-MPA and/O function/B-MPA ./O
For/O the/O putative/O splice/O variant/O c.11322/B-Var -/I-Var 1G/I-Var >/I-Var A/I-Var ,/O we/O showed/O that/O it/O led/O to/O only/O one/O nucleotide/O deletion/O and/O loss/B-NegReg of/O the/O C/B-MPA -/I-MPA terminal/I-MPA part/I-MPA of/I-MPA the/I-MPA protein/I-MPA ./O
For/O two/O studied/O KMT2A/B-Gene missense/O variants/O ,/O c.3460C/B-Var >/I-Var T/I-Var (/O p.(Arg1154Trp/O )/O )/O and/O c.8558T/B-Var >/I-Var G/I-Var (/O p.(Met2853Arg/O )/O )/O ,/O located/O at/O the/O cysteine/O -/O rich/O CXXC/O domain/O and/O the/O transactivation/O domain/O of/O the/O protein/O ,/O respectively/O ,/O we/O found/O altered/B-Reg KMT2A/O target/O genes/O expression/B-MPA in/O patient/O 's/O fibroblasts/O compared/O to/O controls/O ./O
Furthermore/O ,/O we/O found/O a/O disturbed/B-Reg subcellular/B-MPA distribution/I-MPA of/O KMT2A/B-Gene for/O the/O c.3460C/B-Var >/I-Var T/I-Var mutant/O ./O
Taken/O together/O ,/O our/O results/O demonstrated/O the/O deleterious/O impact/O of/O the/O splice/O variant/O and/O of/O the/O missense/O variants/O located/O at/O two/O different/O functional/O domains/O and/O suggested/O reduction/O of/O KMT2A/O function/O as/O the/O disease/O -/O causing/O mechanism/O ./O
First/O Report/O of/O Prenatal/O Ascertainment/O of/O a/O Fetus/O With/O Homozygous/O Loss/O of/O the/O SOX10/O Gene/O and/O Phenotypic/O Correlation/O by/O Autopsy/O Examination/O ./O
The/O SOX10/O gene/O plays/O a/O vital/O role/O in/O neural/O crest/O cell/O development/O and/O migration/O ./O
Abnormalities/B-Var in/O SOX10/B-Gene are/O associated/B-Reg with/O Waardenburg/B-Disease syndrome/I-Disease Types/B-Disease II/I-Disease and/O IV/B-Disease ,/O and/O these/O patients/O have/O recognizable/O clinical/O features/O ./O
This/O case/O report/O highlights/O the/O first/O ever/O reported/O homozygous/O loss/O of/O function/O of/O the/O SOX10/O gene/O in/O a/O human/O ./O
This/O deletion/O is/O correlated/O using/O family/O history/O ,/O prenatal/O ultrasound/O ,/O microarray/O analysis/O of/O amniotic/O fluid/O ,/O and/O ultimately/O ,/O a/O medical/O autopsy/O examination/O to/O further/O elucidate/O phenotypic/O effects/O of/O this/O genetic/O variation/O ./O
Incorporating/O the/O use/O of/O molecular/O pathology/O into/O the/O autopsy/O examination/O of/O fetuses/O with/O suspected/O congenital/O anomalies/O is/O vital/O for/O appropriate/O family/O counseling/O ,/O and/O with/O the/O ability/O to/O use/O formalin/O -/O fixed/O and/O paraffin/O -/O embedded/O tissues/O ,/O has/O become/O a/O practical/O approach/O in/O autopsy/O pathology/O ./O
A/O novel/O NR2F2/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var predisposes/O to/O congenital/B-Disease heart/I-Disease defect/I-Disease ./O
Congenital/O heart/O defect/O (/O CHD/O )/O is/O the/O most/O common/O type/O of/O birth/O defect/O in/O humans/O and/O a/O leading/O cause/O of/O infant/O morbidity/O and/O mortality/O ./O
Previous/O studies/O have/O demonstrated/O that/O genetic/O defects/O play/O a/O pivotal/O role/O in/O the/O pathogenesis/O of/O CHD/O ./O
However/O ,/O the/O genetic/O basis/O of/O CHD/O remains/O poorly/O understood/O due/O to/O substantial/O genetic/O heterogeneity/O ./O
In/O this/O study/O ,/O the/O coding/O exons/O and/O splicing/O boundaries/O of/O the/O NR2F2/O gene/O ,/O which/O encodes/O a/O pleiotropic/O transcription/O factor/O required/O for/O normal/O cardiovascular/O development/O ,/O were/O sequenced/O in/O 168/O unrelated/O patients/O with/O CHD/O ,/O and/O a/O novel/O mutation/O (/O c.247/O G/O >/O T/O ,/O equivalent/O to/O p/O ./O G83X/O )/O was/O detected/O in/O a/O patient/O with/O double/O outlet/O right/O ventricle/O as/O well/O as/O ventricular/O septal/O defect/O ./O
Genetic/O scanning/O of/O the/O mutation/O carrier/O 's/O relatives/O available/O showed/O that/O the/O mutation/O was/O present/O in/O all/O affected/O family/O members/O but/O absent/O in/O unaffected/O family/O members/O ./O
Analysis/O of/O the/O index/O patient/O 's/O pedigree/O displayed/O that/O the/O mutation/O co/O -/O segregated/O with/O CHD/O ,/O which/O was/O transmitted/O as/O an/O autosomal/O dominant/O trait/O with/O complete/O penetrance/O ./O
The/O nonsense/O mutation/O was/O absent/O in/O 230/O unrelated/O ,/O ethnically/O -/O matched/O healthy/O individuals/O used/O as/O controls/O ./O
Functional/O deciphers/O by/O using/O a/O dual/O -/O luciferase/O reporter/O assay/O system/O revealed/O that/O the/O mutant/B-Var NR2F2/B-Gene protein/O had/O no/B-NegReg transcriptional/B-MPA activity/I-MPA as/O compared/O with/O its/O wild/O -/O type/O counterpart/O ./O
Furthermore/O ,/O the/O mutation/B-Var abrogated/B-NegReg the/O synergistic/B-MPA transcriptional/I-MPA activation/I-MPA between/O NR2F2/B-Gene and/O GATA4/B-Gene ,/O another/O core/O cardiac/O transcription/O factor/O associated/O with/O CHD/O ./O
This/O study/O firstly/O associates/O NR2F2/O loss/O -/O of/O -/O function/O mutation/O with/O an/O increased/O susceptibility/O to/O double/O outlet/O right/O ventricle/O in/O humans/O ,/O which/O provides/O further/O significant/O insight/O into/O the/O molecular/O mechanisms/O underpinning/O CHD/O ,/O suggesting/O potential/O implications/O for/O genetic/O counseling/O of/O CHD/O families/O and/O personalized/O treatment/O of/O CHD/O patients/O ./O
Potential/O pathogenic/O mechanisms/O underlying/O Fragile/O X/O Tremor/O Ataxia/O Syndrome/O :/O RAN/O translation/O and/or/O RNA/O gain/O -/O of/O -/O function/O ?/O Fragile/B-Disease X/I-Disease -/I-Disease associated/I-Disease tremor/I-Disease //I-Disease ataxia/I-Disease syndrome/I-Disease (/O FXTAS/O )/O is/O an/O inherited/O neurodegenerative/O disease/O caused/B-Reg by/I-Reg an/O expansion/B-Var of/I-Var 55/I-Var -/I-Var 200/I-Var CGG/I-Var repeats/I-Var located/O in/O the/O FMR1/B-Gene gene/O ./O
The/O main/O clinical/O and/O neuropathological/O features/O of/O FXTAS/O are/O progressive/O intention/O tremor/O and/O gait/O ataxia/O associated/O with/O brain/O atrophy/O ,/O neuronal/O cell/O loss/O and/O presence/O of/O ubiquitin/O -/O positive/O intranuclear/O inclusions/O in/O both/O neurons/O and/O astrocytes/O ./O
At/O the/O molecular/O level/O ,/O FXTAS/O is/O characterized/O by/O increased/O expression/O of/O FMR1/O sense/O and/O antisense/O RNA/O containing/O expanded/O CGG/O or/O GGC/O repeats/O ,/O respectively/O ./O
Here/O ,/O we/O discuss/O the/O putative/O molecular/O mechanisms/O underlying/O FXTAS/O and/O notably/O recent/O reports/O that/O expanded/O CGG/O and/O GGC/O repeats/O may/O be/O pathogenic/O through/O RAN/O translation/O into/O toxic/O proteins/O ./O
Deleterious/O variants/B-Var in/O DCHS1/B-Gene are/O prevalent/B-Reg in/O sporadic/O cases/O of/O mitral/B-Disease valve/I-Disease prolapse/I-Disease ./O
BACKGROUND/O :/O A/O recent/O study/O identified/O DCHS1/O as/O a/O causal/O gene/O for/O mitral/O valve/O prolapse/O ./O
The/O goal/O of/O this/O study/O is/O to/O investigate/O the/O presence/O and/O frequency/O of/O known/O and/O novel/O variants/O in/O this/O gene/O in/O 100/O asymptomatic/O patients/O with/O moderate/O to/O severe/O organic/O mitral/O regurgitation/O ./O
METHODS/O :/O DNA/O sequencing/O assays/O were/O developed/O for/O two/O previously/O identified/O functional/O missense/O variants/O ,/O namely/O p/B-Var ./I-Var R2330C/I-Var and/O p/B-Var ./I-Var R2513H/I-Var ,/O and/O all/O 21/O exons/O of/O DCHS1/B-Gene ./O
Pathogenicity/O of/O variants/O was/O evaluated/O in/O silico/O ./O
RESULTS/O :/O p/O ./O R2330C/O and/O p/O ./O R2513H/O were/O not/O identified/O in/O this/O cohort/O ./O
Sequencing/O all/O coding/O regions/O revealed/O eight/O missense/O variants/O including/O six/O considered/O deleterious/O ./O
This/O includes/O one/O novel/O variant/O (/O p/O ./O A2464P/O )/O and/O two/O rare/O variants/O (/O p/O ./O R2770Q/O and/O p/O ./O R2462Q/O )/O ./O
These/O variants/O are/O predicted/O to/O be/O deleterious/O with/O combined/O annotation/O -/O dependent/O depletion/O (/O CADD/O )/O scores/O greater/O than/O 25/O ,/O which/O are/O in/O the/O same/O range/O as/O p/O ./O R2330C/O (/O CADD/O =/O 28.0/O )/O and/O p/O ./O R2513H/O (/O CADD/O =/O 24.3/O )/O ./O
More/O globally/O ,/O 24/O of/O 100/O cases/O were/O carriers/O of/O at/O least/O one/O in/O silico/O -/O predicted/O deleterious/O missense/O variant/O in/O DCHS1/O ,/O suggesting/O that/O this/O single/O gene/O may/O account/O for/O a/O substantial/O portion/O of/O cases/O ./O
CONCLUSION/O :/O This/O study/O reveals/O an/O important/O contribution/O of/O germline/O variants/O in/O DCHS1/O in/O unrelated/O patients/O with/O mitral/O valve/O prolapse/O and/O supports/O genetic/O testing/O of/O this/O gene/O to/O screen/O individuals/O at/O risk/O ./O
Primary/B-Disease Ovarian/I-Disease Insufficiency/I-Disease and/O Azoospermia/B-Disease in/O Carriers/B-Reg of/O a/O Homozygous/O PSMC3IP/B-Gene Stop/O Gain/O Mutation/B-Var ./O
Context/O :/O The/O etiology/O of/O primary/O ovarian/O insufficiency/O (/O POI/O )/O remains/O unknown/O in/O most/O cases/O ./O
Objective/O :/O We/O sought/O to/O identify/O the/O genes/O causing/O POI/O ./O
Design/O :/O The/O study/O was/O a/O familial/O genetic/O study/O ./O
Setting/O :/O The/O study/O was/O performed/O at/O two/O academic/O institutions/O ./O
Patients/O :/O We/O identified/O a/O consanguineous/O Yemeni/O family/O in/O which/O four/O daughters/O had/O POI/O ./O
A/O brother/O had/O azoospermia/O ./O
Intervention/O :/O DNA/O was/O subjected/O to/O whole/O genome/O sequencing/O ./O
Shared/O regions/O of/O homozygosity/O were/O identified/O using/O Truploidy/O and/O prioritized/O using/O the/O Variant/O Annotation/O ,/O Analysis/O ,/O and/O Search/O Tool/O with/O control/O data/O from/O 387/O healthy/O subjects/O ./O
Imaging/O and/O quantification/O of/O protein/O localization/O and/O mitochondrial/O function/O were/O examined/O in/O cell/O lines/O ./O
Main/O Outcome/O :/O Homozygous/O recessive/O gene/O variants/O shared/O by/O the/O four/O sisters/O ./O
Results/O :/O The/O sisters/O shared/O a/O homozygous/O stop/O gain/O mutation/O in/O exon/O 6/O of/O PSMC3IP/O (/O c.489/O C/O >/O G/O ,/O p/O ./O Tyr163Ter/O )/O and/O a/O missense/O variant/O in/O exon/O 1/O of/O CLPP/O (/B-Var c.100C/I-Var >/I-Var T/I-Var ,/O p/O ./O Pro34Ser/O )/O ./O
The/O affected/O brother/O also/O carried/O the/O homozygous/O PSMC3IP/O mutation/O ./O
Functional/O studies/O demonstrated/B-Reg mitochondrial/B-CPA fragmentation/I-CPA in/O cells/O infected/O with/O the/O CLPP/B-Gene mutation/B-Var ./O
However/O ,/O no/O abnormality/O was/O found/O in/O mitochondrial/O targeting/O or/O respiration/O ./O
Conclusions/O :/O The/O PSMC3IP/O mutation/O provides/O additional/O evidence/O that/O mutations/O in/O meiotic/O homologous/O recombination/O and/O DNA/O repair/O genes/O result/O in/O distinct/O female/O and/O male/O reproductive/O phenotypes/O ,/O including/O delayed/O puberty/O and/O primary/O amenorrhea/O caused/O by/O POI/O (/O XX/O gonadal/O dysgenesis/O )/O in/O females/O but/O isolated/O azoospermia/O with/O normal/O pubertal/O development/O in/O males/O ./O
The/O findings/O also/O suggest/O that/O the/O N/O -/O terminal/O missense/O mutation/O in/O CLPP/O does/O not/O cause/O substantial/O mitochondrial/O dysfunction/O or/O contribute/O to/O ovarian/O insufficiency/O in/O an/O oligogenic/O manner/O ./O
HOP-1/O Presenilin/O Deficiency/O Causes/O a/O Late/O -/O Onset/O Notch/O Signaling/O Phenotype/O That/O Affects/O Adult/O Germline/O Function/O in/O Caenorhabditis/O elegans/O ./O
Functionally/O redundant/O genes/O present/O a/O puzzle/O as/O to/O their/O evolutionary/O preservation/O ,/O and/O offer/O an/O interesting/O opportunity/O for/O molecular/O specialization/O ./O
In/O Caenorhabditis/O elegans/O ,/O either/O one/O of/O two/O presenilin/O genes/O (/O sel-12/O or/O hop-1/O )/O facilitate/O Notch/O activation/O ,/O providing/O the/O catalytic/O subunit/O for/O the/O γ/O secretase/O proteolytic/O enzyme/O complex/O ./O
For/O all/O known/O Notch/O signaling/O events/O ,/O sel-12/O can/O mediate/O Notch/O activation/O ,/O so/O the/O conservation/O of/O hop-1/O remains/O a/O mystery/O ./O
Here/O ,/O we/O uncover/O a/O novel/O "/O late/O -/O onset/O "/O germline/O Notch/O phenotype/O in/O which/O HOP-1-deficient/O worms/O fail/O to/O maintain/O proliferating/O germline/O stem/O cells/O during/O adulthood/O ./O
Either/O SEL-12/O or/O HOP-1/O presenilin/O can/O impart/O sufficient/O Notch/O signaling/O for/O the/O establishment/O and/O expansion/O of/O the/O germline/O ,/O but/O maintenance/O of/O an/O adult/O stem/O cell/O pool/O relies/O exclusively/O on/O HOP-1-mediated/O Notch/O signaling/O ./O
We/O also/O show/O that/O HOP-1/O is/O necessary/O for/O maximum/O fecundity/O and/O reproductive/O span/O ./O
The/O low/B-CPA -/I-CPA fecundity/I-CPA phenotype/O of/O hop-1/B-Gene mutants/B-Var can/O be/O phenocopied/O by/O switching/B-NegReg off/I-NegReg glp-1/B-MPA //I-MPA Notch/I-MPA function/I-MPA during/O the/O last/O stage/O of/O larval/O development/O ./O
We/O propose/O that/O at/O the/O end/O of/O larval/O development/O ,/O dual/O presenilin/O usage/O switches/O exclusively/O to/O HOP-1/O ,/O perhaps/O offering/O opportunities/O for/O differential/O regulation/O of/O the/O germline/O during/O adulthood/O ./O
Additional/O defects/B-NegReg in/O oocyte/B-CPA size/I-CPA and/O production/B-CPA rate/O in/O hop-1/B-Gene and/O glp-1/B-Gene mutants/B-Var indicate/O that/O the/O process/O of/O oogenesis/O is/O compromised/O when/O germline/O Notch/O signaling/O is/O switched/O off/O ./O
We/O calculate/O that/O in/O wild/O -/O type/O adults/O ,/O as/O much/O as/O 86/O %/O of/O cells/O derived/O from/O the/O stem/O cell/O pool/O function/O to/O support/O oogenesis/O ./O
This/O work/O suggests/O that/O an/O important/O role/O for/O Notch/O signaling/O in/O the/O adult/O germline/O is/O to/O furnish/O a/O large/O and/O continuous/O supply/O of/O nurse/O cells/O to/O support/O the/O efficiency/O of/O oogenesis/O ./O
Mild/O Telomere/O Dysfunction/O as/O a/O Force/O for/O Altering/O the/O Adaptive/O Potential/O of/O Subtelomeric/O Genes/O ./O
Subtelomeric/O regions/O have/O several/O unusual/O characteristics/O ,/O including/O complex/O repetitive/O structures/O ,/O increased/O rates/O of/O evolution/O ,/O and/O enrichment/O for/O genes/O involved/O in/O niche/O adaptation/O ./O
The/O adaptive/O telomere/O failure/O hypothesis/O suggests/O that/O certain/O environmental/O stresses/O can/O induce/O a/O low/O level/O of/O telomere/O failure/O ,/O potentially/O leading/O to/O elevated/O subtelomeric/O recombination/O that/O could/O result/O in/O adaptive/O mutational/O changes/O within/O subtelomeric/O genes/O ./O
Here/O ,/O we/O tested/O a/O key/O prediction/O of/O the/O adaptive/O telomere/O failure/O hypothesis/O -/O that/O telomere/O dysfunction/O mild/O enough/O to/O have/O little/O or/O no/O overall/O effect/O on/O cell/O fitness/O could/O still/O lead/O to/O substantial/O increases/O in/O the/O mutation/O rates/O of/O subtelomeric/O genes/O ./O
Our/O results/O show/O that/O a/O mutant/O of/O Kluyveromyces/O lactis/O with/O stably/O short/O telomeres/O produced/O a/O large/O increase/O in/O the/O frequency/O of/O mutations/O affecting/O the/O native/O subtelomeric/O β/O -/O galactosidase/O (/O LAC4/O )/O gene/O ./O
All/O lac4/B-Gene mutants/B-Var examined/O from/O strains/O with/O severe/O telomere/O dysfunction/O underwent/B-Reg terminal/B-MPA deletion/I-MPA //I-MPA duplication/I-MPA events/O consistent/O with/O being/O due/O to/O break/O -/O induced/O replication/O ./O
In/O contrast/O ,/O although/O cells/O with/O mild/O telomere/O dysfunction/O also/O exhibited/O similar/O terminal/O deletion/O and/O duplication/O events/O ,/O up/O to/O 50/O %/O of/O lac4/B-Gene mutants/B-Var from/O this/O background/O unexpectedly/O contained/B-Reg base/B-MPA changes/I-MPA within/O the/O LAC4/O coding/O region/O ./O
This/O mutational/O bias/O for/O producing/O base/O changes/O demonstrates/O that/O mild/O telomere/O dysfunction/O can/O be/O well/O suited/O as/O a/O force/O for/O altering/O the/O adaptive/O potential/O of/O subtelomeric/O genes/O ./O
Patients/O with/O a/O Kabuki/O syndrome/O phenotype/O demonstrate/O DNA/O methylation/O abnormalities/O ./O
Kabuki/B-Disease syndrome/I-Disease is/O a/O monogenic/O disorder/O caused/O by/O loss/B-NegReg of/I-NegReg function/I-NegReg variants/B-Var in/O either/O of/O two/O genes/O encoding/O histone/O -/O modifying/O enzymes/O ./O
We/O performed/O targeted/O sequencing/O in/O a/O cohort/O of/O 27/O probands/O with/O a/O clinical/O diagnosis/O of/O Kabuki/O syndrome/O ./O
Of/O these/O ,/O 12/O had/O causative/O variants/O in/O the/O two/O known/O Kabuki/O syndrome/O genes/O ./O
In/O 2/O ,/O we/O identified/O presumptive/O loss/O of/O function/O de/O novo/O variants/B-Var in/O KMT2A/B-Gene (/O missense/O and/O splice/O site/O variants/O )/O ,/O a/O gene/O that/O encodes/O another/O histone/O modifying/O enzyme/O previously/O exclusively/O associated/B-Reg with/O Wiedermann/B-Disease -/I-Disease Steiner/I-Disease syndrome/I-Disease ./O
Although/O Kabuki/O syndrome/O is/O a/O disorder/O of/O histone/O modification/O ,/O we/O also/O find/O alterations/O in/O DNA/O methylation/O among/O individuals/O with/O a/O Kabuki/O syndrome/O diagnosis/O relative/O to/O matched/O normal/O controls/O ,/O regardless/O of/O whether/O they/O carry/O a/O variant/O in/O KMT2A/O or/O KMT2D/O or/O not/O ./O
Furthermore/O ,/O we/O observed/O characteristic/O global/O abnormalities/O of/O DNA/O methylation/O that/O distinguished/O patients/O with/O a/O loss/O of/O function/O variant/O in/O KMT2D/O or/O missense/O or/O splice/O site/O variants/O in/O either/O KMT2D/O or/O KMT2A/O from/O normal/O controls/O ./O
Our/O results/O provide/O new/O insights/O into/O the/O relationship/O of/O genotype/O to/O epigenotype/O and/O phenotype/O and/O indicate/O cross/O -/O talk/O between/O histone/O and/O DNA/O methylation/O machineries/O exposed/O by/O inborn/O errors/O of/O the/O epigenetic/O apparatus/O ./O
A/O novel/O homozygous/O ARL13B/B-Gene variant/B-Var in/O patients/O with/O Joubert/O syndrome/O impairs/B-NegReg its/O guanine/B-MPA nucleotide/I-MPA -/I-MPA exchange/I-MPA factor/I-MPA activity/I-MPA ./O
ARL13B/O encodes/O for/O the/O ADP/O -/O ribosylation/O factor/O -/O like/O 13B/O GTPase/O ,/O which/O is/O required/O for/O normal/O cilia/O structure/O and/O Sonic/O hedgehog/O (/O Shh/O )/O signaling/O ./O
Disruptions/O in/O cilia/O structure/O or/O function/O lead/O to/O a/O class/O of/O human/O disorders/O called/O ciliopathies/O ./O
Joubert/O syndrome/O is/O characterized/O by/O a/O wide/O spectrum/O of/O symptoms/O ,/O including/O a/O variable/O degree/O of/O intellectual/O disability/O ,/O ataxia/O ,/O and/O ocular/O abnormalities/O ./O
Here/O we/O report/O a/O novel/O homozygous/O missense/O variant/O c.[223G/O >/O A/O ]/O (/O p.(Gly75Arg/O )/O in/O the/O ARL13B/O gene/O ,/O which/O was/O identified/O by/O whole/O -/O exome/O sequencing/O of/O a/O trio/O from/O a/O consanguineous/O family/O with/O multiple/O -/O affected/O individuals/O suffering/O from/O intellectual/O disability/O ,/O ataxia/O ,/O ocular/O defects/O ,/O and/O epilepsy/O ./O
The/O same/O variant/O was/O also/O identified/O in/O a/O second/O family/O ./O
We/O saw/O a/O striking/O difference/O in/O the/O severity/O of/O ataxia/O between/O affected/O male/O and/O female/O individuals/O in/O both/O families/O ./O
Both/O ARL13B/O and/O ARL13B/O -/O c.[223G/O >/O A/O ]/O (/O p.(Gly75Arg/O )/O expression/O rescued/O the/O cilia/O length/O and/O Shh/O defects/O displayed/O by/O Arl13b/O hennin/O (/O null/O )/O cells/O ,/O indicating/O that/O the/O variant/O did/O not/O disrupt/O either/O ARL13B/O function/O ./O
In/O contrast/O ,/O ARL13B/B-Var -/I-Var c.[223G/I-Var >/I-Var A/I-Var ]/I-Var (/O p.(Gly75Arg/O )/O displayed/O a/O marked/O loss/B-NegReg of/O ARL3/B-MPA guanine/I-MPA nucleotide/I-MPA -/I-MPA exchange/I-MPA factor/I-MPA activity/I-MPA ,/O with/O retention/O of/O its/O GTPase/O activities/O ,/O highlighting/O the/O correlation/O between/O its/O loss/O of/O function/O as/O an/O ARL3/O guanine/O nucleotide/O -/O exchange/O factor/O and/O Joubert/B-Disease syndrome/I-Disease ./O
Cantu/O syndrome/O -/O associated/O SUR2/O (/B-Gene ABCC9/I-Gene )/I-Gene mutations/B-Var in/O distinct/O structural/O domains/O result/O in/O KATP/B-MPA channel/I-MPA gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg by/O differential/O mechanisms/O ./O
The/O complex/O disorder/O Cantu/B-Disease syndrome/I-Disease (/O CS/O )/O arises/O from/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O either/O KCNJ8/B-Gene or/O ABCC9/B-Gene ,/O the/O genes/O encoding/O the/O Kir6.1/O and/O SUR2/O subunits/O of/O ATP/O -/O sensitive/O potassium/O (/O KATP/O )/O channels/O ,/O respectively/O ./O
Recent/O reports/O indicate/O that/O such/O mutations/B-Var can/O increase/B-PosReg channel/B-MPA activity/I-MPA by/O multiple/O molecular/O mechanisms/O ./O
In/O this/O study/O ,/O we/O determined/O the/O mechanism/O by/O which/O KATP/B-MPA function/I-MPA is/O altered/B-Reg by/O several/O substitutions/O in/O distinct/O structural/O domains/O of/O SUR2/B-Gene :/I-Gene D207E/B-Var in/O the/O intracellular/O L0-linker/O and/O Y985S/B-Var ,/O G989E/B-Var ,/O M1060I/B-Var ,/O and/O R1154Q/B-Var //I-Var R1154W/I-Var in/O TMD2/O ./O
We/O engineered/O substitutions/O at/O their/O equivalent/O positions/O in/O rat/O SUR2A/O (/O D207E/O ,/O Y981S/O ,/O G985E/O ,/O M1056I/O ,/O and/O R1150Q/O //O R1150W/O )/O and/O investigated/O functional/O consequences/O using/O macroscopic/O rubidium/O (/O 86Rb+/O )/O efflux/O assays/O and/O patch/O -/O clamp/O electrophysiology/O ./O
Our/O results/O indicate/O that/O D207E/B-Var increases/B-PosReg KATP/B-MPA channel/I-MPA activity/I-MPA by/O increasing/B-PosReg intrinsic/B-MPA stability/I-MPA of/I-MPA the/I-MPA open/I-MPA state/I-MPA ,/O whereas/O the/O cluster/O of/O Y981S/B-Var //I-Var G985E/I-Var //I-Var M1056I/I-Var substitutions/O ,/O as/O well/O as/O R1150Q/B-Var //I-Var R1150W/I-Var ,/O augmented/B-PosReg Mg/B-MPA -/I-MPA nucleotide/I-MPA activation/I-MPA ./O
We/O also/O tested/O the/O responses/O of/O these/O channel/O variants/O to/O inhibition/O by/O the/O sulfonylurea/O drug/O glibenclamide/O ,/O a/O potential/O pharmacotherapy/O for/O CS/O ./O
None/O of/O the/O D207E/O ,/O Y981S/O ,/O G985E/O ,/O or/O M1056I/O substitutions/O had/O a/O significant/O effect/O on/O glibenclamide/O sensitivity/O ./O
However/O ,/O Gln/O and/O Trp/O substitution/O at/O Arg-1150/O significantly/O decreased/O glibenclamide/O potency/O ./O
In/O summary/O ,/O these/O results/O provide/O additional/O confirmation/O that/O mutations/O in/O CS/O -/O associated/O SUR2/O mutations/O result/O in/O KATP/O gain/O -/O of/O -/O function/O ./O
They/O help/O link/O CS/O genotypes/O to/O phenotypes/O and/O shed/O light/O on/O the/O underlying/O molecular/O mechanisms/O ,/O including/O consequences/O for/O inhibitory/O drug/O sensitivity/O ,/O insights/O that/O may/O inform/O the/O development/O of/O therapeutic/O approaches/O to/O manage/O CS/O ./O
Arabidopsis/O Phospholipase/O C3/O is/O Involved/O in/O Lateral/O Root/O Initiation/O and/O ABA/O Responses/O in/O Seed/O Germination/O and/O Stomatal/O Closure/O ./O
Phospholipase/O C/O (/O PLC/O )/O is/O well/O known/O for/O its/O role/O in/O animal/O signaling/O ,/O where/O it/O generates/O the/O second/O messengers/O ,/O inositol/O 1,4,5-trisphosphate/O (/O IP3/O )/O and/O diacylglycerol/O (/O DAG/O )/O ,/O by/O hydrolyzing/O the/O minor/O phospholipid/O ,/O phosphatidylinositol/O 4,5-bisphosphate/O (/O PIP2/O )/O ,/O upon/O receptor/O stimulation/O ./O
In/O plants/O ,/O PLC/O 's/O role/O is/O still/O unclear/O ,/O especially/O because/O the/O primary/O targets/O of/O both/O second/O messengers/O are/O lacking/O ,/O i.e./O the/O ligand/O -/O gated/O Ca2/O +/O channel/O and/O protein/O kinase/O C/O ,/O and/O because/O PIP2/O levels/O are/O extremely/O low/O ./O
Nonetheless/O ,/O the/O Arabidopsis/O genome/O encodes/O nine/O PLCs/O ./O
We/O used/O a/O reversed/O -/O genetic/O approach/O to/O explore/O PLC/O 's/O function/O in/O Arabidopsis/O ,/O and/O report/O here/O that/O PLC3/B-Gene is/O required/O for/O proper/O root/O development/O ,/O seed/O germination/O and/O stomatal/O opening/O ./O
Two/O independent/O knock/B-Var -/I-Var down/I-Var mutants/I-Var ,/O plc3/O -/O 2/O and/O plc3/O -/O 3/O ,/O were/O found/O to/O exhibit/O reduced/B-NegReg lateral/B-CPA root/I-CPA densities/I-CPA by/O 10/O -/O 20/O %/O ./O
Mutant/B-Var seeds/O germinated/B-CPA more/O slowly/B-NegReg but/O were/O less/O sensitive/O to/O ABA/O to/O prevent/O germination/O ./O
Guard/O cells/O of/O plc3/O were/O also/O compromised/O in/O ABA/O -/O dependent/O stomatal/O closure/O ./O
Promoter/O -/O β/O -/O glucuronidase/O (/O GUS/O )/O analyses/O confirmed/O PLC3/O expression/O in/O guard/O cells/O and/O germinating/O seeds/O ,/O and/O revealed/O that/O the/O majority/O is/O expressed/O in/O vascular/O tissue/O ,/O most/O probably/O phloem/O companion/O cells/O ,/O in/O roots/O ,/O leaves/O and/O flowers/O ./O
In/O vivo/O 32Pi/O labeling/O revealed/O that/O ABA/O stimulated/O the/O formation/B-MPA of/I-MPA PIP2/I-MPA in/O germinating/O seeds/O and/O guard/O cell/O -/O enriched/O leaf/O peels/O ,/O which/O was/O significantly/O reduced/B-NegReg in/O plc3/B-Gene mutants/B-Var ./O
Overexpression/O of/O PLC3/O had/O no/O effect/O on/O root/O system/O architecture/O or/O seed/O germination/O ,/O but/O increased/O the/O plant/O 's/O tolerance/O to/O drought/O ./O
Our/O results/O provide/O genetic/O evidence/O for/O PLC/O 's/O involvement/O in/O plant/O development/O and/O ABA/O signaling/O ,/O and/O confirm/O earlier/O observations/O that/O overexpression/O increases/O drought/O tolerance/O ./O
Potential/O molecular/O mechanisms/O for/O the/O above/O observations/O are/O discussed/O ./O
Rare/O loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var in/O N/B-Protein -/I-Protein methyl/I-Protein -/I-Protein D/I-Protein -/I-Protein aspartate/I-Protein glutamate/I-Protein receptors/I-Protein and/O their/O contributions/O to/O schizophrenia/B-Disease susceptibility/O ./O
In/O schizophrenia/O (/O SCZ/O )/O and/O autism/O spectrum/O disorder/O (/O ASD/O )/O ,/O the/O dysregulation/O of/O glutamate/O transmission/O through/O N/O -/O methyl/O -/O D/O -/O aspartate/O receptors/O (/O NMDARs/O )/O has/O been/O implicated/O as/O a/O potential/O etiological/O mechanism/O ./O
Previous/O studies/O have/O accumulated/O evidence/O supporting/O NMDAR/O -/O encoding/O genes/O '/O role/O in/O etiology/O of/O SCZ/O and/O ASD/O ./O
We/O performed/O a/O screening/O study/O for/O exonic/O regions/O of/O GRIN1/O ,/O GRIN2A/O ,/O GRIN2C/O ,/O GRIN2D/O ,/O GRIN3A/O ,/O and/O GRIN3B/O ,/O which/O encode/O NMDAR/O subunits/O ,/O in/O 562/O participates/O (/O 370/O SCZ/O and/O 192/O ASD/O )/O ./O
Forty/O rare/O variants/O were/O identified/O including/O 38/O missense/O ,/O 1/O frameshift/O mutation/O in/O GRIN2C/O and/O 1/O splice/O site/O mutation/O in/O GRIN2D./O We/O conducted/O in/O silico/O analysis/O for/O all/O variants/O and/O detected/O seven/O missense/O variants/O with/O deleterious/O prediction/O ./O
De/O novo/O analysis/O was/O conducted/O if/O pedigree/O samples/O were/O available/O ./O
The/O splice/O site/O mutation/O in/O GRIN2D/O is/O predicted/O to/O result/O in/O intron/O retention/O by/O minigene/O assay/O ./O
Furthermore/O ,/O the/O frameshift/O mutation/O in/O GRIN2C/O and/O splice/O site/O mutation/O in/O GRIN2D/O were/O genotyped/O in/O an/O independent/O sample/O set/O comprising/O 1877/O SCZ/O cases/O ,/O 382/O ASD/O cases/O ,/O and/O 2040/O controls/O ./O
Both/O of/O them/O were/O revealed/O to/O be/O singleton/O ./O
Our/O study/O gives/O evidence/O in/O support/O of/O the/O view/O that/O ultra/O -/O rare/O variants/O with/O loss/B-NegReg of/I-NegReg function/I-NegReg (/B-Var frameshift/I-Var ,/O nonsense/B-Var or/I-Var splice/I-Var site/I-Var )/I-Var in/O NMDARs/B-Gene genes/O may/O contribute/O to/O possible/O risk/O of/O SCZ/B-Disease ./O
FRUCTOKINASE/O -/O LIKE/O PROTEIN/O 1/O interacts/O with/O TRXz/O to/O regulate/O chloroplast/O development/O in/O rice/O ./O
Chloroplast/O genes/O are/O transcribed/O by/O the/O plastid/O -/O encoded/O RNA/O polymerase/O (/O PEP/O )/O or/O nucleus/O -/O encoded/O RNA/O polymerase/O ./O
FRUCTOKINASE/O -/O LIKE/O PROTEINS/O (/O FLNs/O )/O are/O phosphofructokinase/O -/O B/O (/O PfkB)-type/O carbohydrate/O kinases/O that/O act/O as/O part/O of/O the/O PEP/O complex/O ;/O however/O ,/O the/O molecular/O mechanisms/O underlying/O FLN/O activity/O in/O rice/O remain/O elusive/O ./O
Previously/O ,/O we/O identified/O and/O characterized/O a/O heat/O -/O stress/O sensitive/O albino/O (/O hsa1/O )/O mutant/O in/O rice/O ./O
Map/O -/O based/O cloning/O revealed/O that/O HSA1/O encodes/O a/O putative/O OsFLN2/O ./O
Here/O ,/O we/O further/O demonstrated/O that/O knockdown/O or/O knockout/O of/O the/O OsFLN1/O ,/O a/O close/O homolog/O of/O HSA1/O //O OsFLN2/O ,/O considerably/O inhibits/O chloroplast/O biogenesis/O and/O the/O fln1/O knockout/O mutants/O ,/O created/O by/O clustered/O regularly/O interspaced/O short/O palindromic/O repeats/O (/O CRISPR/O )/O and/O CRISPR/O -/O associate/O protein/O 9/O ,/O exhibit/O severe/O albino/O phenotype/O and/O seedling/O lethality/O ./O
Moreover/O ,/O OsFLN1/O localizes/O to/O the/O chloroplast/O ./O
Yeast/O two/O -/O hybrid/O ,/O pull/O -/O down/O and/O bimolecular/O fluorescence/O complementation/O experiments/O revealed/O that/O OsFLN1/O and/O HSA1/O //O OsFLN2/O interact/O with/O THIOREDOXINZ/O (/O OsTRXz/O )/O to/O regulate/O chloroplast/O development/O ./O
In/O agreement/O with/O this/O ,/O knockout/O of/O OsTRXz/O resulted/O in/O a/O similar/O albino/O and/O seedling/O lethality/O phenotype/O to/O that/O of/O the/O fln1/O mutants/O ./O
Quantitative/O reverse/O transcription/O polymerase/O chain/O reaction/O and/O immunoblot/O analysis/O revealed/O that/O the/O transcription/B-MPA and/O translation/B-MPA of/O PEP/B-Gene -/I-Gene dependent/I-Gene genes/I-Gene were/O strongly/O inhibited/B-NegReg in/O fln1/B-Gene and/O trxz/O mutants/B-Var ,/O indicating/O that/O loss/O of/O OsFLN1/O ,/O HSA1/O //O OsFLN2/O ,/O or/O OsTRXz/O function/O perturbs/B-NegReg the/O stability/B-CPA of/I-CPA the/I-CPA transcriptionally/I-CPA active/I-CPA chromosome/I-CPA complex/I-CPA and/O PEP/B-Enzyme activity/B-MPA ./O
These/O results/O show/O that/O OsFLN1/O and/O HSA1/O //O OsFLN2/O contribute/O to/O chloroplast/O biogenesis/O and/O plant/O growth/O ./O
The/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O E76/B-Var K/I-Var in/O SHP2/B-Gene promotes/B-PosReg CAC/B-Disease tumorigenesis/B-CPA and/O induces/B-PosReg EMT/B-CPA via/O the/O Wnt/B-Pathway //I-Pathway β/I-Pathway -/I-Pathway catenin/I-Pathway signaling/I-Pathway pathway/I-Pathway ./O
SHP2/O is/O encoded/O by/O the/O protein/O tyrosine/O phosphatase/O 11/O (/O Ptpn11/O )/O gene/O ./O
Several/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutations/O in/O Ptpn11/O have/O been/O identified/O in/O human/O hematopoietic/O malignancies/O and/O solid/O tumors/O ./O
In/O addition/O ,/O the/O mutation/B-Var rate/O for/O SHP2/B-Gene is/O the/O highest/B-Reg for/O colorectal/B-Disease cancer/I-Disease (/O CRC/O )/O among/O solid/O tumors/O ./O
The/O E76/O K/O GOF/O mutation/O is/O the/O most/O common/O and/O active/O SHP2/O mutation/O ;/O however/O ,/O the/O pathogenic/O effects/O and/O function/O of/O this/O mutation/O in/O CRC/O tumor/O progression/O have/O not/O been/O well/O characterized/O ./O
The/O Wnt/O //O β/O -/O catenin/O (/O CTNNB1/O )/O signaling/O pathway/O is/O crucial/O for/O CRC/O ,/O and/O excessive/O activation/O of/O this/O pathway/O has/O been/O observed/O in/O several/O tumors/O ./O
We/O used/O Ptpn11E76/O K/O conditional/O knock/O -/O in/O mice/O to/O study/O this/O GOF/O mutation/O in/O colitis/O -/O associated/O CRC/O (/O CAC/O )/O and/O used/O the/O CRC/O cell/O lines/O HT29/O and/O HCT116/O to/O determine/O the/O relationship/O between/O SHP2/O and/O Wnt/O //O β/O -/O catenin/O signaling/O ./O
Ptpn11E76/B-Var K/I-Var conditional/O knock/O -/O in/O mice/O exhibited/O aggravated/B-PosReg inflammation/B-CPA and/O increased/B-PosReg CAC/B-Disease tumorigenesis/B-CPA ./O
In/O vitro/O ,/O SHP2E76/B-Var K/I-Var and/O SHP2WT/O promoted/B-PosReg malignant/B-CPA biological/I-CPA behaviors/I-CPA of/I-CPA CRC/I-CPA cells/I-CPA and/O induced/B-PosReg epithelial/B-CPA -/I-CPA mesenchymal/I-CPA transition/I-CPA (/O EMT/O )/O via/O the/O Wnt/O //O β/O -/O catenin/O signaling/O pathway/O ./O
Together/O ,/O our/O results/O showed/O that/O SHP2E76/B-Var K/I-Var acts/O as/O an/O oncogene/O that/O promotes/B-PosReg the/O tumorigenesis/B-CPA and/O metastasis/B-CPA of/O CRC/B-Disease ./O
Recessive/O loss/O of/O function/O PIGN/B-Gene alleles/O ,/O including/O an/O intragenic/O deletion/B-Var with/O founder/O effect/O in/O La/O Réunion/O Island/O ,/O in/O patients/O with/O Fryns/O syndrome/O ./O
Fryns/O syndrome/O (/O FS/O )/O is/O a/O multiple/O malformations/O syndrome/O with/O major/O features/O of/O congenital/O diaphragmatic/O hernia/O ,/O pulmonary/O hypoplasia/O ,/O craniofacial/O dysmorphic/O features/O ,/O distal/O digit/O hypoplasia/O ,/O and/O a/O range/O of/O other/O lower/O frequency/O malformations/O ./O
FS/O is/O typically/O lethal/O in/O the/O fetal/O or/O neonatal/O period/O ./O
Inheritance/O is/O presumed/O autosomal/O recessive/O ./O
Although/O no/O major/O genetic/O cause/O has/O been/O identified/O for/O FS/O ,/O biallelic/B-Var truncating/I-Var variants/I-Var in/O PIGN/B-Gene ,/O encoding/O a/O component/O of/O the/O glycosylphosphatidylinositol/O (/O GPI)-anchor/O biosynthesis/O pathway/O ,/O have/O been/O identified/B-Reg in/O a/O limited/O number/O of/O cases/O with/O a/O phenotype/O compatible/O with/O FS/B-Disease ./O
Biallelic/O variants/O in/O PIGN/B-Gene ,/O typically/O missense/B-Var or/O compound/B-Var missense/I-Var with/O truncating/B-MPA ,/O also/O cause/B-Reg multiple/B-Disease congenital/I-Disease anomalies/I-Disease -/I-Disease hypotonia/I-Disease -/I-Disease seizures/I-Disease syndrome/I-Disease 1/I-Disease (/O MCAHS1/O )/O ./O
Here/O we/O report/O six/O further/O patients/O with/O FS/O with/O or/O without/O congenital/O diaphragmatic/O hernia/O and/O recessive/O loss/O of/O function/O PIGN/O alleles/O ,/O including/O an/O intragenic/O deletion/O with/O a/O likely/O founder/O effect/O in/O La/O Réunion/O and/O other/O Indian/O Ocean/O islands/O ./O
Our/O results/O support/O the/O hypothesis/O that/O a/O spectrum/O of/O phenotypic/O severity/O is/O associated/O with/O recessive/O PIGN/O variants/O ,/O ranging/O from/O FS/O at/O the/O extreme/O end/O ,/O caused/O by/O complete/O loss/O of/O function/O ,/O to/O MCAHS1/O ,/O in/O which/O some/O residual/O PIGN/O function/O may/O remain/O ./O
Our/O data/O add/O FS/O resulting/O from/O PIGN/O variants/O to/O the/O catalog/O of/O inherited/O GPI/O deficiencies/O caused/O by/O the/O disruption/O of/O the/O GPI/O -/O anchor/O biosynthesis/O pathway/O ./O
New/O insights/O into/O ANGPLT3/O in/O controlling/O lipoprotein/O metabolism/O and/O risk/O of/O cardiovascular/O diseases/O ./O
Dyslipidemia/O ,/O characterized/O by/O elevation/O of/O plasma/O low/O density/O lipoprotein/O cholesterol/O (/O LDL/O -/O C/O )/O ,/O triglyceride/O (/O TG/O )/O and/O reduction/O of/O plasma/O high/O density/O lipoprotein/O cholesterol/O (/O HDL/O -/O C/O )/O ,/O has/O been/O verified/O as/O a/O causal/O risk/O factor/O for/O cardiovascular/O diseases/O (/O CVD/O )/O ,/O leading/O to/O a/O high/O mortality/O rate/O in/O general/O population/O ./O
It/O is/O important/O to/O understand/O the/O molecular/O metabolism/O underlying/O dyslipidemia/O in/O order/O to/O reduce/O the/O risk/O and/O to/O develop/O effective/O therapeutic/O approaches/O against/O CVD/O ./O
ANGPTL3/O (/O human/O )/O or/O Angptl3/O (/O mouse/O )/O ,/O one/O member/O of/O the/O angiopoietin/O -/O like/O protein/O (/O ANGPTL/O )/O family/O ,/O has/O been/O identified/O as/O an/O important/O regulator/O of/O lipid/O metabolism/O by/O inhibiting/O LPL/O and/O EL/O activity/O ./O
Results/O have/O demonstrated/O that/O inactivation/O of/O Angptl3/O in/O mice/O could/O obviously/O reduce/O the/O level/O of/O TG/O ,/O LDL/O -/O C/O and/O the/O atherosclerotic/O lesion/O size/O ,/O leading/O to/O a/O lower/O risk/O for/O dyslipidemia/O and/O CVD/O ./O
Additionally/O ,/O in/O humans/O ,/O carriers/O with/O homozygous/O LOF/B-NegReg mutations/B-Var in/O ANGPTL3/B-Gene have/O lower/B-NegReg plasma/B-MPA LDL/I-MPA -/I-MPA C/I-MPA ,/O TG/B-MPA levels/I-MPA and/O lower/O risk/O of/O atherosclerosis/O compared/O to/O the/O non/O -/O carriers/O ./O
Here/O ,/O we/O collect/O the/O latest/O data/O and/O results/O ,/O giving/O a/O new/O insight/O into/O the/O important/O role/O of/O ANGPTL3/O in/O controlling/O lipoprotein/O metabolism/O ./O
Finally/O ,/O we/O introduce/O two/O update/O reports/O on/O the/O antisense/O oligonucleotide/O and/O monoclonal/O antibody/O -/O based/O inactivation/O of/O ANGPTL3/O in/O human/O clinical/O trials/O ,/O to/O identify/O that/O ANGPTL3/O could/O be/O a/O novel/O and/O effective/O target/O for/O the/O treatment/O of/O dyslipidemia/O and/O CVD/O ./O
Clonal/O evolution/O mechanisms/B-Reg in/O NT5C2/B-Gene mutant/B-Disease -/I-Disease relapsed/I-Disease acute/I-Disease lymphoblastic/I-Disease leukaemia/I-Disease ./O
Relapsed/B-Disease acute/I-Disease lymphoblastic/I-Disease leukaemia/I-Disease (/O ALL/O )/O is/O associated/O with/O resistance/O to/O chemotherapy/O and/O poor/O prognosis/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O the/O 5'-nucleotidase/O ,/O cytosolic/O II/O (/B-Gene NT5C2/I-Gene )/I-Gene gene/O induce/B-PosReg resistance/B-MPA to/I-MPA 6-mercaptopurine/I-MPA and/O are/O selectively/O present/O in/O relapsed/O ALL/O ./O
Yet/O ,/O the/O mechanisms/O involved/O in/O NT5C2/O mutation/O -/O driven/O clonal/O evolution/O during/O the/O initiation/O of/O leukaemia/O ,/O disease/O progression/O and/O relapse/O remain/O unknown/O ./O
Here/O we/O use/O a/O conditional/O -/O and/O -/O inducible/O leukaemia/O model/O to/O demonstrate/O that/O expression/O of/O NT5C2(R367Q/B-Var )/I-Var ,/O a/O highly/O prevalent/O relapsed/B-Disease -/I-Disease ALL/I-Disease NT5C2/B-Gene mutation/O ,/O induces/B-PosReg resistance/B-MPA to/I-MPA chemotherapy/I-MPA with/I-MPA 6-mercaptopurine/I-MPA at/O the/O cost/O of/O impaired/O leukaemia/O cell/O growth/O and/O leukaemia/O -/O initiating/O cell/O activity/O ./O
The/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg fitness/I-NegReg phenotype/B-CPA of/O NT5C2+/R367Q/B-Var mutant/O cells/O is/O associated/O with/O excess/B-PosReg export/B-MPA of/I-MPA purines/I-MPA to/I-MPA the/I-MPA extracellular/I-MPA space/I-MPA and/O depletion/B-MPA of/I-MPA the/I-MPA intracellular/I-MPA purine/I-MPA -/I-MPA nucleotide/I-MPA pool/I-MPA ./O
Consequently/O ,/O blocking/O guanosine/O synthesis/O by/O inhibition/O of/O inosine-5'-monophosphate/O dehydrogenase/O (/O IMPDH/O )/O induced/O increased/O cytotoxicity/O against/O NT5C2-mutant/O leukaemia/O lymphoblasts/O ./O
These/O results/O identify/O the/O fitness/O cost/O of/O NT5C2/O mutation/O and/O resistance/O to/O chemotherapy/O as/O key/O evolutionary/O drivers/O that/O shape/O clonal/O evolution/O in/O relapsed/O ALL/O and/O support/O a/O role/O for/O IMPDH/O inhibition/O in/O the/O treatment/O of/O ALL/O ./O
The/O protective/O role/O of/O DOT1L/O in/O UV/O -/O induced/O melanomagenesis/O ./O
The/O DOT1L/O histone/O H3/O lysine/O 79/O (/O H3K79/O )/O methyltransferase/O plays/O an/O oncogenic/O role/O in/O MLL/O -/O rearranged/O leukemogenesis/O ./O
Here/O ,/O we/O demonstrate/O that/O ,/O in/O contrast/O to/O MLL/O -/O rearranged/O leukemia/O ,/O DOT1L/O plays/O a/O protective/O role/O in/O ultraviolet/O radiation/O (/O UVR)-induced/O melanoma/O development/O ./O
Specifically/O ,/O the/O DOT1L/B-Gene gene/O is/O located/O in/O a/O frequently/O deleted/O region/O and/O undergoes/O somatic/O mutation/O in/O human/O melanoma/O ./O
Specific/O mutations/B-Var functionally/O compromise/B-NegReg DOT1L/B-Gene methyltransferase/B-Enzyme enzyme/I-Enzyme activity/B-MPA leading/O to/O reduced/B-NegReg H3K79/B-Protein methylation/B-MPA ./O
Importantly/O ,/O in/O the/O absence/O of/O DOT1L/O ,/O UVR/O -/O induced/O DNA/O damage/O is/O inefficiently/O repaired/O ,/O so/O that/O DOT1L/B-Gene loss/B-NegReg promotes/B-PosReg melanoma/B-CPA development/I-CPA in/O mice/O after/O exposure/O to/O UVR/O ./O
Mechanistically/O ,/O DOT1L/O facilitates/O DNA/O damage/O repair/O ,/O with/O DOT1L/O -/O methylated/O H3K79/O involvement/O in/O binding/O and/O recruiting/O XPC/O to/O the/O DNA/O damage/O site/O for/O nucleotide/O excision/O repair/O (/O NER/O )/O ./O
This/O study/O indicates/O that/O DOT1L/O plays/O a/O protective/O role/O in/O UVR/O -/O induced/O melanomagenesis/O ./O
Biallelic/B-Var variants/I-Var in/O KIF14/B-Gene cause/B-Reg intellectual/B-Disease disability/I-Disease with/O microcephaly/B-Disease ./O
Kinesin/O proteins/O are/O critical/O for/O various/O cellular/O functions/O such/O as/O intracellular/O transport/O and/O cell/O division/O ,/O and/O many/O members/O of/O the/O family/O have/O been/O linked/O to/O monogenic/O disorders/O and/O cancer/O ./O
We/O report/O eight/O individuals/O with/O intellectual/O disability/O and/O microcephaly/O from/O four/O unrelated/O families/O with/O parental/O consanguinity/O ./O
In/O the/O affected/O individuals/O of/O each/O family/O ,/O homozygosity/O for/O likely/O pathogenic/B-CPA variants/O in/O KIF14/B-Gene were/O detected/O ;/O two/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/B-Var p/I-Var ./I-Var Asn83Ilefs*3/I-Var and/O p/B-Var ./I-Var Ser1478fs/I-Var )/I-Var ,/O and/O two/O missense/B-Reg substitutions/I-Reg (/B-Var p/I-Var ./I-Var Ser841Phe/I-Var and/O p/B-Var ./I-Var Gly459Arg/I-Var )/I-Var ./O
KIF14/O is/O a/O mitotic/O motor/O protein/O that/O is/O required/O for/O spindle/O localization/O of/O the/O mitotic/O citron/O rho/O -/O interacting/O kinase/O ,/O CIT/B-Gene ,/O also/O mutated/B-Var in/B-Reg microcephaly/B-Disease ./O
Our/O results/O demonstrate/O the/O involvement/O of/O KIF14/O in/O development/O and/O reveal/O a/O wide/O phenotypic/O variability/O ranging/O from/O fetal/O lethality/O to/O moderate/O developmental/O delay/O and/O microcephaly/O ./O
APOC3/B-Gene Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg Mutations/B-Var ,/O Remnant/O Cholesterol/O ,/O Low/O -/O Density/O Lipoprotein/O Cholesterol/O ,/O and/O Cardiovascular/O Risk/O :/O Mediation-/O and/O Meta/O -/O Analyses/O of/O 137/O 895/O Individuals/O ./O
OBJECTIVE/O :/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O APOC3/B-Gene associate/O with/O low/B-NegReg remnant/B-MPA cholesterol/I-MPA levels/I-MPA and/O low/O risk/O of/O ischemic/O vascular/O disease/O (/O IVD/O )/O ./O
Because/O some/O studies/O show/O an/O additional/O association/O with/O low/O levels/O of/O low/O -/O density/O lipoprotein/O cholesterol/O (/O LDL/O -/O C/O )/O ,/O low/O LDL/O -/O C/O may/O explain/O the/O low/O risk/O of/O IVD/O in/O APOC3/O loss/O -/O of/O -/O function/O heterozygotes/O ./O
We/O tested/O to/O what/O extent/O the/O low/O risk/O of/O IVD/O in/O APOC3/O loss/O -/O of/O -/O function/O heterozygotes/O is/O mediated/O by/O low/O plasma/O remnant/O cholesterol/O and/O LDL/O -/O C./O APPROACH/O AND/O RESULTS/O :/O In/O APOC3/O loss/O -/O of/O -/O function/O heterozygotes/O versus/O noncarriers/O ,/O we/O first/O determined/O remnant/O cholesterol/O and/O LDL/O -/O C/O levels/O in/O meta/O -/O analyses/O of/O 137/O 895/O individuals/O ./O
Second/O ,/O we/O determined/O whether/O the/O association/O with/O LDL/O -/O C/O was/O masked/O by/O lipid/O -/O lowering/O therapy/O ./O
Finally/O ,/O using/O mediation/O analysis/O ,/O we/O determined/O the/O fraction/O of/O the/O low/O risk/O of/O IVD/O and/O ischemic/O heart/O disease/O mediated/O by/O remnant/O cholesterol/O and/O LDL/O -/O C./O In/O meta/O -/O analyses/O ,/O remnant/O cholesterol/O was/O 43/O %/O lower/O (/O 95/O %/O confidence/O interval/O ,/O 40%-47/O %/O )/O ,/O and/O LDL/O -/O C/O was/O 4/O %/O lower/O (/O 1%-6/O %/O )/O in/O loss/O -/O of/O -/O function/O heterozygotes/O (/O n=776/O )/O versus/O noncarriers/O ./O
In/O the/O general/O population/O ,/O LDL/O -/O C/O was/O 3/O %/O lower/O in/O loss/O -/O of/O -/O function/O heterozygotes/O versus/O noncarriers/O ,/O 4/O %/O lower/O when/O correcting/O for/O lipid/O -/O lowering/O therapy/O ,/O and/O 3/O %/O lower/O in/O untreated/O individuals/O (/O P/O values/O ,/O 0.06/O -/O 0.008/O )/O ./O
Remnant/O cholesterol/O mediated/O 37/O %/O of/O the/O observed/O 41/O %/O lower/O risk/O of/O IVD/O and/O 54/O %/O of/O the/O observed/O 36/O %/O lower/O risk/O of/O ischemic/O heart/O disease/O ;/O corresponding/O values/O mediated/O by/O LDL/O -/O C/O were/O 1/O %/O and/O 2/O %/O ./O
CONCLUSIONS/O :/O The/O low/O risk/O of/O IVD/O observed/O in/O APOC3/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg heterozygotes/O is/O mainly/O mediated/O by/O the/O associated/O low/B-NegReg remnant/B-MPA cholesterol/I-MPA and/O not/O by/O low/O LDL/O -/O C./O Furthermore/O ,/O the/O contribution/O of/O LDL/O -/O C/O to/O IVD/O risk/O was/O not/O masked/O by/O lipid/O -/O lowering/O therapy/O ./O
This/O suggests/O APOC3/O and/O remnant/O cholesterol/O as/O important/O new/O targets/O for/O reducing/O cardiovascular/O risk/O ./O
Key/O apoptotic/B-Gene genes/I-Gene APAF1/B-Gene and/O CASP9/B-Gene implicated/O in/O recurrent/O folate/O -/O resistant/O neural/O tube/O defects/O ./O
Neural/O tube/O defects/O (/O NTDs/O )/O remain/O one/O of/O the/O most/O serious/O birth/O defects/O ,/O and/O although/O genes/O in/O several/O pathways/O have/O been/O implicated/O as/O risk/O factors/O for/O neural/O tube/O defects/O via/O knockout/O mouse/O models/O ,/O very/O few/O molecular/O causes/O in/O humans/O have/O been/O identified/O ./O
Whole/O exome/O sequencing/O identified/O deleterious/O variants/O in/O key/O apoptotic/O genes/O in/O two/O families/O with/O recurrent/O neural/O tube/O defects/O ./O
Functional/O studies/O in/O fibroblasts/O indicate/O that/O these/O variants/B-Var are/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg ,/O as/O apoptosis/B-CPA is/O significantly/O reduced/B-NegReg ./O
This/O is/O the/O first/O report/O of/O variants/B-Var in/O apoptotic/B-Gene genes/I-Gene contributing/B-Reg to/O neural/B-Disease tube/I-Disease defect/I-Disease risk/O in/O humans/O ./O
Congenital/O diaphragmatic/O hernia/O as/O a/O part/O of/O Nance/O -/O Horan/O syndrome/O ?/O Nance/O -/O Horan/O syndrome/O is/O a/O rare/O X/O -/O linked/O developmental/O disorder/O characterized/O by/O bilateral/O congenital/O cataract/O ,/O dental/O anomalies/O ,/O facial/O dysmorphism/O ,/O and/O intellectual/O disability/O ./O
Here/O ,/O we/O identify/O a/O patient/O with/O Nance/B-Disease -/I-Disease Horan/I-Disease syndrome/I-Disease caused/B-Reg by/I-Reg a/O new/O nonsense/B-Var NHS/B-Gene variant/O ./O
In/O addition/O ,/O the/O patient/O presented/O congenital/B-Disease diaphragmatic/I-Disease hernia/I-Disease ./O
NHS/O gene/O expression/O in/O murine/O fetal/O diaphragm/O was/O demonstrated/O ,/O suggesting/O a/O possible/O involvement/O of/O NHS/O in/O diaphragm/O development/O ./O
Congenital/B-Disease diaphragmatic/I-Disease hernia/I-Disease could/O result/B-Reg from/I-Reg NHS/B-Gene loss/B-NegReg of/I-NegReg function/I-NegReg in/O pleuroperitoneal/O fold/O or/O in/O somites/O -/O derived/O muscle/O progenitor/O cells/O leading/O to/O an/O impairment/O of/O their/O cells/B-CPA migration/I-CPA ./O
[/O The/O formation/O of/O skin/O barrier/O and/O defective/O barrier/O -/O associated/O skin/O diseases/O ]/O ./O
Since/O the/O discovery/O of/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O filaggrin/O (/B-Gene FLG/I-Gene )/I-Gene gene/O in/O atopic/B-Disease dermatitis/I-Disease (/O AD/O )/O individuals/O ,/O significant/O attention/O has/O been/O paid/O against/O the/O skin/O barrier/O as/O an/O initial/O starting/O point/O of/O atopic/O march/O ./O
Although/O FLG/O is/O a/O significant/O cornification/O -/O associated/O gene/O ,/O skin/O barrier/O formation/O is/O a/O complex/O process/O mediated/O by/O an/O array/O of/O genes/O with/O specific/O functions/O ./O
In/O this/O article/O ,/O the/O mechanism/O of/O physical/O skin/O barrier/O formation/O is/O reviewed/O in/O detail/O ,/O focusing/O on/O specific/O gene/O functions/O and/O inherited/O disorders/O caused/O by/O genetic/O aberrations/O ./O
Additionally/O ,/O the/O mechanism/O of/O percutaneous/O sensitization/O with/O environmental/O allergens/O in/O association/O with/O FLG/O -/O deficiency/O is/O reviewed/O in/O order/O to/O clarify/O the/O link/O between/O defective/O skin/O barrier/O and/O atopic/O march/O ./O
Finally/O ,/O updated/O knowledge/O of/O psoriasis/O pathophysiology/O in/O connection/O with/O genetic/O defect/O in/O skin/O barrier/O is/O reviewed/O ./O
This/O article/O would/O provide/O a/O novel/O opportunity/O to/O understand/O the/O allergic/O //O autoimmune/O disorders/O from/O the/O viewpoint/O of/O non/O -/O classical/O immune/O cells/O ./O
Tryptophan/O hydroxylase/O (/B-Gene TRH/I-Gene )/I-Gene loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var induce/O growth/B-CPA and/I-CPA behavioral/I-CPA defects/I-CPA in/O Daphnia/O magna/O ./O
Tryptophan/O hydroxylase/O (/O TRH/O )/O is/O the/O rate/O limiting/O enzyme/O in/O the/O serotonin/O synthesis/O ./O
CRISPR/O -/O Cas9/O technology/O was/O used/O to/O generate/O seven/O indel/O TRH/O mutants/O in/O Daphnia/O magna/O ./O
Mono/O -/O allelic/O indel/O TRH-/+/O clones/O showed/O normal/O levels/O of/O serotonin/O ,/O measured/O by/O both/O immunohistochemistry/O and/O mass/O spectrometry/O (/O LC/O -/O MS/O //O MS/O )/O ,/O whereas/O bi/O -/O allelic/O indel/O TRH-/-/O clones/O showed/O no/O detectable/O levels/O of/O serotonin/O ./O
Life/O history/O and/O behavioral/O responses/O of/O TRH-/-/O clones/O showed/O the/O anti/O -/O phenotype/O of/O those/O exposed/O to/O selective/O serotonin/O reuptake/O inhibitors/O (/O SSRI/O )/O ./O
Mutants/B-Var lacking/B-NegReg serotonin/B-MPA grew/B-CPA less/B-NegReg and/O hence/O reproduced/B-CPA latter/O ,/O produced/O smaller/B-NegReg clutches/B-CPA of/O smaller/B-NegReg offspring/B-CPA and/O responded/O to/O a/O greater/O extent/O to/O light/O than/O wild/O type/O individuals/O ./O
Mono/O -/O allelic/O indel/O TRH-/+/O individuals/O showed/O the/O intermediate/O phenotype/O ./O
The/O SSRI/O fluoxetine/O enhanced/O offspring/O production/O in/O all/O clones/O and/O decreased/O the/O response/O to/O light/O only/O in/O those/O clones/O having/O serotonin/O ,/O thus/O indication/O that/O behavioral/O effects/O of/O this/O drug/O in/O D./O magna/O are/O associated/O to/O serotonin/O ./O
Results/O obtained/O with/O the/O TRH/O mutants/O are/O in/O line/O with/O reported/O ones/O in/O TRH/O knockouts/O of/O Caenorhabditis/O elegans/O ,/O Drosophila/O and/O mice/O ,/O indicating/O that/O there/O is/O one/O gene/O encoding/O TRH/O ,/O which/O is/O the/O serotonin/O limiting/O enzyme/O in/O both/O the/O central/O and/O the/O periphery/O nervous/O system/O in/O Daphnia/O and/O that/O deprivation/O of/O serotonin/O increases/O anxiety/O -/O like/O behavior/O ./O
Internal/B-Var tandem/I-Var duplication/I-Var mutations/I-Var in/O the/O tyrosine/O kinase/O domain/O of/O FLT3/B-Gene display/O a/O higher/B-PosReg oncogenic/B-CPA potential/I-CPA than/O the/O activation/O loop/O D835Y/O mutation/O ./O
Acute/B-Disease myeloid/I-Disease leukemia/I-Disease (/O AML/O )/O remains/O the/O most/O common/O form/O of/O acute/O leukemia/O among/O adults/O and/O accounts/O for/O a/O large/O number/O of/O leukemia/O -/O related/O deaths/O ./O
Mutations/B-Var in/O FMS/O -/O like/O tyrosine/O kinase/O 3/O (/B-Gene FLT3/I-Gene )/I-Gene is/O one/O of/O the/O most/O prevalent/B-Reg findings/O in/O this/O heterogeneous/O disease/O ./O
The/O major/O types/O of/O mutations/O in/O FLT3/O can/O be/O categorized/O as/O internal/O tandem/O duplications/O (/O ITD/O )/O and/O point/O mutations/O ./O
Recent/O studies/O suggest/O that/O ITDs/O not/O only/O occur/O in/O the/O juxtamembrane/O region/O as/O originally/O described/O ,/O but/O also/O in/O the/O kinase/O domain/O ./O
Although/O the/O juxtamembrane/O ITDs/O have/O been/O well/O characterized/O ,/O the/O tyrosine/O kinase/O domain/O ITDs/O have/O not/O yet/O been/O thoroughly/O studied/O due/O to/O their/O recent/O discovery/O ./O
For/O this/O reason/O ,/O we/O compared/O ITD/O mutations/O in/O the/O juxtamembrane/O domain/O with/O those/O in/O the/O tyrosine/O kinase/O domain/O ,/O as/O well/O as/O with/O the/O most/O common/O activating/O point/O mutation/O in/O the/O tyrosine/O kinase/O domain/O ,/O D835Y./O The/O purpose/O of/O this/O study/O was/O to/O understand/O whether/O it/O is/O the/O nature/O of/O the/O mutation/O or/O the/O location/O of/O the/O mutation/O that/O plays/O the/O main/O role/O in/O leukemogenesis/O ./O
The/O various/O FLT3/O mutants/O were/O expressed/O in/O the/O murine/O pro/O -/O B/O cell/O line/O Ba/O //O F3/O and/O examined/O for/O their/O capacity/O to/O form/O colonies/O in/O semisolid/O medium/O ./O
The/O size/O and/O number/O of/O colonies/O formed/O by/O Ba/O //O F3/O cells/O expressing/O either/O the/O internal/O tandem/O duplication/O within/O juxtamembrane/O domain/O of/O the/O receptor/O (/O JMD/O -/O ITD/O )/O or/O the/O tyrosine/O kinase/O domain/O (/O TKD)-ITD/O were/O indistinguishable/O ,/O while/O Ba/O //O F3/O cells/O expressing/O D835Y/O //O FLT3/O failed/O to/O form/O colonies/O ./O
Cell/B-CPA proliferation/I-CPA and/O cell/B-CPA survival/I-CPA was/O also/O significantly/O higher/B-PosReg in/O TKD/B-Var -/I-Var ITD/I-Var expressing/O cells/O ,/O compared/O to/O cells/O expressing/O D835Y/O //O FLT3/O ./O
Furthermore/O ,/O TKD/B-Var -/I-Var ITD/I-Var is/O capable/O of/O inducing/B-PosReg phosphorylation/B-MPA of/O STAT5/B-Protein ,/O while/O D835Y/O //O FLT3/O fails/O to/O induce/O tyrosine/O phosphorylation/O of/O STAT5/O ./O
Other/O signal/O transduction/O pathways/O such/O as/O the/O RAS/O //O ERK/O and/O the/O PI3K/O //O AKT/O pathways/O were/O activated/O to/O the/O same/O level/O in/O TKD/O -/O ITD/O cells/O as/O compared/O to/O D835Y/O //O FLT3/O expressing/O cells/O ./O
Taken/O together/O ,/O our/O data/O suggest/O that/O TKD/O -/O ITD/O displays/O similar/O oncogenic/O potential/O to/O the/O JMD/O -/O ITD/O but/O a/O higher/O oncogenic/O potential/O than/O the/O D835Y/O point/O mutation/O ./O
Reversal/O of/O end/O -/O stage/O heart/O failure/O in/O juvenile/O hemochromatosis/O with/O iron/O chelation/O therapy/O :/O a/O case/O report/O ./O
BACKGROUND/O :/O Juvenile/O hemochromatosis/O is/O the/O most/O severe/O form/O of/O iron/O overloading/O phenotype/O ./O
Although/O rare/O ,/O it/O should/O be/O suspected/O in/O patients/O who/O present/O with/O hypogonadotropic/O hypogonadism/O ,/O diabetes/O mellitus/O ,/O or/O cardiomyopathy/O without/O a/O clear/O cause/O ./O
CASE/O PRESENTATION/O :/O A/O young/O Serbian/O male/O presenting/O with/O end/O -/O stage/O heart/O failure/O was/O referred/O for/O extracorporeal/O membrane/O oxygenation/O ./O
An/O endomyocardial/O biopsy/O revealed/O cytoplasmic/O iron/O deposits/O in/O myocytes/O ./O
His/O condition/O was/O stabilized/O with/O biventricular/O assist/O devices/O and/O he/O was/O listed/O for/O heart/O transplantation/O ./O
Iron/O chelation/O therapy/O was/O commenced/O and/O resulted/O in/O rapid/O removal/O of/O iron/O burden/O ./O
Serial/O outpatient/O echocardiograms/O demonstrated/O myocardial/O recovery/O such/O that/O a/O successful/O biventricular/O assist/O device/O explant/O occurred/O 131/O days/O after/O initial/O implant/O ./O
Targeted/O gene/O sequencing/O revealed/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var within/O the/O HJV/B-Gene gene/O ,/O which/O is/O consistent/O with/O juvenile/B-Disease hemochromatosis/I-Disease ./O
CONCLUSIONS/O :/O This/O rare/O case/O of/O a/O patient/O with/O juvenile/B-Disease hemochromatosis/I-Disease associated/B-Reg with/O a/O HJV/B-Gene mutation/B-Var provides/O histologic/O evidence/O documenting/O the/O reversal/O of/O associated/O end/O -/O stage/O heart/O failure/O ,/O requiring/O emergent/O mechanical/O circulatory/O support/O ,/O with/O iron/O chelation/O therapy/O ./O
TRPV1/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var impairs/B-NegReg pain/B-CPA and/I-CPA itch/I-CPA sensations/I-CPA in/O mice/O ./O
Transient/O receptor/O potential/O vanilloid/O 1/O (/O TRPV1/O )/O is/O a/O non/O -/O selective/O cation/O channel/O ,/O which/O can/O detect/O various/O noxious/O stimuli/O that/O cause/O pain/O ,/O inflammation/O ,/O hyperalgesia/O ,/O and/O itch/O ./O
TRPV1/O knock/O -/O out/O mice/O show/O deficiency/O in/O nociception/O ,/O but/O the/O in/O vivo/O effects/O of/O persistent/O activation/O of/O TRPV1/O are/O not/O completely/O understood/O ./O
Here/O ,/O we/O generated/O TRPV1/O knock/O -/O in/O mice/O with/O a/O G564S/O mutation/O ./O
In/O the/O heterologous/O expression/O system/O ,/O an/O electrophysiological/O study/O showed/O that/O the/O G564S/B-Var mutation/O in/O mouse/O TRPV1/B-Gene caused/O increased/B-PosReg basal/B-CPA current/I-CPA and/O a/O leftward/B-CPA shift/I-CPA of/I-CPA voltage/I-CPA dependence/I-CPA ./O
Intriguingly/O ,/O using/O behavioral/O analysis/O ,/O we/O found/O that/O knock/O -/O in/O mice/O showed/O a/O thermosensory/B-CPA defect/B-NegReg ,/O impaired/B-NegReg inflammatory/B-MPA thermal/I-MPA pain/I-MPA ,/O and/O capsaicin/B-CPA sensitivity/I-CPA ./O
We/O also/O demonstrated/O an/O attenuated/O behavioral/O response/O to/O the/O pruritic/O agent/O histamine/O in/O the/O knock/O -/O in/O mice/O ./O
Indeed/O ,/O calcium/O imaging/O together/O with/O electrophysiology/O showed/O that/O the/O overactive/O mutant/O had/O decreased/O capsaicin/O sensitivity/O ./O
Western/O blot/O analysis/O revealed/O that/O the/O G564S/B-Var mutant/O reduced/B-NegReg TRPV1/B-Protein phosphorylation/B-MPA and/O cell/B-CPA membrane/I-CPA trafficking/I-CPA ./O
Together/O ,/O we/O have/O generated/O a/O mouse/O model/O with/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O Trpv1/B-Gene gene/O and/O demonstrated/O that/O the/O pain/B-CPA and/I-CPA histamine/I-CPA -/I-CPA dependent/I-CPA itch/I-CPA sensations/I-CPA in/O these/O mice/O are/O impaired/B-NegReg due/O to/O a/O decreased/B-NegReg phosphorylation/B-MPA level/I-MPA and/O reduced/B-NegReg membrane/B-MPA localization/I-MPA of/O TRPV1/B-Protein ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg Mutations/B-Var in/O UNC45A/B-Gene Cause/O a/O Syndrome/B-Disease Associating/O Cholestasis/B-Disease ,/O Diarrhea/B-Disease ,/O Impaired/B-Disease Hearing/I-Disease ,/O and/O Bone/B-Disease Fragility/I-Disease ./O
Despite/O the/O rapid/O discovery/O of/O genes/O for/O rare/O genetic/O disorders/O ,/O we/O continue/O to/O encounter/O individuals/O presenting/O with/O syndromic/O manifestations/O ./O
Here/O ,/O we/O have/O studied/O four/O affected/O people/O in/O three/O families/O presenting/O with/O cholestasis/B-Disease ,/O congenital/B-Disease diarrhea/I-Disease ,/O impaired/B-Disease hearing/I-Disease ,/O and/O bone/B-Disease fragility/I-Disease ./O
Whole/O -/O exome/O sequencing/O of/O all/O affected/O individuals/O and/O their/O parents/O identified/O biallelic/B-Var mutations/I-Var in/O Unc-45/O Myosin/O Chaperone/O A/O (/B-Gene UNC45A/I-Gene )/I-Gene as/O a/O likely/O driver/O for/O this/O disorder/O ./O
Subsequent/O in/O vitro/O and/O in/O vivo/O functional/O studies/O of/O the/O candidate/O gene/O indicated/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg paradigm/O ,/O wherein/O mutations/O attenuated/B-NegReg or/O abolished/B-NegReg protein/B-Protein activity/B-MPA with/O concomitant/O defects/B-NegReg in/O gut/B-CPA development/I-CPA and/O function/O ./O
Loss/O -/O of/O -/O function/O and/O gain/O -/O of/O -/O function/O mutations/O in/O PPP3CA/O cause/O two/O distinct/O disorders/O ./O
Calcineurin/O is/O a/O calcium/O (/O Ca2+)/calmodulin/O -/O regulated/O protein/O phosphatase/O that/O mediates/O Ca2/O +/O -dependent/O signal/O transduction/O ./O
Here/O ,/O we/O report/O six/O heterozygous/O mutations/O in/O a/O gene/O encoding/O the/O alpha/O isoform/O of/O the/O calcineurin/O catalytic/O subunit/O (/O PPP3CA/O )/O ./O
Notably/O ,/O mutations/O were/O observed/O in/O different/O functional/O domains/O :/O in/O addition/O to/O three/O catalytic/O domain/O mutations/O ,/O two/O missense/O mutations/O were/O found/O in/O the/O auto/O -/O inhibitory/O (/O AI/O )/O domain/O ./O
One/O additional/O frameshift/O insertion/O that/O caused/O premature/O termination/O was/O also/O identified/O ./O
Detailed/O clinical/O evaluation/O of/O the/O six/O individuals/O revealed/O clinically/O unexpected/O consequences/O of/O the/O PPP3CA/B-Gene mutations/O ./O
First/O ,/O the/O catalytic/B-Var domain/I-Var mutations/I-Var and/O frameshift/B-Var mutation/I-Var were/O consistently/O found/B-Reg in/O patients/O with/O nonsyndromic/B-Disease early/I-Disease onset/I-Disease epileptic/I-Disease encephalopathy/I-Disease ./O
In/O contrast/O ,/O the/O AI/B-Var domain/I-Var mutations/I-Var were/O associated/B-Reg with/O multiple/B-Disease congenital/I-Disease abnormalities/I-Disease including/O craniofacial/B-Disease dysmorphism/I-Disease ,/O arthrogryposis/B-Disease and/O short/B-Disease stature/I-Disease ./O
In/O addition/O ,/O one/O individual/O showed/O severe/O skeletal/O developmental/O defects/O ,/O namely/O ,/O severe/O craniosynostosis/O and/O gracile/O bones/O (/O severe/O bone/O slenderness/O and/O perinatal/O fractures/O )/O ./O
Using/O a/O yeast/O model/O system/O ,/O we/O showed/O that/O the/O catalytic/O and/O AI/B-Var domain/I-Var mutations/I-Var visibly/O result/O in/O decreased/O and/O increased/B-PosReg calcineurin/B-MPA signaling/I-MPA ,/O respectively/O ./O
These/O findings/O indicate/O that/O different/O functional/O effects/O of/O PPP3CA/B-Gene mutations/O are/O associated/O with/O two/O distinct/O disorders/O and/O suggest/O that/O functional/O approaches/O using/O a/O simple/O cellular/O system/O provide/O a/O tool/O for/O resolving/O complex/O genotype/O -/O phenotype/O correlations/O ./O
Genetic/O Suppression/O of/O Basement/O Membrane/O Defects/O in/O Caenorhabditis/O elegans/O by/O Gain/O of/O Function/O in/O Extracellular/O Matrix/O and/O Cell/O -/O Matrix/O Attachment/O Genes/O ./O
Basement/O membranes/O are/O extracellular/O matrices/O essential/O for/O embryonic/O development/O in/O animals/O ./O
Peroxidasins/O are/O extracellular/O peroxidases/O implicated/O in/O the/O unique/O sulfilimine/O cross/O -/O links/O between/O type/O IV/O basement/O membrane/O collagens/O ./O
Loss/B-NegReg of/I-NegReg function/I-NegReg in/O the/O Caenorhabditis/B-Enzyme elegans/I-Enzyme peroxidasin/I-Enzyme PXN-2/I-Enzyme results/O in/O fully/B-CPA penetrant/I-CPA embryonic/I-CPA or/O larval/B-CPA lethality/I-CPA ./O
Using/O genetic/O suppressor/O screening/O ,/O we/O find/O that/O the/O requirement/O for/O PXN-2/O in/O development/O can/O be/O bypassed/O by/O gain/O of/O function/O in/O multiple/O genes/O encoding/O other/O basement/O membrane/O components/O ,/O or/O proteins/O implicated/O in/O cell/O -/O matrix/O attachment/O ./O
We/O identify/O multiple/O alleles/O of/O let-805/O ,/O encoding/O the/O transmembrane/O protein/O myotactin/O ,/O which/O suppress/O phenotypes/O of/O pxn-2/O null/O mutants/O and/O of/O other/O basement/O membrane/O mutants/O such/O as/O F/O -/O spondin/O //O spon-1/O These/O let-805/B-Gene suppressor/O alleles/O cause/O missense/B-Var alterations/I-Var in/O two/O pairs/O of/O FNIII/O repeats/O in/O the/O extracellular/O domain/O ;/O they/O act/O dominantly/O and/O have/O no/O detectable/O phenotypes/O alone/O ,/O suggesting/O they/O cause/O gain/B-PosReg of/I-PosReg function/I-PosReg ./O
We/O also/O identify/O suppressor/O missense/O mutations/O affecting/O basement/O membrane/O components/O type/O IV/O collagen/O (/O emb-9/O ,/O let-2/O )/O and/O perlecan/O (/O unc-52/O )/O ,/O as/O well/O as/O a/O mutation/O affecting/O spectraplakin/O (/O vab-10/O )/O ,/O a/O component/O of/O the/O epidermal/O cytoskeleton/O ./O
These/O suppressor/O alleles/O do/O not/O bypass/O the/O developmental/O requirement/O for/O core/O structural/O proteins/O of/O the/O basement/O membrane/O such/O as/O laminin/O or/O type/O IV/O collagen/O ./O
In/O conclusion/O ,/O putative/O gain/O -/O of/O -/O function/O alterations/O in/O matrix/O proteins/O or/O in/O cell/O -/O matrix/O receptors/O can/O overcome/O the/O requirement/O for/O certain/O basement/O membrane/O proteins/O in/O embryonic/O development/O ,/O revealing/O previously/O unknown/O plasticity/O in/O the/O genetic/O requirements/O for/O the/O extracellular/O matrix/O ./O
Biallelic/B-Var inactivating/I-Var variants/I-Var in/O the/O GTPBP2/B-Gene gene/O cause/B-Reg a/O neurodevelopmental/B-Disease disorder/I-Disease with/O severe/O intellectual/O disability/O ./O
Congenital/O neurological/O disorders/O are/O genetically/O highly/O heterogeneous/O ./O
Rare/O forms/O of/O hereditary/O neurological/O disorders/O are/O still/O difficult/O to/O be/O adequately/O diagnosed/O ./O
Pertinent/O studies/O ,/O especially/O when/O reporting/O only/O single/O families/O ,/O need/O independent/O confirmation/O ./O
We/O present/O three/O unrelated/O families/O in/O which/O whole/O -/O exome/O sequencing/O identified/O the/O homozygous/O non/O -/O sense/O variants/O c.430[C/B-Var >/I-Var T];[C/I-Var >/I-Var T/I-Var ]/I-Var p.(Arg144/I-Var */I-Var )/I-Var ,/O c.1219[C/B-Var >/I-Var T];[C/I-Var >/I-Var T/I-Var ]/I-Var p.(Gln407/I-Var */I-Var )/I-Var and/O c.1408[C/B-Var >/I-Var T];[C/I-Var >/I-Var T/I-Var ]/I-Var p.(Arg470/I-Var */I-Var )/I-Var in/O GTPBP2/B-Gene ./O
Their/O clinical/O presentations/O include/O early/O onset/O and/O apparently/O non/B-CPA -/I-CPA progressive/I-CPA motor/I-CPA and/I-CPA cognitive/I-CPA impairment/I-CPA ,/O and/O thereby/O overlap/O with/O findings/O in/O a/O recently/O described/O family/O harbouring/O a/O homozygous/O GTPBP2/O splice/O site/O variant/O ./O
Notable/O differences/O include/O structural/B-CPA brain/I-CPA abnormalities/I-CPA (/O e.g./O ,/O agenesis/B-CPA of/I-CPA the/I-CPA corpus/I-CPA callosum/I-CPA ,/O exclusive/O to/O our/O patients/O )/O ,/O and/O evidence/O for/O brain/B-CPA iron/I-CPA accumulation/I-CPA (/O exclusive/O to/O the/O previously/O described/O family/O )/O ./O
This/O report/O confirms/O pathogenicity/O of/O biallelic/O GTPBP2/O inactivation/O and/O broadens/O the/O phenotypic/O spectrum/O ./O
It/O also/O underlines/O that/O a/O potential/O involvement/O of/O brain/O iron/O accumulation/O needs/O clarification/O ./O
Further/O patients/O will/O have/O to/O be/O identified/O and/O characterised/O in/O order/O to/O fully/O define/O the/O core/O features/O of/O GTPBP2-associated/O neurological/O disorder/O ,/O but/O future/O approaches/O to/O molecular/O diagnosis/O of/O neurodevelopmental/O disorders/O should/O implement/O GTPBP2/O ./O
Bi/B-Var -/I-Var allelic/I-Var inactivating/I-Var variants/I-Var in/O the/O COCH/B-Gene gene/O cause/B-Reg autosomal/B-Disease recessive/I-Disease prelingual/I-Disease hearing/I-Disease impairment/I-Disease ./O
Pathogenic/O variant/O in/O COCH/O are/O a/O known/O cause/O of/O DFNA9/O autosomal/O dominant/O progressive/O hearing/O loss/O and/O vestibular/O dysfunction/O with/O adult/O onset/O ./O
Hitherto/O ,/O only/O dominant/O nonsynonymous/O variants/O and/O in/O -/O frame/O deletions/O with/O a/O presumed/O dominant/O negative/O or/O gain/O -/O of/O -/O function/O effect/O have/O been/O described/O ./O
Here/O ,/O we/O describe/O two/O brothers/O with/O congenital/O prelingual/O deafness/O and/O a/O homozygous/O nonsense/O c.292C/B-Var >/I-Var T(p/I-Var ./I-Var
Arg98/I-Var */I-Var )/I-Var COCH/B-Gene variant/O ,/O suggesting/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg effect/O ./O
Vestibular/B-Disease dysfunction/I-Disease starting/O in/O the/O first/O decade/O was/O observed/O in/O the/O older/O patient/O ./O
The/O heterozygous/O parents/O and/O sibling/O have/O normal/O hearing/O and/O vestibular/O function/O ,/O except/O for/O the/O mother/O ,/O who/O shows/O vestibular/O hyporeflexia/O and/O abnormal/O smooth/O pursuit/O tests/O ,/O most/O likely/O due/O to/O concomitant/O disease/O ./O
This/O is/O the/O first/O report/O of/O autosomal/O recessive/O inheritance/O of/O cochlea/O -/O vestibular/O dysfunction/O caused/O by/O a/O pathogenic/O variant/O in/O the/O COCH/O gene/O ./O
An/O earlier/O onset/O of/O hearing/O impairment/O and/O vestibular/O dysfunction/O compared/O to/O the/O dominant/O hearing/O loss/O causing/O COCH/O variants/O is/O observed/O ./O
Serum/O vitamin/O C/O levels/O modulate/O the/O lifespan/O and/O endoplasmic/O reticulum/O stress/O response/O pathways/O in/O mice/O synthesizing/O a/O nonfunctional/O mutant/O WRN/O protein/O ./O
Werner/B-Disease syndrome/I-Disease (/O WS/O )/O is/O a/O premature/O aging/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O a/O RecQ/B-Protein -/I-Protein family/I-Protein DNA/I-Protein helicase/I-Protein (/O WRN/O )/O ./O
Mice/O lacking/O part/O of/O the/O helicase/O domain/O of/O the/O WRN/O ortholog/O exhibit/O several/O phenotypic/O features/O of/O WS/O ./O
In/O this/O study/O ,/O we/O generated/O a/O Wrn/O mutant/O line/O that/O ,/O like/O humans/O ,/O relies/O entirely/O on/O dietary/O sources/O of/O vitamin/O C/O (/O ascorbate/O )/O to/O survive/O ,/O by/O crossing/O them/O to/O mice/O that/O lack/O the/O gulonolactone/O oxidase/O enzyme/O required/O for/O ascorbate/O synthesis/O ./O
In/O the/O presence/O of/O 0.01/O %/O ascorbate/O (/O w/O //O v/O )/O in/O drinking/O water/O ,/O double/O -/O mutant/O mice/O exhibited/O a/O severe/O reduction/O in/O lifespan/O ,/O small/O size/O ,/O sterility/O ,/O osteopenia/O ,/O and/O metabolic/O profiles/O different/O from/O wild/O -/O type/O (/O WT/O )/O mice/O ./O
Although/O increasing/O the/O dose/O of/O ascorbate/O to/O 0.4/O %/O improved/O dramatically/O the/O phenotypes/O of/O double/O -/O mutant/O mice/O ,/O the/O metabolic/O and/O cytokine/O profiles/O were/O different/O from/O age/O -/O matched/O WT/O mice/O ./O
Finally/O ,/O double/O -/O mutant/O mice/O treated/O with/O 0.01/O %/O ascorbate/O revealed/O a/O permanent/O activation/O of/O all/O the/O 3/O branches/O of/O the/O ER/O stress/O response/O pathways/O due/O to/O a/O severe/O chronic/O oxidative/O stress/O in/O the/O ER/O compartment/O ./O
In/O addition/O ,/O markers/O associated/O with/O the/O ubiquitin/O -/O proteasome/O -/O dependent/O ER/O -/O associated/O degradation/O pathway/O were/O increased/O ./O
Augmenting/O the/O dose/O of/O ascorbate/O reversed/O the/O activation/O of/O this/O pathway/O to/O WT/O levels/O rendering/O this/O pathway/O a/O potential/O therapeutic/O target/O in/O WS.-Aumailley/O ,/O L./O ,/O Dubois/O ,/O M./O J./O ,/O Brennan/O ,/O T./O A./O ,/O Garand/O ,/O C./O ,/O Paquet/O ,/O E./O R./O ,/O Pignolo/O ,/O R./O J./O ,/O Marette/O ,/O A./O ,/O Lebel/O ,/O M./O Serum/O vitamin/O C/O levels/O modulate/O the/O lifespan/O and/O endoplasmic/O reticulum/O stress/O response/O pathways/O in/O mice/O synthesizing/O a/O nonfunctional/O mutant/O WRN/O protein/O ./O
CgPDR1/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var lead/B-Reg to/I-Reg azole/B-MPA -/I-MPA resistance/I-MPA and/O increased/B-PosReg adhesion/B-MPA in/O clinical/O Candida/O glabrata/O strains/O ./O
Recently/O ,/O Candida/O glabrata/O has/O emerged/O as/O a/O health/O -/O threatening/O pathogen/O and/O the/O rising/O resistance/O to/O antifungal/O agent/O in/O C./O glabrata/O often/O leads/O to/O clinical/O treatment/O failure/O ./O
To/O investigate/O the/O evolution/O of/O drug/O resistance/O and/O adherence/O ability/O in/O four/O paired/O clinical/O isolates/O collected/O before/O and/O after/O antifungal/O treatment/O ./O
Sequence/O analysis/O ,/O gene/O disruption/O ,/O drug/O -/O susceptibility/O ,/O adhesion/O tests/O and/O real/O -/O time/O quantitative/O PCR/O were/O performed/O ./O
The/O azole/O -/O susceptible/O strains/O acquired/O azole/O resistance/O after/O antifungal/O therapy/O ./O
Four/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutations/O in/O CgPDR1/O were/O revealed/O by/O sequence/O analysis/O ,/O namely/O G1099D/O ,/O G346D/O ,/O L344S/O and/O P927S/O ,/O the/O last/O being/O reported/O for/O the/O first/O time/O ./O
CDR1/B-MPA ,/O CDR2/I-MPA and/I-MPA SNQ2/I-MPA efflux/I-MPA pump/I-MPA gene/I-MPA expression/I-MPA levels/I-MPA were/O elevated/B-PosReg in/O strains/O harbouring/O GOF/B-PosReg mutations/B-Var in/O CgPDR1/B-Gene ,/O resulting/O in/O decreased/B-NegReg azole/B-MPA susceptibility/I-MPA ./O
CgPDR1/O alleles/O with/O distinct/O GOF/O mutations/O displayed/O different/O expression/O profiles/O for/O the/O drug/O -/O related/O genes/O ./O
CgPDR1GOF/B-PosReg mutations/B-Var led/O to/O increased/B-PosReg efflux/B-MPA pumps/I-MPA expression/I-MPA levels/I-MPA in/O a/O strain/O background/O independent/O way/O ./O
Hyperactive/O Pdr1G1099D/O and/O Pdr1P927S/O displayed/O strain/O background/O -/O dependent/O increased/O adherence/O to/O host/O cells/O via/O upregulation/O of/O EPA1/O transcription/O ./O
Interestingly/O ,/O the/O drug/O transporter/O gene/O expression/O levels/O did/O not/O always/O correspond/O with/O that/O of/O the/O adhesin/O EPA1/O gene/O ./O
GOF/B-PosReg mutations/B-Var in/O CgPDR1/B-Gene conferred/B-Reg drug/B-MPA resistance/I-MPA and/O increased/B-PosReg adherence/B-MPA in/O the/O clinical/O strains/O ,/O possibly/O endowing/O C./O glabrata/O with/O increased/O viability/O and/O pathogenicity/O ./O
Loss/O of/O Function/O of/O the/O Nuclear/O Receptor/O NR2F2/O ,/O Encoding/O COUP/O -/O TF2/O ,/O Causes/O Testis/O Development/O and/O Cardiac/O Defects/O in/O 46,XX/O Children/O ./O
Emerging/O evidence/O from/O murine/O studies/O suggests/O that/O mammalian/O sex/O determination/O is/O the/O outcome/O of/O an/O imbalance/O between/O mutually/O antagonistic/O male/O and/O female/O regulatory/O networks/O that/O canalize/O development/O down/O one/O pathway/O while/O actively/O repressing/O the/O other/O ./O
However/O ,/O in/O contrast/O to/O testis/O formation/O ,/O the/O gene/O regulatory/O pathways/O governing/O mammalian/O ovary/O development/O have/O remained/O elusive/O ./O
We/O performed/O exome/O or/O Sanger/O sequencing/O on/O 79/O 46,XX/O SRY/O -/O negative/O individuals/O with/O either/O unexplained/O virilization/O or/O with/O testicular/O //O ovotesticular/O disorders/O //O differences/O of/O sex/O development/O (/O TDSD/O //O OTDSD/O )/O ./O
We/O identified/O heterozygous/O frameshift/O mutations/O in/O NR2F2/B-Gene ,/O encoding/O COUP/O -/O TF2/O ,/O in/O three/O children/O ./O
One/O carried/O a/O c.103_109delGGCGCCC/O (/B-Var p/I-Var ./I-Var Gly35Argfs∗75/I-Var )/I-Var mutation/O ,/O while/O two/O others/O carried/O a/O c.97_103delCCGCCCG/O (/B-Var p/I-Var ./I-Var Pro33Alafs∗77/I-Var )/I-Var mutation/O ./O
In/O two/O of/O three/O children/O the/O mutation/O was/O de/O novo/O ./O
All/O three/O children/O presented/B-Reg with/I-Reg congenital/B-Disease heart/I-Disease disease/I-Disease (/O CHD/O )/O ,/O one/O child/O with/O congenital/O diaphragmatic/O hernia/O (/O CDH/O )/O ,/O and/O two/O children/O with/O blepharophimosis/O -/O ptosis/O -/O epicanthus/O inversus/O syndrome/O (/O BPES/O )/O ./O
The/O three/O children/O had/O androgen/O production/O ,/O virilization/O of/O external/O genitalia/O ,/O and/O biochemical/O or/O histological/O evidence/O of/O testicular/O tissue/O ./O
We/O demonstrate/O a/O highly/O significant/O association/O between/O the/O NR2F2/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var and/O this/O syndromic/B-Disease form/I-Disease of/I-Disease DSD/I-Disease (/O p/O =/O 2.44/O ×/O 10/O -/O 8/O )/O ./O
We/O show/O that/O COUP/O -/O TF2/O is/O highly/O abundant/O in/O a/O FOXL2-negative/O stromal/O cell/O population/O of/O the/O fetal/O human/O ovary/O ./O
In/O contrast/O to/O the/O mouse/O ,/O these/O data/O establish/O COUP/O -/O TF2/O as/O a/O human/O "/O pro/O -/O ovary/O "/O and/O "/O anti/O -/O testis/O "/O sex/O -/O determining/O factor/O in/O female/O gonads/O ./O
Furthermore/O ,/O the/O data/O presented/O here/O provide/O additional/O evidence/O of/O the/O emerging/O importance/O of/O nuclear/O receptors/O in/O establishing/O human/O ovarian/O identity/O and/O indicate/O that/O nuclear/O receptors/O may/O have/O divergent/O functions/O in/O mouse/O and/O human/O biology/O ./O
Biallelic/B-Var Mutations/I-Var in/O ATP5F1D/B-Gene ,/O which/O Encodes/O a/O Subunit/O of/O ATP/O Synthase/O ,/O Cause/B-Reg a/O Metabolic/B-MPA Disorder/I-MPA ./O
ATP/O synthase/O ,/O H+/O transporting/O ,/O mitochondrial/O F1/O complex/O ,/O δ/O subunit/O (/O ATP5F1D/O ;/O formerly/O ATP5D/O )/O is/O a/O subunit/O of/O mitochondrial/O ATP/O synthase/O and/O plays/O an/O important/O role/O in/O coupling/O proton/O translocation/O and/O ATP/O production/O ./O
Here/O ,/O we/O describe/O two/O individuals/O ,/O each/O with/O homozygous/O missense/B-Var variants/I-Var in/O ATP5F1D/B-Gene ,/O who/O presented/B-Reg with/O episodic/B-MPA lethargy/I-MPA ,/O metabolic/B-MPA acidosis/I-MPA ,/O 3-methylglutaconic/B-MPA aciduria/I-MPA ,/O and/O hyperammonemia/B-Disease ./O
Subject/O 1/O ,/O homozygous/O for/O c.245C/O >/O T/O (/O p/O ./O Pro82Leu/O )/O ,/O presented/O with/O recurrent/O metabolic/O decompensation/O starting/O in/O the/O neonatal/O period/O ,/O and/O subject/O 2/O ,/O homozygous/O for/O c.317T/O >/O G/O (/O p/O ./O Val106Gly/O )/O ,/O presented/O with/O acute/O encephalopathy/O in/O childhood/O ./O
Cultured/O skin/O fibroblasts/O from/O these/O individuals/O exhibited/O impaired/O assembly/O of/O F1FO/O ATP/O synthase/O and/O subsequent/O reduced/O complex/O V/O activity/O ./O
Cells/O from/O subject/O 1/O also/O exhibited/O a/O significant/O decrease/O in/O mitochondrial/O cristae/O ./O
Knockdown/O of/O Drosophila/O ATPsynδ/O ,/O the/O ATP5F1D/O homolog/O ,/O in/O developing/O eyes/O and/O brains/O caused/O a/O near/O complete/O loss/O of/O the/O fly/O head/O ,/O a/O phenotype/O that/O was/O fully/O rescued/O by/O wild/O -/O type/O human/O ATP5F1D./O In/O contrast/O ,/O expression/O of/O the/O ATP5F1D/O c.245C/O >/O T/O and/O c.317T/O >/O G/O variants/B-Var rescued/B-PosReg the/O head/B-MPA -/I-MPA size/I-MPA phenotype/I-MPA but/O recapitulated/B-NegReg the/O eye/B-MPA and/O antennae/B-MPA defects/I-MPA seen/O in/O other/O genetic/O models/O of/O mitochondrial/O oxidative/O phosphorylation/O deficiency/O ./O
Our/O data/O establish/O c.245C/O >/O T/O (/O p/O ./O Pro82Leu/O )/O and/O c.317T/O >/O G/O (/O p/O ./O Val106Gly/O )/O in/O ATP5F1D/O as/O pathogenic/O variants/B-Var leading/B-Reg to/I-Reg a/O Mendelian/B-Disease mitochondrial/I-Disease disease/I-Disease featuring/O episodic/O metabolic/O decompensation/O ./O
Multifocal/O atrial/O and/O ventricular/O premature/O contractions/O with/O an/O increased/O risk/O of/O dilated/B-Disease cardiomyopathy/I-Disease caused/O by/O a/O Nav1.5/B-Gene gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/O (/B-Var G213D/I-Var )/I-Var ./O
BACKGROUND/O :/O SCN5A/O mutations/B-Var can/O lead/B-Reg to/I-Reg different/O cardiac/B-Disease diseases/I-Disease ./O
Recently/O ,/O SCN5A/O mutations/O have/O been/O linked/O to/O the/O clinical/O entity/O multifocal/O ectopic/O Purkinje/O -/O related/O premature/O contractions/O (/O MEPPC/O )/O characterized/O by/O ventricular/O ectopy/O and/O dilated/O cardiomyopathy/O ./O
METHODS/O &/O RESULTS/O :/O A/O family/O with/O a/O uniform/O MEPPC/O -/O like/O phenotype/O ,/O associated/O with/O complex/O atrial/O and/O ventricular/O arrhythmias/O and/O dilated/O cardiomyopathy/O caused/O by/O a/O high/O frequency/O of/O ventricular/O ectopy/O was/O clinically/O assessed/O ./O
Screening/O of/O the/O SCN5A/B-Gene gene/O revealed/O a/O missense/B-Var mutation/I-Var in/O the/O linker/O between/O segments/O 3/O and/O 4/O in/O domain/O 1/O of/O the/O Nav1.5/O protein/O ,/O resulting/B-Reg in/I-Reg a/O glycine/O to/O aspartate/O substitution/O at/O position/O 213/O (/B-Var G213D/I-Var )/I-Var ./O
The/O phenotype/O co/O -/O segregated/O with/O the/O missense/O mutation/O ./O
Electrophysiological/O studies/O of/O wild/O type/O (/O WT/O )/O hNav1.5/O and/O hNav1.5_G213D/O expressed/O in/O CHO/O -/O K/O cells/O showed/O that/O the/O voltage/O of/O half/O -/O maximal/O activation/O (/O V½/O )/O was/O significantly/O more/O negative/O for/O hNav1.5_G213D/O compared/O to/O WT/O (/O V½=-38.7±0.5mV/O for/O WT/O and/O V½=-42.4±0.5mV/O for/O G213D/O ;/O P<0.001/O )/O ./O
This/O suggests/O activation/O of/O Nav1.5_G231D/O at/O more/O negative/O potentials/O ./O
The/O V½/O of/O steady/O -/O state/O inactivation/O was/O significantly/O shifted/O towards/O more/O positive/O values/O for/O Nav1.5_G213D/O (/O V½=-86.7±0.2mV/O for/O WT/O and/O -82.2±0.3mV/O for/O G213D/O ;/O P<0.001/O )/O ,/O also/O contributing/O to/O a/O gain/O -/O of/O -/O function/O phenotype/O ./O
Flecainide/O and/O amiodarone/O markedly/O reduced/O premature/O atrial/O and/O ventricular/O contractions/O in/O four/O patients/O ./O
CONCLUSION/O :/O The/O Nav1.5_G213D/B-Var mutation/O is/O associated/O with/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg phenotype/O ,/O multifocal/O atrial/O and/O ventricular/O ectopy/O and/O dilated/B-Disease cardiomyopathy/I-Disease ./O
Since/O patients/O with/O a/O MEPPC/O -/O like/O phenotype/O may/O specifically/O benefit/O from/O Class-1/O antiarrhythmic/O drugs/O or/O amiodarone/O ,/O clinical/O identification/O of/O this/O disease/O entity/O is/O important/O ./O
The/O Molecular/O Chaperone/O HSP90/O Promotes/O Notch/O Signaling/O in/O the/O Germline/O of/O Caenorhabditis/O elegans/O ./O
In/O a/O genetic/O screen/O to/O identify/O genes/O that/O promote/O GLP-1/O //O Notch/O signaling/O in/O Caenorhabditis/O elegans/O germline/O stem/O cells/O ,/O we/O found/O a/O single/O mutation/O ,/O om40/O ,/O defining/O a/O gene/O called/O ego-3/O ./O
ego-3(om40/B-Var )/I-Var causes/B-Reg several/O defects/B-MPA in/O the/O soma/O and/O the/O germline/O ,/O including/O paralysis/B-Disease during/O larval/O development/O ,/O sterility/B-Disease ,/O delayed/B-CPA proliferation/I-CPA of/O germline/O stem/O cells/O ,/O and/O ectopic/B-CPA germline/I-CPA stem/I-CPA cell/I-CPA proliferation/I-CPA ./O
Whole/O genome/O sequencing/O identified/O om40/O as/O an/O allele/O of/O hsp-90/O ,/O previously/O known/O as/O daf-21/O ,/O which/O encodes/O the/O C./O elegans/O ortholog/O of/O the/O cytosolic/O form/O of/O HSP90/O ./O
This/O protein/O is/O a/O molecular/O chaperone/O with/O a/O central/O position/O in/O the/O protein/O homeostasis/O network/O ,/O which/O is/O responsible/O for/O proper/O folding/O ,/O structural/O maintenance/O ,/O and/O degradation/O of/O proteins/O ./O
In/O addition/O to/O its/O essential/O role/O in/O cellular/O function/O ,/O HSP90/O plays/O an/O important/O role/O in/O stem/O cell/O maintenance/O and/O renewal/O ./O
Complementation/O analysis/O using/O a/O deletion/O allele/O of/O hsp-90/O confirmed/O that/O ego-3/O is/O the/O same/O gene/O ./O
hsp-90(om40/O )/O is/O an/O I→N/O conservative/O missense/O mutation/O of/O a/O highly/O conserved/O residue/O in/O the/O middle/O domain/O of/O HSP-90/O RNA/O interference/O -/O mediated/O knockdown/O of/O hsp-90/O expression/O partially/O phenocopied/O hsp-90(om40/O )/O ,/O confirming/O the/O loss/O -/O of/O -/O function/O nature/O of/O hsp-90(om40/O )/O Furthermore/O ,/O reduced/O HSP-90/O activity/O enhanced/O the/O effect/O of/O reduced/O function/O of/O both/O the/O GLP-1/O receptor/O and/O the/O downstream/O LAG-1/O transcription/O factor/O ./O
Taken/O together/O ,/O our/O results/O provide/O the/O first/O experimental/O evidence/O of/O an/O essential/O role/O for/O HSP90/O in/O Notch/O signaling/O in/O development/O ./O
Impact/O of/O CYP2C19/O Polymorphisms/O on/O Clinical/O Outcomes/O and/O Antiplatelet/O Potency/O of/O Clopidogrel/O in/O Caucasian/O Poststroke/O Survivors/O ./O
BACKGROUND/O :/O Variable/O response/O after/O clopidogrel/O is/O well/O documented/O and/O may/O affect/O major/O adverse/O clinical/O events/O after/O stroke/O ./O
Impact/O of/O CYP2C19/O genetic/O polymorphisms/O is/O an/O established/O marker/O linked/O to/O variable/O response/O after/O clopidogrel/O ./O
However/O ,/O the/O association/O of/O certain/O genetic/O polymorphisms/O with/O prediction/O of/O major/O adverse/O clinical/O events/O following/O stroke/O still/O remains/O controversial/O ,/O especially/O in/O Caucasians/O ./O
STUDY/O QUESTION/O :/O The/O primary/O aim/O was/O to/O evaluate/O the/O impact/O of/O CYP2C19/O allele/O */O 2/O in/O heterozygote/O form/O on/O major/O adverse/O clinical/O events/O in/O Caucasian/O poststroke/O survivors/O treated/O with/O clopidogrel/O ./O
The/O secondary/O aim/O was/O to/O analyze/O the/O potential/O link/O between/O CYP2C19/O genetic/O polymorphism/O and/O variable/O response/O after/O clopidogrel/O ./O
STUDY/O DESIGN/O :/O One/O hundred/O thirty/O patients/O of/O Caucasian/O origin/O following/O documented/O ischemic/O stroke/O were/O included/O ./O
Platelet/O reactivity/O was/O assessed/O by/O light/O transmittance/O aggregometry/O (/O LTA/O )/O and/O matched/O with/O various/O CYP2C19/O loss/O -/O of/O -/O function/O genetic/O polymorphisms/O and/O major/O adverse/O clinical/O events/O (/O composite/O of/O vascular/O deaths/O ,/O stroke/O //O transient/O ischemic/O attack/O ,/O and/O myocardial/O infarction/O )/O ./O
RESULTS/O :/O Over/O the/O mean/O follow/O -/O up/O of/O 14.9/O months/O ,/O 19/O patients/O experienced/O major/O adverse/O clinical/O events/O ./O
The/O risk/O of/O major/B-MPA adverse/I-MPA clinical/I-MPA events/I-MPA was/O nearly/O 3-fold/O in/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg allele/B-Var carriers/O (/O hazard/O ratio/O =/O 2.904/O ;/O 95/O %/O confidence/O interval/O ,/O 1.083/O -/O 7.786/O ;/O P/O =/O 0.013/O )/O ,/O whereas/O the/O risk/O of/O ischemic/B-MPA stroke/I-MPA or/O transient/B-MPA ischemic/I-MPA attack/I-MPA alone/I-MPA was/O also/O higher/O (/O hazard/O ratio/O =/O 3.170/O ;/O 95/O %/O confidence/O interval/O ,/O 1.281/O -/O 7.849/O ;/O P/O =/O 0.034/O )/O ./O
Platelet/B-MPA activity/I-MPA was/O strongly/O associated/B-Interaction with/O allele/B-Var */I-Var 2/I-Var status/I-Var (/O rs/O =/O 0.21/O ,/O P/O =/O 0.016/O )/O but/O not/O with/O other/O genetic/O polymorphisms/O ./O
Carriers/O of/O allele*2/O exhibited/O lower/O platelet/O response/O to/O adenosine/O diphosphate/O -/O mean/O LTA/O (/O 30.1/O %/O vs./O 42.0/O %/O ;/O P/O =/O 0.017/O )/O ./O
There/O were/O no/O significant/O differences/O in/O LTA/O results/O with/O other/O agonists/O ./O
Strong/O association/O of/O increase/O in/O adenosine/O diphosphate/O -/O induced/O aggregation/O with/O diabetes/O mellitus/O (/O rs/O =/O 0.20/O ,/O P/O =/O 0.023/O )/O ,/O increasing/O age/O (/O rs/O =/O 0.23/O ,/O P/O =/O 0.008/O )/O ,/O and/O conversely/O diminishing/O over/O increased/O weight/O (/O rs/O =/O 0.23/O ,/O P/O =/O 0.009/O )/O was/O also/O detected/O ./O
The/O carriers/O of/O other/O gene/O allele/O variants/O lack/O uniformed/O impact/O on/O variable/O response/O after/O clopidogrel/O ./O
CONCLUSIONS/O :/O Even/O heterozygous/O CYP2C19/O */O 2/O allele/O carriers/O among/O Caucasian/O patients/O after/O ischemic/O stroke/O had/O a/O higher/O risk/O of/O major/O adverse/O clinical/O events/O ./O
The/O LTA/O ,/O however/O ,/O did/O not/O predict/O major/O adverse/O clinical/O events/O ./O
The/O exact/O clinical/O utility/O of/O these/O findings/O is/O still/O uncertain/O and/O requires/O large/O outcome/O -/O driven/O randomized/O trial/O in/O Caucasians/O for/O proof/O of/O concept/O ./O
The/O Arabidopsis/O thaliana/O Mediator/O subunit/O MED8/O regulates/O plant/O immunity/O to/O Botrytis/O Cinerea/O through/O interacting/O with/O the/O basic/O helix/O -/O loop/O -/O helix/O (/O bHLH/O )/O transcription/O factor/O FAMA/O ./O
The/O Mediator/O complex/O is/O at/O the/O core/O of/O transcriptional/O regulation/O and/O plays/O a/O central/O role/O in/O plant/O immunity/O ./O
The/O MEDIATOR25/O (/O MED25/O )/O subunit/O of/O Arabidopsis/O thaliana/O regulates/O jasmonate/O -/O dependent/O resistance/O to/O Botrytis/O cinerea/O through/O interacting/O with/O the/O basic/O helix/O -/O loop/O -/O helix/O (/O bHLH/O )/O transcription/O factor/O of/O jasmonate/O signaling/O ,/O MYC2/O ./O
Another/O Mediator/O subunit/O ,/O MED8/O ,/O acts/O independently/O or/O together/O with/O MED25/O in/O plant/O immunity/O ./O
However/O ,/O unlike/O MED25/O ,/O the/O underlying/O action/O mechanisms/O of/O MED8/O in/O regulating/O B./O cinerea/O resistance/O are/O still/O unknown/O ./O
Here/O ,/O we/O demonstrated/O that/O MED8/O regulated/O plant/O immunity/O to/O B./O cinerea/O through/O interacting/O with/O another/O bHLH/O transcription/O factor/O ,/O FAMA/O ,/O which/O was/O previously/O shown/O to/O control/O the/O final/O proliferation/O //O differentiation/O switch/O during/O stomatal/O development/O ./O
Our/O research/O demonstrates/O that/O FAMA/O is/O also/O an/O essential/O component/O of/O B./O cinerea/O resistance/O ./O
The/O fama/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutants/B-Var (/O fama-1/O and/O fama-2/O )/O increased/B-PosReg susceptibility/B-MPA to/I-MPA B./I-MPA cinerea/I-MPA infection/I-MPA and/O reduced/B-NegReg defense/B-MPA -/I-MPA gene/I-MPA expression/I-MPA ./O
On/O the/O contrary/O ,/O transgenic/O lines/O constitutively/O overexpressing/O FAMA/O showed/O opposite/O B./O cinerea/O responses/O compared/O with/O the/O fama/O loss/O -/O of/O -/O function/O mutants/O ./O
FAMA/O -/O overexpressed/O plants/O displayed/O enhanced/O resistance/O to/O B./O cinerea/O infection/O and/O increased/O expression/O levels/O of/O defensin/O genes/O following/O B./O cinerea/O treatment/O ./O
Genetic/O analysis/O of/O MED8/O and/O FAMA/O suggested/O that/O FAMA/O -/O regulated/O pathogen/O resistance/O was/O dependent/O on/O MED8/O ./O
In/O addition/O ,/O MED8/O and/O FAMA/O were/O both/O associated/O with/O the/O G/O -/O box/O region/O in/O the/O promoter/O of/O ORA59/O ./O
Our/O findings/O indicate/O that/O the/O MED8/O subunit/O of/O the/O A./O thaliana/O Mediator/O regulates/O plant/O immunity/O to/O B./O cinerea/O through/O interacting/O with/O the/O transcription/O factor/O FAMA/O ,/O which/O was/O discovered/O to/O be/O a/O key/O component/O in/O B./O cinerea/O resistance/O ./O
A/O Gain/O -/O of/O -/O Function/O Mutation/O in/O EPO/O in/O Familial/O Erythrocytosis/O ./O
Familial/B-Disease erythrocytosis/I-Disease with/O elevated/O erythropoietin/O levels/O is/O frequently/O caused/B-Reg by/O mutations/B-Var in/O genes/O that/O regulate/O oxygen/O -/O dependent/O transcription/O of/O the/O gene/O encoding/O erythropoietin/O (/O EPO/B-Gene )/I-Gene ./O
We/O identified/O a/O mutation/O in/O EPO/O that/O cosegregated/O with/O disease/O with/O a/O logarithm/O of/O the/O odds/O (/O LOD/O )/O score/O of/O 3.3/O in/O a/O family/O with/O autosomal/O dominant/O erythrocytosis/O ./O
This/O mutation/B-Var ,/O a/O single/O -/O nucleotide/O deletion/O (/O c.32delG/O )/O ,/O introduces/O a/O frameshift/O in/O exon/O 2/O that/O interrupts/B-NegReg translation/O of/O the/O main/B-MPA EPO/I-MPA messenger/I-MPA RNA/I-MPA (/I-MPA mRNA/I-MPA )/I-MPA transcript/I-MPA but/O initiates/O excess/O production/O of/O erythropoietin/O from/O what/O is/O normally/O a/O noncoding/O EPO/O mRNA/O transcribed/O from/O an/O alternative/O promoter/O located/O in/O intron/O 1/O ./O
(/O Funded/O by/O the/O Gebert/O Rüf/O Foundation/O and/O others/O ./O
)/O ./O
Inactivation/B-Var of/O Fgfr2/B-Gene gene/O in/O mouse/O secondary/O palate/O mesenchymal/O cells/O leads/B-Reg to/I-Reg cleft/B-Disease palate/I-Disease ./O
Numerous/O studies/O have/O been/O conducted/O to/O understand/O the/O molecular/O mechanisms/O controlling/O mammalian/O secondary/O palate/O development/O such/O as/O growth/O ,/O reorientation/O and/O fusion/O ./O
However/O ,/O little/O is/O known/O about/O the/O signaling/O factors/O regulating/O palate/O initiation/O ./O
Mouse/O fibroblast/O growth/O factor/O (/O FGF/O )/O receptor/O 2/O gene/O (/O Fgfr2/O )/O is/O expressed/O on/O E11.5/O in/O the/O palate/O outgrowth/O within/O the/O maxillary/O process/O ,/O in/O a/O region/O that/O is/O responsible/O for/O palate/O cell/O specification/O and/O shelf/O initiation/O ./O
Fgfr2/O continues/O to/O express/O in/O palate/O on/O E12.5/O and/O E13.5/O in/O both/O epithelial/O and/O mesenchymal/O cells/O ,/O and/O inactivation/B-Var of/O Fgfr2/B-Gene expression/O in/O mesenchymal/O cells/O using/O floxed/O Fgfr2/O allele/O and/O Osr2-Cre/O leads/B-Reg to/I-Reg cleft/B-Disease palate/I-Disease at/O various/O stages/O including/O reorientation/O ,/O horizontal/O growth/O and/O fusion/O ./O
Notably/O ,/O some/O mutant/O embryos/O displayed/O no/O sign/O of/O palate/O shelf/O formation/O suggesting/O that/O FGF/O receptor/O 2/O mediated/O FGF/O signaling/O may/O play/O an/O important/O role/O in/O palate/O initiation/O ./O
MIB-1/O Is/O Required/O for/O Spermatogenesis/O and/O Facilitates/O LIN-12/O and/O GLP-1/O Activity/O in/O Caenorhabditis/O elegans/O ./O
Covalent/O attachment/O of/O ubiquitin/O to/O substrate/O proteins/O changes/O their/O function/O or/O marks/O them/O for/O proteolysis/O ,/O and/O the/O specificity/O of/O ubiquitin/O attachment/O is/O mediated/O by/O the/O numerous/O E3/O ligases/O encoded/O by/O animals/O ./O
Mind/O Bomb/O is/O an/O essential/O E3/O ligase/O during/O Notch/O pathway/O signaling/O in/O insects/O and/O vertebrates/O ./O
While/O Caenorhabditis/O elegans/O encodes/O a/O Mind/O Bomb/O homolog/O (/O mib-1/O )/O ,/O it/O has/O never/O been/O recovered/O in/O the/O extensive/O Notch/O suppressor/O //O enhancer/O screens/O that/O have/O identified/O numerous/O pathway/O components/O ./O
Here/O ,/O we/O show/O that/O C./O elegans/O mib-1/B-Gene null/O mutants/B-Var have/O a/O spermatogenesis/B-Disease -/I-Disease defective/I-Disease phenotype/I-Disease that/O results/B-Reg in/I-Reg a/O heterogeneous/B-MPA mixture/I-MPA of/I-MPA arrested/I-MPA spermatocytes/I-MPA ,/O defective/O spermatids/O ,/O and/O motility/O -/O impaired/O spermatozoa/O ./O
mib-1/O mutants/O also/O have/O chromosome/O segregation/O defects/O during/O meiosis/O ,/O molecular/O null/O mutants/O are/O intrinsically/O temperature/O -/O sensitive/O ,/O and/O many/O mib-1/O spermatids/O contain/O large/O amounts/O of/O tubulin/O ./O
These/O phenotypic/O features/O are/O similar/O to/O the/O endogenous/O RNA/O intereference/O (/O RNAi/O )/O mutants/O ,/O but/O mib-1/O mutants/O do/O not/O affect/O RNAi/O ./O
MIB-1/O protein/O is/O expressed/O throughout/O the/O germ/O line/O with/O peak/O expression/O in/O spermatocytes/O followed/O by/O segregation/O into/O the/O residual/O body/O during/O spermatid/O formation/O ./O
C./O elegans/O mib-1/O expression/O ,/O while/O upregulated/O during/O spermatogenesis/O ,/O also/O occurs/O somatically/O ,/O including/O in/O vulva/O precursor/O cells/O ./O
Here/O ,/O we/O show/O that/O mib-1/B-Gene mutants/B-Var suppress/B-NegReg both/O lin-12/B-Gene and/O glp-1/B-Gene (/O C./O elegans/O Notch/O )/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutants/B-Var ,/O restoring/B-PosReg anchor/B-MPA cell/I-MPA formation/I-MPA and/O a/O functional/B-MPA vulva/I-MPA to/O the/O former/O and/O partly/O restoring/O oocyte/B-MPA production/I-MPA to/O the/O latter/O ./O
However/O ,/O suppressed/O hermaphrodites/O are/O only/O observed/O when/O grown/O at/O 25/O °/O ,/O and/O they/O are/O self/O -/O sterile/O ./O
This/O probably/O explains/O why/O mib-1/O was/O not/O previously/O recovered/O as/O a/O Notch/O pathway/O component/O in/O suppressor/O //O enhancer/O selection/O experiments/O ./O
The/O curious/O case/O of/O Gαs/O gain/O -/O of/O -/O function/O in/O neoplasia/O ./O
BACKGROUND/O :/O Mutations/B-Var activating/B-PosReg the/O α/O subunit/O of/O heterotrimeric/B-Protein Gs/I-Protein protein/I-Protein are/O associated/O with/O a/O number/O of/O highly/O specific/O pathological/O molecular/O phenotypes/O ./O
One/O of/O the/O best/O characterized/O is/O the/O McCune/B-Disease Albright/I-Disease syndrome/I-Disease ./O
The/O disease/O presents/O with/O an/O increased/O incidence/O of/O neoplasias/O in/O specific/O tissues/O ./O
MAIN/O BODY/O :/O A/O similar/O repertoire/O of/O neoplasms/O can/O develop/O whether/O mutations/O occur/O spontaneously/O in/O somatic/O tissues/O during/O fetal/O development/O or/O after/O birth/O ./O
Glands/O are/O the/O most/O "/O permissive/O "/O tissues/O ,/O recently/O found/O to/O include/O the/O entire/O gastrointestinal/O tract/O ./O
High/O frequency/O of/O activating/B-PosReg Gαs/B-Gene mutations/B-Var is/O associated/O with/O precise/O diagnoses/O (/O e.g./O ,/O IPMN/B-Disease ,/O Pyloric/B-Disease gland/I-Disease adenoma/I-Disease ,/O pituitary/B-Disease toxic/I-Disease adenoma/I-Disease )/I-Disease ./O
Typically/O ,/O most/O neoplastic/O lesions/O ,/O from/O thyroid/O to/O pancreas/O ,/O remain/O well/O differentiated/O but/O may/O be/O a/O precursor/O to/O aggressive/O cancer/O ./O
CONCLUSIONS/O :/O Here/O we/O propose/O the/O possibility/O that/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var of/O Gαs/B-Gene interfere/B-NegReg with/O signals/O in/O the/O microenvironment/B-MPA of/I-MPA permissive/I-MPA tissues/O and/O lead/B-Reg to/I-Reg a/O transversal/B-MPA neoplastic/I-MPA phenotype/I-MPA ./O
Dissecting/O the/O genetic/O basis/O of/O heavy/O panicle/O hybrid/O rice/O uncovered/O Gn1a/O and/O GS3/O as/O key/O genes/O ./O
KEY/O MESSAGE/O :/O Shuhui498/O (/O R498/O )/O is/O an/O elite/O parent/O of/O heavy/O panicle/O hybrid/O rice/O by/O pyramiding/O the/O rare/O gn1a/O and/O null/O gs3/O alleles/O ./O
This/O finding/O reveals/O the/O genetic/O basis/O and/O great/O potential/O application/O in/O future/O breeding/O of/O R498/O ./O
The/O heavy/O panicle/O trait/O ,/O defined/O as/O 5/O g/O or/O more/O of/O grain/O weight/O per/O panicle/O ,/O is/O one/O of/O the/O target/O traits/O in/O super/O -/O high/O -/O yield/O rice/O breeding/O programs/O ./O
The/O use/O of/O heavy/O panicle/O -/O type/O hybrid/O rice/O has/O been/O shown/O to/O be/O a/O successful/O strategy/O for/O super/O -/O high/O -/O yield/O breeding/O programs/O ,/O particularly/O under/O the/O environmental/O conditions/O of/O high/O humidity/O and/O deficient/O solar/O radiation/O in/O southwestern/O China/O ./O
However/O ,/O the/O genetic/O components/O of/O the/O heavy/O panicle/O trait/O in/O hybrid/O rice/O remain/O elusive/O ./O
Here/O ,/O we/O report/O that/O the/O combination/O of/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O Grain/O number/O 1a/O (/B-Gene Gn1a/I-Gene )/I-Gene and/O Grain/O Size/O 3/O (/B-Gene GS3/I-Gene )/I-Gene is/O responsible/B-Reg for/O the/O heavy/B-MPA panicle/I-MPA phenotype/I-MPA of/O the/O elite/O hybrid/O rice/O restorer/O line/O Shuhui498/O (/O R498/O )/O ./O
The/O null/O gn1a/O allele/O is/O the/O determinant/O factor/O for/O heavy/O panicles/O through/O increased/O grain/O number/O ,/O while/O gs3/O is/O associated/O with/O grain/O size/O and/O weight/O ./O
R498/O pyramided/O the/O two/O major/O null/O alleles/O ,/O resulting/O in/O heavy/O panicles/O with/O a/O high/O grain/O number/O and/O large/O grains/O ./O
Clustering/O analysis/O revealed/O that/O the/O null/O gn1aR498/O allele/O is/O a/O rare/O haplotype/O which/O has/O been/O innovatively/O utilized/O in/O R498/O ,/O underscoring/O the/O great/O potential/O of/O R498/O for/O breeding/O purposes/O ./O
Our/O research/O thus/O sheds/O light/O on/O the/O distinct/O genetic/O compositions/O of/O heavy/O panicle/O -/O type/O rice/O and/O may/O potentially/O facilitate/O super/O -/O high/O -/O yield/O rice/O breeding/O ./O
A/O Protein/O -/O Truncating/O HSD17B13/O Variant/O and/O Protection/O from/O Chronic/O Liver/O Disease/O ./O
BACKGROUND/O :/O Elucidation/O of/O the/O genetic/O factors/O underlying/O chronic/O liver/O disease/O may/O reveal/O new/O therapeutic/O targets/O ./O
METHODS/O :/O We/O used/O exome/O sequence/O data/O and/O electronic/O health/O records/O from/O 46,544/O participants/O in/O the/O DiscovEHR/O human/O genetics/O study/O to/O identify/O genetic/O variants/O associated/O with/O serum/O levels/O of/O alanine/O aminotransferase/O (/O ALT/O )/O and/O aspartate/O aminotransferase/O (/O AST/O )/O ./O
Variants/B-Var that/O were/O replicated/O in/O three/O additional/O cohorts/O (/O 12,527/O persons/O )/O were/O evaluated/O for/O association/B-Interaction with/O clinical/O diagnoses/O of/O chronic/B-Disease liver/I-Disease disease/I-Disease in/O DiscovEHR/O study/O participants/O and/O two/O independent/O cohorts/O (/O total/O of/O 37,173/O persons/O )/O and/O with/O histopathological/O severity/O of/O liver/O disease/O in/O 2391/O human/O liver/O samples/O ./O
RESULTS/O :/O A/O splice/B-Var variant/I-Var (/O rs72613567/O :/O TA/O )/O in/O HSD17B13/B-Gene ,/O encoding/O the/O hepatic/O lipid/O droplet/O protein/O hydroxysteroid/O 17-beta/O dehydrogenase/O 13/O ,/O was/O associated/O with/O reduced/B-NegReg levels/O of/O ALT/B-MPA (/O P=4.2×10/O -/O 12/O )/O and/O AST/B-MPA (/O P=6.2×10/O -/O 10/O )/O ./O
Among/O DiscovEHR/O study/O participants/O ,/O this/O variant/B-Var was/O associated/O with/O a/O reduced/B-NegReg risk/O of/O alcoholic/B-Disease liver/I-Disease disease/I-Disease (/O by/O 42/O %/O [/O 95/O %/O confidence/O interval/O {/O CI/O }/O ,/O 20/O to/O 58/O ]/O among/O heterozygotes/O and/O by/O 53/O %/O [/O 95/O %/O CI/O ,/O 3/O to/O 77/O ]/O among/O homozygotes/O )/O ,/O nonalcoholic/B-Disease liver/I-Disease disease/I-Disease (/O by/O 17/O %/O [/O 95/O %/O CI/O ,/O 8/O to/O 25/O ]/O among/O heterozygotes/O and/O by/O 30/O %/O [/O 95/O %/O CI/O ,/O 13/O to/O 43/O ]/O among/O homozygotes/O )/O ,/O alcoholic/B-Disease cirrhosis/I-Disease (/O by/O 42/O %/O [/O 95/O %/O CI/O ,/O 14/O to/O 61/O ]/O among/O heterozygotes/O and/O by/O 73/O %/O [/O 95/O %/O CI/O ,/O 15/O to/O 91/O ]/O among/O homozygotes/O )/O ,/O and/O nonalcoholic/B-Disease cirrhosis/I-Disease (/O by/O 26/O %/O [/O 95/O %/O CI/O ,/O 7/O to/O 40/O ]/O among/O heterozygotes/O and/O by/O 49/O %/O [/O 95/O %/O CI/O ,/O 15/O to/O 69/O ]/O among/O homozygotes/O )/O ./O
Associations/O were/O confirmed/O in/O two/O independent/O cohorts/O ./O
The/O rs72613567/O :/O TA/O variant/B-Var was/O associated/O with/O a/O reduced/B-NegReg risk/O of/O nonalcoholic/B-Disease steatohepatitis/I-Disease ,/O but/O not/O steatosis/O ,/O in/O human/O liver/O samples/O ./O
The/O rs72613567/O :/O TA/O variant/B-Var mitigated/B-NegReg liver/B-Disease injury/I-Disease associated/O with/O the/O risk/O -/O increasing/O PNPLA3/O p/O ./OI148/O M/O allele/O and/O resulted/O in/O an/O unstable/O and/O truncated/O protein/O with/O reduced/O enzymatic/O activity/O ./O
CONCLUSIONS/O :/O A/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variant/B-Var in/O HSD17B13/B-Gene was/O associated/O with/O a/O reduced/B-NegReg risk/O of/O chronic/B-Disease liver/I-Disease disease/I-Disease and/O of/O progression/O from/O steatosis/O to/O steatohepatitis/O ./O
(/O Funded/O by/O Regeneron/O Pharmaceuticals/O and/O others/O ./O
)/O ./O
Gain/O -/O of/O -/O function/O mutations/O in/O granulocyte/O colony/O -/O stimulating/O factor/O receptor/O (/O CSF3R/O )/O reveal/O distinct/O mechanisms/O of/O CSF3R/O activation/O ./O
Granulocyte/O colony/O -/O stimulating/O factor/O (/O G/O -/O CSF/O or/O CSF3/O )/O and/O its/O receptor/O CSF3R/O regulate/O granulopoiesis/O ,/O neutrophil/O function/O ,/O and/O hematopoietic/O stem/O cell/O mobilization/O ./O
Recent/O studies/O have/O uncovered/O an/O oncogenic/O role/O of/O mutations/B-Var in/O the/O CSF3R/B-Gene gene/O in/O many/O hematologic/B-Disease malignancies/I-Disease ./O
To/O find/O additional/O CSF3R/O mutations/O that/O give/O rise/O to/O cell/O transformation/O ,/O we/O performed/O a/O cellular/O transformation/O assay/O in/O which/O murine/O interleukin/O 3/O (/O IL-3)-dependent/O Ba/O //O F3/O cells/O were/O transduced/O with/O WT/O CSF3R/O plasmid/O and/O screened/O for/O spontaneous/O growth/O in/O the/O absence/O of/O IL-3/O ./O
Any/O outgrowth/O clones/O were/O sequenced/O to/O identify/O CSF3R/O mutations/O with/O transformation/O capacity/O ./O
We/O identified/O several/O novel/O mutations/B-Var and/O determined/O that/O they/O transform/B-Reg cells/B-CPA via/O four/O distinct/O mechanisms/O :/O 1/O )/O cysteine-/B-MPA and/I-MPA disulfide/I-MPA bond/I-MPA -/I-MPA mediated/I-MPA dimerization/I-MPA (/O S581C/O )/O ;/O 2/O )/O polar/B-Var ,/O noncharged/I-Var amino/I-Var acid/I-Var substitution/I-Var at/O the/O transmembrane/O helix/O dimer/O interface/O at/O residue/O Thr-640/O ;/O 3/O )/O increased/B-PosReg internalization/B-MPA by/O a/O Glu-524/O substitution/O that/O mimics/O a/O low/O G/O -/O CSF/O dose/O ;/O and/O 4/O )/O hydrophobic/B-Var amino/I-Var acid/I-Var substitutions/I-Var in/O the/O membrane/O -/O proximal/O residues/O Thr-612/O ,/O Thr-615/O ,/O and/O Thr-618/O ./O
Furthermore/O ,/O the/O change/O in/O signaling/O activation/O was/O related/O to/O an/O altered/O CSF3R/O localization/O ./O
We/O also/O found/O that/O CSF3R/O -/O induced/O STAT3/O and/O ERK/O activations/O require/O CSF3R/O internalization/O ,/O whereas/O STAT5/O activation/O occurred/O at/O the/O cell/O surface/O ./O
Cumulatively/O ,/O we/O have/O expanded/O the/O regions/O of/O the/O CSF3R/O extracellular/O and/O transmembrane/O domains/O in/O which/O missense/B-Var mutations/I-Var exhibit/B-PosReg leukemogenic/B-Disease capacity/O and/O have/O further/O elucidated/O the/O mechanistic/O underpinnings/O that/O underlie/O altered/O CSF3R/O expression/O ,/O dimerization/O ,/O and/O signaling/O activation/O ./O
Biallelic/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg WNT5A/B-Gene mutations/B-Var in/O an/O infant/O with/O severe/O and/O atypical/O manifestations/O of/O Robinow/B-Disease syndrome/I-Disease ./O
Robinow/O syndrome/O (/O RS/O )/O is/O a/O well/O -/O recognized/O Mendelian/O disorder/O known/O to/O demonstrate/O both/O autosomal/O dominant/O and/O autosomal/O recessive/O inheritance/O ./O
Typical/O manifestations/O include/O short/O stature/O ,/O characteristic/O facies/O ,/O and/O skeletal/O anomalies/O ./O
Recessive/O inheritance/O has/O been/O associated/O with/O mutations/O in/O ROR2/O while/O dominant/O inheritance/O has/O been/O observed/O for/O mutations/O in/O WNT5A/O ,/O DVL1/O ,/O and/O DVL3/O ./O
Through/O trio/O whole/O genome/O sequencing/O ,/O we/O identified/O a/O homozygous/B-Var frameshifting/I-Var single/I-Var nucleotide/I-Var deletion/I-Var in/O WNT5A/B-Gene in/O a/O previously/O reported/O ,/O deceased/O infant/O with/O a/O unique/O constellation/O of/O features/O comprising/O a/O 46,XY/O disorder/O of/O sex/O development/O with/O multiple/O congenital/O malformations/O including/O congenital/B-Disease diaphragmatic/I-Disease hernia/I-Disease ,/O ambiguous/B-Disease genitalia/I-Disease ,/O dysmorphic/B-Disease facies/I-Disease ,/O shortened/B-Disease long/I-Disease bones/I-Disease ,/O adactyly/B-Disease ,/O and/O ventricular/B-Disease septal/I-Disease defect/I-Disease ./O
The/O parents/O ,/O who/O are/O both/O heterozygous/O for/O the/O deletion/O ,/O appear/O clinically/O unaffected/O ./O
In/O conjunction/O with/O published/O observations/O of/O Wnt5a/O double/O knockout/O mice/O ,/O we/O provide/O evidence/O for/O the/O possibility/O of/O autosomal/O recessive/O inheritance/O in/O association/O with/O WNT5A/O loss/O -/O of/O -/O function/O mutations/O in/O RS/O ./O
Species/O -/O conserved/O SYNGAP1/O phenotypes/O associated/O with/O neurodevelopmental/O disorders/O ./O
SYNGAP1/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg variants/B-Var are/O causally/O associated/O with/O intellectual/B-Disease disability/I-Disease ,/O severe/B-Disease epilepsy/I-Disease ,/O autism/B-Disease spectrum/I-Disease disorder/I-Disease and/O schizophrenia/B-Disease ./O
While/O there/O are/O hundreds/O of/O genetic/O risk/O factors/O for/O neurodevelopmental/O disorders/O (/O NDDs/O )/O ,/O this/O gene/O is/O somewhat/O unique/O because/O of/O the/O frequency/O and/O penetrance/O of/O loss/O -/O of/O -/O function/O variants/O found/O in/O patients/O combined/O with/O the/O range/O of/O brain/O disorders/O associated/O with/O SYNGAP1/O pathogenicity/O ./O
These/O clinical/O findings/O indicate/O that/O SYNGAP1/O regulates/O fundamental/O neurodevelopmental/O processes/O that/O are/O necessary/O for/O brain/O development/O ./O
Here/O ,/O we/O describe/O four/O phenotypic/O domains/O that/O are/O controlled/O by/O Syngap1/O expression/O across/O vertebrate/O species/O ./O
Two/O domains/O ,/O the/O maturation/O of/O cognitive/O functions/O and/O maintenance/O of/O excitatory/O -/O inhibitory/O balance/O ,/O are/O defined/O exclusively/O through/O a/O review/O of/O the/O current/O literature/O ./O
Two/O additional/O domains/O are/O defined/O by/O integrating/O the/O current/O literature/O with/O new/O data/O indicating/O that/O SYNGAP1/O //O Syngap1/O regulates/O innate/O survival/O behaviors/O and/O brain/O structure/O ./O
These/O four/O phenotypic/O domains/O are/O commonly/O disrupted/O in/O NDDs/O ,/O suggesting/O that/O a/O deeper/O understanding/O of/O developmental/O Syngap1/O functions/O will/O be/O generalizable/O to/O other/O NDDs/O of/O known/O or/O unknown/O etiology/O ./O
Therefore/O ,/O we/O discuss/O the/O known/O molecular/O and/O cellular/O functions/O of/O Syngap1/O and/O consider/O how/O these/O functions/O may/O contribute/O to/O the/O emergence/O of/O disease/O -/O relevant/O phenotypes/O ./O
Finally/O ,/O we/O identify/O major/O unexplored/O areas/O of/O Syngap1/O neurobiology/O and/O discuss/O how/O a/O deeper/O understanding/O of/O this/O gene/O may/O uncover/O general/O principles/O of/O NDD/O pathobiology/O ./O
Loss/O -/O of/O -/O function/O PCSK9/O mutants/O evade/O the/O unfolded/O protein/O response/O sensor/O GRP78/O and/O fail/O to/O induce/O endoplasmic/O reticulum/O stress/O when/O retained/O ./O
The/O proprotein/O convertase/O subtilisin/O //O kexin/O type-9/O (/B-Var PCSK9/I-Var )/I-Var plays/O a/O central/O role/O in/O cardiovascular/B-Disease disease/I-Disease (/O CVD/O )/O by/O degrading/B-NegReg hepatic/B-MPA low/I-MPA -/I-MPA density/I-MPA lipoprotein/I-MPA receptor/I-MPA (/O LDLR/O )/O ./O
As/O such/O ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg (/O LOF/O )/O PCSK9/B-Gene variants/B-Var that/O fail/O to/O exit/O the/O endoplasmic/O reticulum/O (/O ER/O )/O increase/B-PosReg hepatic/B-MPA LDLR/I-MPA levels/I-MPA and/O lower/B-NegReg the/O risk/B-MPA of/I-MPA developing/I-MPA CVD/I-MPA ./O
The/O retention/O of/O misfolded/O protein/O in/O the/O ER/O can/O cause/O ER/O stress/O and/O activate/O the/O unfolded/O protein/O response/O (/O UPR/O )/O ./O
In/O this/O study/O ,/O we/O investigated/O whether/O a/O variety/O of/O LOF/O PCSK9/O variants/O that/O are/O retained/O in/O the/O ER/O can/O cause/O ER/O stress/O and/O hepatic/O cytotoxicity/O ./O
Although/O overexpression/B-PosReg of/O these/O PCSK9/B-Gene variants/B-Var caused/O an/O accumulation/B-PosReg in/O the/O ER/B-MPA of/I-MPA hepatocytes/I-MPA ,/O UPR/O activation/O or/O apoptosis/O was/O not/O observed/O ./O
Furthermore/O ,/O ER/O retention/O of/O endogenous/O PCSK9/O via/O splice/O switching/O also/O failed/O to/O induce/O the/O UPR/O ./O
Consistent/O with/O these/O in/O vitro/O studies/O ,/O overexpression/O of/O PCSK9/O in/O the/O livers/O of/O mice/O had/O no/O impact/O on/O UPR/O activation/O ./O
To/O elucidate/O the/O cellular/O mechanism/O to/O explain/O these/O surprising/O findings/O ,/O we/O observed/O that/O the/O 94-kDa/O glucose/O -/O regulated/O protein/O (/O GRP94/O )/O sequesters/O PCSK9/O away/O from/O the/O 78-kDa/O glucose/O -/O regulated/O protein/O (/O GRP78/O )/O ,/O the/O major/O activator/O of/O the/O UPR/O ./O
As/O a/O result/O ,/O GRP94/O knockdown/O increased/O the/O stability/O of/O GRP78-PCSK9/O complex/O and/O resulted/O in/O UPR/O activation/O following/O overexpression/O of/O ER/O -/O retained/O PCSK9/O variants/O relative/O to/O WT/O secreted/O controls/O ./O
Given/O that/O overexpression/O of/O these/O LOF/O PCSK9/O variants/O does/O not/O cause/O UPR/O activation/O under/O normal/O homeostatic/O conditions/O ,/O therapeutic/O strategies/O aimed/O at/O blocking/O the/O autocatalytic/O cleavage/O of/O PCSK9/O in/O the/O ER/O represent/O a/O viable/O strategy/O for/O reducing/O circulating/O PCSK9/O ./O
CBL/B-Gene mutation/B-Var and/O MEFV/B-Gene single/B-Var -/I-Var nucleotide/I-Var variant/I-Var are/O important/O genetic/O predictors/O of/O tumor/B-Disease reduction/B-NegReg in/O glucocorticoid/O -/O treated/O patients/O with/O chronic/B-Disease myelomonocytic/I-Disease leukemia/I-Disease ./O
Glucocorticoid/O (/O GC/O )/O therapy/O occasionally/O relieves/O tumor/O -/O related/O fever/O and/O promotes/O tumor/O reduction/O in/O patients/O with/O chronic/O myelomonocytic/O leukemia/O (/O CMML/O )/O ./O
A/O mutation/O analysis/O of/O 24/O patients/O with/O CMML/O revealed/O the/O relationship/O of/O GC/O effectiveness/O ,/O defined/O as/O a/O monocyte/O reduction/O of/O >/O 50/O %/O within/O 3/O days/O of/O methylprednisolone/O administration/O ,/O with/O the/O MEFV/O single/O -/O nucleotide/O variant/O (/O SNV/O )/O and/O CBL/O mutation/O ./O
Lipopolysaccharide/O -/O stimulated/O monocytes/O harboring/O MEFV/O E148Q/O produced/O greater/O amounts/O of/O IL-1β/O and/O TNF/O -/O α/O than/O did/O wild/O -/O type/O monocytes/O ;/O this/O was/O effectively/O suppressed/O by/O GC/O ./O
Primary/O CMML/O cells/O harboring/O the/O MEFV/O SNV/O and/O CBL/O mutation/O ,/O and/O the/O myelomonocytic/O leukemia/O cell/O line/O GDM-1/O ,/O harboring/O the/O CBL/O mutation/O ,/O were/O both/O more/O significantly/O suppressed/O than/O non/O -/O mutated/O cells/O following/O GC/O treatment/O in/O the/O presence/O of/O GM/O -/O CSF/O ./O
A/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg CBL/B-Gene mutation/B-Var prolonged/B-PosReg STAT5/B-MPA phosphorylation/I-MPA after/O GM/O -/O CSF/O stimulation/O ,/O which/O was/O rapidly/O terminated/O in/O both/O patient/O samples/O and/O GDM-1/O cells/O ./O
In/O conclusion/O ,/O GC/O therapy/O effectively/O treats/O CMML/O cells/O harboring/O the/O MEFV/O SNV/O and/O CBL/O mutation/O by/O reducing/O inflammatory/O cytokine/O production/O and/O terminating/O prolonged/O STAT5/O phosphorylation/O in/O the/O GM/O -/O CSF/O signaling/O pathway/O ./O
Identification/O of/O a/O unique/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var in/O IGF1R/B-Gene and/O a/O crosstalk/B-Reg between/O IGF1R/B-Gene and/O Wnt/B-Pathway //I-Pathway β/I-Pathway -/I-Pathway catenin/I-Pathway signaling/I-Pathway pathways/I-Pathway ./O
IGF1R/O is/O a/O ubiquitous/O receptor/O tyrosine/O kinase/O that/O plays/O critical/O roles/O in/O cell/O proliferation/O ,/O growth/O and/O survival/O ./O
Clinical/O studies/O have/O demonstrated/O upregulation/O of/O IGF1R/O mediated/O signaling/O in/O a/O number/O of/O malignancies/O including/O colon/O ,/O breast/O ,/O and/O lung/O cancers/O ./O
Overexpression/O of/O the/O IGF1R/O in/O these/O malignancies/O is/O associated/O with/O a/O poor/O prognosis/O and/O overall/O survival/O ./O
IGF1R/O specific/O kinase/O inhibitors/O have/O failed/O in/O multiple/O clinical/O trials/O partly/O because/O of/O the/O complex/O nature/O of/O IGF1R/O signaling/O ./O
Thus/O identifying/O new/O binding/O partners/O and/O allosteric/O sites/O on/O IGF1R/O are/O emerging/O areas/O of/O research/O ./O
More/O recently/O ,/O IGF1R/O has/O been/O shown/O to/O translocate/O into/O the/O nucleus/O and/O perform/O many/O functions/O ./O
In/O this/O study/O ,/O we/O generated/O a/O library/O of/O IGF1R/O deletion/O and/O point/O mutants/O to/O examine/O IGF1R/O subcellular/O localization/O and/O activation/O of/O downstream/O signaling/O pathways/O ./O
We/O show/O that/O the/O nuclear/O localization/O of/O IGF1R/O is/O primarily/O defined/O by/O its/O cytoplasmic/O domain/O ./O
We/O identified/O a/O cross/O -/O talk/O between/O IGF1R/O and/O Wnt/O //O β/O -/O catenin/O signaling/O pathways/O and/O showed/O ,/O for/O the/O first/O time/O ,/O that/O IGF1R/O is/O associated/O with/O upregulation/O of/O TCF/O -/O mediated/O β/O -/O catenin/O transcriptional/O activity/O ./O
Using/O loss/O -/O of/O -/O function/O mutants/O ,/O deletion/O analysis/O and/O IGF1R/O specific/O inhibitor(s/O )/O ,/O we/O show/O that/O cytoplasmic/O and/O nuclear/O activities/O are/O two/O independent/O functions/O of/O IGF1R./O Furthermore/O ,/O we/O identified/O a/O unique/O loss/O -/O of/O -/O function/O mutation/O in/O IGF1R./O This/O unique/O loss/O -/O of/O -/O function/O mutant/O retains/O only/O nuclear/O functions/O and/O sits/O in/O a/O pocket/O ,/O outside/O ATP/O and/O substrate/O binding/O region/O ,/O that/O is/O suited/O for/O designing/O allosteric/O inhibitors/O of/O IGF1R./O Clinical/O variability/O and/O onset/O age/O modifiers/O in/O an/O extended/O Belgian/O GRN/O founder/O family/O ./O
We/O previously/O reported/B-Reg a/O granulin/O (/B-Gene GRN/I-Gene )/I-Gene null/O mutation/B-Var ,/O originating/O from/O a/O common/O founder/O ,/O in/O multiple/O Belgian/O families/O with/O frontotemporal/B-Disease dementia/I-Disease ./O
Here/O ,/O we/O used/O data/O of/O a/O 10-year/O follow/O -/O up/O study/O to/O describe/O in/O detail/O the/O clinical/O heterogeneity/O observed/O in/O this/O extended/O founder/O pedigree/O ./O
We/O identified/O 85/O patients/O and/O 40/O unaffected/O mutation/O carriers/O ,/O belonging/O to/O 29/O branches/O of/O the/O founder/O pedigree/O ./O
Most/O patients/O (/O 74.4/O %/O )/O were/O diagnosed/O with/O frontotemporal/O dementia/O ,/O while/O others/O had/O a/O clinical/O diagnosis/O of/O unspecified/O dementia/O ,/O Alzheimer/O 's/O dementia/O or/O Parkinson/O 's/O disease/O ./O
The/O observed/O clinical/O heterogeneity/O can/O guide/O clinical/O diagnosis/O ,/O genetic/O testing/O ,/O and/O counseling/O of/O mutation/O carriers/O ./O
Onset/O of/O initial/O symptomatology/O is/O highly/O variable/O ,/O ranging/O from/O age/O 45/O to/O 80/O years/O ./O
Analysis/O of/O known/O modifiers/O ,/O suggested/O effects/O of/O GRN/O rs5848/O ,/O microtubule/O -/O associated/O protein/O tau/O H1/O //O H2/O ,/O and/O chromosome/O 9/O open/O reading/O frame/O 72/O G4C2/O repeat/O length/O on/O onset/O age/O but/O explained/O only/O a/O minor/O fraction/O of/O the/O variability/O ./O
Contrary/O ,/O the/O extended/O GRN/O founder/O family/O is/O a/O valuable/O source/O for/O identifying/O other/O onset/O age/O modifiers/O based/O on/O exome/O or/O genome/O sequences/O ./O
These/O modifiers/O might/O be/O interesting/O targets/O for/O developing/O disease/O -/O modifying/O therapies/O ./O
A/O rare/O variant/B-Var in/O MLKL/B-Gene confers/O susceptibility/B-Reg to/O ApoE/O ɛ4-negative/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease in/O Hong/O Kong/O Chinese/O population/O ./O
Alzheimer/O 's/O disease/O (/O AD/O )/O is/O the/O most/O common/O neurodegenerative/O disorders/O in/O the/O elderly/O ./O
To/O identify/O rare/O genetic/O factors/O other/O than/O apolipoprotein/O E/O ɛ4/O allele/O (/O ApoE/O ɛ4/O )/O contributing/O to/O the/O pathogenesis/O of/O late/O -/O onset/O AD/O (/O LOAD/O )/O ,/O we/O conducted/O a/O whole/O -/O exome/O analysis/O of/O 246/O ApoE/O ɛ4-negative/O LOAD/O cases/O and/O 172/O matched/O controls/O in/O Hong/O Kong/O Chinese/O population/O ./O
LOAD/O patients/O showed/O a/O significantly/O higher/O burden/O of/O rare/O loss/O -/O of/O -/O function/O variants/O in/O genes/O related/O to/O immune/O function/O than/O healthy/O controls/O ./O
Among/O the/O genes/O involved/O in/O immune/O function/O ,/O we/O identified/O a/O rare/O stop/O -/O gain/O variant/O (/O p/O ./O Q48X/O )/O in/O mixed/O lineage/O kinase/O domain/O like/O pseudokinase/O (/O MLKL/O )/O gene/O present/O exclusively/O in/O 6/O LOAD/O cases/O ./O
MLKL/B-Gene is/O expressed/O in/O neurons/O ,/O and/O the/O its/O expression/B-MPA levels/I-MPA in/O the/O p/B-Var ./I-Var Q48X/I-Var carriers/O were/O significantly/O lower/B-NegReg than/O that/O in/O age/O -/O matched/O wild/O -/O type/O controls/O ./O
The/O ratio/O of/O Aβ42/O to/O Aβ40/O significantly/O increased/O in/O MLKL/O knockdown/O cells/O compared/O to/O scramble/O controls/O ./O
MLKL/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var might/O contribute/O to/O late/O -/O onset/O ApoE/O ɛ4-negative/O AD/B-Disease in/O the/O Hong/O Kong/O Chinese/O population/O ./O
Investigation/O of/O TRPV1/O loss/O -/O of/O -/O function/O phenotypes/O in/O TRPV1/O Leu206Stop/O mice/O generated/O by/O N/O -/O ethyl/O -/O N/O -/O nitrosourea/O mutagenesis/O ./O
N/O -/O ethyl/O -/O N/O -/O nitrosourea/O (/O ENU/O )/O random/O mutagenesis/O was/O used/O to/O generate/O a/O mouse/O model/O for/O the/O analysis/O of/O the/O transient/O receptor/O potential/O vanilloid/O 1/O (/B-Gene TRPV1/I-Gene )/I-Gene cation/O channel/O ./O
A/O transversion/O from/O T→A/O in/O exon/O 4/O led/O to/O a/O Leu206Stop/B-Var mutation/O generating/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutant/O ./O
The/O TRPV1/O agonist/O capsaicin/O was/O used/O to/O analyze/O functional/O and/O nociceptive/O parameters/O in/O vitro/O and/O in/O vivo/O in/O TRPV1/O Leu206Stop/O mice/O and/O congenic/O C3HeB/O //O FeJ/O controls/O ./O
Capsaicin/B-MPA -/I-MPA induced/I-MPA [/I-MPA Ca2+]i/I-MPA changes/O in/O small/O diameter/O DRG/B-CPA neurons/I-CPA were/O significantly/O diminished/B-NegReg in/O TRPV1/B-Gene Leu206Stop/B-Var mice/O and/O administration/O of/O capsaicin/O induced/O neither/O hypothermia/O nor/O nocifensive/O behaviour/O in/O vivo/O ./O
TRPV1/O Leu206Stop/O mice/O were/O tested/O in/O the/O spinal/O nerve/O ligation/O of/O mononeuropathic/O pain/O and/O developed/O mechanical/O hypersensitivity/O two/O weeks/O after/O nerve/O injury/O ./O
In/O the/O open/O field/O test/O ,/O a/O significant/O increase/B-PosReg in/O spontaneous/B-CPA locomotion/I-CPA was/O detected/O in/O TRPV1/B-Gene Leu206Stop/B-Var mice/O as/O compared/O to/O wildtype/O controls/O ./O
TRPV1/O knockout/O mice/O have/O been/O reported/O to/O carry/O a/O similar/O phenotype/O regarding/O capsaicin/O -/O evoked/O responses/O in/O vitro/O and/O in/O vivo/O ./O
However/O ,/O in/O contrast/O to/O TRPV1/O Leu206Stop/O mice/O ,/O TRPV1/O knockout/O mice/O did/O not/O differ/O in/O spontaneous/O locomotion/O as/O compared/O to/O congenic/O C57BL/6/O mice/O ,/O suggesting/O subtle/O ENU/O -/O dependent/O or/O independent/O strain/O differences/O between/O TRPV1/O Leu206Stop/O mice/O and/O their/O wildtype/O controls/O ./O
In/O summary/O ,/O these/O data/O revealed/O a/O target/O -/O related/O (/O i.e./O capsaicin/O -/O evoked/O )/O phenotype/O of/O TRPV1/O Leu206Stop/O mice/O closely/O resembling/O that/O of/O published/O TRPV1/O knockout/O mice/O ./O
However/O ,/O since/O ENU/O -/O mutant/O mice/O are/O congenic/O with/O the/O mouse/O strain/O initially/O used/O in/O random/O mutagenesis/O ,/O direct/O phenotypic/O comparison/O with/O the/O respective/O wildtype/O controls/O is/O possible/O ,/O and/O the/O time/O -/O consuming/O backcrossing/O in/O lines/O with/O targeted/O mutations/O is/O avoided/O ./O
Biallelic/O TP53/B-Gene gain/B-PosReg of/I-PosReg function/I-PosReg mutations/B-Var in/O rapidly/B-Disease progressing/I-Disease solid/I-Disease tumors/I-Disease ./O
Recent/O studies/O are/O discovering/O TP53/B-Gene mutations/B-Var with/O gain/B-PosReg of/I-PosReg function/I-PosReg (/O GOF/O )/O properties/O that/O promote/O tumorigenesis/B-CPA via/O a/O variety/O of/O mechanisms/O ./O
To/O our/O knowledge/O ,/O all/O reported/O compound/O mutations/O are/O allelic/O ./O
We/O identified/O two/O patients/O with/O biallelic/O GOF/O TP53/O mutations/O in/O their/O tumors/O and/O a/O third/O with/O allelic/O compound/O variants/O ./O
The/O correlation/O with/O p53/O expression/O was/O also/O examined/O ./O
Genomic/O DNA/O was/O extracted/O from/O formalin/O -/O fixed/O ,/O paraffin/O -/O embedded/O tissue/O and/O mutational/O analysis/O was/O performed/O using/O Ion/O AmpliSeq/O ™/O Cancer/O HotSpot/O Panel/O V2/O ./O
Biallelic/O GOF/B-PosReg mutations/O (/B-Var p/I-Var ./I-Var R273H/I-Var and/O p/B-Var ./I-Var R273C/I-Var )/I-Var were/O identified/O in/O a/O 19-year/O -/O old/O male/O with/O glioblastoma/B-Disease (/O allele/O frequencies/O 94/O %/O and/O 48/O %/O )/O and/O a/O 54-year/O -/O old/O with/O pT3/O penile/O squamous/O cell/O carcinoma/O (/O allele/O frequencies/O 19/O %/O and/O 27/O %/O )/O ./O
Immunohistochemistry/O showed/O nuclear/O accumulation/O of/O p53/O ./O
The/O third/O patient/O ,/O a/O 62-year/O -/O old/O female/O with/O metastatic/B-Disease lung/I-Disease adenocarcinoma/I-Disease ,/O had/O allelic/O p/B-Var ./I-Var P278S/I-Var (/B-PosReg GOF/I-PosReg )/I-PosReg and/O p/B-Var ./I-Var R283L/I-Var (/B-Reg non/I-Reg -/I-Reg GOF/I-Reg )/I-Reg variants/O at/O frequencies/O of/O 61/O %/O but/O with/O null/O staining/O for/O p53/O ./O
Germline/O testing/O for/O Patient/O 1/O confirmed/O wildtype/O TP53/O ./O
No/O other/O variants/O were/O discovered/O among/O the/O genes/O tested/O in/O these/O cases/O ./O
All/O patients/O succumbed/O within/O two/O years/O of/O diagnosis/O despite/O aggressive/O treatment/O ./O
In/O conclusion/O ,/O implementation/O of/O TP53/O mutation/O analysis/O in/O clinical/O practice/O may/O predict/O patient/O outcome/O ,/O and/O inhibition/O of/O GOF/O p53/O could/O represent/O an/O attractive/O target/O for/O therapy/O ./O
Germline/O pathogenic/O variants/O in/O PALB2/O and/O other/O cancer/O -/O predisposing/O genes/O in/O families/O with/O hereditary/O diffuse/O gastric/O cancer/O without/O CDH1/O mutation/O :/O a/O whole/O -/O exome/O sequencing/O study/O ./O
BACKGROUND/O :/O Germline/O pathogenic/O variants/B-Var in/O the/O E/O -/O cadherin/O gene/O (/B-Gene CDH1/I-Gene )/I-Gene are/O strongly/O associated/B-Reg with/I-Reg the/O development/O of/O hereditary/B-Disease diffuse/I-Disease gastric/I-Disease cancer/I-Disease ./O
There/O is/O a/O paucity/O of/O data/O to/O guide/O risk/O assessment/O and/O management/O of/O families/O with/O hereditary/O diffuse/O gastric/O cancer/O that/O do/O not/O carry/O a/O CDH1/O pathogenic/O variant/O ,/O making/O it/O difficult/O to/O make/O informed/O decisions/O about/O surveillance/O and/O risk/O -/O reducing/O surgery/O ./O
We/O aimed/O to/O identify/O new/O candidate/O genes/O associated/O with/O predisposition/O to/O hereditary/O diffuse/O gastric/O cancer/O in/O affected/O families/O without/O pathogenic/O CDH1/O variants/O ./O
METHODS/O :/O We/O did/O whole/O -/O exome/O sequencing/O on/O DNA/O extracted/O from/O the/O blood/O of/O 39/O individuals/O (/O 28/O individuals/O diagnosed/O with/O hereditary/O diffuse/O gastric/O cancer/O and/O 11/O unaffected/O first/O -/O degree/O relatives/O )/O in/O 22/O families/O without/O pathogenic/O CDH1/O variants/O ./O
Genes/O with/O loss/O -/O of/O -/O function/O variants/O were/O prioritised/O using/O gene/O -/O interaction/O analysis/O to/O identify/O clusters/O of/O genes/O that/O could/O be/O involved/O in/O predisposition/O to/O hereditary/O diffuse/O gastric/O cancer/O ./O
FINDINGS/O :/O Protein/O -/O affecting/O germline/O variants/O were/O identified/O in/O probands/O from/O six/O families/O with/O hereditary/O diffuse/O gastric/O cancer/O ;/O variants/O were/O found/O in/O genes/O known/O to/O predispose/O to/O cancer/O and/O in/O lesser/O -/O studied/O DNA/O repair/O genes/O ./O
A/O frameshift/B-Var deletion/I-Var in/O PALB2/B-Gene was/O found/B-Reg in/O one/O member/O of/O a/O family/O with/O a/O history/O of/O gastric/B-Disease and/O breast/B-Disease cancer/I-Disease ./O
Two/O different/O MSH2/O variants/O were/O identified/O in/O two/O unrelated/O affected/O individuals/O ,/O including/O one/O frameshift/O insertion/O and/O one/O previously/O described/O start/O -/O codon/O loss/O ./O
One/O family/O had/O a/O unique/O combination/O of/O variants/O in/O the/O DNA/O repair/O genes/O ATR/O and/O NBN/O ./O
Two/O variants/O in/O the/O DNA/O repair/O gene/O RECQL5/O were/O identified/O in/O two/O unrelated/O families/O :/O one/O missense/O variant/O and/O a/O splice/O -/O acceptor/O variant/O ./O
INTERPRETATION/O :/O The/O results/O of/O this/O study/O suggest/O a/O role/O for/O the/O known/O cancer/O predisposition/O gene/O PALB2/O in/O families/O with/O hereditary/O diffuse/O gastric/O cancer/O and/O no/O detected/O pathogenic/O CDH1/O variants/O ./O
We/O also/O identified/O new/O candidate/O genes/O associated/O with/O disease/O risk/O in/O these/O families/O ./O
FUNDING/O :/O UK/O Medical/O Research/O Council/O (/O Sackler/O programme/O )/O ,/O European/O Research/O Council/O under/O the/O European/O Union/O 's/O Seventh/O Framework/O Programme/O (/O 2007/O -/O 13/O )/O ,/O National/O Institute/O for/O Health/O Research/O Cambridge/O Biomedical/O Research/O Centre/O ,/O Experimental/O Cancer/O Medicine/O Centres/O ,/O and/O Cancer/O Research/O UK/O ./O
Melanocortin/O 4/O Receptor/O Pathway/O Dysfunction/O in/O Obesity/O :/O Patient/O Stratification/O Aimed/O at/O MC4R/O Agonist/O Treatment/O ./O
Context/O :/O The/O hypothalamic/O melanocortin/O 4/O receptor/O (/O MC4R/O )/O pathway/O serves/O a/O critical/O role/O in/O regulating/O body/O weight/O ./O
Loss/B-NegReg of/I-NegReg function/I-NegReg (/O LoF/O )/O mutations/B-Var in/O the/O MC4R/B-Pathway pathway/I-Pathway ,/O including/O mutations/O in/O the/O pro/O -/O opiomelanocortin/O (/B-Gene POMC/I-Gene )/I-Gene ,/O prohormone/O convertase/O 1/O (/B-Gene PCSK1/I-Gene )/I-Gene ,/O leptin/O receptor/O (/B-Gene LEPR/I-Gene )/I-Gene ,/O or/O MC4R/B-Gene genes/O ,/O have/O been/O shown/O to/O cause/O early/B-Disease -/I-Disease onset/I-Disease severe/I-Disease obesity/I-Disease ./O
Methods/O :/O Through/O a/O comprehensive/O epidemiological/O analysis/O of/O known/O and/O predicted/O LoF/O variants/O in/O the/O POMC/O ,/O PCSK1/O ,/O and/O LEPR/O genes/O ,/O we/O sought/O to/O estimate/O the/O number/O of/O US/O individuals/O with/O biallelic/O MC4R/O pathway/O LoF/O variants/O ./O
Results/O :/O We/O predict/O ~650/O α/O -/O melanocyte/O -/O stimulating/O hormone/O (/O MSH)/POMC/O ,/O 8500/O PCSK1/O ,/O and/O 3600/O LEPR/O homozygous/O and/O compound/O heterozygous/O individuals/O in/O the/O United/O States/O ,/O cumulatively/O enumerating/O >/O 12,800/O MC4R/O pathway/O -/O deficient/O obese/O patients/O ./O
Few/O of/O these/O variants/O have/O been/O genetically/O diagnosed/O to/O date/O ./O
These/O estimates/O increase/O when/O we/O include/O a/O small/O subset/O of/O less/O rare/O variants/O :/O β/O -/O MSH/O //O POMC/O ,/O PCSK1/O N221D/O ,/O and/O a/O PCSK1/O LoF/O variant/O (/O T640A/O )/O ./O
To/O further/O define/O the/O MC4R/O pathway/O and/O its/O potential/O impact/O on/O obesity/O ,/O we/O tested/O associations/O between/O body/O mass/O index/O (/O BMI/O )/O and/O LoF/O mutation/O burden/O in/O the/O POMC/O ,/O PCSK1/O ,/O and/O LEPR/O genes/O in/O various/O populations/O ./O
We/O show/O that/O the/O cumulative/O allele/O burden/O in/O individuals/O with/O two/O or/O more/O LoF/O alleles/O in/O one/O or/O more/O genes/O in/O the/O MC4R/O pathway/O are/O predisposed/O to/O a/O higher/O BMI/O than/O noncarriers/O or/O heterozygous/O LoF/O carriers/O with/O a/O defect/O in/O only/O one/O gene/O ./O
Conclusions/O :/O Our/O analysis/O represents/O a/O genetically/O rationalized/O study/O of/O the/O hypothalamic/O MC4R/O pathway/O aimed/O at/O genetic/O patient/O stratification/O to/O determine/O which/O obese/O subpopulations/O should/O be/O studied/O to/O elucidate/O MC4R/O agonist/O (/O e.g./O ,/O setmelanotide/O )/O treatment/O responsiveness/O ./O
Mutations/B-Var in/O C11orf70/B-Gene Cause/B-Reg Primary/B-Disease Ciliary/I-Disease Dyskinesia/I-Disease with/O Randomization/O of/O Left/O //O Right/O Body/O Asymmetry/O Due/O to/O Defects/B-NegReg of/O Outer/B-Protein and/I-Protein Inner/I-Protein Dynein/I-Protein Arms/I-Protein ./O
Primary/O ciliary/O dyskinesia/O (/O PCD/O )/O is/O characterized/O by/O chronic/O airway/O disease/O ,/O male/O infertility/O ,/O and/O randomization/O of/O the/O left/O //O right/O body/O axis/O as/O a/O result/O of/O defects/O of/O motile/O cilia/O and/O sperm/O flagella/O ./O
We/O identified/O loss/O -/O of/O -/O function/O mutations/O in/O the/O open/O -/O reading/O frame/O C11orf70/O in/O PCD/O individuals/O from/O five/O distinct/O families/O ./O
Transmission/O electron/O microscopy/O analyses/O and/O high/O -/O resolution/O immunofluorescence/O microscopy/O demonstrate/O that/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O C11orf70/B-Gene cause/O immotility/B-CPA of/O respiratory/B-CPA cilia/I-CPA and/O sperm/B-CPA flagella/I-CPA ,/O respectively/O ,/O as/O a/O result/O of/O the/O loss/B-NegReg of/O axonemal/B-Protein outer/I-Protein (/O ODAs/O )/O and/O inner/B-Protein dynein/I-Protein arms/I-Protein (/O IDAs/O )/O ,/O indicating/O that/O C11orf70/O is/O involved/O in/O cytoplasmic/O assembly/O of/O dynein/O arms/O ./O
Expression/O analyses/O of/O C11orf70/O showed/O that/O C11orf70/O is/O expressed/O in/O ciliated/O respiratory/O cells/O and/O that/O the/O expression/O of/O C11orf70/O is/O upregulated/O during/O ciliogenesis/O ,/O similar/O to/O other/O previously/O described/O cytoplasmic/O dynein/O -/O arm/O assembly/O factors/O ./O
Furthermore/O ,/O C11orf70/O shows/O an/O interaction/O with/O cytoplasmic/O ODA/O //O IDA/O assembly/O factor/O DNAAF2/O ,/O supporting/O our/O hypothesis/O that/O C11orf70/O is/O a/O preassembly/O factor/O involved/O in/O the/O pathogenesis/O of/O PCD/O ./O
The/O identification/O of/O additional/O genetic/O defects/O that/O cause/O PCD/O and/O male/O infertility/O is/O of/O great/O importance/O for/O the/O clinic/O as/O well/O as/O for/O genetic/O counselling/O ./O
De/O novo/O and/O inherited/O private/O variants/B-Var in/O MAP1B/B-Gene in/O periventricular/B-Disease nodular/I-Disease heterotopia/I-Disease ./O
Periventricular/O nodular/O heterotopia/O (/O PVNH/O )/O is/O a/O malformation/O of/O cortical/O development/O commonly/O associated/O with/O epilepsy/O ./O
We/O exome/O sequenced/O 202/O individuals/O with/O sporadic/O PVNH/O to/O identify/O novel/O genetic/O risk/O loci/O ./O
We/O first/O performed/O a/O trio/O -/O based/O analysis/O and/O identified/O 219/O de/O novo/O variants/O ./O
Although/O no/O novel/O genes/O were/O implicated/O in/O this/O initial/O analysis/O ,/O PVNH/O cases/O were/O found/O overall/O to/O have/O a/O significant/O excess/O of/O nonsynonymous/O de/O novo/O variants/O in/O intolerant/O genes/O (/O p/O =/O 3.27x10/O -/O 7/O )/O ,/O suggesting/O a/O role/O for/O rare/O new/O alleles/O in/O genes/O yet/O to/O be/O associated/O with/O the/O condition/O ./O
Using/O a/O gene/O -/O level/O collapsing/O analysis/O comparing/O cases/O and/O controls/O ,/O we/O identified/O a/O genome/O -/O wide/O significant/O signal/O driven/O by/O four/O ultra/O -/O rare/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg heterozygous/O variants/B-Var in/O MAP1B/B-Gene ,/O including/O one/O de/O novo/O variant/O ./O
In/O at/O least/O one/O instance/O ,/O the/O MAP1B/B-Gene variant/B-Var was/O inherited/B-Reg from/I-Reg a/O parent/O with/O previously/O undiagnosed/O PVNH/B-Disease ./O
The/O PVNH/O was/O frontally/O predominant/O and/O associated/O with/O perisylvian/O polymicrogyria/O ./O
These/O results/O implicate/O MAP1B/O in/O PVNH/O ./O
More/O broadly/O ,/O our/O findings/O suggest/O that/O detrimental/O mutations/O likely/O arising/O in/O immediately/O preceding/O generations/O with/O incomplete/O penetrance/O may/O also/O be/O responsible/O for/O some/O apparently/O sporadic/O diseases/O ./O
Protein/B-Enzyme kinase/I-Enzyme Cα/I-Enzyme gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg variant/B-Var in/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease displays/O enhanced/B-PosReg catalysis/B-MPA by/O a/O mechanism/O that/O evades/O down/O -/O regulation/O ./O
Conventional/O protein/O kinase/O C/O (/O PKC/O )/O family/O members/O are/O reversibly/O activated/O by/O binding/O to/O the/O second/O messengers/O Ca2/O +/O and/O diacylglycerol/O ,/O events/O that/O break/O autoinhibitory/O constraints/O to/O allow/O the/O enzyme/O to/O adopt/O an/O active/O ,/O but/O degradation/O -/O sensitive/O ,/O conformation/O ./O
Perturbing/O these/O autoinhibitory/O constraints/O ,/O resulting/O in/O protein/O destabilization/O ,/O is/O one/O of/O many/O mechanisms/O by/O which/O PKC/O function/O is/O lost/O in/O cancer/O ./O
Here/O ,/O we/O address/O how/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg germline/B-Var mutation/I-Var in/O PKCα/B-Enzyme in/O Alzheimer/B-Disease 's/I-Disease disease/I-Disease (/O AD/O )/O enhances/B-PosReg signaling/B-MPA without/O increasing/O vulnerability/O to/O down/O -/O regulation/O ./O
Biochemical/O analyses/O of/O purified/O protein/O demonstrate/O that/O this/O mutation/B-Var results/O in/O an/O ∼30/O %/O increase/B-PosReg in/O the/O catalytic/B-MPA rate/O of/O the/O activated/O enzyme/O ,/O with/O no/O changes/O in/O the/O concentrations/O of/O Ca2/O +/O or/O lipid/O required/O for/O half/O -/O maximal/O activation/O ./O
Molecular/O dynamics/O simulations/O reveal/O that/O this/O mutation/B-Var has/O both/O localized/O and/O allosteric/O effects/O ,/O most/O notably/O decreasing/B-NegReg the/O dynamics/B-MPA of/I-MPA the/I-MPA C/I-MPA -/I-MPA helix/I-MPA ,/O a/O key/O determinant/O in/O the/O catalytic/O turnover/O of/O kinases/O ./O
Consistent/O with/O this/O mutation/O not/O altering/O autoinhibitory/O constraints/O ,/O live/O -/O cell/O imaging/O studies/O reveal/O that/O the/O basal/O signaling/O output/O of/O PKCα/O -/O M489V/O is/O unchanged/O ./O
However/O ,/O the/O mutant/B-Var enzyme/B-Enzyme in/O cells/O displays/O increased/B-PosReg sensitivity/B-MPA to/O an/O inhibitor/O that/O is/O ineffective/O toward/O scaffolded/O PKC/O ,/O suggesting/O the/O altered/O dynamics/O of/O the/O kinase/O domain/O may/O influence/B-Reg protein/B-Protein interactions/B-Interaction ./O
Finally/O ,/O we/O show/O that/O phosphorylation/B-MPA of/O a/O key/O PKC/O substrate/O ,/O myristoylated/B-MPA alanine/I-MPA -/I-MPA rich/I-MPA C/I-MPA -/I-MPA kinase/I-MPA substrate/I-MPA ,/O is/O increased/B-PosReg in/O brains/O of/O CRISPR/O -/O Cas9/O genome/O -/O edited/O mice/O containing/O the/O PKCα/B-Var -/I-Var M489V/I-Var mutation/I-Var ./O
Our/O results/O unveil/O how/O an/O AD/B-Reg -/I-Reg associated/I-Reg mutation/B-Var in/O PKCα/B-Enzyme permits/O enhanced/B-PosReg agonist/B-MPA -/I-MPA dependent/I-MPA signaling/I-MPA via/O a/O mechanism/O that/O evades/B-NegReg the/O cell/O 's/O homeostatic/B-MPA down/I-MPA -/I-MPA regulation/I-MPA of/O constitutively/B-Enzyme active/I-Enzyme PKCα/I-Enzyme ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg KCNJ6/B-Gene Mutation/B-Var in/O a/O Severe/B-Disease Hyperkinetic/I-Disease Movement/I-Disease Disorder/I-Disease Phenotype/O ./O
Here/O ,/O we/O describe/O a/O fourth/O case/O of/O a/O human/O with/O a/O de/O novo/O KCNJ6/B-Gene (/O GIRK2/O )/O mutation/B-Var ,/O who/O presented/B-Reg with/O clinical/O findings/O of/O severe/B-Disease hyperkinetic/I-Disease movement/I-Disease disorder/I-Disease and/O developmental/B-CPA delay/I-CPA ,/O similar/O to/O the/O Keppen/O -/O Lubinsky/O syndrome/O but/O without/O lipodystrophy/O ./O
Whole/O -/O exome/O sequencing/O of/O the/O patient/O 's/O DNA/O revealed/O a/O heterozygous/O de/O novo/O variant/O in/O the/O KCNJ6/B-Gene (/B-Var c.512T/I-Var >/I-Var G/I-Var ,/O p/B-Var ./I-Var Leu171Arg/I-Var )/I-Var ./O
We/O conducted/O in/O vitro/O functional/O studies/O to/O determine/O if/O this/O Leu/O -/O to/O -/O Arg/O mutation/O alters/O the/O function/O of/O GIRK2/O channels/O ./O
Heterologous/O expression/O of/O the/O mutant/B-Var GIRK2/B-Gene channel/O alone/O produced/B-PosReg an/O aberrant/O basal/B-MPA inward/I-MPA current/I-MPA that/O lacked/B-NegReg G/B-Protein protein/I-Protein activation/B-MPA ,/O lost/B-NegReg K+/B-MPA selectivity/I-MPA and/O gained/B-PosReg Ca2/B-MPA +/I-MPA permeability/I-MPA ./O
Notably/O ,/O the/O inward/O current/O was/O inhibited/O by/O the/O Na+/O channel/O blocker/O QX-314/O ,/O similar/O to/O the/O previously/O reported/O weaver/O mutation/O in/O murine/O GIRK2/O ./O
Expression/O of/O a/O tandem/O dimer/O containing/O GIRK1/O and/O GIRK2(p/O ./O
Leu171Arg/O )/O did/O not/O lead/O to/O any/O currents/O ,/O suggesting/O heterotetramers/O are/O not/O functional/O ./O
In/O neurons/O expressing/O p/B-Var ./I-Var Leu171Arg/I-Var GIRK2/B-Gene channels/O ,/O these/O changes/O in/O channel/O properties/O would/O be/O expected/O to/O generate/O a/O sustained/O depolarization/B-NegReg ,/O instead/O of/O the/O normal/O G/B-MPA protein/I-MPA -/I-MPA gated/I-MPA inhibitory/I-MPA response/I-MPA ,/O which/O could/O be/O mitigated/O by/O expression/O of/O other/O GIRK/O subunits/O ./O
The/O identification/O of/O the/O p/O ./O Leu171Arg/O GIRK2/O mutation/O potentially/O expands/O the/O Keppen/O -/O Lubinsky/O syndrome/O phenotype/O to/O include/O severe/O dystonia/O and/O ballismus/O ./O
Our/O study/O suggests/O screening/O for/O dominant/O KCNJ6/O mutations/O in/O the/O evaluation/O of/O patients/O with/O severe/O movement/O disorders/O ,/O which/O could/O provide/O evidence/O to/O support/O a/O causal/O role/O of/O KCNJ6/O in/O neurological/O channelopathies/O ./O
De/O Novo/O and/O Inherited/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg Function/I-NegReg Variants/B-Var in/O TLK2/B-Gene :/I-Gene Clinical/O and/O Genotype/O -/O Phenotype/O Evaluation/O of/O a/O Distinct/B-Disease Neurodevelopmental/I-Disease Disorder/I-Disease ./O
Next/O -/O generation/O sequencing/O is/O a/O powerful/O tool/O for/O the/O discovery/O of/O genes/O related/O to/O neurodevelopmental/O disorders/O (/O NDDs/O )/O ./O
Here/O ,/O we/O report/O the/O identification/O of/O a/O distinct/O syndrome/O due/O to/O de/O novo/O or/O inherited/O heterozygous/O mutations/O in/O Tousled/O -/O like/O kinase/O 2/O (/O TLK2/O )/O in/O 38/O unrelated/O individuals/O and/O two/O affected/O mothers/O ,/O using/O whole/O -/O exome/O and/O whole/O -/O genome/O sequencing/O technologies/O ,/O matchmaker/O databases/O ,/O and/O international/O collaborations/O ./O
Affected/O individuals/O had/O a/O consistent/O phenotype/O ,/O characterized/O by/O mild/O -/O borderline/O neurodevelopmental/O delay/O (/O 86/O %/O )/O ,/O behavioral/O disorders/O (/O 68/O %/O )/O ,/O severe/O gastro/O -/O intestinal/O problems/O (/O 63/O %/O )/O ,/O and/O facial/O dysmorphism/O including/O blepharophimosis/O (/O 82/O %/O )/O ,/O telecanthus/O (/O 74/O %/O )/O ,/O prominent/O nasal/O bridge/O (/O 68/O %/O )/O ,/O broad/O nasal/O tip/O (/O 66/O %/O )/O ,/O thin/O vermilion/O of/O the/O upper/O lip/O (/O 62/O %/O )/O ,/O and/O upslanting/O palpebral/O fissures/O (/O 55/O %/O )/O ./O
Analysis/O of/O cell/O lines/O from/O three/O affected/O individuals/O showed/O that/O mutations/O act/O through/O a/O loss/O -/O of/O -/O function/O mechanism/O in/O at/O least/O two/O case/O subjects/O ./O
Genotype/O -/O phenotype/O analysis/O and/O comparison/O of/O computationally/O modeled/O faces/O showed/O that/O phenotypes/O of/O these/O and/O other/O individuals/O with/O loss/O -/O of/O -/O function/O variants/O significantly/O overlapped/O with/O phenotypes/O of/O individuals/O with/O other/O variant/O types/O (/O missense/O and/O C/O -/O terminal/O truncating/O )/O ./O
This/O suggests/O that/O haploinsufficiency/O of/O TLK2/O is/O the/O most/O likely/O underlying/O disease/O mechanism/O ,/O leading/O to/O a/O consistent/O neurodevelopmental/O phenotype/O ./O
This/O work/O illustrates/O the/O power/O of/O international/O data/O sharing/O ,/O by/O the/O identification/O of/O 40/O individuals/O from/O 26/O different/O centers/O in/O 7/O different/O countries/O ,/O allowing/O the/O identification/O ,/O clinical/O delineation/O ,/O and/O genotype/O -/O phenotype/O evaluation/O of/O a/O distinct/O NDD/O caused/O by/O mutations/O in/O TLK2/O ./O
Progranulin/O as/O a/O therapeutic/O target/O for/O dementia/O ./O
INTRODUCTION/O :/O Progranulin/O (/O PGRN/O )/O is/O an/O acrosomal/O glycoprotein/O that/O is/O synthesized/O during/O spermatogenesis/O ./O
It/O is/O overexpressed/O in/O tumors/O and/O has/O anti/O -/O inflammatory/O properties/O ./O
The/O protein/O may/O be/O cleaved/O into/O granulins/O which/O display/O pro/O -/O inflammatory/O properties/O ./O
In/O 2006/O ,/O mutations/B-Var in/O progranulin/O gene/O (/B-Gene GRN/I-Gene )/I-Gene that/O cause/O haploinsufficiency/O were/O found/O in/O familial/O cases/B-Reg of/O frontotemporal/B-Disease dementia/I-Disease (/O FTD/O )/O ./O
Patients/O with/O null/O mutations/O in/O GRN/O display/O very/O low/O -/O plasma/O PGRN/O levels/O ;/O this/O analysis/O is/O useful/O for/O identifying/O mutation/O carriers/O ,/O independent/O of/O the/O clinical/O presentation/O ,/O and/O in/O those/O before/O the/O appearance/O of/O symptoms/O ./O
Areas/O covered/O :/O Here/O ,/O we/O review/O the/O current/O knowledge/O of/O PGRN/O physiological/O functions/O and/O GRN/O mutations/O associated/O with/O FTD/O ;/O we/O also/O summarize/O state/O of/O the/O art/O clinical/O trials/O and/O those/O compounds/O able/O to/O replace/O PGRN/O loss/O in/O preclinical/O models/O ./O
Expert/O opinion/O :/O PGRN/O represents/O a/O promising/O therapeutic/O target/O for/O FTD/O ./O
Cohorts/O suitable/O for/O treatment/O ,/O ideally/O at/O the/O preclinical/O stage/O ,/O where/O pathogenic/O mechanisms/O ongoing/O in/O the/O brain/O are/O targeted/O ,/O are/O available/O ./O
However/O ,/O PGRN/O may/O have/O side/O effects/O ,/O such/O as/O the/O risk/O of/O tumorigenesis/O ,/O and/O the/O risk/O //O benefit/O ratio/O of/O any/O intervention/O can/O not/O be/O predicted/O ./O
Furthermore/O ,/O at/O present/O ,/O the/O situation/O is/O complicated/O by/O the/O absence/O of/O adequate/O outcome/O measures/O ./O
Quantitative/O phosphoproteomic/O analysis/O of/O the/O molecular/O substrates/O of/O sleep/O need/O ./O
Sleep/O and/O wake/O have/O global/O effects/O on/O brain/O physiology/O ,/O from/O molecular/O changes1/O -/O 4/O and/O neuronal/O activities/O to/O synaptic/O plasticity3/O -/O 7/O ./O
Sleep/O -/O wake/O homeostasis/O is/O maintained/O by/O the/O generation/O of/O a/O sleep/O need/O that/O accumulates/O during/O waking/O and/O dissipates/O during/O sleep8/O -/O 11/O ./O
Here/O we/O investigate/O the/O molecular/O basis/O of/O sleep/O need/O using/O quantitative/O phosphoproteomic/O analysis/O of/O the/O sleep/O -/O deprived/O and/O Sleepy/O mouse/O models/O of/O increased/O sleep/O need/O ./O
Sleep/O deprivation/O induces/O cumulative/O phosphorylation/O of/O the/O brain/O proteome/O ,/O which/O dissipates/O during/O sleep/O ./O
Sleepy/O mice/O ,/O owing/O to/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O the/O Sik3/B-Gene gene/O 12/O ,/O have/O a/O constitutively/O high/O sleep/O need/O despite/O increased/O sleep/O amount/O ./O
The/O brain/B-Protein proteome/I-Protein of/O these/O mice/O exhibits/O hyperphosphorylation/B-MPA ,/O similar/O to/O that/O seen/O in/O the/O brain/O of/O sleep/O -/O deprived/O mice/O ./O
Comparison/O of/O the/O two/O models/O identifies/O 80/O mostly/O synaptic/O sleep/O -/O need/O -/O index/O phosphoproteins/O (/O SNIPPs/O )/O ,/O in/O which/O phosphorylation/O states/O closely/O parallel/O changes/O of/O sleep/O need/O ./O
SLEEPY/O ,/O the/O mutant/B-Var SIK3/B-Gene protein/B-Protein ,/O preferentially/B-PosReg associates/B-Interaction with/I-Interaction and/O phosphorylates/B-MPA SNIPPs/B-Protein ./O
Inhibition/O of/O SIK3/O activity/O reduces/O phosphorylation/O of/O SNIPPs/O and/O slow/O wave/O activity/O during/O non/O -/O rapid/O -/O eye/O -/O movement/O sleep/O ,/O the/O best/O known/O measurable/O index/O of/O sleep/O need/O ,/O in/O both/O Sleepy/O mice/O and/O sleep/O -/O deprived/O wild/O -/O type/O mice/O ./O
Our/O results/O suggest/O that/O phosphorylation/O of/O SNIPPs/O accumulates/O and/O dissipates/O in/O relation/O to/O sleep/O need/O ,/O and/O therefore/O SNIPP/O phosphorylation/O is/O a/O molecular/O signature/O of/O sleep/O need/O ./O
Whereas/O waking/O encodes/O memories/O by/O potentiating/O synapses/O ,/O sleep/O consolidates/O memories/O and/O restores/O synaptic/O homeostasis/O by/O globally/O downscaling/O excitatory/O synapses4/O -/O 6/O ./O
Thus/O ,/O the/O phosphorylation/O -/O dephosphorylation/O cycle/O of/O SNIPPs/O may/O represent/O a/O major/O regulatory/O mechanism/O that/O underlies/O both/O synaptic/O homeostasis/O and/O sleep/O -/O wake/O homeostasis/O ./O
Germline/O mutations/O and/O somatic/O inactivation/O of/O TRIM28/O in/O Wilms/O tumour/O ./O
Wilms/O tumour/O is/O a/O childhood/O tumour/O that/O arises/O as/O a/O consequence/O of/O somatic/O and/O rare/O germline/O mutations/O ,/O the/O characterisation/O of/O which/O has/O refined/O our/O understanding/O of/O nephrogenesis/O and/O carcinogenesis/O ./O
Here/O we/O report/O that/O germline/O loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var in/O TRIM28/B-Gene predispose/O children/O to/O Wilms/B-Disease tumour/I-Disease ./O
Loss/O of/O function/O of/O this/O transcriptional/O co/O -/O repressor/O ,/O which/O has/O a/O role/O in/O nephrogenesis/O ,/O has/O not/O previously/O been/O associated/O with/O cancer/O ./O
Inactivation/B-NegReg of/O TRIM28/B-Gene ,/O either/O germline/O or/O somatic/O ,/O occurred/O through/O inactivating/B-Var mutations/I-Var ,/O loss/B-Var of/I-Var heterozygosity/I-Var or/O epigenetic/B-Var silencing/I-Var ./O
TRIM28-mutated/O tumours/O had/O a/O monomorphic/O epithelial/O histology/O that/O is/O uncommon/O for/O Wilms/O tumour/O ./O
Critically/O ,/O these/O tumours/O were/O negative/O for/O TRIM28/O immunohistochemical/O staining/O whereas/O the/O epithelial/O component/O in/O normal/O tissue/O and/O other/O Wilms/O tumours/O stained/O positively/O ./O
These/O data/O ,/O together/O with/O a/O characteristic/O gene/O expression/O profile/O ,/O suggest/O that/O inactivation/O of/O TRIM28/O provides/O the/O molecular/O basis/O for/O defining/O a/O previously/O described/O subtype/O of/O Wilms/O tumour/O ,/O that/O has/O early/O age/O of/O onset/O and/O excellent/O prognosis/O ./O
Mutational/O and/O functional/O studies/O on/O NR5A1/B-Gene gene/O in/O 46,XY/B-Disease disorders/I-Disease of/I-Disease sex/I-Disease development/I-Disease :/I-Disease identification/O of/O six/O novel/O loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var ./O
OBJECTIVE/O :/O To/O study/O the/O functional/O properties/O of/O six/O novel/O missense/O mutations/O of/O the/O NR5A1/O gene/O encoding/O the/O steroidogenic/O factor/O 1/O (/O SF-1/O )/O identified/O in/O six/O patients/O with/O 46,XY/O disorders/O of/O sex/O development/O (/O DSD/O )/O and/O to/O describe/O their/O relative/O phenotype/O -/O genotype/O relationship/O ./O
DESIGN/O :/O Genetic/O and/O functional/O studies/O ./O
SETTING/O :/O University/O department/O ./O
PATIENT(S/O )/O :/O Six/O 46,XY/O DSD/O patients/O ./O
INTERVENTION(S/O )/O :/O None/O ./O
MAIN/O OUTCOME/O MEASURE(S/O )/O :/O Sanger/O sequencing/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O analysis/O to/O identify/O the/O mutations/O or/O deletions/O //O duplications/O of/O the/O NR5A1/O gene/O ./O
Functional/O studies/O by/O transactivation/O assays/O to/O predict/O the/O impact/O of/O mutations/O on/O molecular/O function/O ./O
RESULT(S/O )/O :/O NR5A1/B-Gene exons/O sequencing/O identified/B-Reg in/I-Reg six/O 46,XY/B-Disease DSD/I-Disease patients/O six/O novel/O mutations/O :/O p/B-Var ./I-Var T40R/I-Var ,/O p/B-Var ./I-Var T47C/I-Var ,/O p/B-Var ./I-Var G328W/I-Var ,/O p/B-Var ./I-Var A351E/I-Var ,/O p/B-Var ./I-Var R427W/I-Var ,/O and/O p/B-Var ./I-Var Q460R./I-Var Five/O missense/O variants/O were/O heterozygous/O ,/O and/O one/O was/O homozygous/O (/O p/O ./O R427W/O )/O ./O
Functional/O analysis/O revealed/O a/O significant/O loss/B-NegReg of/O DNA/B-Interaction -/I-Interaction binding/I-Interaction and/O transactivation/B-MPA ability/O for/O all/O variants/O ,/O except/O for/O p/O ./O Q460R/O ,/O which/O showed/O a/O modest/O reduced/O activity/O compared/O with/O that/O of/O the/O wild/O -/O type/O protein/O ./O
Phenotypes/O associated/O with/O these/O mutations/O varied/O from/O males/O with/O spontaneous/O puberty/O ,/O substantial/O T/O production/O ,/O and/O possible/O fertility/O ,/O to/O females/O with/O and/O without/O müllerian/O structures/O and/O primary/O amenorrhea/O ./O
CONCLUSION(S/O )/O :/O We/O describe/O six/O novel/O mutations/B-Var in/O NR5A1/B-Gene gene/O and/O showed/O that/O they/O might/O affect/B-Reg protein/B-MPA structure/I-MPA ,/O therefore/O compromising/B-NegReg seriously/O the/O SF-1/B-MPA role/O in/O regulating/O gonadal/B-CPA development/I-CPA ./O
Clinically/O ,/O we/O suggest/O that/O NR5A1/O analysis/O should/O be/O performed/O whenever/O atypical/O sex/O organs/O are/O evidenced/O or/O there/O is/O an/O abnormal/O sexual/O development/O ,/O to/O have/O proper/O diagnosis/O and/O better/O management/O of/O patients/O ./O
Multiple/O regions/O in/O the/O extracellular/O domain/O of/O the/O glycine/O receptor/O determine/O receptor/O activity/O ./O
Glycine/O receptors/O (/O GlyRs/O )/O are/O Cys/O -/O loop/O receptors/O that/O mediate/O fast/O synaptic/O inhibition/O in/O the/O brain/O stem/O and/O spinal/O cord/O ./O
They/O are/O involved/O in/O the/O generation/O of/O motor/O rhythm/O ,/O reflex/O circuit/O coordination/O ,/O and/O sensory/O signal/O processing/O and/O therefore/O represent/O targets/O for/O therapeutic/O interventions/O ./O
The/O extracellular/O domains/O (/O ECDs/O )/O of/O Cys/O -/O loop/O receptors/O typically/O contain/O many/O aromatic/O amino/O acids/O ,/O but/O only/O those/O in/O the/O receptor/O binding/O pocket/O have/O been/O extensively/O studied/O ./O
Here/O ,/O we/O show/O that/O many/O Phe/O residues/O in/O the/O ECD/O that/O are/O not/O located/O in/O the/O binding/O pocket/O are/O also/O involved/O in/O GlyR/O function/O ./O
We/O examined/O these/O Phe/O residues/O by/O creating/O several/O GlyR/O variants/O ,/O characterizing/O these/O variants/O with/O the/O two/O -/O electrode/O voltage/O clamp/O technique/O in/O Xenopus/O oocytes/O ,/O and/O interpreting/O changes/O in/O receptor/O parameters/O by/O using/O currently/O available/O structural/O information/O on/O the/O open/O and/O closed/O states/O of/O the/O GlyR./O Substitution/B-Var of/O six/O of/O the/O eight/O Phe/O residues/O in/O the/O ECD/O with/O Ala/O resulted/O in/O loss/B-NegReg of/O function/B-MPA or/O significantly/O increased/B-PosReg the/O EC50/B-MPA and/O also/O altered/B-Reg the/O maximal/B-MPA response/I-MPA to/I-MPA the/I-MPA partial/I-MPA GlyR/I-MPA agonist/I-MPA taurine/I-MPA compared/O with/O glycine/O in/O those/O receptor/O variants/O that/O were/O functional/O ./O
Substitutions/O with/O other/O amino/O acids/O ,/O combined/O with/O examination/O of/O nearby/O residues/O that/O could/O potentially/O interact/O with/O these/O Phe/O residues/O ,/O suggested/O interactions/O that/O could/O be/O important/O for/O GlyR/O function/O ,/O and/O possibly/O similar/O interactions/O could/O contribute/O to/O the/O function/O of/O other/O members/O of/O the/O Cys/O -/O loop/O receptor/O family/O ./O
Overall/O ,/O our/O results/O suggest/O that/O many/O ECD/O regions/O are/O important/O for/O GlyR/O function/O and/O that/O these/O regions/O could/O inform/O the/O design/O of/O therapeutic/O agents/O targeting/O GlyR/O activity/O ./O
RES/O complex/O is/O associated/O with/O intron/O definition/O and/O required/O for/O zebrafish/O early/O embryogenesis/O ./O
Pre/O -/O mRNA/O splicing/O is/O a/O critical/O step/O of/O gene/O expression/O in/O eukaryotes/O ./O
Transcriptome/O -/O wide/O splicing/O patterns/O are/O complex/O and/O primarily/O regulated/O by/O a/O diverse/O set/O of/O recognition/O elements/O and/O associated/O RNA/O -/O binding/O proteins/O ./O
The/O retention/O and/O splicing/O (/O RES/O )/O complex/O is/O formed/O by/O three/O different/O proteins/O (/O Bud13p/O ,/O Pml1p/O and/O Snu17p/O )/O and/O is/O involved/O in/O splicing/O in/O yeast/O ./O
However/O ,/O the/O importance/O of/O the/O RES/O complex/O for/O vertebrate/O splicing/O ,/O the/O intronic/O features/O associated/O with/O its/O activity/O ,/O and/O its/O role/O in/O development/O are/O unknown/O ./O
In/O this/O study/O ,/O we/O have/O generated/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutants/B-Var for/O the/O three/O components/O of/O the/O RES/O complex/O in/O zebrafish/O and/O showed/O that/O they/O are/O required/O during/O early/O development/O ./O
The/O mutants/O showed/O a/O marked/O neural/O phenotype/O with/O increased/O cell/O death/O in/O the/O brain/O and/O a/O decrease/B-NegReg in/O differentiated/B-CPA neurons/I-CPA ./O
Transcriptomic/O analysis/O of/O bud13/B-Gene ,/O snip1/B-Gene (/O pml1/O )/O and/O rbmx2/B-Gene (/O snu17/O )/O mutants/B-Var revealed/O a/O global/O defect/B-NegReg in/O intron/B-MPA splicing/I-MPA ,/O with/O strong/O mis/B-MPA -/I-MPA splicing/I-MPA of/I-MPA a/I-MPA subset/I-MPA of/I-MPA introns/I-MPA ./O
We/O found/O these/O RES/O -/O dependent/O introns/O were/O short/O ,/O rich/O in/O GC/O and/O flanked/O by/O GC/O depleted/O exons/O ,/O all/O of/O which/O are/O features/O associated/O with/O intron/O definition/O ./O
Using/O these/O features/O ,/O we/O developed/O and/O validated/O a/O predictive/O model/O that/O classifies/O RES/O dependent/O introns/O ./O
Altogether/O ,/O our/O study/O uncovers/O the/O essential/O role/O of/O the/O RES/O complex/O during/O vertebrate/O development/O and/O provides/O new/O insights/O into/O its/O function/O during/O splicing/O ./O
Mutant/B-Var p53/B-Gene gain/B-PosReg of/I-PosReg function/I-PosReg induces/B-Reg HER2/B-Protein over/B-MPA -/I-MPA expression/I-MPA in/O cancer/O cells/O ./O
BACKGROUND/O :/O HER2/O over/O -/O expression/O is/O related/O with/O a/O poor/O prognosis/O in/O patients/O with/O invasive/O breast/O cancer/O tumors/O ./O
Clinical/O associations/O have/O reported/O that/O somatic/O mutations/O of/O p53/O more/O frequently/O detected/O in/O cases/O of/O sporadic/O breast/O cancer/O of/O the/O HER2/O subtypes/O ,/O besides/O a/O high/O percentage/O of/O HER2-amplifying/O tumors/O carry/O germline/O mutations/O of/O p53/O ./O
The/O mechanisms/O responsible/O for/O the/O acquisition/O of/O oncogenic/O functions/O of/O p53/O mutant/O proteins/O (/O mtp53/O )/O ,/O known/O as/O Gain/O of/O Function/O (/O GOF/O )/O ,/O over/O HER2/O expression/O have/O not/O been/O reported/O ./O
The/O objective/O of/O this/O study/O was/O to/O evaluate/O a/O possible/O relationship/O between/O p53/O mutants/O and/O HER2/O regulation/O ./O
METHODS/O :/O HER2/O expression/O (/O transcription/O and/O protein/O )/O ,/O as/O well/O as/O HER2/O protein/O stabilization/O have/O been/O evaluated/O after/O inducing/O or/O silencing/O of/O p53/O mutants/O '/O expression/O in/O cell/O lines/O ./O
Finally/O ,/O we/O evaluated/O the/O interaction/O of/O the/O p53/O mutants/O over/O the/O HER2/O receptor/O promoter/O ./O
RESULTS/O :/O Higher/B-PosReg HER2/B-Protein expression/B-MPA in/O cell/O lines/O harboring/O endogenous/O mtp53/B-Var compared/O with/O wt/O or/O null/O expression/O of/O p53/O cell/O lines/O ./O
Transfection/O of/O p53/B-Gene mutants/O (/B-Var R248Q/I-Var and/O R273C/B-Var )/I-Var in/O cell/O lines/O increased/B-PosReg the/O expression/B-MPA of/O HER2/B-Protein ./O
Silencing/O of/O p53/O mutants/O ,/O decrease/O HER2/O expression/O ./O
The/O p53/B-Gene mutants/O R248Q/B-Var and/O R273C/B-Var significantly/O increase/B-PosReg the/O luciferase/B-Enzyme activity/B-MPA on/O the/O HER2/O promoter/O ,/O and/O both/O mutants/O also/O promote/B-PosReg acetylation/B-MPA of/O H3/B-Protein and/O H4/B-Protein histones/I-Protein binding/B-Interaction in/O it/O ./O
CONCLUSIONS/O :/O These/O findings/O show/O for/O the/O first/O time/O that/O p53/B-Gene mutants/B-Var induce/B-Reg over/B-MPA -/I-MPA expression/I-MPA of/O HER2/B-Protein at/O transcriptional/O level/O of/O the/O HER2/O protein/O ./O
Our/O results/O could/O have/O clinical/O implications/O in/O breast/O cancer/O and/O other/O types/O of/O cancer/O where/O HER2/O is/O over/O -/O expressed/O and/O used/O as/O a/O therapy/O target/O ./O
Mice/O harboring/O the/O human/O SLC30A8/B-Gene R138X/B-Var loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/O have/O increased/B-PosReg insulin/B-MPA secretory/I-MPA capacity/I-MPA ./O
SLC30A8/O encodes/O a/O zinc/O transporter/O that/O is/O primarily/O expressed/O in/O the/O pancreatic/O islets/O of/O Langerhans/O ./O
In/O β/O -/O cells/O it/O transports/O zinc/O into/O insulin/O -/O containing/O secretory/O granules/O ./O
Loss/O -/O of/O -/O function/O (/O LOF/O )/O mutations/O in/O SLC30A8/O protect/O against/O type/O 2/O diabetes/O in/O humans/O ./O
In/O this/O study/O ,/O we/O generated/O a/O knockin/O mouse/O model/O carrying/O one/O of/O the/O most/O common/O human/O LOF/O mutations/O for/O SLC30A8/O ,/O R138X./O The/O R138X/O mice/O had/O normal/O body/O weight/O ,/O glucose/O tolerance/O ,/O and/O pancreatic/O β/O -/O cell/O mass/O ./O
Interestingly/O ,/O in/O hyperglycemic/O conditions/O induced/O by/O the/O insulin/O receptor/O antagonist/O S961/O ,/O the/O R138X/B-Var mice/O showed/O a/O 50/O %/O increase/B-PosReg in/O insulin/B-MPA secretion/I-MPA ./O
This/O effect/O was/O not/O associated/O with/O enhanced/O β/O -/O cell/O proliferation/O or/O mass/O ./O
Our/O data/O suggest/O that/O the/O SLC30A8/B-Gene R138X/O LOF/B-NegReg mutation/B-Var may/O exert/O beneficial/B-PosReg effects/I-PosReg on/O glucose/B-MPA metabolism/I-MPA by/O increasing/B-PosReg the/O capacity/O of/O β/O -/O cells/O to/O secrete/B-MPA insulin/I-MPA under/O hyperglycemic/O conditions/O ./O
The/O lateral/O meningocele/O syndrome/O mutation/O causes/O marked/O osteopenia/O in/O mice/O ./O
Lateral/O meningocele/O syndrome/O (/O LMS/O )/O is/O a/O rare/O genetic/O disorder/O characterized/O by/O neurological/O complications/O and/O osteoporosis/O ./O
LMS/B-Disease is/O associated/O with/O mutations/B-Var in/I-Var exon/I-Var 33/I-Var of/O NOTCH3/B-Gene leading/O to/O a/O truncated/B-MPA protein/B-Protein lacking/B-NegReg sequences/B-MPA for/I-MPA NOTCH3/I-MPA degradation/I-MPA and/O presumably/O causing/O NOTCH3/B-Gene gain/B-PosReg of/I-PosReg function/I-PosReg ./O
To/O create/O a/O mouse/O model/O reproducing/O human/O LMS/O -/O associated/O mutations/O ,/O we/O utilized/O CRISPR/O //O Cas9/O to/O introduce/O a/O tandem/O termination/O codon/O at/O bases/O 6691/O -/O 6696/O (/O ACCAAG→TAATGA/O )/O and/O verified/O this/O mutation/O (/O Notch3tm1.1Ecan/O )/O by/O DNA/O sequencing/O of/O F1/O mice/O ./O
One/O -/O month/O -/O old/O male/O and/O female/O heterozygous/O Notch3tm1.1Ecan/B-Var mice/O had/O cancellous/B-CPA and/I-CPA cortical/I-CPA bone/I-CPA osteopenia/B-NegReg but/O exhibited/O no/O obvious/O neurological/O alterations/O ,/O and/O histopathology/O of/O multiple/O organs/O revealed/O no/O abnormalities/O ./O
Microcomputed/O tomography/O of/O these/O mutants/B-Var revealed/O a/O 35/O -/O 60/O %/O decrease/B-NegReg in/O cancellous/B-CPA bone/I-CPA volume/I-CPA associated/O with/O a/O reduction/B-NegReg in/O trabecular/B-CPA number/I-CPA and/O decreased/B-NegReg connectivity/B-CPA ./O
During/O maturation/O ,/O cancellous/O and/O cortical/O bones/O were/O restored/O in/O female/O but/O not/O in/O male/O mice/O ,/O which/O exhibited/O cancellous/O bone/O osteopenia/O at/O 4/O months/O ./O
Cancellous/O bone/O histomorphometry/O revealed/O increased/O osteoblast/O and/O osteocyte/O numbers/O and/O a/O modest/O increase/O in/O osteoclast/O surface/O and/O bone/O formation/O rate/O ./O
Notch3tm1.1Ecan/B-Var calvarial/B-CPA osteoblasts/I-CPA had/O increased/B-PosReg proliferation/O and/O increased/B-PosReg bone/B-Protein γ/I-Protein -/I-Protein carboxyglutamate/I-Protein protein/I-Protein (/I-Protein Bglap/I-Protein )/I-Protein and/O TNF/B-Gene superfamily/I-Gene member/I-Gene 11/I-Gene (/I-Gene Tnfsf11/I-Gene )/I-Gene mRNA/B-MPA levels/I-MPA and/O lower/B-NegReg Tnfrsf11b/B-MPA levels/I-MPA ./O
Tnfsf11/O mRNA/O was/O increased/O in/O osteocyte/O -/O rich/O femora/O from/O Notch3tm1.1Ecan/O mice/O ./O
Cultures/O of/O bone/O marrow/O -/O derived/O macrophages/O from/O Notch3tm1.1Ecan/O mice/O revealed/O increased/O osteoclast/O formation/O ,/O particularly/O in/O cocultures/O with/O osteoblasts/O from/O Notch3tm1.1Ecan/O mice/O ./O
In/O conclusion/O ,/O the/O Notch3tm1.1Ecan/B-Var mutation/I-Var causes/O osteopenia/B-Disease despite/O an/O increase/B-PosReg in/O osteoblast/B-CPA proliferation/I-CPA and/O function/B-CPA and/O is/O associated/O with/O enhanced/B-PosReg Tnfsf11/B-Gene expression/B-MPA in/O osteoblasts/O and/O osteocytes/O ./O
Heterogeneous/O nature/O of/O diabetes/B-Disease in/O a/O family/O with/O a/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O the/O ATP/O -/O binding/O cassette/O subfamily/O C/O member/O 8/O (/B-Gene ABCC8/I-Gene )/I-Gene gene/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg ATP/O -/O binding/O cassette/O subfamily/O C/O member/O 8/O (/B-Gene ABCC8/I-Gene )/I-Gene mutations/B-Var are/O known/O to/O cause/B-Reg neonatal/B-Disease diabetes/I-Disease mellitus/I-Disease and/O maturity/B-Disease -/I-Disease onset/I-Disease diabetes/I-Disease in/O the/O young/O ./O
However/O ,/O the/O intrafamilial/O heterogeneous/O nature/O of/O diabetes/O caused/O by/O the/O ABCC8/O mutation/O is/O not/O fully/O understood/O to/O date/O ./O
To/O clarify/O the/O intrafamilial/O heterogeneous/O nature/O of/O monogenetic/O diabetes/O ,/O we/O conducted/O a/O case/O study/O on/O a/O family/O with/O ABCC8/O mutations/O ./O
We/O investigated/O eight/O family/O members/O ,/O including/O a/O neonatal/O diabetes/O patient/O ,/O based/O on/O metabolic/O features/O and/O genetic/O analysis/O ./O
All/O coding/O exons/O and/O exon/O -/O intron/O boundaries/O of/O the/O KCNJ11/O ,/O ABCC8/O ,/O GCK/O ,/O HNF1A/O ,/O and/O HNF4A/O genes/O were/O amplified/O from/O genomic/O DNA/O and/O directly/O sequenced/O ./O
Five/O gene/O mutation/O carriers/O with/O ABCC8/O (/O c.1819G/O >/O A/O //O p/O ./O V607/O M/O )/O were/O identified/O in/O this/O family/O ,/O and/O the/O onset/O and/O severity/O of/O diabetes/O progressively/O worsened/O across/O the/O three/O generations/O ./O
Each/O of/O the/O ABCC8/O gene/O mutation/O carrier/O family/O members/O were/O diagnosed/O with/O diabetes/O as/O follows/O :/O the/O grandfather/O with/O type/O 2/O diabetes/O at/O 35/O years/O of/O age/O ,/O the/O aunt/O with/O slowly/O -/O progressive/O insulin/O -/O dependent/O diabetes/O at/O 18/O years/O of/O age/O ,/O the/O mother/O with/O ketosis/O -/O onset/O insulin/O -/O dependent/O diabetes/O at/O 14/O years/O of/O age/O ,/O the/O sister/O with/O impaired/O glucose/O tolerance/O at/O 9/O years/O of/O age/O ,/O and/O the/O proband/O with/O transient/O neonatal/O diabetes/O at/O birth/O ./O
The/O present/O study/O shows/O the/O heterogeneous/O nature/O of/O diabetes/O in/O a/O family/O with/O a/O gain/O -/O of/O -/O function/O mutation/O in/O the/O ABCC8/O gene/O ./O
Activating/O human/O epidermal/O growth/O factor/O receptor/O 2/O (/O HER2/O )/O gene/O mutation/O in/O bone/O metastases/O from/O breast/O cancer/O ./O
In/O addition/O to/O amplification/O ,/O point/B-Var mutations/I-Var of/O the/O human/O epidermal/O growth/O factor/O receptor/O 2/O (/O HER2/O )/O gene/O (/B-Gene ERBB2/I-Gene )/I-Gene have/O been/O shown/O to/O activate/B-PosReg the/O corresponding/O signaling/B-Pathway pathway/I-Pathway in/O breast/B-Disease cancer/I-Disease ./O
The/O prevalence/O of/O ERBB2/O //O HER2/O mutation/O in/O bone/O metastasis/O of/O breast/O cancer/O and/O the/O associated/O phenotype/O are/O not/O known/O ./O
In/O this/O study/O ,/O bone/O metastases/O from/O breast/O cancer/O patients/O (/O n/O =/O 231/O )/O were/O analyzed/O for/O ERBB2/O //O HER2/O mutation/O ./O
In/O 7/O patients/O (/O 3/O %/O ;/O median/O age/O 70/O years/O ,/O range/O 50/O -/O 83/O years/O )/O ,/O gain/O -/O of/O -/O function/O mutations/O of/O ERBB2/O //O HER2/O were/O detected/O ./O
The/O most/O frequent/O mutation/O was/O p/O ./O L755S/O (/O 71/O %/O )/O ./O
In/O 29/O %/O of/O mutated/O cases/O ,/O p/O ./O V777L/O was/O found/O ./O
Lobular/O breast/O cancer/O was/O present/O in/O 71/O %/O of/O mutated/O cases/O (/O n/O =/O 5/O )/O and/O in/O 49/O %/O of/O all/O samples/O (/O n/O =/O 231/O ;/O p/O =/O 0.275/O )/O ./O
Mutation/O frequency/O was/O 4.4/O %/O in/O the/O lobular/O subgroup/O and/O 17.4/O %/O in/O the/O pleomorphic/O subtype/O of/O lobular/O cancer/O (/O n/O =/O 23/O )/O ,/O respectively/O ./O
All/O but/O one/O mutated/O lobular/O cancers/O were/O of/O the/O pleomorphic/O subtype/O (/O p/O =/O 0.006/O )/O ./O
Mutated/O cancers/O belonged/O either/O to/O the/O luminal/O (/O n/O =/O 4/O )/O or/O to/O the/O triple/O -/O negative/O types/O (/O n/O =/O 3/O )/O ./O
With/O regard/O to/O protein/O expression/O and/O gene/O amplification/O ,/O HER2/O was/O negative/O in/O all/O mutated/O cases/O ./O
Among/O the/O 14/O %/O of/O metastatic/O luminal/O cancers/O with/O estrogen/O receptor/O gene/O (/O ESR1/O )/O mutation/O ,/O conveying/O resistance/O against/O aromatase/O inhibitors/O ,/O no/O concomitant/O ERBB2/O //O HER2/O mutation/O occurred/O ./O
We/O conclude/O that/O activating/B-PosReg HER2/B-Gene mutation/B-Var is/O present/O in/O about/O 3/O %/O of/O bone/B-CPA metastases/I-CPA from/O breast/B-Disease cancers/I-Disease ,/O with/O significantly/O higher/B-PosReg rates/I-PosReg in/O the/O pleomorphic/O subtype/O of/O lobular/O cancer/O ./O
Since/O mutated/O cases/O appear/O to/O be/O HER2-negative/O by/O conventional/O testing/O ,/O the/O opportunity/O for/O specific/O anti/O -/O HER2/O therapy/O may/O be/O missed/O ./O
Altered/O ER/O -/O mitochondria/O contact/O impacts/O mitochondria/O calcium/O homeostasis/O and/O contributes/O to/O neurodegeneration/O in/O vivo/O in/O disease/O models/O ./O
Calcium/O (/O Ca2/O +/O )/O homeostasis/O is/O essential/O for/O neuronal/O function/O and/O survival/O ./O
Altered/O Ca2/O +/O homeostasis/O has/O been/O consistently/O observed/O in/O neurological/O diseases/O ./O
How/O Ca2/O +/O homeostasis/O is/O achieved/O in/O various/O cellular/O compartments/O of/O disease/O -/O relevant/O cell/O types/O is/O not/O well/O understood/O ./O
Here/O we/O show/O in/O Drosophila/O Parkinson/O 's/O disease/O (/O PD/O )/O models/O that/O Ca2/O +/O transport/O from/O the/O endoplasmic/O reticulum/O (/O ER/O )/O to/O mitochondria/O through/O the/O ER/O -/O mitochondria/O contact/O site/O (/O ERMCS/O )/O critically/O regulates/O mitochondrial/O Ca2/O +/O (/O mito/O -/O Ca2/O +/O )/O homeostasis/O in/O dopaminergic/O (/O DA/O )/O neurons/O ,/O and/O that/O the/O PD/O -/O associated/O PINK1/O protein/O modulates/O this/O process/O ./O
In/O PINK1/B-Gene mutant/B-Var DA/O neurons/O ,/O the/O ERMCS/B-MPA is/O strengthened/B-PosReg and/O mito/B-MPA -/I-MPA Ca2/I-MPA +/I-MPA level/I-MPA is/O elevated/B-PosReg ,/O resulting/O in/O mitochondrial/B-MPA enlargement/B-PosReg and/O neuronal/O death/O ./O
Miro/O ,/O a/O well/O -/O characterized/O component/O of/O the/O mitochondrial/O trafficking/O machinery/O ,/O mediates/O the/O effects/O of/O PINK1/O on/O mito/O -/O Ca2/O +/O and/O mitochondrial/O morphology/O ,/O apparently/O in/O a/O transport/O -/O independent/O manner/O ./O
Miro/O overexpression/O mimics/O PINK1/O loss/O -/O of/O -/O function/O effect/O ,/O whereas/O inhibition/O of/O Miro/O or/O components/O of/O the/O ERMCS/O ,/O or/O pharmacological/O modulation/O of/O ERMCS/O function/O ,/O rescued/O PINK1/O mutant/O phenotypes/O ./O
Mito/O -/O Ca2/O +/O homeostasis/O is/O also/O altered/O in/O the/O LRRK2-G2019S/O model/O of/O PD/O and/O the/O PAR-1/O //O MARK/O model/O of/O neurodegeneration/O ,/O and/O genetic/O or/O pharmacological/O restoration/O of/O mito/O -/O Ca2/O +/O level/O is/O beneficial/O in/O these/O models/O ./O
Our/O results/O highlight/O the/O importance/O of/O mito/O -/O Ca2/O +/O homeostasis/O maintained/O by/O Miro/O and/O the/O ERMCS/O to/O mitochondrial/O physiology/O and/O neuronal/O integrity/O ./O
Targeting/O this/O mito/O -/O Ca2/O +/O homeostasis/O pathway/O holds/O promise/O for/O a/O therapeutic/O strategy/O for/O neurodegenerative/O diseases/O ./O
